<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.65, http://www.edgar-online.com -->
<TITLE> Trillium Therapeutics Inc. (Form: 40-F, Received: 03/09/2016 17:24:31) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_CONTROL_AND_PROCEDURES **FIS_ACCOUNTANT_FEES **FIS_OFF_BALANCE_SHEET_ARRANGEMENTS **FIS_DISCLOSURE_OF_OBLIGATIONS **FIS_AUDIT_COMMITTEE **FIS_MINE_SAFETY_DISCLOSURE **FIS_UNDERTAKING_AND_CONSENT **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_99 **FIS_BUSINESS FIS_EXHIBIT_99_2 FIS_EXHIBIT_99_3 **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_CASH_FLOW FIS_EXHIBIT_99_4 FIS_EXHIBIT_99_5 FIS_EXHIBIT_99_6 FIS_EXHIBIT_99_7 FIS_EXHIBIT_99_8 ">
<META NAME="DETECTED PAGES" CONTENT="139">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="FORM40F_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<HR NOSHADE ALIGN="CENTER" WIDTH=100% SIZE=3 COLOR="BLACK">
<A NAME="FORM40F_HTM_PAGE_1">
</A>
<P ALIGN=CENTER>
<B>
<FONT SIZE=5>
	UNITED STATES
</FONT>
</B>
<BR>
<B>
<FONT SIZE=5>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
</B>
<BR>
	Washington, D.C. 20549
</P>
<P ALIGN=CENTER>
<B>
<FONT SIZE=5>
	FORM 40-F
</FONT>
</B>
</P>
<P ALIGN=JUSTIFY>
	(Check One)
</P>
<P ALIGN=JUSTIFY>
	[&nbsp;&nbsp; ]&nbsp; Registration statement pursuant to Section 12 of
	the Securities Exchange Act of 1934 or
</P>
<P ALIGN=JUSTIFY>
	[X]&nbsp; Annual report pursuant to section 13(a) or 15(d) of
	the Securities Exchange Act of 1934
</P>
<P ALIGN=JUSTIFY>
	For the fiscal year ended December 31, 2015
</P>
<P ALIGN=JUSTIFY>
	Commission file number
<B>
	1-36596
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P ALIGN=CENTER>
<B>
<FONT SIZE=5>
	TRILLIUM THERAPEUTICS INC.
</FONT>
<BR>
</B>
	(Exact name of registrant as specified in its charter)
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER>
<B>
	Ontario, Canada
</B>
</TD>
<TD ALIGN=CENTER WIDTH="33%">
<B>
	2834
</B>
</TD>
<TD ALIGN=CENTER WIDTH="33%">
<B>
	Not applicable
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=CENTER>
	(Province or other jurisdiction of
</TD>
<TD ALIGN=CENTER WIDTH="33%">
	(Primary Standard Industrial
</TD>
<TD ALIGN=CENTER WIDTH="33%">
	(I.R.S. Employer
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=CENTER>
	incorporation or organization)
</TD>
<TD ALIGN=CENTER WIDTH="33%">
	Classification Code Number
</TD>
<TD ALIGN=CENTER WIDTH="33%">
	Identification Number (if applicable))
</TD>
</TR>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER COLSPAN=3>
	&nbsp;(if applicable))&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
<B>
	96 Skyway Avenue, Toronto, Ontario, Canada M9W 4Y9
<BR>
	Telephone: (416) 595-0627
<BR>
</B>
	(Address and Telephone Number of
	Registrant&#146;s Principal Executive Offices)
</P>
<P ALIGN=CENTER>
<B>
	Puglisi &amp; Associates, 850 Library Avenue, Suite 204,
	Newark, Delaware 19711
<BR>
	Telephone: (302) 738-6680
<BR>
</B>
	(Name,
	Address (Including Zip Code) and Telephone Number
<BR>
	(Including Area Code) of
	Agent For Service in the United States)
</P>
<P ALIGN=CENTER>
	Securities registered or to be registered pursuant to Section
	12(b) of the Act.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER>
<U>
<B>
	Title of each class
</B>
</U>
</TD>
<TD ALIGN=CENTER WIDTH="50%">
<U>
<B>
	Name of each exchange on which
	registered
</B>
</U>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=CENTER>
<B>
	Common Shares
</B>
</TD>
<TD ALIGN=CENTER WIDTH="50%">
<B>
	The NASDAQ Stock Market LLC
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	Securities registered or to be
	registered pursuant to Section 12(g) of the Act.
<B>
	None
</B>
</P>
<P ALIGN=CENTER>
	Securities for
	which there is a reporting obligation pursuant to Section 15(d) of the Act.
<B>
	None
</B>
</P>
<P ALIGN=CENTER>
	For annual reports, indicate by check mark the information filed
	with this Form:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER>
	[X]&nbsp; Annual Information Form
</TD>
<TD ALIGN=CENTER WIDTH="50%">
	[X]&nbsp; Audited Annual Financial
	Statements
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Indicate the number of outstanding shares of each of the
	issuer&#146;s classes of capital or common stock as of the close of the period
	covered by the annual report: 7,796,137 common shares
<B>
</B>
</P>
<P ALIGN=JUSTIFY>
	Indicate by check mark whether the registrant: (1) has filed
	all reports required to be filed by Section 13 or 15(d) of the Securities
	Exchange Act of 1934 (the &#147;Exchange Act&#148;) during the preceding 12 months (or for
	such shorter period that the registrant was required to file such reports); and
	(2) has been subject to such filing requirements for the past 90 days.
</P>
<P ALIGN=CENTER>
	Yes&nbsp;[X]&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; No [&nbsp;&nbsp; ]
</P>
<P ALIGN=JUSTIFY>
	Indicate by check mark whether the registrant has submitted
	electronically and posted on its corporate Web site, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule 405 of Regulation
	S-T (s.232.405 of this chapter) during the preceding 12 months (or for such
	shorter period that the registrant was required to submit and post such files).
</P>
<P ALIGN=CENTER>
	Yes&nbsp; [&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp; [&nbsp;&nbsp; ]
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage2"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_2">
</A>
<P ALIGN=CENTER>
<B>
	FORM 40-F
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	Principal Documents
</B>
</P>
<P ALIGN=JUSTIFY>
	The following documents, filed as Exhibits 99.1, 99.2 and 99.3
	to this Annual Report on Form 40-F, are hereby incorporated by reference into
	this Annual Report on Form 40-F:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	(a)
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Annual Information Form for the fiscal year ended
	December 31, 2015;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	(b)
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Management&#146;s Discussion and Analysis for the years ended
	December 31, 2015 and 2014; and
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	(c)
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Audited Consolidated Financial Statements for the years
	ended December 31, 2015 and 2014, prepared under International Financial
	Reporting Standards as issued by the International Accounting Standards
	Board.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	US-1
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage3"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_3">
</A>
<P ALIGN=CENTER>
<B>
	ADDITIONAL DISCLOSURE
</B>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P ALIGN=JUSTIFY>
<B>
	Certifications and Disclosure Regarding Controls and
	Procedures.
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(a)
</TD>
<TD>
<P ALIGN=JUSTIFY>
<U>
	Certifications
</U>
	. See Exhibits 99.4, 99.5, 99.6 and
	99.7 to this Annual Report on Form 40-F.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(b)
</TD>
<TD>
<P ALIGN=JUSTIFY>
<U>
	Disclosure Controls and Procedures
</U>
	. As of the end
	of Trillium Therapeutics Inc.&#146;s (&#147;Trillium&#148; or the &#147;Company&#148;) fiscal year
	ended December 31, 2015, an evaluation of the effectiveness of Trillium&#146;s
	&#147;disclosure controls and procedures&#148; (as such term is defined in Rules
	13a-15(e) and 15d-15(e) under the Exchange Act) was carried out by the
	management of Trillium, with the participation of the President and Chief
	Executive Officer (&#147;CEO&#148;) and the Chief Financial Officer (&#147;CFO&#148;) of
	Trillium. Based upon that evaluation, the CEO and CFO have concluded that
	as of the end of that fiscal year, Trillium&#146;s disclosure controls and
	procedures were effective to ensure that information required to be
	disclosed by Trillium in reports that it files or submits under the
	Securities Exchange Act of 1934, as amended, is (i) recorded, processed,
	summarized and reported within the time periods specified in Securities
	and Exchange Commission (the &#147;Commission&#148;) rules and forms and (ii)
	accumulated and communicated to the management of Trillium, including the
	CEO and CFO, to allow timely decisions regarding required
	disclosure.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	It should be noted that while the CEO and CFO believe
	that Trillium&#146;s disclosure controls and procedures provide a reasonable
	level of assurance that they are effective, they do not expect that
	Trillium&#146;s disclosure controls and procedures or internal control over
	financial reporting will prevent all errors and fraud. A control system,
	no matter how well conceived or operated, can provide only reasonable, not
	absolute, assurance that the objectives of the control system are
	met.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(c)
</TD>
<TD>
<P ALIGN=JUSTIFY>
<U>
	Management&#146;s Annual Report on Internal Control Over
	Financial Reporting
</U>
	.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Management is responsible for establishing and
	maintaining adequate internal control over Trillium&#146;s financial reporting.
	Trillium&#146;s internal control system was designed to provide reasonable
	assurance that all transactions are accurately recorded, that transactions
	are recorded as necessary to permit preparation of financial statements in
	accordance with generally accepted accounting principles, and that
	Trillium&#146;s assets are safeguarded.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Management has assessed the effectiveness of Trillium&#146;s
	internal control over financial reporting as at December 31, 2015. In
	making its assessment, management used the Committee of Sponsoring
	Organizations of the Treadway Commission (&#147;COSO&#148;) framework in Internal
	Control &#150; Integrated Framework (2013) to evaluate the effectiveness of
	Trillium&#146;s internal control over financial reporting. Based on this
	assessment, management has concluded that Trillium&#146;s internal control over
	financial reporting was effective as of December 31,
	2015.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	US-2
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage4"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_4">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(d)
</TD>
<TD>
<P ALIGN=JUSTIFY>
<U>
	Attestation Report of the Registered Public Accounting
	Firm
</U>
	.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	This annual report does not include an attestation report
	of the Company&#146;s independent registered public accounting firm regarding
	internal control over financial reporting because emerging growth
	companies are exempt from this requirement for so long as they remain
	emerging growth companies. Therefore, management&#146;s report on internal
	control over financial reporting is not subject to attestation by the
	Company&#146;s independent registered public accounting firm.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(e)
</TD>
<TD>
<P ALIGN=JUSTIFY>
<U>
	Changes in Internal Control Over Financial
	Reporting
</U>
	. The required disclosure is included under the heading
	&#147;Disclosure Controls and Internal Controls Over Financial Reporting&#148; in
	Trillium&#146;s Management&#146;s Discussion and Analysis for the years ended
	December 31, 2015 and 2014, filed as Exhibit 99.2 to this Annual Report on
	Form 40-F.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	Notices Pursuant to Regulation BTR.
</B>
</P>
<P ALIGN=JUSTIFY>
	None.
</P>
<P ALIGN=JUSTIFY>
<B>
	Audit Committee Financial Expert.
</B>
</P>
<P ALIGN=JUSTIFY>
	Trillium&#146;s board of directors has determined that Luke Beshar,
	a member of Trillium&#146;s audit committee, qualifies as an &#147;audit committee
	financial expert&#148; (as such term is defined in Form 40-F) and is &#147;independent&#148; as
	that term is defined in the rules of the Nasdaq Stock Market.
</P>
<P ALIGN=JUSTIFY>
<B>
	Code of Business Conduct
</B>
	.
<B>
</B>
</P>
<P ALIGN=JUSTIFY>
	Trillium has adopted a Code of Business Conduct and Ethics,
	which qualifies as a &#147;code as ethics&#148; within the meaning of Form 40-F, that is
	applicable to each of Trillium&#146;s directors, officers and employees, including
	its principal executive officer, principal financial officer, principal
	accounting officer or controller and persons performing similar functions.
</P>
<P ALIGN=JUSTIFY>
	The Code of Business Conduct and Ethics is available for
	viewing on Trillium&#146;s website at
<FONT COLOR="#0000FF">
<U>
	www.trilliumtherapeutics.com
</U>
</FONT>
	, and is
	available in print, without charge, to any shareholder who requests a copy of
	it. Requests for copies of the Code of Business Conduct and Ethics should be
	made by contacting: James Parsons, Chief Financial Officer, by phone at (416)
	595-0627 or by e-mail to info@trilliumtherapeutics.com.
</P>
<P ALIGN=JUSTIFY>
	Since the date on which Trillium became subject to the
	reporting requirements of Section 13(a) or 15(d) of the Exchange Act, there have
	not been any amendments to, or waivers, including implicit waivers, granted
	from, any provision of the Code of Business Conduct and Ethics.
</P>
<P ALIGN=CENTER>
	US-3
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage5"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_5">
</A>
<P ALIGN=JUSTIFY>
	If any amendment to the Code of Ethics is made, or if any
	waiver from the provisions thereof is granted, Trillium may elect to disclose
	the information about such amendment or waiver required by Form 40-F to be
	disclosed, by posting such disclosure on its website, which may be accessed at
	www.trilliumtherapeutics.com.
</P>
<P ALIGN=CENTER>
	US-4
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage6"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_6">
</A>
</EFX_CONTROL_AND_PROCEDURES>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P ALIGN=JUSTIFY>
<B>
	Principal Accountant Fees and Services.
</B>
</P>
<P ALIGN=JUSTIFY>
	The required disclosure is included under the heading &#147;Audit
	Committee Information &#150; External Auditors Service Fees (By Category)&#148; in
	Trillium&#146;s Annual Information Form for the year ended December 31, 2015, filed
	as Exhibit 99.1 to this Annual Report on Form 40-F.
</P>
<P ALIGN=JUSTIFY>
<B>
	Pre-Approval Policies and Procedures.
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(a)
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The audit committee of Trillium&#146;s board of directors has
	adopted an Auditor Services Pre-Approval Policy (the "Policy") with
	respect to the pre-approval of audit and permitted non-audit services to
	be provided by Ernst &amp; Young LLP, Trillium&#146;s independent auditor.
	Pursuant to the Policy, the audit committee on an annual basis may approve
	the provision of a specified list of audit and permitted non-audit
	services that the audit committee believes to be typical, reoccurring or
	otherwise likely to be provided by the external auditor during the then
	current fiscal year. All pre-approvals granted under this Policy shall be
	sufficiently detailed as to the particular services being provided that it
	will not be necessary for management of Trillium to exercise any
	discretion in determining whether a particular service has been
	pre-approved.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	In addition, pursuant to the Policy the audit committee
	has delegated its pre- approval authority to the Chair of the audit
	committee for services where the aggregate fees are estimated to be less
	than or equal to Cdn. $50,000. The Chair of the audit committee is required to report any
	such granted pre-approvals to the audit committee at its next scheduled
	meeting. The audit committee shall not delegate to management the audit
	committee's responsibilities for pre-approving audit and non-audit
	services to be performed by the external auditor.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Pursuant to the Policy, there is an exception to the
	pre-approval requirements for permitted non-audit services, provided all
	such services were not recognized at the time of the engagement to be
	non-audit services and, once recognized, are promptly brought to the
	attention of the audit committee and approved prior to the completion of
	the audit. The aggregate amount of all services approved in this manner
	may not constitute more than five percent of the total fees paid to the
	external auditor during the fiscal year in which the services are
	provided.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	(b)
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Of the fees reported in this Annual Report on Form 40-F
	under the heading &#147;Principal Accountant Fees and Services&#148;, none of the
	fees billed by Ernst &amp; Young LLP were approved by Trillium&#146;s audit
	committee pursuant to the
<I>
	de minimus
</I>
	exception provided by Section
	(c)(7)(i)(C) of Rule 2-01 of Regulation S- X.
</P>
</TD>
</TR>
</TABLE>
</EFX_ACCOUNTANT_FEES>
<EFX_OFF_BALANCE_SHEET_ARRANGEMENTS>
<A NAME="FIS_OFF_BALANCE_SHEET_ARRANGEMENTS"></A>
<P ALIGN=JUSTIFY>
<B>
	Off-Balance Sheet Arrangements.
</B>
</P>
<P ALIGN=JUSTIFY>
	Trillium does not have any off-balance sheet arrangements that
	have, or are reasonably likely to have, a current or future effect on its
	financial condition, revenues or expenses, results of operations, liquidity,
	capital expenditures or capital resources that are material to investors.
</P>
<P ALIGN=CENTER>
	US-5
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage7"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_7">
</A>
</EFX_OFF_BALANCE_SHEET_ARRANGEMENTS>
<EFX_DISCLOSURE_OF_OBLIGATIONS>
<A NAME="FIS_DISCLOSURE_OF_OBLIGATIONS"></A>
<P ALIGN=JUSTIFY>
<B>
	Tabular Disclosure of Contractual Obligations.
</B>
</P>
<P ALIGN=JUSTIFY>
	The required disclosure is included under the heading
	&#147;Contractual Obligations and Contingencies&#148; in Trillium&#146;s Management&#146;s
	Discussion and Analysis for the years ended December 31, 2015 and 2014, filed as
	Exhibit 99.2 to this Annual Report on Form 40-F.
</P>
</EFX_DISCLOSURE_OF_OBLIGATIONS>
<EFX_AUDIT_COMMITTEE>
<A NAME="FIS_AUDIT_COMMITTEE"></A>
<P ALIGN=JUSTIFY>
<B>
	Identification of the Audit Committee.
</B>
</P>
<P ALIGN=JUSTIFY>
	Trillium has a separately-designated standing audit committee
	established in accordance with Section 3(a)(58)(A) of the Exchange Act. The
	members of the audit committee are: Luke Beshar, Henry Friesen and Robert
	Kirkman.
<B>
</B>
</P>
</EFX_AUDIT_COMMITTEE>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P ALIGN=JUSTIFY>
<B>
	Mine Safety Disclosure.
</B>
</P>
<P ALIGN=JUSTIFY>
	Not applicable.
</P>
<P ALIGN=CENTER>
	US-6
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage8"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_8">
</A>
<P ALIGN=JUSTIFY>
<B>
	Disclosure Pursuant to the Requirements of the Nasdaq Stock
	Market.
</B>
</P>
<P ALIGN=JUSTIFY>
	As a Canadian corporation listed on the NASDAQ Stock Market, we
	are not required to comply with most of the NASDAQ corporate governance
	standards, so long as we comply with Canadian corporate governance practices. In
	order to claim such an exemption, however, we must disclose the significant
	differences between our corporate governance practices and those required to be
	followed by U.S. domestic issuers under NASDAQ&#146;s corporate governance standards.
</P>
<P ALIGN=JUSTIFY>
	Our corporate governance practices meet or exceed all
	applicable Canadian requirements. They also incorporate some best practices
	derived from the NASDAQ rules and comply with applicable rules adopted by the
	Securities and Exchange Commission to give effect to the provisions of the
	United States Sarbanes-Oxley Act of 2002.
</P>
<P ALIGN=JUSTIFY>
	We expect that further information about our corporate
	governance practices will be included in our Information Circulars in respect of
	future annual meetings of shareholders.
</P>
<P ALIGN=JUSTIFY>
	The following is a summary of the significant ways in which our
	corporate governance practices differ from those required to be followed by U.S.
	domestic issuers under NASDAQ&#146;s corporate governance standards. Except as
	described in this summary, we are in compliance with the NASDAQ corporate
	governance standards in all significant respects.
</P>
<P ALIGN=JUSTIFY>
<B>
	Shareholder Approval
</B>
</P>
<P ALIGN=JUSTIFY>
	Section 5635 of the NASDAQ Marketplace Rules requires
	shareholder approval to be obtained in connection with the undertaking of
	certain actions. The circumstances under which shareholder approval is required
	under the NASDAQ Marketplace Rules are not identical to the circumstances under
	which shareholder approval is required under Canadian and TSX requirements. For
	example, but without limitation, Section 5635 requires shareholder approval of
	most equity compensation plans and material revisions to such plans. This
	requirement covers plans that provide for the delivery of both newly issued and
	treasury securities. The TSX rules provide that only the creation of or certain
	material amendments to equity compensation plans that provide for new issuances
	of securities are subject to shareholder approval. We follow the TSX rules with
	respect to the requirements for shareholder approval of potential transactions,
	including, without limitation, shareholder approval of equity compensation plans
	and material revisions to such plans.
</P>
<P ALIGN=CENTER>
	US-7
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage9"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_9">
</A>
</EFX_MINE_SAFETY_DISCLOSURE>
<EFX_UNDERTAKING_AND_CONSENT>
<A NAME="FIS_UNDERTAKING_AND_CONSENT"></A>
<P ALIGN=CENTER>
<B>
	UNDERTAKING AND CONSENT TO SERVICE OF PROCESS
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	A.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Undertaking.
</B>
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY STYLE="TEXT-INDENT:5%">
	Trillium undertakes to make
	available, in person or by telephone, representatives to respond to inquiries
	made by the Commission staff, and to furnish promptly, when requested to do so
	by the Commission staff, information relating to: the securities registered
	pursuant to Form 40-F; the securities in relation to which the obligation to
	file an annual report on Form 40-F arises; or transactions in said securities.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	B.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Consent to Service of
	Process.
</B>
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY STYLE="TEXT-INDENT:5%">
	Trillium has previously filed a
	Form F-X in connection with the class of securities in relation to which the
	obligation to file this report arises.
</P>
<P ALIGN=JUSTIFY STYLE="TEXT-INDENT:5%">
	Any change to the name or address
	of the agent for service of process of Trillium shall be communicated promptly
	to the Commission by an amendment to the Form F-X referencing the file number of
	Trillium.
</P>
</EFX_UNDERTAKING_AND_CONSENT>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P ALIGN=CENTER>
<B>
	SIGNATURES
</B>
</P>
<P ALIGN=JUSTIFY STYLE="TEXT-INDENT:5%">
	Pursuant to the requirements of
	the Exchange Act, Trillium Therapeutics Inc. certifies that it meets all of the
	requirements for filing on Form 40-F and has duly caused this annual report to
	be signed on its behalf by the undersigned, thereunto duly authorized, on March
	9, 2016.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%">
<B>
	Trillium Therapeutics Inc.
</B>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BORDERCOLOR="#000000">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%" STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1" BORDERCOLOR="#000000">
	By: /s/ James Parsons
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%" STYLE="BORDER-TOP-STYLE: SOLID; BORDER-TOP-WIDTH: 1">
	Name: James Parsons
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	Title: Chief Financial Officer
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	US-8
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage10"></A>
<!--$$/PAGE=-->
<A NAME="FORM40F_HTM_PAGE_10">
</A>
</EFX_SIGNATURES>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P ALIGN=CENTER>
<B>
	EXHIBIT INDEX
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
<U>
	Exhibit
</U>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
<U>
	Description
</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-1_HTM">
	99.1
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-1_HTM">
	Annual Information Form for the fiscal year ended
	December 31, 2015
</A>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-2_HTM">
	99.2
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-2_HTM">
	Management&#146;s Discussion and Analysis for the years ended
	December 31, 2015 and 2014
</A>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-3_HTM">
	99.3
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-3_HTM">
	Audited Consolidated Financial Statements for the years
	ended December 31, 2015 and 2014, prepared under International Financial
	Reporting Standards as issued by the International Accounting Standards
	Board
</A>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-4_HTM">
	99.4
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-4_HTM">
	Certification of President &amp; Chief Executive Officer
	pursuant to Rule 13a-14(a) or 15d-14 of the Securities Exchange Act of
	1934
</A>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-5_HTM">
	99.5
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-5_HTM">
	Certification of Chief Financial Officer pursuant to Rule
	13a-14(a) or 15d-14 of the Securities Exchange Act of 1934
</A>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-6_HTM">
	99.6
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-6_HTM">
	Certification of Chief Executive Officer pursuant to 18
	U.S.C. Section 1350
</A>
</P>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-7_HTM">
	99.7
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-7_HTM">
	Certification of Chief Financial Officer pursuant to 18
	U.S.C. Section 1350
</A>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD ALIGN=LEFT>
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%">
<P ALIGN=JUSTIFY>
	&nbsp;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-8_HTM">
	99.8
</A>
</P>
</TD>
<TD ALIGN=LEFT WIDTH="92%" BGCOLOR=#EEEEEE>
<P ALIGN=JUSTIFY>
<A HREF="#EXHIBIT99-8_HTM">
	Consent of Ernst &amp; Young LLP
</A>
</P>
</TD>
</TR>
</TABLE>
<BR>
<HR COLOR="#000000" SIZE="5">
</EFX_EXHIBIT_INDEX>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage11"></A>
<A NAME="EXHIBIT99-1_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99"></A>
<HR NOSHADE ALIGN="CENTER" WIDTH=100% SIZE=3 COLOR="BLACK">
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_1">
</A>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-1X1X1.JPG" BORDER=0 WIDTH="322" HEIGHT="203">
</P>
<BR>
<P ALIGN=CENTER>
<B>
	(formerly Stem Cell Therapeutics Corp.)
</B>
</P>
<P ALIGN=CENTER>
<B>
	ANNUAL INFORMATION FORM
</B>
</P>
<P ALIGN=CENTER>
<B>
	FOR THE YEAR ENDED DECEMBER 31, 2015
</B>
</P>
<P ALIGN=CENTER>
	96 Skyway Avenue
<BR>
	Toronto, Ontario M9W 4Y9
<BR>
	www.trilliumtherapeutics.com
</P>
<P ALIGN=CENTER>
	Unless otherwise indicated, all information in the Annual
	Information Form
<BR>
	is presented as at and for the year ended December 31, 2015
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P ALIGN=CENTER>
<B>
	March 9, 2016
</B>
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage12"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_2">
</A>
<P ALIGN=CENTER>
<B>
<U>
	TABLE OF CONTENTS
</U>
</B>
<B>
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_3">
	CAUTIONARY
	STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</A>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_3">
	3
</A>
</TD>
</TR>
<TR>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_5">
	CORPORATE
	INFORMATION
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_5">
	5
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_5">
	BUSINESS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_5">
	5
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_16">
	GENERAL
	DEVELOPMENT OF THE BUSINESS &#150; 3 YEAR SUMMARY
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_16">
	16
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_18">
	RISK
	FACTORS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_18">
	18
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_32">
	DESCRIPTION
	OF SHARE CAPITAL
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_32">
	32
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_36">
	MARKET
	FOR SECURITIES
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_36">
	36
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_37">
	BOARD
	OF DIRECTORS AND MANAGEMENT
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_37">
	37
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_39">
	CEASE
	TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_39">
	39
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_39">
	CONFLICTS
	OF INTEREST
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_39">
	39
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	LEGAL
	PROCEEDINGS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	40
</A>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	INTEREST
	OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	40
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	INTEREST
	OF EXPERTS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	40
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	TRANSFER
	AGENT
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	40
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	MATERIAL
	CONTRACTS
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_40">
	40
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_41">
	AUDIT
	COMMITTEE INFORMATION
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_41">
	41
</A>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_44">
	ADDITIONAL
	INFORMATION
</A>
</TD>
<TD ALIGN=RIGHT WIDTH="5%" BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_44">
	44
</A>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#EEEEEE>
<A HREF="#EXHIBIT99-1_HTM_PAGE_45">
	SCHEDULE A - CHARTER OF THE AUDIT COMMITTEE
</A>
</TD>
<TD ALIGN=LEFT WIDTH="5%" BGCOLOR=#EEEEEE>
	&nbsp;
</TD>
</TR>
</TABLE>
<BR>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage13"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_3">
</A>
<P ALIGN=CENTER>
<B>
	CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B>
</P>
<P ALIGN=JUSTIFY>
	This Annual Information Form, or AIF, contains forward-looking
	statements within the meaning of applicable securities laws. All statements
	contained herein that are not clearly historical in nature are forward-looking,
	and the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;expect&#148;, &#147;estimate&#148;, &#147;may&#148;, &#147;will&#148;,
	&#147;could&#148;, &#147;leading&#148;, &#147;intend&#148;, &#147;contemplate&#148;, &#147;shall&#148; and similar expressions are
	generally intended to identify forward-looking statements. Forward-looking
	statements in this AIF include, but are not limited to, statements with respect
	to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expected future loss and accumulated deficit levels;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our projected financial position and estimated cash burn
	rate;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about the timing of achieving milestones
	and the cost of our development programs;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our observations and expectations regarding the relative
	low binding of SIRP&#945;Fc to red blood cells compared to anti-CD47 monoclonal
	antibodies and proprietary CD47-blocking agents, and the potential
	benefits to patients;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our requirements for, and the ability to obtain, future
	funding on favorable terms or at all;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our projections for the SIRP&#945;Fc development plan and
	progress of each of our products and technologies, particularly with
	respect to the timely and successful completion of studies and trials and
	availability of results from such studies and trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about the differentiated nature and
	potential for best-in-class product development programs and discovery
	research capabilities of Fluorinov Pharma Inc., or Fluorinov;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to generate future product development
	programs with improved pharmacological properties using Fluorinov
	technology;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about whether various clinical and
	regulatory milestones with an existing Fluorinov compound will be
	achieved;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations of the final quantum and form of any
	future contingent milestone payments related to the Fluorinov acquisition;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations of the ability to secure the requisite
	approvals (including the Toronto Stock Exchange, or TSX, and NASDAQ Stock
	Market, or NASDAQ approvals) with respect to the issuance of any common
	shares in satisfaction of future milestone payments;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about our products&#146; safety and efficacy;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations regarding our ability to arrange for the
	manufacturing of our products and technologies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations regarding the progress, and the
	successful and timely completion, of the various stages of the regulatory
	approval process;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to secure strategic partnerships with larger
	pharmaceutical and biotechnology companies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our strategy to acquire and develop new products and
	technologies and to enhance the safety and efficacy of existing products
	and technologies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our plans to market, sell and distribute our products and
	technologies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations regarding the acceptance of our products
	and technologies by the market;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to retain and access appropriate staff,
	management, and expert advisers;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations with respect to existing and future
	corporate alliances and licensing transactions with third parties, and the
	receipt and timing of any payments to be made by us or to us in respect of
	such arrangements; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our strategy with respect to the protection of our
	intellectual property.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	All forward-looking statements reflect our beliefs and
	assumptions based on information available at the time the assumption was made.
	These forward-looking statements are not based on historical facts but rather on
	management&#146;s expectations regarding future activities, results of operations,
	performance, future capital and other expenditures (including the amount, nature
	and sources of funding thereof), competitive advantages, business prospects and
	opportunities. By its nature, forward-looking information involves numerous
	assumptions, inherent risks and uncertainties, both general and specific, known
	and unknown, that contribute to the possibility that the predictions, forecasts,
	projections or other forward-looking statements will not occur. Factors which
	could cause future outcomes to differ materially from those set forth in the
	forward-looking statements include, but are not limited to:
</P>
<P ALIGN=CENTER>
	3
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage14"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_4">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the effect of continuing operating losses on our ability
	to obtain, on satisfactory terms, or at all, the capital required to
	maintain us as a going concern;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the ability to obtain sufficient and suitable financing
	to support operations, preclinical development, clinical trials, and
	commercialization of products;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks associated with the development of novel
	compounds at early stages of development in our intellectual property
	portfolio;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks of reliance on third-parties for the planning,
	conduct and monitoring of clinical trials and for the manufacture of drug
	product;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks associated with the development of our product
	candidates including the demonstration of efficacy and safety;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks related to clinical trials including potential
	delays, cost overruns and the failure to demonstrate efficacy and safety;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks of delays and inability to complete clinical
	trials due to difficulties enrolling patients;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risks associated with our inability to successfully
	develop companion diagnostics for our development candidates;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	delays or negative outcomes from the regulatory approval
	process;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to successfully compete in our targeted
	markets;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to attract and retain key personnel,
	collaborators and advisors;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risks relating to the increase in operating costs from
	expanding existing programs, acquisition of additional development
	programs and increased staff;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risk of negative results of clinical trials or adverse
	safety events by us or others related to our product candidates;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the potential for product liability claims;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to achieve our forecasted milestones and
	timelines on schedule;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	financial risks related to the fluctuation of foreign
	currency rates and expenses denominated in foreign currencies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to adequately protect proprietary information
	and technology from competitors;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risks related to changes in patent laws and their
	interpretations;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to source and maintain licenses from
	third-party owners; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risk of patent-related litigation and the ability to
	protect trade secrets,
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	all as further and more fully described under the section of
	this AIF entitled &#147;Risk Factors&#148;.
</P>
<P ALIGN=JUSTIFY>
	Although the forward-looking statements contained in this AIF
	are based upon what our management believes to be reasonable assumptions, we
	cannot assure readers that actual results will be consistent with these
	forward-looking statements.
</P>
<P ALIGN=JUSTIFY>
	Any forward-looking statements represent our estimates only as
	of the date of this AIF and should not be relied upon as representing our
	estimates as of any subsequent date. We undertake no obligation to update any
	forward-looking statement or statements to reflect events or circumstances after
	the date on which such statement is made or to reflect the occurrence of
	unanticipated events, except as may be required by securities legislation.
</P>
<P ALIGN=JUSTIFY>
	All references in this AIF to &#147;the Company&#148;, &#147;Trillium&#148;, &#147;we&#148;,
	&#147;us&#148;, or &#147;our&#148; refer to Trillium Therapeutics Inc. and the subsidiaries through
	which it conducts its business, unless otherwise indicated.
</P>
<P ALIGN=JUSTIFY>
	All amounts are in Canadian dollars, unless otherwise
	indicated.
</P>
<P ALIGN=CENTER>
	4
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage15"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_5">
</A>
<P ALIGN=CENTER>
<B>
	CORPORATE INFORMATION
</B>
</P>
<P ALIGN=JUSTIFY>
	We were incorporated under the
<I>
	Business Corporations Act
</I>
	(Alberta) on March 31, 2004 as Neurogenesis Biotech Corp. On October 19, 2004,
	we amended our articles of incorporation to change our name from Neurogenesis
	Biotech Corp. to Stem Cell Therapeutics Corp., or SCT. On November 7, 2013 SCT
	was continued under the Business Corporations Act (Ontario), or OBCA. On June 1,
	2014 we filed articles of amalgamation to amalgamate SCT with our wholly-owned
	subsidiary, Trillium Therapeutics Inc., or Trillium Privateco, and renamed the
	combined company Trillium Therapeutics Inc. We are a company domiciled in
	Ontario, Canada.
</P>
<P ALIGN=JUSTIFY>
	As of December 31, 2015 we had one wholly-owned subsidiary,
	Trillium Therapeutics USA Inc. which was incorporated March 26, 2015 in the
	State of Delaware. A wholly-owned and inactive subsidiary, Stem Cell
	Therapeutics Inc. was dissolved on September 17, 2014.
</P>
<P ALIGN=JUSTIFY>
	On January 26, 2016, we acquired all the outstanding shares of
	Fluorinov, a corporation existing under the OBCA. See &#147;Business - Small Molecule
	Program&#148;, below.
</P>
<P ALIGN=JUSTIFY>
	Our head and registered offices are located at 96 Skyway
	Avenue, Toronto, Ontario, Canada M9W 4Y9. Our website address is
	www.trilliumtherapeutics.com.
</P>
<P ALIGN=CENTER>
<B>
	BUSINESS
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	Overview
</B>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P ALIGN=JUSTIFY>
	We are an immuno-oncology company developing innovative
	therapies for the treatment of cancer. Our lead program, SIRP&#945;Fc, is a novel,
	antibody-like protein that harnesses the innate immune system by blocking the
	activity of CD47, a molecule whose expression is increased on cancer cells to
	evade the host immune system. Expressed at high levels on the cell surface of a
	variety of liquid and solid tumors, CD47 functions as a signal that inhibits the
	destruction of tumor cells by macrophages via phagocytosis. By blocking the
	activity of CD47, we believe SIRP&#945;Fc has the ability to promote the
	macrophage-mediated killing of tumor cells in a broad variety of cancers both as
	a monotherapy and in combination with other immune therapies.
</P>
<P ALIGN=JUSTIFY>
	The immune system is the body&#146;s mechanism to identify and
	eliminate pathogens, and can be divided into the innate immune system and the
	adaptive immune system. The innate immune system is the body&#146;s first line of
	defense to identify and eliminate pathogens and consists of proteins and cells,
	such as macrophages, that identify and provide an immediate response to
	pathogens. The adaptive immune system is activated by, and adapts to, pathogens,
	creating a targeted and durable response. Cancer cells often have the ability to
	reduce the immune system&#146;s ability to recognize and destroy them. We believe
	SIRP&#945;Fc could play an important role in enhancing the innate immune system and
	importantly, because of its ability to target macrophages, also may have an
	important downstream effect on the adaptive immune system.
</P>
</EFX_BUSINESS>
<P ALIGN=JUSTIFY>
<I>
	Immuno-oncology is altering cancer treatment
</I>
</P>
<P ALIGN=JUSTIFY>
	While the concept of using the immune system to treat cancer
	can trace its roots back to late nineteenth century, it was only recently that
	the field of immuno-oncology received validation with the approval of antibodies
	that block CTLA-4 (ipilimumab) and PD-1 (pembrolizumab and nivolumab). These
	drugs have established the clinical principle that anti-tumor responses can be
	induced by interfering with the negative signals that normally shut down immune
	responses.
</P>
<P ALIGN=JUSTIFY>
<B>
	Our Strategy
</B>
</P>
<P ALIGN=JUSTIFY>
	Our goal is to become a leading innovator in the field of
	immuno-oncology by targeting immune-regulatory pathways that tumor cells exploit
	to evade the host immune system. We believe that SIRP&#945;Fc has the potential to
	improve survival and quality of life for cancer patients.
</P>
<P ALIGN=CENTER>
	5
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage16"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_6">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Rapidly advance the clinical development of
	SIRP&#945;Fc
</I>
</B>
	. We have initiated a
	first-in-human trial of SIRP&#945;Fc in patients with relapsed or refractory
	lymphoma in a dose escalation phase of up to 36 patients,&nbsp; and expect to enroll up to 8 cohorts of 12-15 patients with
	advanced hematologic malignancies in an expansion phase of the trial after
	an optimal dose has been determined.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Expand our SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc
	clinical program to include additional cancer indications
</I>
</B>
	. Because
	CD47 is highly expressed by multiple liquid and solid tumors, and high
	expression is correlated with worse clinical outcomes, we believe SIRP&#945;Fc
	has potential to be effective in a wide variety of cancers. We are
	carrying out preclinical work necessary to select additional, high
	potential cancer indications for clinical development.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Maximize value of
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc through scientific
	collaborations
</I>
</B>
	. SIRP&#945;Fc has broad potential applicability in
	various cancer indications, and we believe it is well suited for use as
	both a monotherapy and in combination with other agents. We plan to
	continue to selectively and opportunistically pursue scientific
	collaborations with academic researchers as well as with other companies
	in order to realize the full value proposition of SIRP&#945;Fc.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Initiate IND-enabling studies in 2016 with a
	Fluorinov product
</I>
</B>
	. TTI-281 is an oral bromodomain inhibitor that
	we believe has strong potency and has shown efficacy in AML xenograft
	models. We plan to initiate scale up and manufacturing for TTI-281 in
	2016.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	SIRP
</B>
<B>
	&#945;
</B>
<B>
	Fc Key Attributes
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Potential efficacy in a broad range of
	cancers
</I>
</B>
	. SIRP&#945;Fc blocks the tumor&#146;s ability to transmit a &#147;do not
	eat&#148; signal allowing macrophages to destroy tumor cells; a mechanism that
	we believe could have broad applicability.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Potential for use as monotherapy and in combination
	with other therapies
</I>
</B>
	. We intend to develop SIRP&#945;Fc as a
	monotherapy as well as potentially for use in combination with other
	cancer immuno- therapies.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Differentiated pharmacokinetic and safety
	profile
</I>
</B>
	. We believe SIRP&#945;Fc&#146;s low level of binding to red blood
	cells lowers the risk of anemia and lowers the loss of drug from
	circulation. This pharmacokinetic profile potentially allows for lower
	dosing and an improved safety profile.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	May enhance both innate and adaptive immune
	response
</I>
</B>
	. SIRP&#945;Fc may enhance stimulation of tumor attacking T
	cells since macrophages, in addition to their role in phagocytosis, can
	also prime T cells through antigen presentation.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc Clinical development
	plan
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We commenced a phase I study in patients with advanced
	hematologic malignancies. The two-part clinical trial is designed as a
	multi-center, open-label Phase 1a/1b trial, evaluating TTI-621 as a single-agent
	in patients with relapsed or refractory hematologic malignancies. During the
	dose escalation phase set to enroll up to 36 subjects, the safety, tolerability,
	pharmacokinetics and pharmacodynamics will be characterized to determine the
	optimal dose for subsequent enrollment in the expansion phase. To characterize
	potential changes in hematologic parameters that might occur with blockade of
	CD47, the dose-escalation portion of the phase I trial will include lymphoma
	patients with normal hematologic parameters and acceptable marrow function. Once
	a reasonably well-tolerated dose and schedule of SIRP&#945;Fc has been established
	for further study, safety and antitumor activity will be estimated in expansion
	cohorts of up to 15 patients with advanced hematologic malignancies including
	indolent B-cell lymphoma, aggressive B-cell lymphoma, T-cell lymphoma, Hodgkin
	lymphoma, chronic lymphocytic leukemia, multiple myeloma, acute myeloid
	leukemia, and myelodysplastic syndrome. We plan to engage five trial sites in
	the United States for the dose escalation part of the trial.
</P>
<P ALIGN=CENTER>
	6
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage17"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_7">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Blocking the CD47 &#147;do not eat&#148; signal using a
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc decoy receptor
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Macrophages are a type of white blood cell that can ingest and
	destroy (phagocytose) other cells. They are part of the innate immune system
	that helps to protect the body from infection. More recently, a role for
	macrophages in the control of tumors has been described.
</P>
<P ALIGN=JUSTIFY>
	Macrophage activity is controlled by both positive &#147;eat&#148; and
	negative &#147;do not eat&#148; signals. Tumor cells may express &#147;eat&#148; signals (e.g.,
	calreticulin) that make themselves visible to macrophages. To counterbalance
	this increased visibility the tumor cells often express high levels of CD47,
	which transmits a &#147;do not eat&#148; signal by binding signal regulatory protein
	alpha, or SIRP&#945;, on the surface of macrophages. We believe that the higher
	expression of CD47 on the tumor cell helps it evade destruction by the
	macrophage by overwhelming any activating &#147;eat&#148; signals.
</P>
<P ALIGN=JUSTIFY>
	SIRP&#945;Fc is an antibody-like protein that consists of the
	CD47-binding domain of human SIRP&#945; linked to the Fc region of a human
	immunoglobulin. It is designed to act as a soluble decoy receptor, preventing
	CD47 from delivering its inhibitory signal. Neutralization of the inhibitory
	CD47 signal enables the activation of macrophage anti-tumor effects by the
	pro-phagocytic &#147;eat&#148; signals. The Fc region of SIRP&#945;Fc may, depending on its
	identity, also assist in the activation of macrophages by engaging Fc receptors.
</P>
<P ALIGN=JUSTIFY>
	Figure 1, below, illustrates how SIRP&#945;Fc blocks the CD47 &#147;do
	not eat&#148; signal and engages activating Fc receptors on macrophages, leading to
	tumor cell phagocytosis.
</P>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-1X7X1.JPG" BORDER=0 WIDTH="622" HEIGHT="309">
</P>
<BR>
<P ALIGN=JUSTIFY>
	In addition to their direct anti-tumor activity, macrophages
	can also function as antigen-presenting cells and stimulate antigen-specific T
	cells. Thus it is possible that increasing tumor cell phagocytosis after SIRP&#945;Fc
	exposure may result in enhanced adaptive immunity. In support of this, CD47
	antibody blockade has been recently shown to augment antigen presentation and
	prime an anti-tumor cytotoxic T cell response in immune-competent mice. CD47
	blockade has also been reported to promote tumor-specific T cell responses
	through a dendritic cell-based mechanism, although the effect of SIRP&#945;Fc on
	dendritic cells is currently unknown.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc has broad clinical
	potential
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We believe that SIRP&#945;Fc has broad clinical potential in both
	hematological and solid tumors. High expression of the CD47 &#147;do not eat&#148; signal
	on tumor cells has been observed in acute lymphoblastic leukemia, or AML,
	myelodysplastic syndrome, chronic myeloid leukemia, or CML, acute lymphoblastic
	leukemia, or ALL, diffuse large B cell lymphoma, or DLBCL, chronic lymphocytic
	leukemia, or CLL, follicular lymphoma, mantle cell lymphoma, marginal zone
	lymphoma, multiple myeloma and in the following solid tumors: bladder, brain,
	breast, colon, leiomyosarcoma, liver, melanoma, ovarian, pancreatic and
	prostate. In a number of these cancers high CD47 expression was shown to have
	negative clinical consequences, correlating with more aggressive disease and
	poor survival. In normal karyotype AML patients, for example, high CD47
	expression was correlated with worse event-free survival (6.8 vs. 17.1 months)
	and worse overall survival (9.1 vs. 22.1 months) compared to low CD47
	expression. These data are consistent with CD47 providing a survival advantage
	to tumor cells. Furthermore, numerous studies have shown that antibody blockade
	of CD47 has demonstrated activity in mice engrafted with human tumors. We
	collaborate with academic investigators to explore the therapeutic potential of
	SIRP&#945;Fc in a variety of solid tumor models.
</P>
<P ALIGN=CENTER>
	7
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage18"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_8">
</A>
<P ALIGN=JUSTIFY>
<I>
	In vitro
</I>
	studies with primary tumor samples obtained
	from AML, MDS, multiple myeloma, B cell-ALL and T-cell ALL demonstrated that
	SIRP&#945;Fc frequently triggered significantly macrophage-mediated tumor cell
	phagocytosis compared to control treatment. Similar results were observed with
	tumor cell lines established from patients with B lymphoma and CML.
</P>
<P ALIGN=JUSTIFY>
	Figure 2, below, shows how SIRP&#945;Fc (TTI-621) triggers
	macrophage-mediated phagocytosis of many different human blood cancer samples.
</P>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-1X8X1.JPG" BORDER=0 WIDTH="643" HEIGHT="400">
</P>
<BR>
<P ALIGN=JUSTIFY>
	The
<I>
	p
</I>
	value is a probability value, with values &lt;0.05
	considered statistically significant versus control treatment. NS indicates
<I>
	p
</I>
	&gt;0.05, which is considered not statistically significant versus
	control treatment.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	&#150; Minimal Red Blood
	Cell Binding - Competition
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	SIRP&#945;Fc competes directly with CD47 blocking antibodies from
	Forty Seven Inc. (recently licensed from Stanford University) and Celgene
	Corporation, both of which have entered early clinical development. Novimmune SA
	has a bispecific (anti-CD47/anti-CD19) antibody program in preclinical
	development. Vasculox is also developing a CD47 antibody. Alexo Therapeutics is
	developing mutated, high affinity SIRP&#945; monomers as adjuvants for use with
	anti-cancer antibodies. Both Vasculox and Alexo Therapeutics are in the
	preclinical phase of development.
</P>
<P ALIGN=CENTER>
	8
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage19"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_9">
</A>
<P ALIGN=JUSTIFY>
	We believe that our approach of using SIRP&#945;, the natural
	binding partner for CD47, may have important advantages over treatment with
	CD47-specific antibodies. In April 2015, we presented data at the 106th American
	Association for Cancer Research annual meeting demonstrating that our SIRP&#945;Fc
	fusion proteins exhibit minimal binding to human red blood cells, or RBCs,
	compared to anti-CD47 monoclonal antibodies. These data build upon preliminary
	results announced at the 2014 American Association for Cancer Research annual
	meeting.
</P>
<P ALIGN=JUSTIFY>
	Figure 3, below, shows how SIRP&#945;Fc binding to human RBCs (n=43
	donors) compares to five CD47-specific antibodies.
</P>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-1X9X1.JPG" BORDER=0 WIDTH="339" HEIGHT="277">
</P>
<BR>
<P ALIGN=JUSTIFY>
	The very low RBC binding profile of our SIRP&#945;Fc proteins may
	provide three important advantages over other CD47 blocking agents. First, there
	may be a lower risk of experiencing drug-induced anemia with SIRP&#945;Fc. This
	potential advantage may translate into improved patient care, particularly in
	diseases such as AML where almost all patients experience cytopenias including
	anemia. Second, SIRP&#945;Fc may remain in circulation for longer intervals compared
	to CD47 antibodies, which have been demonstrated to bind strongly to circulating
	RBCs and may thus be more likely to be removed from circulation. The ability of
	RBCs to absorb and remove circulating CD47-specific antibodies, an &#147;antigen-sink
	effect&#148;, may necessitate high doses of antibody in order to effectively target
	the tumor cells, which may lead to potentially higher off-target toxicity.
	Therefore, SIRP&#945;Fc may be associated with both improved tolerability and drug
	kinetics compared with CD47-specific antibodies based on these preclinical
	analyses. Third, antibodies that bind RBCs have the potential to interfere with
	laboratory blood typing tests. The minimal binding of TTI-621 to human RBCs may
	minimize this interference compared to anti-CD47 antibodies.
</P>
<P ALIGN=CENTER>
	9
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage20"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_10">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Combination Therapy
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We believe that SIRP&#945;Fc enhancement of macrophage activity and
	possibly T cell responses could be synergistic with other immune-mediated
	therapies. Published studies conducted by third parties provide evidence that
	SIRP&#945;Fc may be useful in combination with approved anti-cancer antibodies (e.g.
	Rituxan&#174;, Herceptin&#174;, Campath&#174;, and Erbitux&#174;). Since many cancer antibodies work
	at least in part by activating cells of the innate immune system, it may be
	possible to enhance the potency of these agents by blocking the negative &#147;do not
	eat&#148; CD47 signal that tumor cells deliver to macrophages. We hypothesize that
	SIRP&#945;Fc may act synergistically with other immunological agents, including T
	cell checkpoint inhibitors (e.g. pembrolizumab and nivolumab), cancer vaccines,
	oncolytic viruses or chimeric antigen receptor, or CAR T cells.
</P>
<P ALIGN=JUSTIFY>
<B>
	Small Molecule Program
</B>
</P>
<P ALIGN=JUSTIFY>
	On January 26, 2016, we acquired all the outstanding shares of
	Fluorinov, a privately-held oncology company that has developed a proprietary
	medicinal chemistry platform using unique fluorine chemistry, which permits the
	creation of new chemical entities from validated drugs and drug candidates with
	improved pharmacological properties, potentially leading to increased safety and
	efficacy. Fluorinov&#146;s most advanced preclinical oncology programs include
	potent, orally-available, bromodomain and proteasome inhibitors, as well as
	epidermal growth factor receptor antagonists with increased uptake in the brain,
	all of which have been differentiated from competitors and have potential for
	best-in-class status. In addition, a number of compounds directed at undisclosed
	immuno-oncology targets are currently in the discovery phase.
</P>
<P ALIGN=JUSTIFY>
<B>
	Plan of Operations
</B>
</P>
<P ALIGN=JUSTIFY>
	Over the next 12 months, our primary focus is the advancement
	of our Phase I clinical trial of SIRP&#945;Fc in patients with advanced hematologic
	malignancies. We also plan to conduct preclinical research in solid tumors and
	in combination studies to identify future potential clinical indications.
</P>
<P ALIGN=JUSTIFY>
	We also plan to advance one, or possibly two, of Fluorinov&#146;s preclinical programs through the IND-enabling
	phase using our internal development group, while at the same time focusing our
	new chemistry group on several immuno-oncology discovery programs.
</P>
<P ALIGN=JUSTIFY>
<B>
	Product for Development with Partners &#150; CD200 Monoclonal
	Antibodies
</B>
</P>
<P ALIGN=JUSTIFY>
	Our CD200 monoclonal antibody program also targets a key
	pathway that tumor cells use to evade attack from the immune system. There is
	evidence that CD200 is highly expressed by many different types of blood cell
	and solid tumors, and in numerous cases this high expression correlates with
	disease progression and poor clinical outcome. This is consistent with tumor
	cells using CD200 as a means of evading immune-mediated destruction.
	Tumor-expressed CD200 can modulate anti-tumor responses in vitro and in vivo,
	and antibodies that block CD200 have been shown to promote anti-tumor immunity
	in animal models of cancer.
</P>
<P ALIGN=JUSTIFY>
	Our CD200 monoclonal antibody is a fully human monoclonal
	antibody that blocks the activity of CD200. We have conducted in vitro and in
	vivo preclinical oncology-focused studies. Our antibodies bind strongly to human
	CD200, potently neutralizing CD200 function in vitro, and have shown anti-tumor
	activity in a transplanted human tumor cell model. We are seeking a development
	partner to advance this program into formal preclinical IND-enabling
	studies.
</P>
<P ALIGN=JUSTIFY>
<B>
	Intellectual Property
</B>
</P>
<P ALIGN=JUSTIFY>
	We own or control patent rights covering our key products and
	their therapeutic end uses. The patents and patent applications are either
	granted or pending in major pharmaceutical markets. In all, the patent estate
	includes fourteen different inventions in three different areas that include
	SIRP&#945;, CD200, and modified new chemical entities. These are supported by 40
	patents and applications. In connection specifically with patent coverage for
	SIRP&#945;Fc, we control two patent families that comprise fifteen individual
	filings. One family has claims that embrace species of SIRP&#945;Fc found to have
	certain therapeutic benefits, and their use for the treatment of cancer. We own
	these patent rights outright and national patent filings have been made in the
	U.S., Europe, Japan, Canada, Australia, China and India. Patents emerging from
	this family will expire in 2033. A second SIRP&#945; patent family was in-licensed on
	an exclusive basis from co-owners UHN and HSC. This family has
	also been filed in major markets. The claims cover the use of various forms of
	SIRP&#945; to treat CD47-positive cancers. Patents in this family begin to expire in
	the year 2030.
</P>
<P ALIGN=CENTER>
	10
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage21"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_11">
</A>
<P ALIGN=JUSTIFY>
	Most recently, our patent estate expanded with the acquisition
	of Fluorinov. This estate covers eleven different inventions in the small
	molecule therapeutics field and in a diverse range of medical end-uses. Six of
	these are provisional filings in the United States. Three others were filed
	recently using the Patent Cooperation Treaty, with coverage for bromodomain
	inhibitors, EGFR inhibitors and for a generic chemical process useful to produce
	the novel classes of small molecule drugs. As well, there are two patent
	families relating to proteasome inhibition that have been nationalized in the
	US, Canada, Europe and Australia. Most patents in these families will have
	patent terms that reach out to 2035 and beyond.
</P>
<P ALIGN=JUSTIFY>
	In connection specifically with CD200, Trillium and its partner
	have made a patent filing that covers superior species of human antibodies to
	human CD200. A patent family based on this filing would expire in 2037.
</P>
<P ALIGN=JUSTIFY>
	We intend to protect additional intellectual property developed
	by us through the filing of patent applications within appropriate jurisdictions
	throughout the world.
</P>
<P ALIGN=JUSTIFY>
<B>
	Regulatory Process
</B>
</P>
<P ALIGN=JUSTIFY>
	Government authorities in the United States, including federal,
	state, and local authorities, and in other countries, extensively regulate,
	among other things, the manufacturing, research and clinical development,
	marketing, labeling and packaging, storage, distribution, post-approval
	monitoring and reporting, advertising and promotion, and export and import of
	biological products, such as those we are developing. The process of obtaining
	regulatory approvals and the subsequent compliance with appropriate federal,
	state, local, and foreign statutes and regulations require the expenditure of
	substantial time and financial resources.
</P>
<P ALIGN=JUSTIFY>
	Securing final regulatory approval for the manufacture and sale
	of biological products in the U.S., Europe, Canada and other commercial
	territories, is a long and costly process that is controlled by that particular
	territory&#146;s regulatory agency. The regulatory agency in the U.S. is the U.S.
	Food and Drug Administration, or FDA, in Canada it is Health Canada, or HC, and
	in Europe it is the European Medicines Agency. Other regulatory agencies have
	similar regulatory approval processes, but each regulatory agency has its own
	approval processes. Approval in the U.S., Canada or Europe does not assure
	approval by other regulatory agencies, although often test results from one
	country may be used in applications for regulatory approval in another country.
</P>
<P ALIGN=JUSTIFY>
	None of our products have been completely developed or tested
	and, therefore, we are not yet in a position to seek final regulatory approval
	to market any of our products. The time required to obtain approval by such
	regulatory authorities is unpredictable but typically takes many years following
	the commencement of preclinical studies and clinical trials and will require
	significant additional capital.
<B>
</B>
	See &#147;Risk Factors - Risks Related to our
	Business and our Industry&#148; below.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	U.S. Government Regulation
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	In the U.S., the FDA regulates drugs under the Federal Food,
	Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and biologics
	under the FDCA and the Public Health Service Act, or PHSA, and its implementing
	regulations. FDA approval is required before any new unapproved drug or biologic
	or dosage form, including a new use of a previously approved drug, can be
	marketed in the United States. Drugs and biologics are also subject to other
	federal, state, and local statutes and regulations. If we fail to comply with
	applicable FDA or other requirements at any time during the product development
	process, clinical testing, the approval process or after approval, we may become
	subject to administrative or judicial sanctions. These sanctions could include
	the FDA&#146;s refusal to approve pending applications, license suspension or
	revocation, withdrawal of an approval, warning letters, product recalls, product
	seizures, total or partial suspension of production or distribution, civil
	monetary penalties or criminal prosecution. Any FDA enforcement action could
	have a material adverse effect on us.
</P>
<P ALIGN=CENTER>
	11
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage22"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_12">
</A>
<P ALIGN=JUSTIFY>
	The process required by the FDA before product candidates may
	be marketed in the United States generally involves the following:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	completion of extensive preclinical laboratory tests and
	preclinical animal studies, all performed in accordance with the Good
	Laboratory Practices regulations;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	submission to the FDA of an investigational new drug
	application, or IND, which must become effective before human clinical
	trials may begin and must be updated annually;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	approval by an independent institutional review board, or
	IRB, or ethics committee representing each clinical site before each
	clinical trial may be initiated;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	performance of adequate and well-controlled human
	clinical trials to establish the safety and efficacy of the product
	candidate for each proposed indication;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	preparation of and submission to the FDA of a new drug
	application, or NDA, or biologics license application, or BLA, after
	completion of all pivotal clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	potential review of the product application by an FDA
	advisory committee, where appropriate and if applicable;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	a determination by the FDA within 60 days of its receipt
	of an NDA or BLA to file the application for review;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	satisfactory completion of an FDA pre-approval inspection
	of the manufacturing facilities where the proposed product is produced to
	assess compliance with current Good Manufacturing Practices, or cGMP;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	a potential FDA audit of the preclinical research and
	clinical trial sites that generated the data in support of the NDA or BLA;
	and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	FDA review and approval of an NDA or BLA prior to any
	commercial marketing or sale of the product in the U.S.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The preclinical research and clinical testing and approval
	process require substantial time, effort, and financial resources, and we cannot
	be certain that any approvals for our product candidates will be granted on a
	timely basis, if at all.
</P>
<P ALIGN=JUSTIFY>
	An IND is a request for authorization from the FDA to
	administer an investigational new drug product to humans in clinical trials. The
	central focus of an IND submission is on the general investigational plan and
	the protocol(s) for human clinical trials. The IND also includes results of
	animal studies assessing the toxicology, pharmacokinetics, pharmacology, and
	pharmacodynamic characteristics of the product; chemistry, manufacturing, and
	controls information; and any available human data or literature to support the
	use of the investigational new drug. An IND must become effective before human
	clinical trials may begin. An IND will automatically become effective 30 days
	after receipt by the FDA, unless before that time the FDA raises concerns or
	questions related to the proposed clinical trials. In such a case, the IND may
	be placed on clinical hold and the IND sponsor and the FDA must resolve any
	outstanding concerns or questions before clinical trials can begin. Accordingly,
	submission of an IND may or may not result in the FDA allowing clinical trials
	to commence.
</P>
<P ALIGN=JUSTIFY>
<I>
	Clinical Trials
</I>
</P>
<P ALIGN=JUSTIFY>
	Clinical trials involve the administration of the
	investigational new drug to human subjects under the supervision of qualified
	investigators in accordance with Good Clinical Practices, or GCPs, which include
	the requirement that all research subjects provide their informed consent for
	their participation in any clinical trial. Clinical trials are conducted under
	protocols detailing, among other things, the objectives of the study, the
	parameters to be used in monitoring safety, and the efficacy criteria to be
	evaluated. A protocol for each clinical trial and any subsequent protocol
	amendments must be submitted to the FDA as part of the IND. Additionally,
	approval must also be obtained from each clinical trial site&#146;s IRB or ethics
	committee, before the trials may be initiated, and the IRB or ethics committee
	must monitor the trial until completed. There are also requirements governing
	the reporting of ongoing clinical trials and clinical trial results to public
	registries.
</P>
<P ALIGN=JUSTIFY>
	The clinical investigation of a drug is generally divided into
	three or four phases. Although the phases are usually conducted sequentially,
	they may overlap or be combined.
</P>
<P ALIGN=CENTER>
	12
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage23"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_13">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Phase I. The drug is initially introduced into healthy
	human subjects or patients with the target disease or condition. These
	studies are designed to evaluate the safety, dosage tolerance, metabolism
	and pharmacologic actions of the investigational new drug in humans, the
	side effects associated with increasing doses, and if possible, to gain
	early evidence on effectiveness.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Phase II. The drug is administered to a limited patient
	population to evaluate dosage tolerance and optimal dosage, identify
	possible adverse side effects and safety risks, and preliminarily evaluate
	efficacy.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Phase III. The drug is administered to an expanded
	patient population, generally at geographically dispersed clinical trial
	sites to generate enough data to statistically evaluate dosage, clinical
	effectiveness and safety, to establish the overall benefit-risk
	relationship of the investigational new drug product, and to provide an
	adequate basis for physician labeling.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Phase IV. In some cases, the FDA may condition approval
	of an NDA or BLA for a product candidate on the sponsor&#146;s agreement to
	conduct additional clinical trials after approval. In other cases, a
	sponsor may voluntarily conduct additional clinical trials after approval
	to gain more information about the drug. Such post-approval studies are
	typically referred to as phase IV clinical trials.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Clinical trial sponsors must also report to the FDA, within
	certain timeframes, serious and unexpected adverse reactions, any clinically
	important increase in the rate of a serious suspected adverse reaction over that
	listed in the protocol or investigator&#146;s brochure, or any findings from other
	studies or animal testing that suggest a significant risk in humans exposed to
	the product candidate. The FDA, the IRB or ethics committee, or the clinical
	trial sponsor may suspend or terminate a clinical trial at any time on various
	grounds, including a finding that the research subjects are being exposed to an
	unacceptable health risk. Additionally, some clinical trials are overseen by an
	independent group of qualified experts organized by the clinical trial sponsor,
	known as a data safety monitoring board or committee. This group provides
	authorization for whether or not a trial may move forward at designated check
	points based on access to certain data from the trial.
</P>
<P ALIGN=JUSTIFY>
	The clinical trial process can take years to complete, and
	there can be no assurance that the data collected will support FDA approval or
	licensure of the product. Results from one trial are not necessarily predictive
	of results from later trials. We may also suspend or terminate a clinical trial
	based on evolving business objectives and/or competitive climate.
</P>
<P ALIGN=JUSTIFY>
<I>
	Submission of an NDA or BLA to the FDA
</I>
</P>
<P ALIGN=JUSTIFY>
	Assuming successful completion of all required preclinical
	studies and clinical testing in accordance with all applicable regulatory
	requirements, detailed investigational new drug product information is submitted
	to the FDA in the form of an NDA or BLA requesting approval to market the
	product for one or more indications. Under federal law, the submission of most
	NDAs and BLAs is subject to an application user fee. For fiscal year 2016, the
	application user fee exceeds $2.3 million, and the sponsor of an approved NDA or
	BLA is also subject to annual product and establishment user fees, set at
	$114,450 per product and $585,200 per establishment. These fees are typically
	increased annually. Applications for orphan drug products are exempted from the
	NDA and BLA application user fee, unless the application includes an indication
	for other than a rare disease or condition, and may be exempted from product and
	establishment user fees under certain conditions.
</P>
<P ALIGN=JUSTIFY>
	An NDA or BLA must include all relevant data available from
	pertinent preclinical studies and clinical trials, including negative or
	ambiguous results as well as positive findings, together with detailed
	information relating to the product&#146;s chemistry, manufacturing, controls, and
	proposed labeling, among other things. Data comes from company-sponsored
	clinical trials intended to test the safety and effectiveness of a use of a
	product, and may also come from a number of alternative sources, including
	trials initiated by investigators. To support marketing approval, the data
	submitted must be sufficient in quality and quantity to establish the safety and
	effectiveness of the investigational new drug product to the satisfaction of the
	FDA.
</P>
<P ALIGN=JUSTIFY>
	Once an NDA or BLA has been submitted, the FDA&#146;s goal is to
	review the application within ten months after it accepts the application for
	filing, or, if the application relates to an unmet medical need in a serious or
	life-threatening indication, six months after the FDA accepts the application
	for filing. The review process is often significantly extended by the FDA&#146;s
	requests for additional information or clarification.
</P>
<P ALIGN=CENTER>
	13
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage24"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_14">
</A>
<P ALIGN=JUSTIFY>
	Before approving an NDA or BLA, the FDA typically will inspect
	the facility or facilities where the product is manufactured. The FDA will not
	approve an application unless it determines that the manufacturing processes and
	facilities are in compliance with cGMP requirements and adequate to assure
	consistent production of the product within required specifications.
	Additionally, before approving an NDA or BLA, the FDA will typically inspect one
	or more clinical sites to assure compliance with GCP.
</P>
<P ALIGN=JUSTIFY>
	The FDA is required to refer an NDA or BLA for a novel drug (in
	which no active ingredient has been approved in any other application) to an
	advisory committee or explain why such referral was not made. Typically, an
	advisory committee is a panel of independent experts, including clinicians and
	other scientific experts, that reviews, evaluates and provides a recommendation
	as to whether the application should be approved and under what conditions. The
	FDA is not bound by the recommendations of an advisory committee, but it
	considers such recommendations carefully when making decisions.
</P>
<P ALIGN=JUSTIFY>
<I>
	The FDA&#146;s Decision on an NDA or BLA
</I>
</P>
<P ALIGN=JUSTIFY>
	After the FDA evaluates the NDA or BLA and conducts inspections
	of manufacturing facilities where the product will be produced, the FDA will
	issue either an approval letter or a Complete Response Letter. An approval
	letter authorizes commercial marketing of the drug with specific prescribing
	information for specific indications. A Complete Response Letter indicates that
	the review cycle of the application is complete and the application is not ready
	for approval. In order to satisfy deficiencies identified in a Complete Response
	Letter, additional clinical data and/or an additional phase III clinical
	trial(s), and/or other significant, expensive and time-consuming requirements
	related to clinical trials, preclinical studies or manufacturing may be required
	for the product candidate. Even if such additional information is submitted, the
	FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for
	approval. The FDA could also approve the NDA or BLA with a risk evaluation and
	mitigation strategy, plan to mitigate risks, which could include medication
	guides, physician communication plans, or elements to assure safe use, such as
	restricted distribution methods, patient registries and other risk minimization
	tools. The FDA also may condition approval on, among other things, changes to
	proposed labeling, development of adequate controls and specifications, or a
	commitment to conduct one or more post-market studies or clinical trials. Such
	post-market testing may include phase IV clinical trials and surveillance to
	further assess and monitor the product&#146;s safety and effectiveness after
	commercialization. New government requirements, including those resulting from
	new legislation, may be established, or the FDA&#146;s policies may change, which
	could delay or prevent regulatory approval of our products under development.
</P>
<P ALIGN=JUSTIFY>
<I>
	Patent Term Restoration
</I>
</P>
<P ALIGN=JUSTIFY>
	Depending upon the timing, duration, and specifics of the FDA
	approval of the use of our product candidates, some of our U.S. patents may be
	eligible for limited patent term extension under the Drug Price Competition and
	Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman
	Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up
	to five years as compensation for patent term lost during product development
	and the FDA regulatory review process. However, patent term restoration cannot
	extend the remaining term of a patent beyond a total of 14 years from the
	product&#146;s approval date. The patent term restoration period is generally
	one-half the time between the effective date of an IND and the submission date
	of an NDA or BLA, plus the time between the submission date and the approval of
	that application. Only one patent applicable to an approved product is eligible
	for the extension and the application for the extension must be submitted prior
	to the expiration of the patent and within 60 days of the product&#146;s approval.
	The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and
	approves the application for any patent term extension or restoration. In the
	future, we may apply for restoration of patent term for one of our currently
	owned or licensed patents to add patent life beyond its current expiration date,
	depending on the expected length of the clinical trials and other factors
	involved in the filing of the relevant NDA or BLA.
</P>
<P ALIGN=JUSTIFY>
<I>
	Companion Diagnostics
</I>
</P>
<P ALIGN=JUSTIFY>
	In its August 6, 2014, guidance document entitled &#147;In Vitro
	Companion Diagnostic Devices,&#148; the FDA defines an IVD companion diagnostic
	device to be an in vitro diagnostic device that provides information that is
	essential for the safe and effective use of a corresponding therapeutic product.
	Use of an IVD companion diagnostic device is considered essential when its use
	is required in the labeling of a therapeutic product, for example, to select
	appropriate patients for a product or those who should not use
	the product, or to monitor patients to achieve safety or effectiveness. In most
	circumstances, the IVD companion diagnostic device should be approved or cleared
	by FDA under the device authorities of the FDCA contemporaneously with the
	therapeutic product&#146;s approval under section 505 of the FDCA for a drug or
	section 351 of the PHSA for a biological product. FDA expects the therapeutic
	product sponsor to address the need for an approved or cleared IVD companion
	diagnostic device in its therapeutic product development plan. The therapeutic
	product sponsor may develop its own IVD companion diagnostic device, partner
	with a diagnostic device sponsor to develop an IVD companion diagnostic device,
	or explore modifying an existing IVD diagnostic device to develop a new intended
	use. The FDA explains if a diagnostic device and a therapeutic device are
	studied together to support their respective approvals, both products can be
	studied in the same investigational study that meets both the requirements of
	the Investigational Device Exemption, or IDE, regulations and the IND
	regulations. Depending on the study plan and participants, a sponsor may seek to
	submit an IND alone, or both an IND and IDE.
<B>
</B>
</P>
<P ALIGN=CENTER>
	14
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage25"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_15">
</A>
<P ALIGN=JUSTIFY>
<B>
	Raw Materials, Manufacturing, and Supply
</B>
</P>
<P ALIGN=JUSTIFY>
	We have limited experience in manufacturing products for
	clinical or commercial purposes. We produce small quantities of our products in
	our laboratories for internal use. We believe that sources of raw materials
	pertinent to our laboratory operations and for manufacturing of our products by
	a CMO are generally available.
</P>
<P ALIGN=JUSTIFY>
	We have established a contract manufacturing relationship for
	the supply of SIRP&#945;Fc that we believe will provide sufficient material for early
	clinical trials. In addition, we are establishing the basis for long-term
	commercial production capabilities. However, there can be no assurance that our
	contract manufacturer will be successful at scaling up and producing our product
	with the required quality and in the quantities and timelines that we will need
	for clinical and/or commercial purposes.
</P>
<P ALIGN=JUSTIFY>
	We expect to similarly rely on contract manufacturing
	relationships for any products that we may further develop, or in-license or
	acquire in the future. However, there can be no assurance that we will be able
	to successfully contract with such manufacturers on terms acceptable to us, or
	at all.
</P>
<P ALIGN=JUSTIFY>
	Contract manufacturers are subject to ongoing periodic and
	unannounced inspections by the FDA, the U.S. Drug Enforcement Administration and
	corresponding state agencies to ensure strict compliance with cGMP and other
	state and federal regulations. We do not have control over third-party
	manufacturers&#146; compliance with these regulations and standards, other than
	through contractual obligations and periodic auditing. If they are deemed out of
	compliance with such regulations, approvals could be delayed, product recalls
	could result, inventory could be destroyed, production could be stopped and
	supplies could be delayed or otherwise disrupted.
</P>
<P ALIGN=JUSTIFY>
	If we need to change manufacturers after commercialization, the
	FDA and corresponding foreign regulatory agencies must approve these new
	manufacturers in advance, which will involve testing and additional inspections
	to ensure compliance with FDA regulations and standards and may require
	significant lead times and delay, and disruption of supply. Furthermore,
	switching manufacturers may be difficult because the number of potential
	manufacturers is limited. It may be difficult or impossible for us to find a
	replacement manufacturer quickly or on terms acceptable to us, or at all.
</P>
<P ALIGN=JUSTIFY>
<B>
	Property, Plant and Equipment
</B>
</P>
<P ALIGN=JUSTIFY>
	We currently operate from approximately 10,000 square feet of
	leased laboratory and office space at 96 Skyway Avenue, Toronto, Ontario,
	Canada, M9W 4Y9. Due to the growth of our staff and programs, we have secured a
	lease of approximately 22,000 square feet of laboratory and office space at 2488
	Dunwin Avenue, Mississauga, Ontario, L5L 1J9, and plan to relocate there in the
	second quarter of 2016. We perform research and development in our facility and
	use qualified vendors and collaborators to conduct research and development and
	manufacturing on our behalf. We incur capital expenditures mainly for laboratory
	equipment, office equipment, computer equipment and leaseholds in the operation
	of our business. As at December 31, 2015 the net carrying value of our property
	and equipment was $874,390.
</P>
<P ALIGN=CENTER>
	15
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage26"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_16">
</A>
<P ALIGN=JUSTIFY>
<B>
	Employees
</B>
</P>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, we had twenty-eight full-time
	employees including five senior management, twenty research and development
	staff and three finance and administrative staff. Twenty-six employees are
	located at our head office and lab facilities in Toronto, Ontario, Canada and
	two employees are located at in the United States.
</P>
<P ALIGN=JUSTIFY>
	We also use consultants and outside contractors to carry on
	many of our activities, including preclinical testing and validation,
	formulation, assay development, manufacturing, clinical and regulatory affairs,
	toxicology and clinical trials.
</P>
<P ALIGN=JUSTIFY>
<B>
	Legal Proceedings
</B>
</P>
<P ALIGN=JUSTIFY>
	To our knowledge, there have not been any legal or arbitration
	proceedings, including those relating to bankruptcy, receivership or similar
	proceedings, those involving any third party, and governmental proceedings
	pending or known to be contemplated, which may have, or have had in the recent
	past, significant effect our financial position or profitability.
</P>
<P ALIGN=JUSTIFY>
	Also, to our knowledge, there have been no material proceedings
	in which any director, any member of senior management, or any of our affiliates
	is either a party adverse to us or any of our subsidiaries or has a material
	interest adverse to us or any of our subsidiaries.
</P>
<P ALIGN=CENTER>
<B>
	GENERAL DEVELOPMENT OF THE BUSINESS &#150; 3 YEAR SUMMARY
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	Acquisition of Fluorinov Pharma Inc.
</B>
</P>
<P ALIGN=JUSTIFY>
	On January 26, 2016, we acquired all the outstanding shares of
	Fluorinov, a privately-held oncology company that has developed a proprietary
	medicinal chemistry platform using unique fluorine chemistry. The terms of the
	acquisition were an upfront payment of $10 million plus up to $35 million of
	additional future payments that are contingent on us achieving certain clinical
	and regulatory milestones with an existing Fluorinov compound. We will also have
	an obligation to pay royalty payments on future sales of such compounds. The
	upfront payment was subject to adjustment based on the net working capital of
	Fluorinov and other adjustments at the time of closing. At our discretion, up to
	50% of the future contingent payments can be satisfied through the issuance of
	common shares of Trillium provided that the aggregate number of common shares
	issuable under such payments will not exceed 1,558,447 common shares unless
	shareholder approval has first been obtained. In addition, any such future share
	issuance remains subject to final approval from our board of directors and
	receipt of any requisite approvals under the applicable rules of the Toronto
	Stock Exchange and the NASDAQ Stock Market. We have also committed to use
	commercially reasonable efforts to monetize Fluorinov&#146;s central nervous system,
	or CNS, assets and share 50% of the net proceeds with Fluorinov
	shareholders.
</P>
<P ALIGN=JUSTIFY>
<B>
	Acquisition of Trillium Privateco
</B>
</P>
<P ALIGN=JUSTIFY>
	During 2013, we refocused our product pipeline through the
	strategic acquisition of Trillium Privateco, a private biopharmaceutical company
	specializing in immune regulation and the development of cancer therapeutics,
	which included the SIRP&#945;Fc and CD200 preclinical cancer programs. On April 9,
	2013, we completed a merger with Trillium Privateco, to access its SIRP&#945;Fc
	immuno-oncology program. Prior to this merger, we were focused on regenerative
	stem cell technologies. Following the merger, in July 2013, we ceased all
	activities associated with our regenerative neurology programs and abandoned all
	related intellectual property filings.
</P>
<P ALIGN=JUSTIFY>
	As consideration for the merger, we paid $1,200,000 in cash and
	issued 92,639 common shares and 110,000 units. Each unit consisted of one common
	share and 30 common share purchase warrants, with each 30 common share purchase
	warrants allowing their holder to acquire one additional common share at an
	exercise price of $12.00 until March 15, 2018. Cash used in the investment of
	$647,996 was determined by subtracting cash acquired of $552,004 from cash consideration of $1,200,000. Post-closing, Trillium
	Privateco shareholders held approximately 16% of the issued and outstanding
	common shares, and Trillium Privateco became our wholly-owned subsidiary.
</P>
<P ALIGN=CENTER>
	16
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage27"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_17">
</A>
<P ALIGN=JUSTIFY>
	Trillium Privateco&#146;s SIRP&#945;Fc program originated from leading
	researchers in the field, including Drs. John Dick and Jean Wang of the UHN and
	Dr. Jayne Danska of HSC. Exclusive rights to SIRP&#945;Fc have been licensed from UHN
	and HSC pursuant to a license agreement amended and restated as of June 1, 2012.
	The licensed intellectual property relates to methods and compounds used in the
	modulation of SIRP&#945;-CD47 interaction for therapeutic cancer applications. The
	license agreement requires us to use commercially reasonable efforts to
	commercialize the licensed technology. The license agreement will terminate on a
	country-by-country basis, in countries where a valid claim exists, when the last
	valid claim expires in such country, or if no valid claim exists, when the last
	valid claim expires in the U.S.
</P>
<P ALIGN=JUSTIFY>
	Under the license agreement for SIRP&#945;Fc, we have future
	contingent milestones payable of $35,000 related to successful patent grants,
	$100,000, $200,000 and $300,000 on the first patient dosed in phase I, II and
	III trials respectively, and regulatory milestones on their first achievement
	totalling $5,000,000. The Company is required to pay 20% of any sublicensing
	revenues to the licensors on the first $50 million of sublicensing revenues, and
	pay 15% of any sublicensing revenues to the licensors after the first $50
	million of sublicensing revenue received.
</P>
<P ALIGN=JUSTIFY>
<B>
	Tigecycline License
</B>
</P>
<P ALIGN=JUSTIFY>
	On April 16, 2013, we signed an agreement with UHN to gain
	rights to intellectual property related to the use of tigecycline for the
	treatment of leukemia which included a UHN sponsored, open label phase I
	multicenter dose-escalation tigecycline trial in patients with relapsed or
	refractory AML. The initial consideration for the UHN license of $1,085,714 was
	satisfied by the issuance of 167,619 common shares and 1,600,000 common share
	purchase warrants, with each 30 warrants allowing their holder to acquire one
	additional common share at an exercise price of $12.00 until March 15, 2018.
	Additional consideration under the UHN license included an annual license
	maintenance fee and future development milestones. The fair value of the common
	shares issued was based on the closing price of our common shares of $6.00 on
	April 16, 2013 and $7.50 per unit based on the fair value of the common share
	and common share purchase warrant components as of the date of acquisition.
</P>
<P ALIGN=JUSTIFY>
	In August 2014, we completed an evaluation of this program with
	respect to its scientific merit, commercial potential, strength of intellectual
	property, as well as its overall fit with our current focus and expertise. We
	concluded that we should focus our business plan on expanding the SIRP&#945;Fc
	program, rather than continue development of tigecycline, and returned the
	licensed rights to UHN and recorded an impairment loss of $429,763 in the second
	quarter of 2014.
</P>
<P ALIGN=JUSTIFY>
<B>
	Agreements with Catalent Pharma Solutions
</B>
</P>
<P ALIGN=JUSTIFY>
	In connection with our development of SIRP&#945;Fc, we entered into
	two agreements on August 12, 2014 with Catalent pursuant to which we acquired
	the right to use two of Catalent&#146;s proprietary GPEx&#174; expression cell lines for
	the manufacture of SIRP&#945;Fc. One agreement relates to the manufacture of TTI-621
	and the other agreement relates to the manufacture of TTI-622. In consideration
	for the purchase of the expression cell lines, each agreement provides that we
	will pay Catalent up to US$875,000 upon reaching certain pre-marketing approval
	milestones and up to an additional US$28.8 million for reaching certain sales
	milestones. We will also pay Catalent an annual product maintenance fee until
	the first product derived from the expression cell lines receives a regulatory
	approval other than a pricing approval.
</P>
<P ALIGN=JUSTIFY>
	Under the agreements, we may use the two expression cell lines
	to secure such regulatory approvals and to develop, test, market and otherwise
	commercially exploit products originating from the cell lines. We may transfer
	the expression cell lines to a third party contract manufacturer who may utilize
	the cell lines in a similar fashion. We, or a third-party, cannot use or modify
	the cell lines, or any portions of the cell lines, to create a new cell line.
</P>
<P ALIGN=JUSTIFY>
	We plan to further develop the expression cell lines for use in
	our pre-IND toxicology and pharmacology studies, as well as to supply our phase
	I clinical trial. We will be required to indemnify Catalent for any costs
	Catalent incurs related to regulatory filings and related claims or proceedings,
	for the conduct of any clinical trials and for any manufacture, packaging, sale, promotion, distribution, use of
	or exposure to the expression cell lines or products. As a result of this risk,
	we are obligated to maintain several designated insurance policies throughout
	the term of the agreements.
</P>
<P ALIGN=CENTER>
	17
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage28"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_18">
</A>
<P ALIGN=JUSTIFY>
	We may terminate the agreements upon 90 days&#146; written notice to
	Catalent, upon their bankruptcy or upon their material breach and failure to
	cure within 30 days. Similarly, Catalent may terminate the agreements upon our
	bankruptcy or upon our material breach and failure to cure within 30 days. If
	our material breach is for nonpayment, however, we will only have 10 days to
	cure before Catalent may terminate the agreement.
</P>
<P ALIGN=JUSTIFY>
<B>
	Financings
</B>
</P>
<P ALIGN=JUSTIFY>
	See details of our financings completed over the past three
	years under &#147;Description of Share Capital&#148; below.
</P>
<P ALIGN=JUSTIFY>
<B>
	Capital Markets
</B>
</P>
<P ALIGN=JUSTIFY>
	We were listed on the TSX Venture Exchange, or TSXV, until
	April 22, 2014 when we migrated to the Toronto Stock Exchange, or TSX. We traded
	under the symbol &#147;SSS&#148; until June 6, 2014 when the symbol was changed to &#147;TR&#148;.
	We were listed on the OTCQX International under the symbol &#147;SCTPF&#148; from May 20,
	2013 until we began trading on the NASDAQ Capital Market under the symbol &#147;TRIL&#148;
	on December 19, 2014.
</P>
<P ALIGN=JUSTIFY>
<B>
	Capital Expenditures
</B>
</P>
<P ALIGN=JUSTIFY>
	Capital expenditures for 2015 were mainly for laboratory
	equipment, leasehold improvements for our new office and laboratory location,
	office equipment, and information technology equipment. Capital expenditures for
	2014 were mainly for laboratory equipment. Capital expenditures in the years
	ended December 31, 2015 and 2014 are set out in the following table.
</P>
<DIV>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="27%" COLSPAN=4>
<B>
	Year ended December 31,
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="12%">
<B>
	2014
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Capital expenditures
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;750,382&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	173,603
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P ALIGN=JUSTIFY>
<B>
	Trend Information
</B>
</P>
<P ALIGN=JUSTIFY>
	Historical patterns of expenditures cannot be taken as an
	indication of future expenditures. The amount and timing of expenditures and
	therefore liquidity and capital resources vary substantially from period to
	period depending on the number of research and development programs being
	undertaken at any one time, the stage of the development programs, the timing of
	significant expenditures for manufacturing, toxicology and pharmacology studies
	and clinical trials, and the availability of funding from investors and
	prospective commercial partners.
</P>
<P ALIGN=CENTER>
<B>
	RISK FACTORS
</B>
</P>
<P ALIGN=JUSTIFY>
<I>
	An investment in our common shares involves a high degree of
	risk and should be considered speculative. An investment in our common shares
	should only be undertaken by those persons who can afford the total loss of
	their investment. You should carefully consider the risks and uncertainties
	described below, as well as other information contained in this AIF. The risks
	and uncertainties below are not the only ones we face. Additional risks and
	uncertainties not presently known to us or that we believe to be immaterial may
	also adversely affect our business. If any of the following risks occur, our
	business, financial condition and results of operations could be seriously
	harmed and you could lose all or part of your investment. Further, if we fail to
	meet the expectations of the public
</I>
<I>
	market in any given period, the market price of our common
	shares could decline. We operate in a highly competitive environment that
	involves significant risks and uncertainties, some of which are outside of our
	control.
</I>
</P>
<P ALIGN=CENTER>
	18
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage29"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_19">
</A>
<P ALIGN=JUSTIFY>
<B>
	Risks Related to our Business and our Industry
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We expect to incur future losses and we may never become
	profitable.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have incurred losses of $14.7 million, $12.9 million and
	$4.3 million for the years ended December 31, 2015, 2014, and 2013,
	respectively, and expect to incur an operating loss for the year ending December
	31, 2016. We have an accumulated deficit since inception through December 31,
	2015 of $65.3 million. We believe that operating losses will continue as we are
	planning to incur significant costs associated with the clinical development of SIRP&#945;Fc. Our net losses have had and will continue to have an adverse effect on,
	among other things, our shareholders&#146; equity, total assets and working capital.
	We expect that losses will fluctuate from quarter to quarter and year to year,
	and that such fluctuations may be substantial. We cannot predict when we will
	become profitable, if at all.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We currently have no product revenue and will not be able
	to maintain our operations and research and development without additional
	funding.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	To date, we have generated no product revenue and cannot
	predict when and if we will generate product revenue. Our ability to generate
	product revenue and ultimately become profitable depends upon our ability, alone
	or with partners, to successfully develop our product candidates, obtain
	regulatory approval, and commercialize products, including any of our current
	product candidates, or other product candidates that we may develop, in-license
	or acquire in the future. We do not anticipate generating revenue from the sale
	of products for the foreseeable future. We expect our research and development
	expenses to increase in connection with our ongoing activities, particularly as
	we advance our product candidates through clinical trials.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our prospects depend on the success of our product
	candidates which are at early stages of development, and we may not generate
	revenue for several years, if at all, from these products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Given the early stage of our product development, we can make
	no assurance that our research and development programs will result in
	regulatory approval or commercially viable products. To achieve profitable
	operations, we, alone or with others, must successfully develop, gain regulatory
	approval, and market our future products. We currently have no products that
	have been approved by the FDA, HC, or any similar regulatory authority. To
	obtain regulatory approvals for our product candidates being developed and to
	achieve commercial success, clinical trials must demonstrate that the product
	candidates are safe for human use and that they demonstrate efficacy. While we
	have commenced a phase I trial for SIRP&#945;Fc, we have not yet completed a phase I
	clinical trial or subsequent required clinical trials.
</P>
<P ALIGN=JUSTIFY>
	Many product candidates never reach the stage of clinical
	testing and even those that do have only a small chance of successfully
	completing clinical development and gaining regulatory approval. Product
	candidates may fail for a number of reasons, including, but not limited to,
	being unsafe for human use or due to the failure to provide therapeutic benefits
	equal to or better than the standard of treatment at the time of testing.
	Unsatisfactory results obtained from a particular study relating to a research
	and development program may cause us or our collaborators to abandon commitments
	to that program. Positive results of early preclinical research may not be
	indicative of the results that will be obtained in later stages of preclinical
	or clinical research. Similarly, positive results from early-stage clinical
	trials may not be indicative of favorable outcomes in later-stage clinical
	trials. We can make no assurance that any future studies, if undertaken, will
	yield favorable results.
</P>
<P ALIGN=JUSTIFY>
	We recently acquired several preclinical and discovery research
	programs in our acquisition of Fluorinov, including certain assets relating to
	the treatment of central nervous system disorders. While we conducted extensive
	due diligence before making this acquisition, our assessment of the Fluorinov
	technologies may not be accurate. Therefore, our expectations about whether
	various clinical and regulatory milestones with an existing Fluorinov compound
	or development of a future program on the Fluorinov development platform will be
	achieved may not be borne out fully or at all. We have made a commitment to
	attempt to monetize the Fluorinov central nervous system assets and, if
	successful, to share the net proceeds
	with the Fluorinov vendors. As this is not a core competency of the Company, our
	efforts to monetize these assets or any other Fluorinov assets may not be
	successful. We can make no assurances that toxicology, or other preclinical,
	studies will yield results that will allow us to proceed with clinical trials in
	humans.
<BR>
<BR>
	The early stage of our product development makes it
	particularly uncertain whether any of our product development efforts will prove
	to be successful and meet applicable regulatory requirements, and whether any of
	our product candidates will receive the requisite regulatory approvals, be
	capable of being manufactured at a reasonable cost or be successfully marketed. If we are successful in developing
	our current and future product candidates into approved products, we will still
	experience many potential obstacles such as the need to develop or obtain
	manufacturing, marketing and distribution capabilities. If we are unable to
	successfully commercialize any of our products, our financial condition and
	results of operations may be materially and adversely affected.
</P>
<P ALIGN=CENTER>
	19
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage30"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_20">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	We rely and will continue to rely on third parties to
	plan, conduct and monitor our preclinical studies and clinical trials, and their
	failure to perform as required could cause substantial harm to our
	business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We rely and will continue to rely on third parties to conduct a
	significant portion of our preclinical and clinical development activities.
	Preclinical activities include in vivo studies providing access to specific
	disease models, pharmacology and toxicology studies, and assay development.
	Clinical development activities include trial design, regulatory submissions,
	clinical patient recruitment, clinical trial monitoring, clinical data
	management and analysis, safety monitoring and project management. If there is
	any dispute or disruption in our relationship with third parties, or if they are
	unable to provide quality services in a timely manner and at a feasible cost,
	our active development programs will face delays. Further, if any of these third
	parties fails to perform as we expect or if their work fails to meet regulatory
	requirements, our testing could be delayed, cancelled or rendered
	ineffective.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We rely on contract manufacturers over whom we have
	limited control. If we are subject to quality, cost or delivery issues with the
	preclinical and clinical grade materials supplied by contract manufacturers, our
	business operations could suffer significant harm.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have limited manufacturing experience and rely on contract
	manufacturing organizations, or CMOs, to manufacture our product candidates for
	larger preclinical studies and clinical trials. We produce small quantities of
	our product candidates at bench scale in our laboratory facilities for use in
	smaller preclinical studies. We rely on CMOs for manufacturing, filling,
	packaging, storing and shipping of drug product in compliance with cGMP
	regulations applicable to our products. The FDA ensures the quality of drug
	products by carefully monitoring drug manufacturers&#146; compliance with cGMP
	regulations. The cGMP regulations for drugs contain minimum requirements for the
	methods, facilities and controls used in manufacturing, processing and packing
	of a drug product.
</P>
<P ALIGN=JUSTIFY>
	We contracted with Catalent for the manufacture of the SIRP&#945;Fc
	protein to supply drug product for our phase I clinical trial. The manufacture
	of recombinant proteins uses well established processes including a protein
	expression system. Catalent is producing SIRP&#945;Fc using their proprietary GPEx&#174;
	expression system. We believe that Catalent has the capacity, the systems, and
	the experience to supply SIRP&#945;Fc for our phase I clinical trial and we may
	consider using Catalent for manufacturing for later clinical trials. However,
	since the Catalent manufacturing facility where SIRP&#945;Fc is being produced was
	only recently established, it has not been inspected by the FDA. Any
	manufacturing failures or delays or compliance issues could cause delays in the
	conduct of SIRP&#945;Fc preclinical studies and clinical trials.
</P>
<P ALIGN=JUSTIFY>
	There can be no assurances that CMOs will be able to meet our
	timetable and requirements. We have not contracted with alternate suppliers in
	the event Catalent is unable to scale up production, or if Catalent otherwise
	experiences any other significant problems. If we are unable to arrange for
	alternative third-party manufacturing sources on commercially reasonable terms
	or in a timely manner, we may be delayed in the development of our product
	candidates. Further, contract manufacturers must operate in compliance with cGMP
	and failure to do so could result in, among other things, the disruption of
	product supplies. Our dependence upon third parties for the manufacture of our
	products may adversely affect our profit margins and our ability to develop and
	deliver products on a timely and competitive basis.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If clinical trials of our product candidates fail to
	demonstrate safety and efficacy to the satisfaction of regulatory authorities or
	do not otherwise produce positive results, we would incur additional costs or
	experience delays in completing, or ultimately be unable to complete, the
	development and commercialization of our product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Before obtaining marketing approval from regulatory authorities
	for the sale of our product candidates, we must conduct preclinical studies in
	animals and extensive clinical trials in humans to demonstrate the safety and
	efficacy of the product candidates. Clinical testing is expensive and difficult
	to design and implement, can take many years to complete and has uncertain
	outcomes. The outcome of preclinical studies and early clinical trials may not
	predict the success of later clinical trials, and interim results of a clinical
	trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries
	have suffered significant setbacks in advanced clinical trials due to lack of
	efficacy or unacceptable safety profiles, notwithstanding promising results in
	earlier trials. We do not know whether the clinical trials we may conduct will
	demonstrate adequate efficacy and safety to result in regulatory approval to
	market any of our product candidates in any jurisdiction. A product candidate
	may fail for safety or efficacy reasons at any stage of the testing process. A
	major risk we face is the possibility that none of our product candidates under
	development will successfully gain market approval from the FDA or other
	regulatory authorities, resulting in us being unable to derive any commercial
	revenue from them after investing significant amounts of capital in multiple
	stages of preclinical and clinical testing.
</P>
<P ALIGN=CENTER>
	20
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage31"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_21">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we experience delays in clinical testing, we will be
	delayed in commercializing our product candidates, and our business may be
	substantially harmed.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We cannot predict whether any clinical trials will begin as
	planned, will need to be restructured, or will be completed on schedule, or at
	all. Our product development costs will increase if we experience delays in
	clinical testing. Significant clinical trial delays could shorten any periods
	during which we may have the exclusive right to commercialize our product
	candidates or allow our competitors to bring products to market before us, which
	would impair our ability to successfully commercialize our product candidates
	and may harm our financial condition, results of operations and prospects. The
	commencement and completion of clinical trials for our products may be delayed
	for a number of reasons, including delays related, but not limited, to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure by regulatory authorities to grant permission to
	proceed or placing the clinical trial on hold;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	patients failing to enroll or remain in our trials at the
	rate we expect;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	suspension or termination of clinical trials by
	regulators for many reasons, including concerns about patient safety or
	failure of our contract manufacturers to comply with cGMP requirements;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	any changes to our manufacturing process that may be
	necessary or desired;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	delays or failure to obtain clinical supply from contract
	manufacturers of our products necessary to conduct clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	product candidates demonstrating a lack of safety or
	efficacy during clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	patients choosing an alternative treatment for the
	indications for which we are developing any of our product candidates or
	participating in competing clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	patients failing to complete clinical trials due to
	dissatisfaction with the treatment, side effects or other reasons;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	reports of clinical testing on similar technologies and
	products raising safety and/or efficacy concerns;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	competing clinical trials and scheduling conflicts with
	participating clinicians;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	clinical investigators not performing our clinical trials
	on their anticipated schedule, dropping out of a trial, or employing
	methods not consistent with the clinical trial protocol, regulatory
	requirements or other third parties not performing data collection and
	analysis in a timely or accurate manner;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure of our contract research organizations, or CROs,
	to satisfy their contractual duties or meet expected deadlines;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	inspections of clinical trial sites by regulatory
	authorities or Institutional Review Boards, or IRBs, or ethics committees
	finding regulatory violations that require us to undertake corrective
	action, resulting in suspension or termination of one or more sites or the
	imposition of a clinical hold on the entire study;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	one or more IRBs or ethics committees rejecting,
	suspending or terminating the study at an investigational site, precluding
	enrollment of additional subjects, or withdrawing its approval of the
	trial; or
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure to reach agreement on acceptable terms with
	prospective clinical trial sites
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Our product development costs will increase if we experience
	delays in testing or approval or if we need to perform more or larger clinical
	trials than planned. Additionally, changes in regulatory requirements and
	policies may occur, and we may need to amend study protocols to reflect these
	changes. Amendments may require us to resubmit our study protocols to regulatory
	authorities or IRBs or ethics committees for re-examination, which may impact
	the cost, timing or successful completion of that trial. Delays or increased
	product development costs may have a material adverse effect on our business,
	financial condition and prospects.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we have difficulty enrolling patients in clinical
	trials, the completion of the trials may be delayed or cancelled.
</I>
</B>
</P>
<P ALIGN=CENTER>
	21
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage32"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_22">
</A>
<P ALIGN=JUSTIFY>
	As our product candidates advance from preclinical testing to
	clinical testing, and then through progressively larger and more complex
	clinical trials, we will need to enroll an increasing number of patients that
	meet our eligibility criteria. There is significant competition for recruiting
	cancer patients in clinical trials, and we may be unable to enroll the patients
	we need to complete clinical trials on a timely basis or at all. The factors
	that affect our ability to enroll patients are largely uncontrollable and
	include, but are not limited to, the following:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	size and nature of the patient population;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	eligibility and exclusion criteria for the
	trial;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	design of the study protocol;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	competition with other companies for clinical
	sites or patients;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the perceived risks and benefits of the product
	candidate under study;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the patient referral practices of physicians;
	and
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the number, availability, location and
	accessibility of clinical trial sites
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we are unable to successfully develop companion
	diagnostics for our therapeutic product candidates, or experience significant
	delays in doing so, we may not achieve marketing approval or realize the full
	commercial potential of our therapeutic product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We may develop companion diagnostics for our therapeutic
	product candidates. We expect that, at least in some cases, regulatory
	authorities may require the development and regulatory approval of a companion
	diagnostic as a condition to approving our therapeutic product candidates. We
	have limited experience and capabilities in developing or commercializing
	diagnostics and plan to rely in large part on third parties to perform these
	functions. We have not begun to develop companion diagnostics for any of our
	therapeutic product candidates.
</P>
<P ALIGN=JUSTIFY>
	Companion diagnostics are subject to regulation by the FDA, HC,
	and comparable foreign regulatory authorities as medical devices and may require
	separate regulatory approval or clearance prior to commercialization. If we, or
	any third parties that we engage to assist us, are unable to successfully
	develop companion diagnostics for our therapeutic product candidates, or
	experience delays in doing so, our business may be substantially harmed.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Regulatory approval processes are lengthy, expensive and
	inherently unpredictable. Our inability to obtain regulatory approval for our
	product candidates would substantially harm our business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our development and commercialization activities and product
	candidates are significantly regulated by a number of governmental entities,
	including the FDA, HC, and comparable authorities in other countries. Regulatory
	approvals are required prior to each clinical trial and we may fail to obtain
	the necessary approvals to commence or continue clinical testing. We must comply
	with regulations concerning the manufacture, testing, safety, effectiveness,
	labeling, documentation, advertising, and sale of products and product
	candidates and ultimately must obtain regulatory approval before we can
	commercialize a product candidate. The time required to obtain approval by such
	regulatory authorities is unpredictable but typically takes many years following
	the commencement of preclinical studies and clinical trials. Any analysis of
	data from clinical activities we perform is subject to confirmation and
	interpretation by regulatory authorities, which could delay, limit or prevent
	regulatory approval. Even if we believe results from our clinical trials are
	favorable to support the marketing of our product candidates, the FDA or other
	regulatory authorities may disagree. In addition, approval policies,
	regulations, or the type and amount of clinical data necessary to gain approval
	may change during the course of a product candidate&#146;s clinical development and
	may vary among jurisdictions. We have not obtained regulatory approval for any
	product candidate and it is possible that none of our existing product
	candidates or any future product candidates will ever obtain regulatory
	approval.
</P>
<P ALIGN=JUSTIFY>
	We could fail to receive regulatory approval for our product
	candidates for many reasons, including, but not limited to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	disagreement with the design or implementation of our
	clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure to demonstrate that a product candidate is safe
	and effective for its proposed indication;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure of clinical trials to meet the level of
	statistical significance required for approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure to demonstrate that a product candidate&#146;s
	clinical and other benefits outweigh its safety risks;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	disagreement with our interpretation of data from
	preclinical studies or clinical trials;
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	22
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage33"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_23">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the insufficiency of data collected from clinical trials
	of our product candidates to support the submission and filing of a BLA or
	other submission to obtain regulatory approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	deficiencies in the manufacturing processes or the
	failure of facilities of CMOs with whom we contract for clinical and
	commercial supplies to pass a pre-approval inspection; or
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	changes in the approval policies or regulations that
	render our preclinical and clinical data insufficient for approval.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	A regulatory authority may require more information, including
	additional preclinical or clinical data to support approval, which may delay or
	prevent approval and our commercialization plans, or we may decide to abandon
	the development program. If we were to obtain approval, regulatory authorities
	may approve any of our product candidates for fewer or more limited indications
	than we request, may grant approval contingent on the performance of costly
	post-marketing clinical trials, or may approve a product candidate with a label
	that does not include the labeling claims necessary or desirable for the
	successful commercialization of that product candidate. Moreover, depending on
	any safety issues associated with our product candidates that garner approval,
	the FDA may impose a risk evaluation and mitigation strategy, thereby imposing
	certain restrictions on the sale and marketability of such products.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We will require additional capital to finance our
	operations, which may not be available to us on acceptable terms, or at all. As
	a result, we may not complete the development and commercialization of our
	product candidates or develop new product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As a research and development company, our operations have
	consumed substantial amounts of cash since inception. We expect to spend
	substantial funds to continue the research, development and testing of our
	product candidates and to prepare to commercialize products subject to FDA
	approval in the U.S. and similar approvals in other jurisdictions. We will also
	require significant additional funds if we expand the scope of our current
	clinical plans for the SIRP&#945;Fc program or if we were to acquire any new assets
	and advance their development. Therefore, for the foreseeable future, we will
	have to fund all of our operations and development expenditures from cash on
	hand, equity or debt financings, through collaborations with other biotechnology
	or pharmaceutical companies or through financings from other sources. We expect
	that our existing cash at December 31, 2015 of $86,770,542 will enable us to
	fund our current operating plan requirements for at least the next twelve
	months. Additional financing will be required to meet our long term liquidity
	needs. If we do not succeed in raising additional funds on acceptable terms, we
	might not be able to complete planned preclinical studies and clinical trials or
	pursue and obtain approval of any product candidates from the FDA and other
	regulatory authorities. It is possible that future financing will not be
	available or, if available, may not be on favorable terms. The availability of
	financing will be affected by the achievement of our corporate goals, the
	results of scientific and clinical research, the ability to obtain regulatory
	approvals, the state of the capital markets generally and with particular
	reference to drug development companies, the status of strategic alliance
	agreements and other relevant commercial considerations. If adequate funding is
	not available, we may be required to delay, reduce or eliminate one or more of
	our product development programs, or obtain funds through corporate partners or
	others who may require us to relinquish significant rights to product candidates
	or obtain funds on less favorable terms than we would otherwise accept. To the
	extent that external sources of capital become limited or unavailable or
	available on onerous terms, our intangible assets and our ability to continue
	our clinical development plans may become impaired, and our assets, liabilities,
	business, financial condition and results of operations may be materially or
	adversely affected.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We face competition from other biotechnology and
	pharmaceutical companies and our financial condition and operations will suffer
	if we fail to effectively compete.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	The biotechnology and pharmaceutical industries are intensely
	competitive and subject to rapid and significant technological change. Our
	competitors include large, well-established pharmaceutical companies,
	biotechnology companies, and academic and research institutions developing
	cancer therapeutics for the same indications we are targeting and competitors
	with existing marketed therapies. Many other companies are developing or
	commercializing therapies to treat the same diseases or indications for which
	our product candidates may be useful. Although there are no approved therapies
	that specifically target the CD47 pathway, some competitors use therapeutic
	approaches that may compete directly with our product candidates. For example,
	SIRP&#945;Fc is in direct competition with CD47 blocking antibodies from Stanford
	University, Celgene Corporation, and Novimmune SA.
</P>
<P ALIGN=CENTER>
	23
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage34"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_24">
</A>
<P ALIGN=JUSTIFY>
	Many of our competitors have substantially greater financial,
	technical and human resources than we do and have significantly greater
	experience than us in conducting preclinical testing and human clinical trials
	of product candidates, scaling up manufacturing operations and obtaining
	regulatory approvals of products. Accordingly, our competitors may succeed in
	obtaining regulatory approval for products more rapidly than we do. Our ability
	to compete successfully will largely depend on:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the efficacy and safety profile of our product candidates
	relative to marketed products and other product candidates in development;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to develop and maintain a competitive
	position in the product categories and technologies on which we focus;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the time it takes for our product candidates to complete
	clinical development and receive marketing approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to obtain required regulatory approvals;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to commercialize any of our product
	candidates that receive regulatory approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to establish, maintain and protect
	intellectual property rights related to our product candidates; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	acceptance of any of our product candidates that receive
	regulatory approval by physicians and other healthcare providers and
	payers.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Competitors have developed and may develop technologies that
	could be the basis for products that challenge the differentiated nature and
	potential for best-in-class product development programs and discovery research
	capabilities of Fluorinov. Some of those products may have an entirely different
	approach or means of accomplishing the desired therapeutic effect than our
	products and may be more effective or less costly than our products. The success
	of our competitors and their products and technologies relative to our
	technological capabilities and competitiveness could have a material adverse
	effect on the future pre-clinical and clinical trials of our products, including
	our ability to obtain the necessary regulatory approvals for the conduct of such
	trials. This may further negatively impact our ability to generate future
	product development programs with improved pharmacological properties using
	Fluorinov technology.
</P>
<P ALIGN=JUSTIFY>
	If we are not able to compete effectively against our current
	and future competitors, our business will not grow and our financial condition
	and operations will substantially suffer.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We heavily rely on the capabilities and experience of our
	key executives and scientists and the loss of any of them could affect our
	ability to develop our products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	The loss of Dr. Niclas Stiernholm, our President and Chief
	Executive Officer, or other key members of our staff, including Dr. Robert Uger,
	our Chief Scientific Officer, Dr. Eric Sievers, our Chief Medical Officer, James
	Parsons, our Chief Financial Officer, Dr. Penka Petrova, our Chief Development
	Officer, or Dr. Malik Slassi, our Senior Vice President, Discovery Research
	could harm us. We have employment agreements with Drs. Stiernholm, Uger,
	Sievers, Petrova and Slassi and Mr. Parsons, although such employment agreements
	do not guarantee their retention. We also depend on our scientific and clinical
	collaborators and advisors, all of whom have outside commitments that may limit
	their availability to us. In addition, we believe that our future success will
	depend in large part upon our ability to attract and retain highly skilled
	scientific, managerial, medical, clinical and regulatory personnel, particularly
	as we expand our activities and seek regulatory approvals for clinical trials.
	We enter into agreements with our scientific and clinical collaborators and
	advisors, key opinion leaders and academic partners in the ordinary course of
	our business. We also enter into agreements with physicians and institutions who
	will recruit patients into our clinical trials on our behalf in the ordinary
	course of our business. Notwithstanding these arrangements, we face significant
	competition for these types of personnel from other companies, research and
	academic institutions, government entities and other organizations. We cannot
	predict our success in hiring or retaining the personnel we require for
	continued growth. The loss of the services of any of our executive officers or
	other key personnel could potentially harm our business, operating results or
	financial condition.
</P>
<P ALIGN=CENTER>
	24
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage35"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_25">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our employees may engage in misconduct or other improper
	activities, including noncompliance with regulatory standards and requirements,
	which could have a material adverse effect on our business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are exposed to the risk of employee fraud or other
	misconduct. Misconduct by employees could include failures to comply with FDA
	regulations, provide accurate information to the FDA, comply with manufacturing
	standards we have established, comply with federal and state health-care fraud
	and abuse laws and regulations, report financial information or data accurately
	or disclose unauthorized activities to us. In particular, sales, marketing and
	business arrangements in the healthcare industry are subject to extensive laws
	and regulations intended to prevent fraud, kickbacks, self-dealing, and other
	abusive practices. These laws and regulations may restrict or prohibit a wide
	range of pricing, discounting, marketing and promotion, sales commission,
	customer incentive programs and other business arrangements. Employee misconduct
	could also involve the improper use of information obtained in the course of
	clinical trials, which could result in regulatory sanctions and serious harm to
	our reputation. If any such actions are instituted against us, and we are not
	successful in defending ourselves or asserting our rights, those actions could
	have a substantial impact on our business and results of operations, including
	the imposition of substantial fines or other sanctions.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We may expand our business through the acquisition of
	companies or businesses or by entering into collaborations or by in-licensing
	product candidates, each of which could disrupt our business and harm our
	financial condition.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have in the past and may in the future seek to expand our
	pipeline and capabilities by acquiring one or more companies or businesses,
	entering into collaborations, or in-licensing one or more product candidates.
	For example, in January 2016, we acquired Fluorinov, a small molecule medicinal
	chemistry company with preclinical oncology assets and a potential discovery
	platform. In April 2013, we in-licensed tigecycline which was subsequently
	returned to the UHN in 2014. Acquisitions, collaborations and in-licenses
	involve numerous risks, including, but not limited to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	substantial cash expenditures;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	technology development risks;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	potentially dilutive issuances of equity securities;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	incurrence of debt and contingent liabilities, some of
	which may be difficult or impossible to identify at the time of
	acquisition;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	difficulties in assimilating the operations of the
	acquired companies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	potential disputes regarding contingent consideration;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	diverting our management&#146;s attention away from other
	business concerns;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	entering markets in which we have limited or no direct
	experience; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	potential loss of our key employees or key employees of
	the acquired companies or businesses.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	We have experience in making acquisitions, entering
	collaborations, and in-licensing product candidates, however, we cannot provide
	assurance that any acquisition, collaboration or in-license will result in
	short-term or long-term benefits to us. We may incorrectly judge the value or
	worth of an acquired company or business or in-licensed product candidate. In
	addition, our future success would depend in part on our ability to manage the
	rapid growth associated with some of these acquisitions, collaborations and
	in-licenses. We cannot provide assurance that we would be able to successfully
	combine our business with that of acquired businesses, manage a collaboration or
	integrate in-licensed product candidates. Furthermore, the development or
	expansion of our business may require a substantial capital investment by
	us.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Negative results from clinical trials or studies of
	others and adverse safety events involving the targets of our products may have
	an adverse impact on our future commercialization efforts.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	From time to time, studies or clinical trials on various
	aspects of biopharmaceutical products are conducted by academic researchers,
	competitors or others. The results of these studies or trials, when published,
	may have a significant effect on the market for the biopharmaceutical product
	that is the subject of the study. The publication of negative results of studies
	or clinical trials or adverse safety events related to our product candidates,
	or the therapeutic areas in which our product candidates compete, could
	adversely affect our share price and our ability to finance future development
	of our product candidates, and our business and financial results could be
	materially and adversely affected.
</P>
<P ALIGN=CENTER>
	25
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage36"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_26">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	We face the risk of product liability claims, which could
	exceed our insurance coverage and produce recalls, each of which could deplete
	our cash resources.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are exposed to the risk of product liability claims alleging
	that use of our product candidates caused an injury or harm. These claims can
	arise at any point in the development, testing, manufacture, marketing or sale
	of our product candidates and may be made directly by patients involved in
	clinical trials of our product candidates, by consumers or healthcare providers
	or by individuals, organizations or companies selling our products. Product
	liability claims can be expensive to defend, even if the product or product
	candidate did not actually cause the alleged injury or harm.
</P>
<P ALIGN=JUSTIFY>
	Insurance covering product liability claims becomes
	increasingly expensive as a product candidate moves through the development
	pipeline to commercialization. We currently maintain clinical trial liability
	insurance coverage of $10 million. However, there can be no assurance that such
	insurance coverage is or will continue to be adequate or available to us at a
	cost acceptable to us or at all. We may choose or find it necessary under our
	collaborative agreements to increase our insurance coverage in the future. We
	may not be able to secure greater or broader product liability insurance
	coverage on acceptable terms or at reasonable costs when needed. Any liability
	for damages resulting from a product liability claim could exceed the amount of
	our coverage, require us to pay a substantial monetary award from our own cash
	resources and have a material adverse effect on our business, financial
	condition and results of operations. Moreover, a product recall, if required,
	could generate substantial negative publicity about our products and business,
	inhibit or prevent commercialization of other products and product candidates or
	negatively impact existing or future collaborations.
</P>
<P ALIGN=JUSTIFY>
	In addition, some of our licensing and other agreements with
	third parties require or might require us to maintain product liability
	insurance. If we cannot maintain acceptable amounts of coverage on commercially
	reasonable terms in accordance with the terms set forth in these agreements, the
	corresponding agreements would be subject to termination, which could have a
	material adverse impact on our operations.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We may not achieve our publicly announced milestones
	according to schedule, or at all.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	From time to time, we may announce the timing of certain events
	we expect to occur, such as the anticipated timing of results from our clinical
	trials. These statements are forward-looking and are based on the best estimates
	of management at the time relating to the occurrence of such events. However,
	the actual timing of such events may differ from what has been publicly
	disclosed. The timing of events such as initiation or completion of a clinical
	trial, filing of an application to obtain regulatory approval, or announcement
	of additional clinical trials for a product candidate may ultimately vary from
	what is publicly disclosed. These variations in timing may occur as a result of
	different events, including the nature of the results obtained during a clinical
	trial or during a research phase, problems with a CMO or a CRO or any other
	event having the effect of delaying the publicly announced timeline. We
	undertake no obligation to update or revise any forward-looking information,
	whether as a result of new information, future events or otherwise, except as
	otherwise required by law. Any variation in the timing of previously announced
	milestones could have a material adverse effect on our business plan, financial
	condition or operating results and the trading price of common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We are exposed to the financial risk related to the
	fluctuation of foreign exchange rates and the degrees of volatility of those
	rates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We may be adversely affected by foreign currency fluctuations.
	To date, we have been primarily funded through issuances of equity, proceeds
	from the exercise of warrants and stock options and from interest income on
	funds available for investment, which are all denominated both in Canadian and
	U.S. dollars. Also, a growing portion of our expenditures are in U.S. dollars,
	and we are therefore subject to foreign currency fluctuations which may, from
	time to time, impact our financial position and results of operations.
</P>
<P ALIGN=JUSTIFY>
<B>
	Risks Related to Intellectual Property
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we are unable to adequately protect and enforce our
	intellectual property, our competitors may take advantage of our development
	efforts or acquired technology and compromise our prospects of marketing and
	selling our key products.
</I>
</B>
</P>
<P ALIGN=CENTER>
	26
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage37"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_27">
</A>
<P ALIGN=JUSTIFY>
	We control two patent families relating to SIRP&#945;. One family
	relates to the use of SIRP&#945; to treat cancer. The other family relates our drug
	as a composition of matter, SIRP&#945;Fc.
</P>
<P ALIGN=JUSTIFY>
	More recently, we acquired the patent portfolio of Fluorinov,
	which embraces patent filings that cover eleven different inventions. With the
	exception of one process scheme, these patent filings each claim a family of
	small molecule drugs as compositions of matter, together with claims for their
	production and their medical uses. These drugs target cancer for the most part,
	and some related medical end-uses.
</P>
<P ALIGN=JUSTIFY>
	Our success will depend in part upon our ability to protect our
	intellectual property and proprietary technologies and upon the nature and scope
	of the intellectual property protection we receive. For example, some of our
	patent portfolio covers primarily methods of medical use but not compositions of
	matter. The ability to compete effectively and to achieve partnerships will
	depend on our ability to develop and maintain proprietary aspects of our
	technology and to operate without infringing on the proprietary rights of
	others. The presence of such proprietary rights of others could severely limit
	our ability to develop and commercialize our products, to conduct our existing
	research and could require financial resources to defend litigation, which may
	be in excess of our ability to raise such funds. There is no assurance that our
	pending patent applications or those that we intend to acquire will be approved
	in a form that will be sufficient to protect our proprietary technology and gain
	or keep any competitive advantage that we may have.
</P>
<P ALIGN=JUSTIFY>
	The patent positions of pharmaceutical companies can be highly
	uncertain and involve complex legal, scientific and factual questions for which
	important legal principles remain unresolved. Patents issued to us or our
	respective licensors may be challenged, invalidated or circumvented. To the
	extent our intellectual property, including licensed intellectual property,
	offers inadequate protection, or is found to be invalid or unenforceable, we are
	exposed to a greater risk of direct competition. If our intellectual property
	does not provide adequate protection against our competitors&#146; products, our
	competitive position could be adversely affected, as could our business,
	financial condition and results of operations. Both the patent application
	process and the process of managing patent disputes can be time consuming and
	expensive, and the laws of some foreign countries may not protect our
	intellectual property rights to the same extent as do the laws of Canada and the
	United States.
</P>
<P ALIGN=JUSTIFY>
	We will be able to protect our intellectual property from
	unauthorized use by third parties only to the extent that our proprietary
	technologies, key products, and any future products are covered by valid and
	enforceable intellectual property rights including patents or are effectively
	maintained as trade secrets, and provided we have the funds to enforce our
	rights, if necessary.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we lose our licenses from third-party owners we may be
	unable to continue a substantial part of our business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are party to licenses that give us rights to intellectual
	property that is necessary or useful for a substantial part of our business.
	Pursuant to our exclusive license agreement with UHN and the HSC, under which we
	license certain patent rights for our key products and their uses, we are
	required to use commercially reasonable efforts to commercialize products based
	on the licensed rights and pay certain royalties and sublicensing revenue to UHN
	and HSC. These licenses require that we pay development milestone payments,
	regulatory milestone payments, royalties on net sales, and sublicensing
	revenues, as well as annual maintenance fees.
</P>
<P ALIGN=JUSTIFY>
	We have also entered into agreements allowing us to manufacture
	SIRP&#945;Fc using Catalent&#146;s proprietary GPEx&#174; expression system. The consideration
	includes payments at the time we successfully reach a series of development and
	sales milestones. We may also enter into licenses in the future to access
	additional third-party intellectual property.
</P>
<P ALIGN=JUSTIFY>
	If we fail to pay annual maintenance fees, development and
	sales milestones, or it is determined that we did not use commercially
	reasonable efforts to commercialize licensed products, we could lose our
	licenses which could have a material adverse effect on our business and
	financial condition.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We may require additional third-party licenses to
	effectively develop and manufacture our key products and are currently unable to
	predict the availability or cost of such licenses.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	A substantial number of patents have already been issued to
	other biotechnology and pharmaceutical companies. To the extent that valid
	third-party patent rights cover our products or services, we or our strategic
	collaborators would be required to seek licenses from the holders of these patents
	in order to manufacture, use or sell these products and services, and payments
	under them would reduce our profits from these products and services. We are
	currently unable to predict the extent to which we may wish or be required to
	acquire rights under such patents, the availability and cost of acquiring such
	rights, and whether a license to such patents will be available on acceptable
	terms or at all. There may be patents in the U.S. or in foreign countries or
	patents issued in the future that are unavailable to license on acceptable
	terms. Our inability to obtain such licenses may hinder or eliminate our ability
	to manufacture and market our products.
</P>
<P ALIGN=CENTER>
	27
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage38"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_28">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Changes in patent law and its interpretation could
	diminish the value of patents in general, thereby impairing our ability to
	protect our product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As is the case with other biotechnology and pharmaceutical
	companies, our success is heavily dependent on intellectual property rights,
	particularly patents. Obtaining and enforcing patents in the biopharmaceutical
	industry involves technological and legal complexity, and obtaining and
	enforcing biopharmaceutical patents is costly, time-consuming and inherently
	uncertain. The U.S. Supreme Court has ruled on several patent cases in recent
	years, either narrowing the scope of patent protection available in certain
	circumstances or weakening the rights of patent owners in certain situations. In
	addition to increasing uncertainty with regard to our and our licensors&#146; or
	collaborators&#146; ability to obtain patents in the future, this combination of
	events has created uncertainty with respect to the value of patents, once
	obtained. Depending on decisions by the U.S. Congress, the federal courts, and
	the U.S. Patent and Trademark Office, or USPTO, the laws and regulations
	governing patents could change in unpredictable ways that would weaken our and
	our licensors&#146; or collaborators&#146; ability to obtain new patents or to enforce
	existing patents and patents we and our licensors or collaborators may obtain in
	the future.
</P>
<P ALIGN=JUSTIFY>
	Recent patent reform legislation could increase the
	uncertainties and costs surrounding the prosecution of our and our licensors&#146; or
	collaborators&#146; patent applications and the enforcement or defense of our or our
	licensors&#146; or collaborators&#146; issued patents. On September 16, 2011, the
	Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law.
	The Leahy-Smith Act includes a number of significant changes to U.S. patent law.
	These include provisions that affect the way patent applications are prosecuted
	and may also affect patent litigation. The USPTO recently developed new
	regulations and procedures to govern administration of the Leahy-Smith Act, and
	many of the substantive changes to patent law associated with the Leahy-Smith
	Act, and in particular, the first to file provisions, only became effective on
	March 16, 2013. Accordingly, it is not clear what, if any, impact the
	Leahy-Smith Act will have on the operation of our business. However, the
	Leahy-Smith Act and its implementation could increase the uncertainties and
	costs surrounding the prosecution of our or our licensors&#146; or collaborators&#146;
	patent applications and the enforcement or defense of our or our licensors&#146; or
	collaborators&#146; issued patents, all of which could have a material adverse effect
	on our business and financial condition.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Litigation regarding patents, patent applications, and
	other proprietary rights may be expensive, time consuming and cause delays in
	the development and manufacturing of our key products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our success will depend in part on our ability to operate
	without infringing the proprietary rights of third parties. The pharmaceutical
	industry is characterized by extensive patent litigation. Other parties may
	have, or obtain in the future, patents and allege that the use of our
	technologies infringes these patent claims or that we are employing their
	proprietary technology without authorization.
</P>
<P ALIGN=JUSTIFY>
	In addition, third parties may challenge or infringe upon our
	existing or future patents. Proceedings involving our patents or patent
	applications or those of others could result in adverse decisions regarding:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the patentability of our inventions relating to our key
	products; and/or
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the enforceability, validity, or scope of protection
	offered by our patents relating to our key products.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	If we are unable to avoid infringing the patent rights of
	others, we may be required to seek a license, defend an infringement action, or
	challenge the validity of the patents in court. Regardless of the outcome,
	patent litigation is costly and time consuming. In some cases, we may not have
	sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a
	license, develop or obtain non-infringing technology, fail to defend an
	infringement action successfully or have infringed patents declared invalid, we
	may:
</P>
<P ALIGN=CENTER>
	28
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage39"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_29">
</A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	incur substantial monetary damages;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	encounter significant delays in bringing our key products
	to market; and/or
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	be precluded from participating in the manufacture, use
	or sale of our key products or methods of treatment requiring licenses.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Even if we are successful in these proceedings, we may incur
	substantial costs and divert management time and attention in pursuing these
	proceedings, which could have a material adverse effect on us.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our reliance on third parties requires us to share our
	trade secrets, which increases the possibility that a competitor will discover
	them.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Because we rely on third parties to develop our products, we
	must share trade secrets with them. We seek to protect our proprietary
	technology in part by entering into confidentiality agreements and, if
	applicable, material transfer agreements, collaborative research agreements,
	consulting agreements or other similar agreements with our collaborators,
	advisors, employees and consultants prior to beginning research or disclosing
	proprietary information. These agreements typically restrict the ability of our
	collaborators, advisors, employees and consultants to publish data potentially
	relating to our trade secrets. Our academic collaborators typically have rights
	to publish data, provided that we are notified in advance and may delay
	publication for a specified time in order to secure our intellectual property
	rights arising from the collaboration. In other cases, publication rights are
	controlled exclusively by us, although in some cases we may share these rights
	with other parties. We also conduct joint research and development programs
	which may require us to share trade secrets under the terms of research and
	development collaboration or similar agreements. Despite our efforts to protect
	our trade secrets, our competitors may discover our trade secrets, either
	through breach of these agreements, independent development or publication of
	information including our trade secrets in cases where we do not have
	proprietary or otherwise protected rights at the time of publication. A
	competitor&#146;s discovery of our trade secrets may impair our competitive position
	and could have a material adverse effect on our business and financial
	condition.
</P>
<P ALIGN=JUSTIFY>
<B>
	Risks Related to Our Common Shares
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our common share price has been volatile in recent years,
	and may continue to be volatile.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	The market prices for securities of biopharmaceutical
	companies, including ours, have historically been volatile. In the year ended
	December 31, 2015, our common shares traded on the TSX, at a high of $37.27 and
	a low of $10.50 per share. In the year ended December 31, 2014, on the TSXV/TSX
	our common shares traded at a high of $22.20 and a low of $6.30 per share. A
	number of factors could influence the volatility in the trading price of our
	common shares, including changes in the economy or in the financial markets,
	industry related developments, the results of product development and
	commercialization, changes in government regulations, and developments
	concerning proprietary rights, litigation and cash flow. Our quarterly losses
	may vary because of the timing of costs for manufacturing, preclinical studies
	and clinical trials. Also, the reporting of adverse safety events involving our
	products and public rumors about such events could cause our share price to
	decline or experience periods of volatility. Each of these factors could lead to
	increased volatility in the market price of our common shares. In addition,
	changes in the market prices of the securities of our competitors may also lead
	to fluctuations in the trading price of our common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We have never paid dividends and do not expect to do so
	in the foreseeable future.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have not declared or paid any cash dividends on our common
	or preferred shares to date. The payment of dividends in the future will be
	dependent on our earnings and financial condition in addition to such other
	factors as our board of directors considers appropriate. Unless and until we pay
	dividends, shareholders may not receive a return on their shares. There is no
	present intention by our board of directors to pay dividends on our shares.
</P>
<P ALIGN=CENTER>
	29
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage40"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_30">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Future sales or issuances of equity securities and the
	conversion of outstanding securities to common shares could decrease the value
	of the common shares, dilute investors&#146; voting power, and reduce our earnings
	per share.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We may sell additional equity securities in future offerings,
	including through the sale of securities convertible into equity securities, to
	finance operations, acquisitions or projects, and issue additional common shares
	if outstanding warrants or stock options are exercised, or preferred shares are
	converted to common shares, which may result in dilution. See &#147;Description of
	Share Capital&#148;, below, for details of our outstanding securities convertible
	into common shares. We filed a base shelf prospectus with securities commissions
	in Canada and a Form F-10 registration statement with the U.S. Securities and
	Exchange Commission (&#147;SEC&#148;) on June 4, 2015, that provides that we may sell
	under the prospectus from time to time over the following 25 months up to U.S.
	$100 million, in one or more offerings, of common shares, First Preferred
	shares, warrants to purchase common shares, or units comprising a combination of
	common shares, First Preferred shares and/or warrants. Subject to receipt of any
	required regulatory approvals, subscribers of the December 2013 private
	placement who purchased a minimum of 10% of the securities sold under the
	offering received rights to purchase our securities in future financings to
	enable each such shareholder to maintain their percentage holding in our common
	shares for so long as the subscriber holds at least 10% of the outstanding
	common shares on a fully-diluted basis. Shareholders who do not have this future
	financing participation right may be disadvantaged in participating in such
	financings.
</P>
<P ALIGN=JUSTIFY>
	Our board of directors has the authority to authorize certain
	offers and sales of additional securities without the vote of, or prior notice
	to, shareholders. Based on the need for additional capital to fund expected
	expenditures and growth, it is likely that we will issue additional securities
	to provide such capital. Such additional issuances may involve the issuance of a
	significant number of common shares at prices less than the current market price
	for our common shares.
</P>
<P ALIGN=JUSTIFY>
	Sales of substantial amounts of our securities, or the
	availability of such securities for sale, as well as the issuance of substantial
	amounts of our common shares upon conversion of outstanding convertible equity
	securities, could adversely affect the prevailing market prices for our
	securities and dilute investors&#146; earnings per share. A decline in the market
	prices of our securities could impair our ability to raise additional capital
	through the sale of securities should we desire to do so.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We are likely a &#147;passive foreign investment company,&#148;
	which may have adverse U.S. federal income tax consequences for U.S.
	shareholders.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	U.S. investors should be aware that we believe we were
	classified as a passive foreign investment company, or PFIC, during the tax
	years ended December 31, 2015 and 2014, and based on current business plans and
	financial expectations, we expect that we will be a PFIC for the current tax
	year and may be a PFIC in future tax years. If we are a PFIC for any year during
	a U.S. shareholder&#146;s holding period of our common shares, then such U.S.
	shareholder generally will be required to treat any gain realized upon a
	disposition of our common shares, or any so-called &#147;excess distribution&#148;
	received on our common shares, as ordinary income, and to pay an interest charge
	on a portion of such gain or distributions, unless the shareholder makes a
	timely and effective &#147;qualified electing fund&#148; election, or QEF Election, or a
	&#147;mark-to-market&#148; election with respect to our shares. A U.S. shareholder who
	makes a QEF Election generally must report on a current basis its share of our
	net capital gain and ordinary earnings for any year in which we are a PFIC,
	whether or not we distribute any amounts to our shareholders. A U.S. shareholder
	who makes the mark-to-market election generally must include as ordinary income
	each year the excess of the fair market value of the common shares over the
	shareholder&#146;s adjusted tax basis therein. Each U.S. shareholder should consult
	its own tax advisors regarding the PFIC rules and the U.S. federal income tax
	consequences of the acquisition, ownership and disposition of our common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	It may be difficult for non-Canadian investors to obtain
	and enforce judgments against us because of our Canadian incorporation and
	presence.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are a corporation existing under the laws of the Province of
	Ontario, Canada. Several of our directors and officers, and several of the
	experts are residents of Canada, and all or a substantial portion of their
	assets, and a substantial portion of our assets, are located outside the United
	States. Consequently, although we have appointed an agent for service of process
	in the United States, it may be difficult for holders of our securities who
	reside in the United States to effect service within the United States upon
	those directors and officers, and the experts who are not residents of the
	United States. It may also be difficult for holders of our securities who reside
	in the United States to realize in the United States upon judgments of courts of
	the United States predicated upon our civil liability and the civil liability of
	our directors, officers and experts under the United States federal securities
	laws. Investors should not assume that Canadian courts (i) would enforce
	judgments of United States courts obtained in actions against us or such
	directors, officers or experts predicated upon the civil liability provisions of
	the United States federal securities laws or the securities or &#147;blue sky&#148; laws
	of any state or jurisdiction of the United States or (ii) would enforce, in
	original actions, liabilities against us or such directors, officers or experts
	predicated upon the United States federal securities laws or any securities or
	&#147;blue sky&#148; laws of any state or jurisdiction of the United States. In addition,
	the protections afforded by Canadian securities laws may not be available to
	investors in the United States.
</P>
<P ALIGN=CENTER>
	30
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage41"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_31">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	If there are substantial sales of our common shares, the
	market price of our common shares could decline.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Sales of substantial numbers of our common shares could cause a
	decline in the market price of our common shares. Any sales by existing
	shareholders or holders who exercise their warrants or stock options may have an
	adverse effect on our ability to raise capital and may adversely affect the
	market price of our common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We are an &#147;emerging growth company,&#148; and we cannot be
	certain if the reduced reporting requirements applicable to emerging growth
	companies will make our common shares less attractive to investors.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are an &#147;emerging growth company,&#148; as defined in the JOBS
	Act. For as long as we continue to be an emerging growth company, we may take
	advantage of exemptions from various reporting requirements that are applicable
	to other public companies that are not emerging growth companies, including not
	being required to comply with the auditor attestation requirements of Section
	404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
	executive compensation in our periodic reports and exemptions from the
	requirements of holding a nonbinding advisory vote on executive compensation and
	shareholder approval of any golden parachute payments not previously approved.
	We could be an emerging growth company for up to five years, although
	circumstances could cause us to lose that status earlier. We cannot predict if
	investors will find our common shares less attractive because we may rely on
	these exemptions. If some investors find our common shares less attractive as a
	result, there may be a less active trading market for our common shares and our
	share price may be more volatile.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Any failure to maintain an effective system of internal
	controls may result in material misstatements of our consolidated financial
	statements or cause us to fail to meet our reporting obligations or fail to
	prevent fraud; and in that case, our shareholders could lose confidence in our
	financial reporting, which would harm our business and could negatively impact
	the price of our common shares.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Effective internal controls are necessary for us to provide
	reliable financial reports and prevent fraud. If we fail to maintain an
	effective system of internal controls, we might not be able to report our
	financial results accurately or prevent fraud; and in that case, our
	shareholders could lose confidence in our financial reporting, which would harm
	our business and could negatively impact the price of our common shares. While
	we believe that we have sufficient personnel and review procedures to allow us
	maintain an effective system of internal controls, we cannot provide assurance
	that we will not experience potential material weaknesses in our internal
	control. Even if we conclude that our internal control over financial reporting
	provides reasonable assurance regarding the reliability of financial reporting
	and the preparation of consolidated financial statements for external purposes
	in accordance with International Financial Reporting Standards, as issued by the
	International Accounting Standards Board, because of its inherent limitations,
	internal control over financial reporting may not prevent or detect fraud or
	misstatements. Failure to implement required new or improved controls, or
	difficulties encountered in their implementation, could harm our results of
	operations or cause us to fail to meet our future reporting obligations.
</P>
<P ALIGN=JUSTIFY>
	If we fail to timely achieve and maintain the adequacy of our
	internal control over financial reporting, we may not be able to produce
	reliable financial reports or help prevent fraud. Our failure to achieve and
	maintain effective internal control over financial reporting could prevent us
	from complying with our reporting obligations on a timely basis, which could
	result in the loss of investor confidence in the reliability of our consolidated
	financial statements, harm our business and negatively impact the trading price
	of our common shares.
</P>
<P ALIGN=CENTER>
	31
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage42"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_32">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	As a foreign private issuer, we are not subject to
	certain United States securities law disclosure requirements that apply to a
	domestic United States issuer, which may limit the information which would be
	publicly available to our shareholders.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As a foreign private issuer, we are not required to comply with
	all the periodic disclosure requirements of the Exchange Act, and therefore,
	there may be less publicly available information about us than if we were a
	United States domestic issuer. For example, we are not subject to the proxy
	rules in the United States and disclosure with respect to our annual meetings
	will be governed by Canadian requirements.
<B>
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our charter documents and certain Canadian legislation
	could delay or deter a change of control, limit attempts by our shareholders to
	replace or remove our current management and limit the market price of our
	common shares.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our authorized preferred shares are available for issuance from
	time to time at the discretion of our board of directors, without shareholder
	approval. Our articles grant our board of directors the authority to determine
	the special rights and restrictions granted to or imposed on any unissued series
	of preferred shares, and those rights may be superior to those of our common
	shares. Further, the Investment Canada Act subjects any acquisition of control
	of a company by a non-Canadian to government review if the value of the assets
	as calculated pursuant to the legislation exceeds a threshold amount or in other
	circumstances determined at the discretion of the Canadian government. A
	reviewable acquisition may not proceed unless the relevant minister is satisfied
	that the investment is likely to be of net benefit to Canada and the Canadian
	government is satisfied that no other important concerns arise from the
	acquisition of control. Any of the foregoing could prevent or delay a change of
	control and may deprive or limit strategic opportunities to our shareholders to
	sell their shares.
</P>
<P ALIGN=CENTER>
<B>
	DESCRIPTION OF SHARE CAPITAL
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	Overview
</B>
</P>
<P ALIGN=JUSTIFY>
	Our authorized share capital consists of an unlimited number of
	common shares, Class B Shares, First Preferred Shares, Series I Non-Voting
	Convertible First Preferred Shares, or Series I First Preferred Shares, and
	Series II Non-Voting Convertible First Preferred Shares, or Series II First
	Preferred Shares, in each case without nominal or par value.
</P>
<P ALIGN=JUSTIFY>
	The holders of common shares are entitled to receive notice of
	and to attend all annual and special meetings of our shareholders and to one
	vote per share held at each such meeting, and they are entitled to receive
	dividends as determined and declared by our board of directors.
</P>
<P ALIGN=JUSTIFY>
	Subject to the rights of the holders of any other class of our
	shares entitled to receive dividends in priority to or concurrently with the
	holders of the common shares, our board of directors may in its sole discretion
	declare dividends on the common shares to the exclusion of any other class of
	shares of the Company.
</P>
<P ALIGN=JUSTIFY>
	In the event of our liquidation, dissolution or winding up or
	other distribution of our assets among our shareholders for the purpose of
	winding up our affairs, the holders of the common shares shall, subject to the
	rights of the holders of any other class of shares entitled to receive our
	assets upon such a distribution in priority to or concurrently with the holders
	of the common shares, be entitled to participate in the distribution. Such
	distribution shall be made in equal amounts per share on all the common shares
	at the time outstanding without preference or distinction.
</P>
<P ALIGN=JUSTIFY>
	The holders of the Class B Shares are entitled to receive
	notice of and to attend any meeting of our shareholders but shall not be
	entitled to vote any of their Class B Shares at any such meeting. Each issued
	and fully paid Class B Share may at any time be converted, at the option of the
	holder, into one common share. In the event of our liquidation, dissolution or
	winding up or other distribution of our assets among our shareholders for the
	purpose of winding up our affairs, the holders of the Class B Shares shall be
	entitled to participate rateably with the common shares in any distribution of
	the assets of the Company.
</P>
<P ALIGN=CENTER>
	32
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage43"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_33">
</A>
<P ALIGN=JUSTIFY>
	The First Preferred Shares may at any time and from time to
	time be issued in one or more series and our board of directors may before the
	issue thereof fix the number of shares in, and determine the designation,
	rights, privileges, restrictions and conditions attaching to the shares of, each
	series of First Preferred Shares.
</P>
<P ALIGN=JUSTIFY>
	The First Preferred Shares shall be entitled to priority over
	the common shares and Class B Shares and all other shares ranking junior to the
	First Preferred Shares with respect to the payment of dividends and the
	distribution of our assets in the event of our liquidation, dissolution or
	winding up or other distribution of our assets among our shareholders for the
	purpose of winding up our affairs.
</P>
<P ALIGN=JUSTIFY>
	The First Preferred Shares of each series rank on a parity with
	the First Preferred Shares of every other series with respect to priority in the
	payment of dividends and in the distribution of our assets in the event of our
	liquidation, dissolution or winding up or other distribution of our assets among
	our shareholders for the purpose of winding up our affairs.
</P>
<P ALIGN=JUSTIFY>
	During 2013, we created a new series of shares, our Series I
	First Preferred Shares. The holders of Series I First Preferred Shares are not
	entitled to vote at any meeting of our shareholders (except in limited
	circumstances provided for in the OBCA), and they are entitled to receive
	dividends as determined and declared at the discretion of our board of directors
	equally on a one-for-one basis with the holders of shares of the other series of
	First Preferred Shares. Each issued and fully paid Series I First Preferred
	Share may at any time be converted, at the option of the holder, into
	one-thirtieth (1/30
<SUP>
	th
</SUP>
	) of a common share, subject to adjustment. In
	the event of a take-over bid, that is a &#147;formal bid&#148;, the Offeror of such bid
	shall make an offer to acquire the same percentage of outstanding Series I First
	Preferred Shares as the percentage of common shares for which the bid is made,
	on the same terms and for the same amount and kind of consideration.
</P>
<P ALIGN=JUSTIFY>
	During 2015, we created a new series of shares, our Series II
	First Preferred Shares. The holders of Series II First Preferred Shares are not
	entitled to vote at any meeting of our shareholders (except in limited
	circumstances provided for in the OBCA), and they are entitled to receive
	dividends as determined and declared at the discretion of our board of directors
	equally on a one-for-one basis with the holders of shares of the other series of
	First Preferred Shares. Each issued and fully paid Series II First Preferred
	Share may at any time be converted, at the option of the holder, into one common
	share, subject to adjustment. In the event of a take-over bid, that is a &#147;formal
	bid&#148;, the Offeror of such bid shall make an offer to acquire the same percentage
	of outstanding Series II First Preferred Shares as the percentage of common
	shares for which the bid is made, on the same terms and for the same amount and
	kind of consideration.
</P>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, 7,796,137 common shares were
	outstanding, 53,788,579 Series I Preferred Shares were outstanding and
	convertible into 1,792,953 common shares, and no Class B Shares were
	outstanding. As at December 31, 2015, 106,096,356 common share purchase warrants
	were outstanding and convertible into 3,536,545 common shares at a weighted
	average exercise price of $8.72 per common share.
</P>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, there were 927,834 stock options
	outstanding to purchase common shares. The terms and conditions of such stock
	options are contained in the 2014 Stock Option Plan.
</P>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, we have issued 51,788 deferred share
	units. The terms and conditions of such deferred share units are contained in
	the 2014 DSU Plan.
</P>
<P ALIGN=JUSTIFY>
<B>
	Share capital issued &#150; for the year ended December 31, 2015
</B>
</P>
<P ALIGN=JUSTIFY>
	On April 7, 2015, the Company completed an underwritten public
	offering of common shares and non-voting convertible preferred shares in the
	United States. In the offering, Trillium sold 1,750,754 common shares and
	1,077,605 Series II First Preferred Shares at a price of U.S. $19.50 per share,
	including 228,359 common shares sold pursuant to the full exercise of the
	underwriters&#146; option to purchase additional common shares. The gross proceeds to
	Trillium from this offering were $68,875,067 (U.S. $55,153,000) before deducting
	offering expenses of $4,913,443.
</P>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2015, 1,087,603 common
	shares were issued on the exercise of 32,628,425 warrants for proceeds of
	$9,515,154 and 6,666 stock options were exercised for proceeds of $49,995.
</P>
<P ALIGN=CENTER>
	33
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage44"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_34">
</A>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2015, 15,716,110 Series I
	First Preferred Shares were converted into 523,870 common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
	Share capital issued &#150; for the year ended December 31, 2014
</B>
</P>
<P ALIGN=JUSTIFY>
	On November 14, 2014, we consolidated our outstanding common
	shares issuing one post-consolidated share for each 30 pre-consolidated shares.
	All references in this AIF to the number of common shares, stock options and
	deferred share units, or DSUs, refer to the post-consolidated amounts.
</P>
<P ALIGN=JUSTIFY>
	In the year ended December 31, 2014, 2,596,251 warrants were
	exercised for 86,540 common shares and for proceeds of $946,813 and 2,614 stock
	options were exercised for proceeds of $19,600. Also, 909,091 warrants issued in
	March 2011 expired unexercised.
</P>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2014, 8,390,476 Series I
	First Preferred Shares were converted into 279,682 common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
	Share capital issued &#150; for the year ended December 31, 2013
</B>
</P>
<P ALIGN=JUSTIFY>
	On February 6, 2013, we consolidated our outstanding common
	shares issuing one post-consolidated share for each 10 pre-consolidated
	shares.
</P>
<P ALIGN=JUSTIFY>
	In March 2013, we completed an offering pursuant to a base
	shelf prospectus and prospectus supplement and in the U.S. pursuant to a private
	placement memorandum for a total of 424,500 units at a price of $7.50 per unit,
	for aggregate gross proceeds to us of $3,185,080 ($2,615,240 net of issuance
	costs). Each unit consisted of one common share and 30 common share purchase
	warrants. Each 30 warrants entitle the holder to purchase one common share at a
	price of $12.00 per share at any time prior to expiry on March 15, 2018
	(12,315,000 warrants) and March 27, 2018 (420,000 warrants). In connection with
	the financing, we issued 814,051 compensation warrants having an aggregate fair
	value of $48,843 estimated using the Black-Scholes option pricing model. Each 30
	compensation warrants entitle the holder to acquire one common share at an
	exercise price of $7.50 per share prior to expiry on March 16, 2015.
</P>
<P ALIGN=JUSTIFY>
	On April 9, 2013, we issued 202,639 common shares and 3,300,000
	common share purchase warrants for partial consideration for the acquisition of
	Trillium Privateco.
</P>
<P ALIGN=JUSTIFY>
	On April 16, 2013, we issued 167,619 common shares and
	1,600,000 common share purchase warrants as consideration for the acquisition of
	certain rights related to tigecycline from UHN.
</P>
<P ALIGN=JUSTIFY>
	On December 13, 2013, we completed a private placement of
	2,641,590 common share units (each common share unit consisting of one common
	share and 22.5 common share purchase warrants) at a price of $6.30 per unit and
	77,895,165 preferred share units (each preferred share unit consisting of one
	Series I First Preferred Share and three-quarters of a common share purchase
	warrant) at a price of $0.21 per unit for gross proceeds of $32,866,025
	($30,713,841 net of issuance costs). Each 30 warrants entitle the holder to
	purchase one common share at a price of $8.40 at any time prior to expiry on
	December 13, 2018. In connection with the financing, we issued 5,014,839
	compensation warrants having an aggregate fair value of $651,929 estimated using
	the Black-Scholes option pricing model. Each 30 compensation warrants entitle
	the holder to acquire one common share at an exercise price of $6.30 per share
	prior to expiry on December 13, 2015.
</P>
<P ALIGN=JUSTIFY>
	In the December 2013 private placement, subscribers who
	purchased preferred share units and certain subscribers who purchased common
	share units were subject to restrictions on the conversion and exercise of
	securities of ours convertible into common shares. Such subscribers cannot
	convert or exercise securities of ours convertible or exercisable into common
	shares if, after giving effect to the exercise of conversion, the subscriber and
	its joint actors would have beneficial ownership or direction or control over
	common shares in excess of 4.99% of the then outstanding common shares. This
	limit may be increased at the option of the subscriber on 61 days prior written
	notice: (i) up to 9.99%, (ii) up to 19.99%, subject to stock exchange clearance
	of a personal information form submitted by the subscriber, and (iii) above
	19.99%, subject to stock exchange approval and shareholder approval.
</P>
<P ALIGN=JUSTIFY>
	Subject to
	receipt of any required regulatory approvals, subscribers who purchased a
	minimum of 10% of the securities sold under the offering have been given rights
	to purchase securities of ours in future financings to enable each such subscriber to maintain its percentage holding in us
	for so long as the subscriber holds at least 10% of the outstanding common
	shares on a fully-diluted basis.
</P>
<P ALIGN=CENTER>
	34
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage45"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_35">
</A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P ALIGN=JUSTIFY>
<B>
	Fully Diluted Share Capital
</B>
</P>
<P ALIGN=JUSTIFY>
	The number of issued and outstanding common shares, Series I
	First Preferred Shares, Series II First Preferred Shares warrants, stock options
	and DSUs on a fully converted basis as at December 31, 2015 was as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="15%">
	Number of common
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="15%">
	share equivalents
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Common shares
</TD>
<TD ALIGN=RIGHT WIDTH="15%" BGCOLOR=#E6EFFF>
	7,796,137
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Series I First Preferred Shares
</TD>
<TD ALIGN=RIGHT WIDTH="15%">
	1,792,953
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Series II First Preferred Shares
</TD>
<TD ALIGN=RIGHT WIDTH="15%" BGCOLOR=#E6EFFF>
	1,077,605
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Warrants
</TD>
<TD ALIGN=RIGHT WIDTH="15%">
	3,536,545
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Stock options
</TD>
<TD ALIGN=RIGHT WIDTH="15%" BGCOLOR=#E6EFFF>
	927,834
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Deferred share
	units
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="15%">
	51,788
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Fully diluted common shares as at December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=RIGHT WIDTH="15%" BGCOLOR=#E6EFFF>
	15,182,862
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P ALIGN=JUSTIFY>
<B>
	Warrants
</B>
</P>
<P ALIGN=JUSTIFY>
	The following table shows the number of warrants outstanding,
	the exercise prices, and the number of common shares issuable on exercise of the
	warrants and the exercise price per common share for 30 warrants at December 31,
	2015:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Common shares
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Price per
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Issuable
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Common Share
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	Expiry dates
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	on Exercise
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	(30 Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	March 15, 2018
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9,213,780
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	0.40
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	307,126
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	12.00
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	March 27, 2018
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	300,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	0.40
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	10,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	12.00
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	December 13, 2018
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	96,582,576
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	0.28
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	3,219,419
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	8.40
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	106,096,356
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	3,536,545
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Our board of directors authorized or ratified the issuances of
	the warrants set forth in the table below and the issuance of one common share
	upon the due exercise of each 30 warrants in accordance with its terms and the
	receipt by us of the designated exercise price payable in respect of the share
	prior to the time of expiry on the designated expiry date.
</P>
<P ALIGN=JUSTIFY>
<B>
	Stock Options
</B>
</P>
<P ALIGN=JUSTIFY>
	Our board of directors authorized or ratified the issuances of
	the options set forth in the table below and the issuance of one common share
	upon the due exercise of each option in accordance with its terms and the
	receipt by us of the designated exercise price payable in respect of the share
	prior to the time of expiry on the designated expiry date.
</P>
<P ALIGN=JUSTIFY>
<B>
	Deferred Share Units
</B>
</P>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, we had 51,788 issued and outstanding
	DSUs which are convertible into common shares.
</P>
<P ALIGN=CENTER>
	35
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage46"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_36">
</A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P ALIGN=JUSTIFY>
<B>
	Prior Sales
</B>
</P>
<P ALIGN=JUSTIFY>
	The following table summarizes details of each class of
	securities that is outstanding but not listed or quoted on a marketplace issued
	by the Company during the year ended December 31, 2015.
</P>
<DIV>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " BORDERCOLOR=#000000 CELLSPACING=0 CELLPADDING=3 WIDTH="100%" BORDER=1>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	Date of Issuance
<BR>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="33%">
	Price per Security or
<BR>
	Exercise
	Price as Applicable
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="33%">
	Number of and
<BR>
	Description of
	Securities
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	April 1, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$23.441
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	85,000
<BR>
	Options
<B>
<SUP>
	(1)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	April 7, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	USD$19.50
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	1,077,605
<BR>
	Series II First Preferred Shares
<B>
<SUP>
	(2)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	May 27, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$28.045
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	29,000
<BR>
	Options
<B>
<SUP>
	(1)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	May 27, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$28.045
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	8,558
<BR>
	Deferred Share
	Units
<B>
<SUP>
	(3)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	June 4, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$28.519
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	12,500
<BR>
	Options
<B>
<SUP>
	(1)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	June 16, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$29.422
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	2,039
<BR>
	Deferred Share
	Units
<B>
<SUP>
	(3)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	November 19, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$19.333
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	220,859
<BR>
	Options
<B>
<SUP>
	(1)
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	November 19, 2015
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	$19.333
</TD>
<TD ALIGN=RIGHT WIDTH="33%">
	12,414
<BR>
	Deferred Share
	Units
<B>
<SUP>
	(3)
</SUP>
</B>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Note:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(1)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Issued under the 2014 Stock Option Plan.
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(2)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Issued in an underwritten public offering of common
	shares and non-voting convertible preferred shares in the United
	States.
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(3)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Issued under the 2014 DSU Plan.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	MARKET FOR SECURITIES
</B>
</P>
<P ALIGN=JUSTIFY>
	We are listed on the TSX under the symbol &#147;TR and on the NASDAQ
	Capital Market under the symbol &#147;TRIL&#148;. The following table shows the price
	ranges and volumes traded on the TSX and NASDAQ for the periods noted:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<DIV>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " BORDERCOLOR=#000000 CELLSPACING=0 CELLPADDING=3 WIDTH="100%" BORDER=1>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=CENTER ROWSPAN=2>
<BR>
	Month
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="42%" COLSPAN=3>
	TSX
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="42%" COLSPAN=3>
	NASDAQ
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=CENTER WIDTH="14%">
	High ($)
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="14%">
	Low ($)
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="14%">
	Volume (#)
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="14%">
	High (US$)
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="14%">
	Low (US$)
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="14%">
	Volume (#)
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	December 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 20.000
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 16.010
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	50,495
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 15.020
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 11.494
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	987,213
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	November 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 21.980
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 17.850
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	49,350
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 16.690
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 13.420
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	839,500
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	October 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 21.800
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 16.000
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	116,560
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 16.650
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 12.200
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	1,590,038
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	September 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 25.000
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 15.950
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	89,362
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 19.080
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 12.000
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	1,320,768
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	August 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 28.080
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 18.150
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	114,851
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 22.200
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 13.380
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	1,984,450
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	July 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 30.010
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 24.200
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	123,555
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 23.300
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 18.770
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	1,777,870
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	June 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 32.760
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 25.000
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	154,336
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 26.720
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 19.990
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	2,823,681
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	May 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 30.570
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 21.210
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	180,416
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 24.560
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 17.572
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	3,303,704
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	April 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 37.270
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 22.690
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	538,051
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 27.989
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 18.800
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	7,607,223
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	March 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 26.065
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 17.000
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	307,858
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 20.880
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 13.060
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	2,542,925
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	February 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 20.210
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 15.140
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	204,365
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 16.500
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 12.610
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	1,321,813
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	January 2015
</TD>
<TD ALIGN=LEFT WIDTH="14%">
	&nbsp;$ 18.370
</TD>
<TD ALIGN=CENTER WIDTH="14%">
	$ 10.500
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	361,364
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 15.647
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	$ 9.050
</TD>
<TD ALIGN=RIGHT WIDTH="14%">
	3,046,079
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	36
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage47"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_37">
</A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P ALIGN=JUSTIFY>
<B>
	BOARD OF DIRECTORS AND MANAGEMENT
</B>
</P>
<P ALIGN=JUSTIFY>
	The following table and summary of business experience set
	forth the name, office held, and functions and areas of experience in the
	Company, principal business activities and other principal directorships of each
	of our directors and senior management:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=CENTER STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1" BORDERCOLOR="#000000">
<B>
	Name
</B>
<BR>
<B>
	Present Office Held
</B>
<BR>
<B>
	Province/State and
</B>
<BR>
<B>
	Country of Residence
</B>
<BR>
<B>
	Position Held Since
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="2%" BORDERCOLOR="#000000">
<BR>
<BR>
<BR>
<BR>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="73%" STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1" BORDERCOLOR="#000000">
<BR>
<BR>
<BR>
<BR>
<B>
	Principal Business
	Activities, Other Principal Directorships and Function
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BORDERCOLOR="#000000" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
<B>
	Luke Beshar
</B>
<BR>
<I>
	Director
</I>
<SUP>
	(1)
<BR>
</SUP>
	New
	Jersey, USA
</TD>
<TD ALIGN=LEFT WIDTH="2%" BORDERCOLOR="#000000" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
</TD>
<TD ALIGN=LEFT WIDTH="73%" BORDERCOLOR="#000000" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
	Mr. Beshar is an independent biotechnology
	consultant and financial expert. He was most recently the Executive/Senior
	Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a
	global biopharmaceutical company from November 2007 to February 2015.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: 1PX SOLID #000000; ; BORDER-TOP-STYLE:NONE; BORDER-TOP-WIDTH:MEDIUM" ALIGN=LEFT>
<BR>
	March 10, 2014
</TD>
<TD ALIGN=LEFT WIDTH="2%" STYLE="BORDER-TOP-STYLE: NONE; BORDER-TOP-WIDTH: MEDIUM">
</TD>
<TD STYLE="BORDER-BOTTOM: 1PX SOLID #000000; ; BORDER-TOP-STYLE:NONE; BORDER-TOP-WIDTH:MEDIUM" ALIGN=LEFT WIDTH="73%">
	As an
	independent director, Mr. Beshar supervises our management and helps to
	ensure compliance with our corporate governance policies and standards.
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1">
<B>
	Henry Friesen
</B>
<BR>
<I>
	Director
</I>
<SUP>
	(1)(2)
</SUP>
<BR>
	Manitoba, Canada
<P>
	June 28, 2011
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="73%" STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1">
	Dr. Friesen is a Distinguished University
	Professor Emeritus at University of Manitoba since October 2000.
<P>
	As an
	independent director, Dr. Friesen supervises our management and helps to
	ensure compliance with our corporate governance policies and standards.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<P>
<B>
	Robert Kirkman
</B>
<BR>
<I>
	Director
</I>
<SUP>
	(1)(3)
</SUP>
<BR>
	Washington, USA
</P>
<P>
	December 17, 2013
</P>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
<P>
	Dr. Kirkman was President and Chief Executive Officer and director of
	Oncothyreon Inc., an oncology-focused biotechnology company from September
	2006 to January 2016.
</P>
<P>
	As an independent director, Dr. Kirkman supervises our management and
	helps to ensure compliance with our corporate governance policies and
	standards.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<P>
<B>
	Michael Moore
</B>
<BR>
<I>
	Director
</I>
<SUP>
	(2)(3)
</SUP>
<BR>
	Surrey,
	UK
</P>
<P>
	April 9, 2013
</P>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD ALIGN=LEFT WIDTH="73%">
	Dr. Moore is the Executive Chair of
<I>
	MISSION
</I>
	Therapeutics Ltd. since 2012 and a Board Chair or Director of several
	private biopharmaceutical companies in the UK. From 2004 to 2013, Dr.
	Moore was the Chair of Trillium Privateco, and from 2003 to 2008, Dr.
	Moore was the Chief Executive Officer and Director of PIramed Ltd, a UK-
	based oncology company sold to Roche in 2008.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
	As an
	independent director, Dr. Moore supervises our management and helps to
	ensure compliance with our corporate governance policies and standards.
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
<B>
	Thomas Reynolds
<BR>
</B>
<I>
	Director
</I>
<SUP>
	(2)(3)
</SUP>
<BR>
	Washington, USA
</TD>
<TD ALIGN=LEFT WIDTH="2%" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
</TD>
<TD ALIGN=LEFT WIDTH="73%" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
	Dr. Reynolds is an independent biotechnology
	consultant since February 2013, and was Chief Medical Officer of Seattle
	Genetics, Inc., a biotechnology company focused on antibody-based
	therapies for the treatment of cancer from March 2007 to January 2013. Dr.
	Reynolds also sits on the board of MEI Pharma, Inc.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: 1PX SOLID #000000; ; BORDER-TOP-STYLE:NONE; BORDER-TOP-WIDTH:MEDIUM" ALIGN=LEFT>
<BR>
	March 10, 2014
</TD>
<TD ALIGN=LEFT WIDTH="2%" STYLE="BORDER-TOP-STYLE: NONE; BORDER-TOP-WIDTH: MEDIUM">
</TD>
<TD STYLE="BORDER-BOTTOM: 1PX SOLID #000000; ; BORDER-TOP-STYLE:NONE; BORDER-TOP-WIDTH:MEDIUM" ALIGN=LEFT WIDTH="73%">
	As an
	independent director, Dr. Reynolds supervises our management and helps to
	ensure compliance with our corporate governance policies and standards.
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
<B>
	Calvin Stiller
<BR>
</B>
<I>
	Director, Chair of the
</I>
<I>
	Board
</I>
<BR>
	Ontario, Canada
</TD>
<TD ALIGN=LEFT WIDTH="2%" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
</TD>
<TD ALIGN=LEFT WIDTH="73%" STYLE="BORDER-BOTTOM-STYLE: NONE; BORDER-BOTTOM-WIDTH: MEDIUM">
	Dr. Stiller is the Chair of Ontario Institute
	for Cancer Research and Professor Emeritus at Western University. Dr.
	Stiller also sits on the board of Revera Corporation and Magor
	Corporation.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: 1PX SOLID #000000; ; BORDER-TOP-STYLE:NONE; BORDER-TOP-WIDTH:MEDIUM" ALIGN=LEFT>
<BR>
	July 18, 2011
</TD>
<TD ALIGN=LEFT WIDTH="2%" STYLE="BORDER-TOP-STYLE: NONE; BORDER-TOP-WIDTH: MEDIUM">
</TD>
<TD STYLE="BORDER-BOTTOM: 1PX SOLID #000000; ; BORDER-TOP-STYLE:NONE; BORDER-TOP-WIDTH:MEDIUM" ALIGN=LEFT WIDTH="73%">
	As an
	independent director, Dr. Stiller supervises our management and helps to
	ensure compliance with our corporate governance policies and standards.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	37
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage48"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_38">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Niclas Stiernholm
</B>
<BR>
<I>
	President and Chief
</I>
<I>
	Executive Officer, Director
</I>
<BR>
	Ontario, Canada
<P>
	Director since
	July 18, 2011; President and CEO since April 9, 2013
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
<P>
	Dr. Stiernholm is the President and Chief Executive Officer of Trillium
	since April 9, 2013 and was the President and Chief Executive Officer of
	Trillium Privateco prior thereto from 2002. He joined Trillium from YM
	BioSciences where he was Executive Vice President and Chief Scientific
	Officer.
</P>
<P>
	As President and Chief Executive Officer, Dr. Stiernholm is responsible
	for overseeing our strategic direction, executing business development
	plans and ensuring that our scientific programs remain funded and advance
	on schedule. As a director, Dr. Stiernholm participates in management
	oversight and helps to ensure compliance with our corporate governance
	policies and standards.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Robert Uger
</B>
<BR>
<I>
	Chief Scientific
	Officer
<BR>
</I>
	Ontario, Canada
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD ALIGN=LEFT WIDTH="73%">
	Dr. Uger is the Chief Scientific Officer of
	Trillium since April 9, 2013 and was the Vice President, Research of
	Trillium Privateco prior thereto from 2003. He joined Trillium from
	Aventis Pasteur where he was a Senior Research Scientist involved in
	cancer vaccine research.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<BR>
	April 9, 2013
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
	As
	Chief Scientific Officer, Dr. Uger is responsible for developing and
	implementing our scientific direction, and oversees both internal product
	development and external research and development programs.
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<P>
<B>
	James Parsons
</B>
<BR>
<I>
	Chief Financial Officer
</I>
<BR>
	Ontario,
	Canada
</P>
<P>
	August 25, 2011
</P>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
<P>
	Mr. Parsons is the Chief Financial Officer of Trillium since August 25,
	2011 and was also the Director, Finance of Trillium Privateco. He was
	previously the Vice President, Finance of DiaMedica Inc. from October 2010
	to May 2014, and Chief Financial Officer of Amorfix Life Sciences Ltd.
	from 2006 to 2010. Mr. Parsons sits on the board of Sernova Corp and
	DiaMedica Inc.
</P>
<P>
	As Chief Financial Officer, Mr. Parsons is responsible for financial
	and risk management, investor relations, corporate governance and
	administration.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<P>
<B>
	Penka Petrova
<BR>
</B>
<I>
	Chief Development Officer
</I>
<BR>
	Ontario,
	Canada
</P>
<P>
	May 29, 2015
</P>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
<P>
	Dr. Petrova is the Chief Development Officer of Trillium since May 29,
	2015 and was the Vice President, Drug Development from April 2013 to May
	2015. Dr. Petrova joined Trillium Privateco from Prescient Neuropharma in
	2003.
</P>
<P>
	As Chief Development Officer, Dr. Petrova is responsible for managing
	our formal drug development efforts, including all outsourced activities
	to contract manufacturers and contract research organizations.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<P>
<B>
	Eric Sievers
</B>
<BR>
<I>
	Chief Medical Officer
</I>
<BR>
	Washington,
	USA
</P>
<P>
	April 1, 2015
</P>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="73%">
<P>
	Dr. Sievers is the Chief Medical Officer of Trillium since April 1,
	2015. He previously held several senior roles at Seattle Genetics
	including the Senior Vice President, Clinical Development from October
	2013 to March 2015, the Vice President and Interim Chief Medical Officer
	from 2012 to October 2013, and Vice President, Clinical Affairs from 2011
	to 2012, and Executive Medical Director from 2010 to 2011.
</P>
<P>
	As Chief Medical Officer, Dr. Sievers is responsible for the design and
	execution of our clinical and regulatory strategy.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Notes:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(1)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Member of our audit committee.
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(2)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Member of our corporate governance and nominating
	committee.
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(3)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Member of our compensation
	committee.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Directors are elected annually and hold office until a
	successor is elected at a subsequent annual meeting of the Company, unless a
	director&#146;s office is earlier vacated in accordance with the by-laws of the
	Company. The business address for our directors and senior management is Trillium
	Therapeutics Inc., 96 Skyway Avenue, Toronto, Ontario, Canada, M9W 4Y9.
</P>
<P ALIGN=CENTER>
	38
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage49"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_39">
</A>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, the directors and senior officers of
	the Company, as a group, beneficially owned, directly or indirectly, 31,000
	common shares of the Company constituting approximately 0.4% of the issued and
	outstanding common shares.
</P>
<P ALIGN=CENTER>
<B>
	CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS
</B>
</P>
<P ALIGN=JUSTIFY>
<I>
	Cease Trade Orders
</I>
</P>
<P ALIGN=JUSTIFY>
	To the knowledge of the Company, no director or executive
	officer of the Company is, or within the ten years prior to the date hereof has
	been, a director, chief executive officer, or chief financial officer, of any
	company (including the Company) that was subject to (a) a cease trade order; (b)
	an order similar to a cease trade order; or (c) an order that denied the
	relevant company access to any exemption under securities legislation, that was
	in effect for a period of more than thirty consecutive days, issued while that
	person was acting in such capacity or issued thereafter but resulted from an
	event that occurred while that person was acting in such capacity.
</P>
<P ALIGN=JUSTIFY>
<I>
	Bankruptcies
</I>
</P>
<P ALIGN=JUSTIFY>
	To the knowledge of the Company, no director or executive
	officer or shareholder holding a sufficient number of securities of the Company
	to affect materially the control of the Company is, or within the ten years
	prior to the date hereof has been, a director or executive officer of any
	company (including the Company) that, while that person was acting in such
	capacity or within a year of that person ceasing to act in such capacity, became
	bankrupt, made a proposal under any legislation relating to bankruptcy or
	insolvency or was subject to or instituted any proceedings, arrangement or
	compromise with creditors or had a receiver, receiver manager or trustee
	appointed to hold its assets.
</P>
<P ALIGN=JUSTIFY>
	To the knowledge of the Company, no director or executive
	officer or shareholder holding a sufficient number of securities of the Company
	to affect materially the control of the Company has, within the ten years prior
	to the date hereof, become bankrupt, made a proposal under any legislation
	relating to bankruptcy or insolvency, or become subject to or instituted any
	proceedings, arrangement, or compromise with creditors, or had a receiver,
	receiver manager or trustee appointed to hold that person&#146;s assets.
</P>
<P ALIGN=JUSTIFY>
<I>
	Penalties and Sanctions
</I>
</P>
<P ALIGN=JUSTIFY>
	No director or executive officer of the Corporation, or a
	shareholder holding a sufficient number of securities of the Company to affect
	materially the control of the Corporation has been subject to (a) any penalties
	or sanctions imposed by a court relating to securities legislation or by a
	securities regulatory authority or has entered into a settlement agreement with
	a securities regulatory authority; or (b) any other penalties or sanctions
	imposed by a court or regulatory body that would likely be considered important
	to a reasonable investor in making an investment decision.
</P>
<P ALIGN=JUSTIFY>
	All of the above disclosure also applies to any personal
	holding companies of any of the persons referred to above.
</P>
<P ALIGN=CENTER>
<B>
	CONFLICTS OF INTEREST
</B>
</P>
<P ALIGN=JUSTIFY>
	Certain of our officers and directors are also officers and/or
	directors of other companies engaged in the biotechnology industry and research
	business generally. As a result, situations arise where the interest of such
	directors and officers conflict with their interests as directors and officers
	of other companies. The resolution of such conflicts is governed by applicable
	corporate laws, which require that directors act honestly, in good faith and
	with a view to the best interests of the Company. In addition, the OBCA, our
	governing statute, requires our officers and directors to disclose any personal
	interest which they may have in any material contract or transaction which is
	proposed to be entered into with the Company and, in the case of directors, to
	abstain from voting as a director for the approval of any such contract or
	transaction, unless otherwise permitted under the OBCA.
</P>
<P ALIGN=JUSTIFY>
	In relation to the acquisition of Fluorinov on January 26,
	2016, two directors declared a conflict of interest and recused themselves from
	discussions and board decisions relating to the acquisition. One director was
	also a director of Fluorinov and had an ownership position in Fluorinov at the
	time of acquisition of less than 2%. A second of our directors was a director of
	the Ontario Institute of Cancer Research (being a beneficiary of the Fight
	Against Cancer Innovation Trust, a shareholder and debenture holder of
	Fluorinov).
</P>
<P ALIGN=CENTER>
	39
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage50"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_40">
</A>
<P ALIGN=CENTER>
<B>
	LEGAL PROCEEDINGS
</B>
</P>
<P ALIGN=JUSTIFY>
	We are and were not a party to, and none of our property or
	assets are or were subject to, any material legal proceedings during the last
	financial year, nor to our knowledge are any such proceedings contemplated.
</P>
<P ALIGN=CENTER>
<B>
	INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS
</B>
</P>
<P ALIGN=JUSTIFY>
	Except as provided herein, there are no material interests,
	direct or indirect, of directors, executive officers, any shareholders who
	beneficially own, or controls or directs, directly or indirectly, more than 10%
	of our outstanding common shares, or any known associates or affiliates of such
	persons, in any transaction within the last three completed financial years or
	during the current financial year which has materially affected or is reasonably
	expected to materially affect the Company.
</P>
<P ALIGN=JUSTIFY>
	For the years ended December 31, 2015 and 2014, $0 and $7,916,
	respectively, was paid to our former Executive Chair, a director, for consulting
	fees. These transactions were in the normal course of operations and were
	measured at the exchange amount, which is the amount of consideration
	established and agreed to by the parties.
</P>
<P ALIGN=CENTER>
<B>
	INTEREST OF EXPERTS
</B>
</P>
<P ALIGN=JUSTIFY>
	Our auditors are Ernst &amp; Young LLP, Chartered Professional
	Accountants, Licensed Public Accountants, Toronto, Ontario, Canada. Our
	consolidated financial statements as at December 31, 2015 and 2014 have been
	audited by Ernst &amp; Young LLP, Independent Registered Public Accounting Firm,
	as indicated in their report dated March 9, 2016. Ernst &amp; Young LLP has been
	the Corporation's auditors since inception on March 31, 2004.
</P>
<P ALIGN=JUSTIFY>
	Ernst &amp; Young LLP has advised that they are independent
	with respect to the Corporation within the meaning of the Rules of Professional
	Conduct of the Chartered Professional Accountants of Ontario (registered name of
	the Institute of Chartered Accountants of Ontario) and the rules and standards
	of the Public Company Accounting Oversight Board (United States) and the
	securities laws and regulations administered by the United States Securities and
	Exchange Commission.
</P>
<P ALIGN=CENTER>
<B>
	TRANSFER AGENT
</B>
</P>
<P ALIGN=JUSTIFY>
	Our registrar and transfer agent is Computershare Trust Company
	of Canada, located at 100 University Avenue, Toronto, Ontario, M5J 2Y1.
</P>
<P ALIGN=CENTER>
<B>
	MATERIAL CONTRACTS
</B>
</P>
<P ALIGN=JUSTIFY>
	There are no other contracts, other than those disclosed in
	this AIF and those entered into in the ordinary course of our business, that are
	material to us and which were entered into in the last completed fiscal year or
	which were entered into before the most recently completed fiscal year but are
	still in effect as of the date of this AIF:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	1.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	License Agreement between Trillium Privateco, UHN and HSC
	dated February 1, 2010 pursuant to which we licensed intellectual property
	relating to methods and compounds for the modulation of the SIRP&#945;-CD47
	interaction for therapeutic cancer applications. The license agreement
	requires us to use commercially reasonable efforts to commercialize the
	licensed technology. The license agreement will terminate on a
	country-by-country basis, in countries where a valid claim exists, when
	the last valid claim expires in such country, or if no valid claim exists,
	when the last valid claim expires in the U.S. We paid an up-front license
	fee of $150,000 and committed to pay an annual maintenance fee of $25,000,
	as well as payments on patent issuances, development milestone payments
	ranging from $100,000 to $300,000 on the initiation of phase I, II and III
	clinical trials respectively, and payments upon the achievement of certain
	regulatory milestones as well as royalties of either 3% or 1% of net
	revenues on commercial sales. The regulatory milestone payments amount to
	$1 million on each of the submission of a first BLA in the U.S. and
	receipt of first regulatory approval in the U.S.
	and proportionate payments in other territories worldwide.
	The aggregate milestones payable on their first achievement under the
	agreement in the major markets of the U.S., Europe and Asia combined are
	$5,660,000. Under the license agreement, Trillium is required to pay 20%
	of any sublicensing revenues to the licensors on the first $50 million of
	sublicensing revenues, and pay 15% of any sublicensing revenues to the
	licensors after the first $50 million of sublicensing revenue
	received.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	40
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage51"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_41">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	2.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	GPEx&#174;-Derived Cell Line Sale Agreement between Trillium
	Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014
	pursuant to which we acquired the right to use the GPEx&#174; expression system
	for the manufacture of TTI-621 (SIRP&#945;Fc). Consideration for the license
	includes potential pre-marketing approval milestones of up to US$875,000
	and aggregate sales milestone payments of up to US$28.8 million.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	3.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	GPEx&#174;-Derived Cell Line Sale Agreement between Trillium
	Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014
	pursuant to which we acquired the right to use the GPEx&#174; expression system
	for the manufacture of TTI-622 (SIRP&#945;Fc). Consideration for the license
	includes potential pre-marketing approval milestones of up to US$875,000
	and aggregate sales milestone payments of up to US $28.8
	million.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	4.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Share purchase agreement among the Company, Fluorinov and
	Fluorinov shareholders dated January 26, 2016 pursuant to which we
	purchased all of the issued and outstanding shares in the capital of
	Fluorinov. See &#147;General Development of the Business &#150; 3 Year
	Summary&#148;.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	5.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Royalty agreement among the Company, Fluorinov and
	Fluorinov shareholders dated January 26, 2016 which sets out contingent
	future royalty payments. See the discussion in the section of this AIF
	entitled &#147;General Development of the Business &#150; 3 Year
	Summary&#148;.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	AUDIT COMMITTEE INFORMATION
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	Audit Committee
</B>
</P>
<P ALIGN=JUSTIFY>
	The Charter of the Audit Committee is attached hereto as
	Schedule A. The purpose of our audit committee is to assist our Board in:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	overseeing the integrity of our financial statements and
	our accounting and financial reporting processes and financial statement
	audits;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;&nbsp;&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	overseeing our compliance with legal and regulatory
	requirements;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	overseeing the qualifications and independence of our
	registered public accounting firm (independent auditor);
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;&nbsp;&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	overseeing the performance of our independent auditor;
	and
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	overseeing the design, implementation and ongoing
	effectiveness of our systems of disclosure controls and procedures, risk
	management systems, internal control over financial reporting and
	compliance with ethical standards adopted by us.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	Composition of the Audit Committee
</B>
</P>
<P ALIGN=JUSTIFY>
	Our audit committee is comprised of a minimum of three members,
	each of whom, in the determination of our board of directors, satisfies the
	independence, financial literacy and experience requirements of applicable U.S.
	and National Instrument 52- 110
<I>
	Audit Committees
</I>
	(&#147;
<B>
	NI 52-110
</B>
	&#148;),
	rules and guidelines, any applicable stock exchange requirements or guidelines
	and any other applicable regulatory rules.
</P>
<P ALIGN=JUSTIFY>
	In particular:
</P>
<P ALIGN=CENTER>
	41
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage52"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_42">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;&nbsp;&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	each member shall be (a) an &#147;Independent Director,&#148; as
	defined in NASDAQ Stock Market Rule 5605(a)(2), and (b) &#147;independent&#148;
	within the meaning of Rule 10A-3 under the Exchange Act, and the
	determination of independence will be affirmatively made by our board
	annually, provided that our board may elect to take advantage of any
	exemption from such requirements provided in the rules of NASDAQ or the
	Exchange Act;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;&nbsp;&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	each member shall meet the independence and financial
	literacy requirements set forth in Canadian NI 52-110;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;&nbsp;&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	each member shall not have participated in the
	preparation of the financial statements of ours (or any then current
	subsidiary of ours) at any time during the past three years;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;&nbsp;&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	each member shall be able to read and understand
	fundamental financial statements in accordance with the audit committee
	requirements for companies listed on NASDAQ in NASDAQ Stock Market Rule
	5605(c)(2)(A)(iv); and
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	at least one (1) member shall, in the judgment of our board, be
	an &#147;audit committee financial expert&#148; within the meaning of such term in Item
	407(d) of Regulation S-K under the United States
<I>
	Securities Act of 1933
</I>
	.
</P>
<P ALIGN=JUSTIFY>
	Our audit committee members are Mr. Luke Beshar (chair), Dr.
	Henry Friesen and Dr. Robert Kirkman, each of whom is a non-executive member of
	our Board. Our Board has determined that each of the members of our audit
	committee is financially literate and has sufficient financial expertise, and is
	independent within the meaning of such term in the rules of NASDAQ, the SEC and
	Canadian provincial securities regulatory authorities. Our Board has determined
	that Mr. Luke Beshar is a financial expert in accordance with the rules and
	regulations of the SEC.
</P>
<P ALIGN=JUSTIFY>
<B>
	Relevant Education and Experience
</B>
</P>
<P ALIGN=JUSTIFY>
	The following describes the education and experience of each
	audit committee member that is relevant in the performance of his
	responsibilities as an audit committee member:
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Luke Beshar, CPA
</I>
</B>
	-
<I>
	Director, Chair of the
	Audit Committee
</I>
</P>
<P ALIGN=JUSTIFY>
	Mr. Beshar was Executive Vice President and Chief Financial
	Officer of NPS Pharmaceuticals until February 2015 when the company was sold to
	Shire plc. He joined NPS Pharmaceuticals in 2007 and has been responsible for
	financial management, investor relations, information technology, technical
	operations, supply-chain management, facilities, project management, contracts
	and outsourcing and strategic and alliance management. Prior to joining NPS, Mr.
	Beshar served as Executive Vice President and Chief Financial Officer of Cambrex
	Corporation, a global life sciences company. Mr. Beshar began his career with
	Arthur Andersen &amp; Co. and is a certified public accountant.
</P>
<P ALIGN=JUSTIFY>
	He obtained his bachelor&#146;s degree in Accounting and Finance
	from Michigan State University and is a graduate of The Executive Program at the
	Darden Graduate School of Business at the University of Virginia.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Dr. Henry Friesen
</I>
</B>
	-
<I>
	Director
</I>
</P>
<P ALIGN=JUSTIFY>
	Dr. Friesen was the President of the Canadian Government&#146;s
	Medical Research Council, and the architect and lead champion for the creation
	the Canadian Institutes for Health Research, President of the National Cancer
	Institute of Canada and President of the Canadian Society for Clinical
	Investigation. He is the Past Founding Chair of Genome Canada. A Fellow of the
	Royal Society of Canada, Dr. Friesen was named a Companion of the Order of
	Canada and was inducted into the Canadian Medical Hall of Fame in 2001 and,
	later the Order of Manitoba. He was also awarded the Gairdner Foundation
	Wightman Award, the McLaughlin Medal of the Royal Society of Canada, and the
	Koch Medal, the highest award of the Endocrine Society. He was presented with
	the Frederic Newton Gisborne Starr Award by the Canadian Medical Association,
	the association&#146;s highest award, in 2006. Dr. Friesen also holds eight Honorary
	Doctorates from Canadian universities.
</P>
<P ALIGN=CENTER>
	42
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage53"></A>
<A NAME="EXHIBIT99-1_HTM_PAGE_43">
</A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Dr. Robert Kirkman
</I>
</B>
	-
<I>
	Director
</I>
</P>
<P ALIGN=JUSTIFY>
	Dr. Kirkman served as Oncothyreon&#146;s President and Chief
	Executive Officer from September 2006 to January 2016. From 2005 to 2006, he was
	acting President and Chief Executive Officer of Xcyte Therapies, which concluded
	a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceutical
	companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was Chief Business
	Officer and Vice President of Xcyte. From 1998 to 2003, Dr. Kirkman was Vice
	President, Business Development and Corporate Communications of Protein Design
	Labs, a biopharmaceutical company. Dr. Kirkman holds a M.D. degree from Harvard
	Medical School and a B.A. in economics from Yale University.
</P>
<P ALIGN=JUSTIFY>
<B>
	Audit Committee Oversight
</B>
</P>
<P ALIGN=JUSTIFY>
	Since the commencement of our most recently completed fiscal
	year and adoption of the audit committee charter, the Board has not failed to
	adopt a recommendation of the audit committee to nominate or compensate an
	external auditor.
</P>
<P ALIGN=JUSTIFY>
<B>
	Pre-Approval Policies and Procedures
</B>
</P>
<P ALIGN=JUSTIFY>
	The audit committee has adopted specific policies and
	procedures for the engagement of audit and non-audit services as set out in our
	Auditor Services Pre-Approval Policy. Pursuant to the Policy, the audit
	committee on an annual basis may approve the provision of a specified list of
	audit and permitted non-audit services that the audit committee believes to be
	typical, reoccurring or otherwise likely to be provided by the external auditor
	during the then current fiscal year. All pre-approvals granted under this Policy
	shall be sufficiently detailed as to the particular services being provided that
	it will not be necessary for management of Trillium to exercise any discretion
	in determining whether a particular service has been pre-approved.
</P>
<P ALIGN=JUSTIFY>
	In addition, pursuant to the Policy the audit committee has
	delegated its pre-approval authority to the Chair of the audit committee for
	services where the aggregate fees are estimated to be less than or equal to Cdn.
	$50,000. The Chair of the audit committee is required to report any such granted
	pre-approvals to the audit committee at its next scheduled meeting. The audit
	committee shall not delegate to management the audit committee's
	responsibilities for pre-approving audit and non-audit services to be performed
	by the external auditor.
</P>
<P ALIGN=JUSTIFY>
	Pursuant to the Policy, there is an exception to the
	pre-approval requirements for permitted non-audit services, provided all such
	services were not recognized at the time of the engagement to be non-audit
	services and, once recognized, are promptly brought to the attention of the
	audit committee and approved prior to the completion of the audit. The aggregate
	amount of all services approved in this manner may not constitute more than five
	percent of the total fees paid to the external auditor during the fiscal year in
	which the services are provided.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P ALIGN=JUSTIFY>
<B>
	External Auditors Service Fees (By Category)
</B>
</P>
<P ALIGN=JUSTIFY>
	The aggregate fees billed and accrued by our external auditor
	in the last two fiscal years for auditor service fees were as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Audit Related
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;&nbsp;&nbsp;
<B>
	Financial Year Ending
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Audit Fees
</B>
<B>
<SUP>
	(1)
</SUP>
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Fees
</B>
<B>
<SUP>
	(2)
</SUP>
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Tax
	Fees
</B>
<B>
<SUP>
	(3)
</SUP>
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	All Other Fees
</B>
<B>
<SUP>
	(4)
</SUP>
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	December 31, 2015
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	378,970
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	Nil
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	22,805
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	Nil
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	313,820
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	Nil
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	2,050
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	Nil
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Notes:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(1)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	&#147;Audit fees&#148; are the aggregate fees billed by Ernst &amp;
	Young LLP for the audit of Trillium&#146;s consolidated annual financial
	statements, reviews of interim financial statements and attestation
	services that are provided in connection with statutory and regulatory
	filings or engagements. During 2014, the services also consisted of fees
	related to the filing of a base shelf prospectus and
	procedures for the Form 20-F filing.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	43
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage54"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_44">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(2)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	&#147;Audit-related fees&#148; are fees charged by Ernst &amp;
	Young LLP for assurance and related services that are reasonably related
	to the performance of the audit or review of the Trillium&#146;s financial
	statements and are not reported under &#147;Audit Fees.&#148;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(3)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	&#147;Tax fees&#148; are fees billed by Ernst &amp; Young LLP for
	tax compliance and tax advice.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(4)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	&#147;All other fees&#148; are fees billed by Ernst &amp; Young LLP
	for services not described above.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	ADDITIONAL INFORMATION
</B>
</P>
<P ALIGN=JUSTIFY>
	Additional information about us may be found on SEDAR at
	www.sedar.com. Additional information, including directors&#146; and officers&#146;
	remuneration and indebtedness, principal holders of our securities, options to
	purchase securities and securities authorized for issuance under equity
	compensation plans, is contained in our Management Information Circular for our
	most recent annual meeting of shareholders. Additional information may also be
	found in our audited financial statements and related management&#146;s discussion
	and analysis for our most recently completed financial year.
</P>
<P ALIGN=CENTER>
	44
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage55"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_45">
</A>
<P ALIGN=CENTER>
<B>
	SCHEDULE A
</B>
</P>
<P ALIGN=CENTER>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
<BR>
<B>
	CHARTER OF THE AUDIT
	COMMITTEE
</B>
<BR>
<B>
	OF THE BOARD OF DIRECTORS
</B>
</P>
<P ALIGN=CENTER>
<I>
	Approved by the Board of Directors on November 19,
	2015
</I>
<B>
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	POWER, AUTHORITY AND PURPOSE OF THE COMMITTEE
</B>
</P>
<P ALIGN=JUSTIFY>
	The purpose of the Audit Committee (the &#147;Committee&#148;) of the
	Board of Directors (the &#147;Board&#148;) of Trillium Therapeutics Inc. (together with
	its subsidiaries,
<B>
</B>
	the &#147;Company&#148;) is to assist the Board in:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Overseeing the integrity of the Company&#146;s financial
	statements and the Company&#146;s accounting and financial reporting processes
	and financial statement audits.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Overseeing the Company&#146;s compliance with legal and
	regulatory requirements.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Overseeing the qualifications and independence of the
	Company&#146;s registered public accounting firm (independent auditor).
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Overseeing the performance of the Company&#146;s independent
	auditor.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD WIDTH="90%">
<P ALIGN=JUSTIFY>
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	Overseeing the design, implementation and on-going
	effectiveness of the Company&#146;s systems of disclosure controls and
	procedures, risk management systems, internal control over financial
	reporting and compliance with ethical standards adopted by the Company.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The operation of the Committee shall be subject to the Bylaws
	of the Company, as in effect from time to time, and the rules and regulations
	promulgated by the Ontario Securities Commission, the Toronto Stock Exchange,
	the U.S. Securities and Exchange Commission (&#147;SEC&#148;) and the NASDAQ Stock Market
	LLC (&#147;NASDAQ&#148;), as in effect from time to time. The Committee shall have the
	full power and authority to carry out the duties and responsibilities listed
	below.
</P>
<P ALIGN=JUSTIFY>
	While the Committee has the responsibilities and powers set
	forth in this charter (this &#147;Charter&#148;), it is not the duty of the Committee to
	plan or conduct audits or to determine that the Company&#146;s financial statements
	are complete and accurate and are in accordance with generally accepted
	accounting principles. Management is responsible for preparing the Company&#146;s
	financial statements, and the Company&#146;s independent auditor is responsible for
	auditing those financial statements.
</P>
<P ALIGN=JUSTIFY>
	The Committee has the authority to undertake the specific
	duties and responsibilities listed below and such other duties as the Board may
	from time to time prescribe. It is acknowledged, however, that all of the areas
	of oversight listed below may not be relevant to all of the matters and tasks
	that the Committee may consider and act upon from time to time, and the members
	of the Committee in their judgment may determine the relevance thereof and the
	attention such items will receive in any particular context.
</P>
<P ALIGN=JUSTIFY>
	The Committee shall have the power and authority to act
	independently of management, conduct investigations into any matters within its
	scope of responsibility, hire and obtain advice from its own outside legal,
	accounting or other advisors who will report solely to the Committee, set and
	pay the compensation for any advisors employed by the Committee and communicate
	directly with internal and external auditors.
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage56"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_46">
</A>
<P ALIGN=JUSTIFY>
	Committee members and the Committee Chair shall receive such
	remuneration for their service on the Committee as the Board may determine from
	time to time, on the recommendation of the Compensation Committee.
</P>
<P ALIGN=JUSTIFY>
<B>
	COMPOSITION
</B>
</P>
<P ALIGN=JUSTIFY>
	The Committee shall be comprised of a minimum of three members,
	each of whom, in the determination of the Board, satisfies the independence,
	financial literacy and experience requirements of applicable U.S. and Canadian
	securities laws, rules and guidelines, any applicable stock exchange
	requirements or guidelines and any other applicable regulatory rules.
</P>
<P ALIGN=JUSTIFY>
	In particular:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	1.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	each member shall be (a) an &#147;Independent Director,&#148; as
	defined in NASDAQ Marketplace Rule 5605(a)(2), and (b) &#147;independent&#148;
	within the meaning of Rule 10A-3 under the United States Securities
	Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and the
	determination of independence will be affirmatively made by the Board
	annually, provided that the Board may elect to take advantage of any
	exemption from such requirements provided in the NASDAQ rules or the
	Exchange Act;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	2.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	each member shall meet the independence and financial
	literacy requirements set forth in Canadian National Instrument 52-110
<I>
	Audit Committees
</I>
	and such additional criteria for independence as
	the Board may establish;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	3.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	each member shall not have participated in the
	preparation of the financial statements of the Company (or any then
	current subsidiary of the Company) at any time during the past three
	years;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	4.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	each member shall be able to read and understand
	fundamental financial statements in accordance with the audit committee
	requirements for companies listed on NASDAQ in NASDAQ Marketplace Rule
	5605(c)(2)(A)(iv); and
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	5.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	at least one (1) member shall, in the judgment of the
	Board, be an &#147;audit committee financial expert&#148; within the meaning of such
	term in Item 407(d) of Regulation S-K of the SEC.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The chairperson of the Committee (the &#147;Chair&#148;) will be
	appointed by the Board on the recommendation of the Corporate Governance and
	Nominating Committee and will serve at the discretion of the Board, and all
	members will serve at the pleasure of the Board, continuing as a member of the
	Committee until resignation or replacement. The Board may fill vacancies on the
	Committee by appointment, on the recommendation of the Corporate Governance and
	Nominating Committee, from qualified members of the Board.
</P>
<P ALIGN=JUSTIFY>
	The designation of the Chair shall occur annually at the first
	meeting of the Board after a meeting of shareholders at which Directors are
	elected. If the Chair is not so designated, the Director who is then serving as
	Chair shall continue as Chair until his or her successor is appointed.
</P>
<P ALIGN=JUSTIFY>
<B>
	COMMITTEE FUNCTION AND PROCESS
</B>
</P>
<P ALIGN=JUSTIFY>
	The Committee will meet at least once each fiscal quarter. The
	Committee may establish its own schedule and call additional meetings as it
	deems necessary to fulfill its responsibilities. The Committee shall fix its own
	rules of procedure, which shall be consistent with the Bylaws of the Company and
	this Charter. A majority of the Committee members, but not less than two, shall
	constitute a quorum. Committee meetings may be attended in person or by
	telephone or video conferencing or any other electronic means of communication.
	The Committee may request that any directors, officers or employees of the
	Company, or other persons whose advice and counsel are sought by the Committee,
	attend any meeting to provide such information as the Committee requests. The
	Committee may take action by unanimous written consent when deemed necessary or
	desirable by the Committee or its Chair, subject to the requirements of any
	applicable law, regulation or rule.
</P>
<P ALIGN=CENTER>
	A - 2
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage57"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_47">
</A>
<P ALIGN=JUSTIFY>
	The Committee Chair will approve the agenda for the Committee&#146;s
	meetings and any member may suggest items for consideration. Committee members
	may raise any subjects that are not set on the agenda by the Committee Chair.
	Each regularly scheduled meeting will conclude with an executive session of the
	Committee absent members of management.
</P>
<P ALIGN=JUSTIFY>
	The Committee will meet separately with the Chief Executive
	Officer and the Chief Financial Officer at such times as it deems appropriate to
	review the financial affairs of the Company. The Committee will meet separately
	with the independent auditor and without management present, at such times as it
	deems appropriate, but not less than quarterly, to fulfill the responsibilities
	of the Committee under this Charter.
</P>
<P ALIGN=JUSTIFY>
	The independent auditor shall receive notice of each meeting of
	the Committee and shall be entitled to attend and be heard at any such meeting
	at the Company's expense.
</P>
<P ALIGN=JUSTIFY>
	The Committee shall maintain copies of minutes of each meeting
	and each written consent to action taken without a meeting, reflecting the
	actions so authorized or taken by the Committee. After approval, the minutes
	shall be signed by the Chair or Secretary of the meeting and a copy of the
	minutes and all consents shall be placed in the Company&#146;s minute book.
</P>
<P ALIGN=JUSTIFY>
	The Committee will summarize its examinations and
	recommendations to the Board as may be appropriate, consistent with this
	Charter.
</P>
<P ALIGN=JUSTIFY>
<B>
	ROLE OF THE CHAIR
</B>
</P>
<P ALIGN=JUSTIFY>
	The Chair&#146;s primary role is to ensure that the Committee
	functions properly, meets its obligations and responsibilities, fulfills its
	purpose and that its organization and mechanisms are in place and working
	effectively. More specifically, the Chair shall:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	1.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	chair meetings of the Committee;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	2.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	in consultation with the Chair of the Board, the members,
	and the Chief Financial Officer, set the agendas for the meetings of the
	Committee;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	3.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	in collaboration with the Chair of the Board, the Chief
	Executive Officer, and the Chief Financial Officer, ensure that agenda
	items for all Committee meetings are ready for presentation and that
	adequate information is distributed to members in advance of such meetings
	in order that members may properly inform themselves on matters to be
	acted upon;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	4.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	assign work to members;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	5.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	act as liaison and maintain communication with the Chair
	of the Board and the Board to optimize and co- ordinate input from
	directors, and to optimize the effectiveness of the Committee;
	and
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	6.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	provide leadership to the Committee with respect to its
	functions as described in this Charter and as otherwise may be
	appropriate.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	DUTIES AND RESPONSIBILITIES
</B>
</P>
<P ALIGN=JUSTIFY>
	The Committee shall:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	1.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Be responsible for overseeing the design, implementation
	and on-going effectiveness of policies and procedures for providing
	reasonable assurance regarding the reliability of financial reporting and
	the preparation of financial statements for external purposes in
	accordance with generally accepted accounting principles, including those
	policies and procedures that: (i) pertain to the maintenance of records
	that in reasonable detail accurately and fairly reflect the
	transactions and dispositions of the assets of the Company; (ii) provide
	reasonable assurance that transactions are recorded as necessary to permit
	preparation of financial statements in accordance with generally accepted
	accounting principles, and that receipts and expenditures of the Company
	are being made only in accordance with authorizations of management and
	directors of the Company; and (iii) provide reasonable assurance regarding
	prevention or timely detection of unauthorized acquisition, use or
	disposition of the Company&#146;s assets that could have a material effect on
	the financial statements.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	A - 3
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage58"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_48">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	2.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Periodically review the adequacy and effectiveness of the
	Company&#146;s system of internal control over financial reporting and
	disclosure controls and procedures, by meeting with the Company&#146;s
	management, the independent auditor and the Chair of the Disclosure
	Committee to review the adequacy and effectiveness of such controls; and
	review before its release the disclosure regarding such system of internal
	control and disclosure controls required to be contained in the Company&#146;s
	periodic filings and the attestations or reports by the independent
	auditor relating to such disclosure.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	3.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review with the chief executive officer, the chief
	financial officer, and the independent auditor: (i) all significant
	deficiencies and material weaknesses in the design or operation of the
	Company&#146;s internal controls that could adversely affect the Company&#146;s
	ability to record, process, summarize and report financial information
	required to be disclosed by the Company in the reports that it files or
	submits with applicable securities regulators within the required time
	periods, and (ii) any fraud, whether or not material, that involves
	management of the Company or other employees who have a significant role
	in the Company&#146;s internal controls.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	4.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Be directly responsible, in its capacity as a committee
	of the Board and subject to the rights of shareholders and applicable law,
	for the selection, nomination, retention, termination and oversight of the
	work of any independent auditor (including the resolution of disagreements
	between management and the independent auditor regarding financial
	reporting) engaged for the purpose of preparing or issuing an audit report
	or performing other audit, review or attest services for the Company. The
	Committee shall recommend to the Board the independent auditor to be
	nominated for approval by the shareholders and the compensation of the
	independent auditor. Each such independent auditor shall report directly
	to the Committee.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	5.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Pre-approve all audit services to be provided to the
	Company by the independent auditor, and pre-approve, or establish policies
	and procedures for the review and pre-approval of all permitted non-audit
	services to be provided to the Company by the independent
	auditor.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	6.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review and provide guidance with respect to the external
	audit and the Company&#146;s relationship with its independent auditor by (a)
	reviewing the independent auditor&#146;s proposed audit plan (including scope,
	fees and schedule), approach and independence; (b) obtaining on a periodic
	basis, but no less frequently than annually, a formal written statement
	from the independent auditor delineating all relationships between the
	independent auditor and the Company concerning auditor independence; being
	actively engaged in dialogue with the independent auditor with respect to
	any disclosed relationship or services with the Company that may impact
	the objectivity and independence of the independent auditor, presenting
	this statement to the Board, and to the extent there are relationships,
	monitoring and investigating them; (c) taking, or recommending to the
	Board to take, appropriate action to oversee the independence of the
	independent auditor; (d) reviewing any publicly available inspection
	report on the independent auditor issued by the Public Company Accounting
	Oversight Board or the Canadian Public Accountability Board; (e)
	discussing with the Company&#146;s independent auditor the financial statements
	and audit findings, including any significant adjustments, management
	judgments and accounting estimates, significant new accounting policies
	and disagreements with management; (f) reviewing with both management and
	the independent auditor the appropriateness and acceptability of the
	Company&#146;s critical accounting policies and any proposed changes thereto;
	and (g) reviewing reports submitted to the audit committee by the
	independent auditor in accordance with the applicable regulatory
	requirements.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	7.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review any problems experienced by the independent
	auditor in performing audits.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	A - 4
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage59"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_49">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	8.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review and discuss with management and the independent
	auditor, and approve the annual audited financial statements and quarterly
	unaudited financial statements, including the Company&#146;s disclosures under
	&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
	of Operations,&#148; prior to filing with regulatory authorities.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	9.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Recommend to the Board the approval and filing of the
	annual audited financial statements.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	10.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Periodically review and discuss with the Chair of the
	Disclosure Committee the disclosures contained in the Company&#146;s filings
	with the regulatory authorities prior to filing and the processes and
	procedures followed to ensure the accuracy of such disclosure.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	11.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Direct the Company&#146;s independent auditor to review before
	filing with all regulatory authorities the Company&#146;s interim financial
	statements, using professional standards and procedures for conducting
	such reviews.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	12.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review all material written communications between the
	independent auditor and management, including post audit or management
	letters containing recommendations of the independent auditor,
	management&#146;s response and follow up with respect to the identified
	weaknesses.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	13.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review before release any press release including annual
	and quarterly results or forecasts.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	14.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Satisfy itself that adequate procedures are in place for
	the review of the Company&#146;s public disclosure of financial information
	extracted or derived from the Company&#146;s financial statements (including,
	without limitation, the use of &#147;pro forma&#148; or non-GAAP financial
	information), other than the public dissemination referred to in the
	foregoing paragraph, and periodically assess the adequacy of those
	procedures.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	15.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Oversee compliance with the regulatory requirements for
	disclosure of auditor&#146;s services and audit committee members, member
	qualifications and activities.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	16.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review and reassess the adequacy of the Whistleblower
	Policy, the Auditor Services Pre-Approval Policy, and the Corporate
	Disclosure and Confidentiality Policy on at least an annual basis and
	recommend any proposed changes to the Board for approval.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	17.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review, in conjunction with counsel, any legal matters
	that could have a significant impact on the Company&#146;s financial
	statements.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	18.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Engage, as appropriate, outside legal, accounting and
	other advisors, with (a) the authority to retain such counsel or other
	advisors as the Committee may deem appropriate in its sole discretion, and
	(b) the sole authority to determine funding, approve fees and retention
	terms for such counsel and advisors.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	19.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review and approve in advance any proposed related-party
	transactions, and report any such transactions to the Board.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	20.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review and reassess the adequacy of the Audit Committee
	charter, structure, processes and membership requirements on at least an
	annual basis and recommend any proposed changes to the Board for
	approval.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	21.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Establish procedures for the receipt, retention and
	treatment of complaints received by the Company regarding accounting,
	internal accounting controls or auditing matters; and establish procedures
	for the confidential, anonymous submission by employees of the Company of
	concerns regarding questionable accounting or auditing matters.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	22.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review, approve and monitor the Company&#146;s investment
	policy, investment portfolio, cash management objectives, and exposure to
	market risk.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	A - 5
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage60"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-1_HTM_PAGE_50">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	23.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review the effectiveness of the Company&#146;s risk management
	system to assure that material risks are identified and appropriate risk
	management processes are in place.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	24.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review and discuss with management the Company&#146;s major
	financial risk exposures and the steps management has taken to monitor and
	control such exposures.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	25.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review with management and the external auditor the
	presentation and impact of significant risks and uncertainties associated
	with the Company&#146;s business, all alternative treatments of financial
	information with generally accepted accounting principles that have been
	discussed with management, the material assumptions made by management
	relating to them and their effect on the Company&#146;s financial
	statements.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	26.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Periodically review the Company&#146;s practices to maintain
	the security of its information technology systems.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	27.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Ensure the regular rotation of the lead audit partner,
	the concurring partner and other audit partners engaged in the Company&#146;s
	annual audit to the extent required by applicable law;
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	28.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Perform an evaluation of its performance at least
	annually to determine whether it is functioning effectively.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	29.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Establish, or review and approve, in accordance with
	applicable law, hiring policies for partners, employees or former partners
	and employees of the present and former independent auditor and oversee
	the hiring of any personnel from the independent auditor into positions
	within the Company.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	30.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Obtain assurance from the independent auditor that
	disclosure to the Committee is not required pursuant to the provisions of
	the Exchange Act regarding the discovery of illegal acts by the
	independent auditor.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	31.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review management&#146;s processes in place to prevent and
	detect fraud.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	32.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review policies and practices with respect to off-balance
	sheet transactions and trading and hedging activities, and consider the
	results of any review of these areas by the independent auditor.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	33.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Review with the chief executive officer and the chief
	financial officer their certifications required to be included in periodic
	reports filed with securities regulators.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="5%">
	34.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Perform any other activities consistent with this
	Charter, the Company&#146;s bylaws and governing laws that the Board or the
	Committee determines are necessary or appropriate.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	DELEGATION OF AUTHORITY
</B>
</P>
<P ALIGN=JUSTIFY>
	The Committee may, in accordance with law, delegate to one or
	more independent members of the Committee the authority to pre-approve audit and
	permitted non-audit services, provided that such pre-approval decision is
	presented to the full Committee at its first scheduled meeting following such
	pre-approval.
</P>
<P ALIGN=JUSTIFY>
<B>
	RESOURCES AND ADDITIONAL AUTHORITY OF THE COMMITTEE
</B>
</P>
<P ALIGN=JUSTIFY>
	The Committee shall have the resources and authority
	appropriate to discharge its duties and responsibilities in accordance with this
	Charter. The Company shall provide appropriate funding, as determined by the
	Committee, in its capacity as a committee of the Board, for payment of (i)
	compensation to any independent auditor engaged for the purpose of preparing or
	issuing an audit report or performing other audit, review or attest services for
	the Company; (ii) compensation to any advisors employed by the Committee
	pursuant to the foregoing paragraph; and (iii) ordinary administrative expenses
	of the Committee that are necessary or appropriate in carrying out its duties.
</P>
<P ALIGN=CENTER>
	A - 6
</P>
<HR ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage61"></A>
<A NAME="EXHIBIT99-2_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_2"></A>
<HR NOSHADE ALIGN="CENTER" WIDTH=100% SIZE=3 COLOR="BLACK">
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_1">
</A>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-2X1X1.JPG" BORDER=0 WIDTH="305" HEIGHT="207">
</P>
<P ALIGN=CENTER>
	(formerly Stem Cell Therapeutics Corp.)
<B>
</B>
</P>
<P ALIGN=CENTER>
<B>
	MANAGEMENT&#146;S DISCUSSION AND ANALYSIS
</B>
</P>
<P ALIGN=CENTER>
<B>
	FOR THE YEARS ENDED
<BR>
</B>
<B>
	DECEMBER 31, 2015 AND 2014
</B>
</P>
<P ALIGN=CENTER>
	Dated: March 9, 2016
</P>
<P ALIGN=CENTER>
	96 Skyway Avenue
<BR>
	Toronto, Ontario, M9W 4Y9
<BR>
	www.trilliumtherapeutics.com
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage62"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_2">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	ABOUT THIS MANAGEMENT DISCUSSION AND ANALYSIS
</B>
</P>
<P ALIGN=JUSTIFY>
	All references in this management&#146;s discussion and analysis, or
	MD&amp;A to &#147;the Company&#148;, &#147;Trillium&#148;, &#147;we&#148;, &#147;us&#148;, or &#147;our&#148; refer to Trillium
	Therapeutics Inc. and the subsidiaries through which it conducts its business,
	unless otherwise indicated.
</P>
<P ALIGN=JUSTIFY>
	The following MD&amp;A is prepared as of March 9, 2016 for
	Trillium Therapeutics Inc. for the years ended December 31, 2015 and 2014, and
	should be read in conjunction with the audited consolidated financial statements
	for the years ended December 31, 2015 and 2014, which have been prepared by
	management in accordance with International Financial Reporting Standards, or
	IFRS, as issued by the International Accounting Standards Board, or IASB. Our
	IFRS accounting policies are set out in note 3 of the annual audited
	consolidated financial statements for the years ended December 31, 2015 and
	2014.
</P>
<P ALIGN=JUSTIFY>
	On June 1, 2014, we amalgamated with our wholly-owned
	subsidiary Trillium Therapeutics Inc., or Trillium Privateco and changed its
	name to Trillium Therapeutics Inc. All amounts are in Canadian dollars, unless
	otherwise indicated.
</P>
<P ALIGN=CENTER>
<B>
	CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
</B>
</P>
<P ALIGN=JUSTIFY>
	This MD&amp;A contains forward-looking statements within the
	meaning of applicable securities laws. All statements contained herein that are
	not clearly historical in nature are forward-looking, and the words
	&#147;anticipate&#148;, &#147;believe&#148;, &#147;expect&#148;, &#147;estimate&#148;, &#147;may&#148;, &#147;will&#148;, &#147;could&#148;,
	&#147;leading&#148;, &#147;intend&#148;, &#147;contemplate&#148;, &#147;shall&#148; and similar expressions are
	generally intended to identify forward-looking statements. Forward-looking
	statements in this MD&amp;A include, but are not limited to, statements with
	respect to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expected future loss and accumulated deficit levels;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our projected financial position and estimated cash burn
	rate;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about the timing of achieving milestones
	and the cost of our development programs;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our observations and expectations regarding the relative
	low binding of SIRP&#945;Fc to red blood cells compared to anti-CD47 monoclonal
	antibodies and proprietary CD47-blocking agents and the potential benefits
	to patients;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our requirements for, and the ability to obtain, future
	funding on favorable terms or at all;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our projections for the SIRP&#945;Fc development plan and
	progress of each of our products and technologies, particularly with
	respect to the timely and successful completion of studies and trials and
	availability of results from such studies and trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about the differentiated nature and
	potential for best-in-class product development programs and discovery
	research capabilities of Fluorinov Pharma Inc., or Fluorinov;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to generate future product development
	programs with improved pharmacological properties using Fluorinov
	technology;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about whether various clinical and
	regulatory milestones with an existing Fluorinov compound will be
	achieved;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations of the final quantum and form of any
	future contingent milestone payments related to the Fluorinov acquisition;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations of the ability to secure the requisite
	approvals (including TSX and NASDAQ approvals) with respect to the
	issuance of any common shares in satisfaction of future milestone
	payments;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations about our products&#146; safety and efficacy;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations regarding our ability to arrange for the
	manufacturing of our products and technologies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations regarding the progress, and the
	successful and timely completion, of the various stages of the regulatory
	approval process;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to secure strategic partnerships with larger
	pharmaceutical and biotechnology companies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our strategy to acquire and develop new products and
	technologies and to enhance the safety and efficacy of existing products
	and technologies;
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 2 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage63"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_3">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our plans to market, sell and distribute our products and
	technologies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations regarding the acceptance of our products
	and technologies by the market;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to retain and access appropriate staff,
	management, and expert advisers;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our expectations with respect to existing and future
	corporate alliances and licensing transactions with third parties, and the
	receipt and timing of any payments to be made by us or to us in respect of
	such arrangements; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our strategy with respect to the protection of our
	intellectual property.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	All forward-looking statements reflect our beliefs and
	assumptions based on information available at the time the assumption was made.
	These forward-looking statements are not based on historical facts but rather on
	management&#146;s expectations regarding future activities, results of operations,
	performance, future capital and other expenditures (including the amount, nature
	and sources of funding thereof), competitive advantages, business prospects and
	opportunities. By its nature, forward-looking information involves numerous
	assumptions, inherent risks and uncertainties, both general and specific, known
	and unknown, that contribute to the possibility that the predictions, forecasts,
	projections or other forward-looking statements will not occur. Factors which
	could cause future outcomes to differ materially from those set forth in the
	forward-looking statements include, but are not limited to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the effect of continuing operating losses on our ability
	to obtain, on satisfactory terms, or at all, the capital required to
	maintain us as a going concern;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the ability to obtain sufficient and suitable financing
	to support operations, preclinical development, clinical trials, and
	commercialization of products;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks associated with the development of novel
	compounds at early stages of development in our intellectual property
	portfolio;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks of reliance on third-parties for the planning,
	conduct and monitoring of clinical trials and for the manufacture of drug
	product;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks associated with the development of our product
	candidates including the demonstration of efficacy and safety;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks related to clinical trials including potential
	delays, cost overruns and the failure to demonstrate efficacy and safety;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risks of delays and inability to complete clinical
	trials due to difficulties enrolling patients;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risks associated with our inability to successfully
	develop companion diagnostics for our development candidates;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	delays or negative outcomes from the regulatory approval
	process;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to successfully compete in our targeted
	markets;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to attract and retain key personnel,
	collaborators and advisors;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risks relating to the increase in operating costs from
	expanding existing programs, acquisition of additional development
	programs and increased staff;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risk of negative results of clinical trials or adverse
	safety events by us or others related to our product candidates;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the potential for product liability claims;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to achieve our forecasted milestones and
	timelines on schedule;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	financial risks related to the fluctuation of foreign
	currency rates and expenses denominated in foreign currencies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to adequately protect proprietary information
	and technology from competitors;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	risks related to changes in patent laws and their
	interpretations;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to source and maintain licenses from
	third-party owners; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the risk of patent-related litigation and the ability to
	protect trade secrets,
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	all as further and more fully described under the heading &#147;Risk
	Factors&#148; in this MD&amp;A and in our Annual Information Form.
</P>
<P ALIGN=CENTER>
	- 3 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage64"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_4">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Although the forward-looking statements contained in this
	MD&amp;A are based upon what our management believes to be reasonable
	assumptions, we cannot assure readers that actual results will be consistent
	with these forward looking statements.
</P>
<P ALIGN=JUSTIFY>
	Any forward-looking statements represent our estimates only as
	of the date of this MD&amp;A and should not be relied upon as representing our
	estimates as of any subsequent date. We undertake no obligation to update any
	forward-looking statement or statements to reflect events or circumstances after
	the date on which such statement is made or to reflect the occurrence of
	unanticipated events, except as may be required by securities legislation.
</P>
<P ALIGN=CENTER>
<B>
	BUSINESS
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	Overview
</B>
</P>
<P ALIGN=JUSTIFY>
	We are an immuno-oncology company developing innovative
	therapies for the treatment of cancer. Our lead program, SIRP&#945;Fc, is a novel,
	antibody-like protein that harnesses the innate immune system by blocking the
	activity of CD47, a molecule whose expression is increased on cancer cells to
	evade the host immune system. Expressed at high levels on the cell surface of a
	variety of liquid and solid tumors, CD47 functions as a signal that inhibits the
	destruction of tumor cells by macrophages via phagocytosis. By blocking the
	activity of CD47, we believe SIRP&#945;Fc has the ability to promote the
	macrophage-mediated killing of tumor cells in a broad variety of cancers both as
	a monotherapy and in combination with other immune therapies.
</P>
<P ALIGN=JUSTIFY>
	The immune system is the body&#146;s mechanism to identify and
	eliminate pathogens, and can be divided into the innate immune system and the
	adaptive immune system. The innate immune system is the body&#146;s first line of
	defense to identify and eliminate pathogens and consists of proteins and cells,
	such as macrophages, that identify and provide an immediate response to
	pathogens. The adaptive immune system is activated by, and adapts to, pathogens,
	creating a targeted and durable response. Cancer cells often have the ability to
	reduce the immune system&#146;s ability to recognize and destroy them. We believe
	SIRP&#945;Fc could play an important role in enhancing the innate immune system and
	importantly, because of its ability to target macrophages, also has an important
	downstream effect on the adaptive immune system.
</P>
<P ALIGN=JUSTIFY>
<B>
	Our Strategy
</B>
</P>
<P ALIGN=JUSTIFY>
	Our goal is to become a leading innovator in the field of
	immuno-oncology by targeting immune-regulatory pathways that tumor cells exploit
	to evade the host immune system. We believe that SIRP&#945;Fc has the potential to
	improve survival and quality of life for cancer patients.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Rapidly advance the clinical development of
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc
</I>
</B>
	. We have initiated a
	first-in-human trial of SIRP&#945;Fc in patients with relapsed or refractory
	lymphoma in a dose escalation phase of up to 36 patients,&nbsp; and expect to enroll up to 8 cohorts of 12-15 patients with
	advanced hematologic malignancies in an expansion phase of the trial after
	an optimal dose has been determined.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Expand our SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc
	clinical program to include additional cancer indications
</I>
</B>
	. Because
	CD47 is highly expressed by multiple liquid and solid tumors, and high
	expression is correlated with worse clinical outcomes, we believe SIRP&#945;Fc
	has potential to be effective in a wide variety of cancers. We are
	carrying out preclinical work necessary to select additional, high
	potential cancer indications for clinical development.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Maximize value of
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc through scientific
	collaborations
</I>
</B>
	. SIRP&#945;Fc has broad potential applicability in
	various cancer indications, and we believe it is well suited for use as
	both a monotherapy and in combination with other agents. We plan to
	continue to selectively and opportunistically pursue scientific
	collaborations with academic researchers as well as with other companies
	in order to realize the full value proposition of SIRP&#945;Fc.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Initiate IND-enabling studies in 2016 with a
	Fluorinov product
</I>
</B>
	. TTI-281 is an oral bromodomain inhibitor that
	we believe has strong potency and has shown efficacy in AML xenograft
	models. We plan to initiate scale up and manufacturing for TTI-281 in
	2016.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 4 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage65"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_5">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	SIRP
</B>
<B>
	&#945;
</B>
<B>
	Fc Key Attributes
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Potential efficacy in a broad range of
	cancers
</I>
</B>
	. SIRP&#945;Fc blocks the tumor&#146;s ability to transmit a &#147;do not
	eat&#148; signal allowing macrophages to destroy tumor cells; a mechanism that
	we believe could have broad applicability.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Potential for use as monotherapy and in combination
	with other therapies
</I>
</B>
	. We intend to develop SIRP&#945;Fc as a
	monotherapy as well as potentially for use in combination with other
	cancer immuno- therapies.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	Differentiated pharmacokinetic and safety
	profile
</I>
</B>
	. We believe SIRP&#945;Fc&#146;s low level of binding to red blood
	cells lowers the risk of anemia and lowers the loss of drug from
	circulation. This pharmacokinetic profile potentially allows for lower
	dosing and an improved safety profile.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
<B>
<I>
	May enhance both innate and adaptive immune
	response
</I>
</B>
	. SIRP&#945;Fc may enhance stimulation of tumor attacking T
	cells since macrophages, in addition to their role in phagocytosis, can
	also prime T cells through antigen presentation.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc Clinical development
	plan
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We commenced a phase I study in patients with advanced
	hematologic malignancies. The two-part clinical trial is designed as a
	multi-center, open-label Phase 1a/1b trial, evaluating TTI-621 as a single-agent
	in patients with relapsed or refractory hematologic malignancies. During the
	dose escalation phase set to enroll up to 36 subjects, the safety, tolerability,
	pharmacokinetics and pharmacodynamics will be characterized to determine the
	optimal dose for subsequent enrollment in the expansion phase. To characterize
	potential changes in hematologic parameters that might occur with blockade of
	CD47, the dose-escalation portion of the phase I trial will include lymphoma
	patients with normal hematologic parameters and acceptable marrow function. Once
	a reasonably well-tolerated dose and schedule of SIRP&#945;Fc has been established
	for further study, safety and antitumor activity will be estimated in expansion
	cohorts of up to 15 patients with advanced hematologic malignancies including
	indolent B-cell lymphoma, aggressive B-cell lymphoma, T-cell lymphoma, Hodgkin
	lymphoma, chronic lymphocytic leukemia, multiple myeloma, acute myeloid
	leukemia, and myelodysplastic syndrome. We plan to engage five trial sites in
	the United States for the dose escalation part of the trial.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Blocking the CD47 &#147;do not eat&#148; signal using a
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc decoy receptor
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Macrophages are a type of white blood cell that can ingest and
	destroy (phagocytose) other cells. They are part of the innate immune system
	that helps to protect the body from infection. More recently, a role for
	macrophages in the control of tumors has been described.
</P>
<P ALIGN=JUSTIFY>
	Macrophage activity is controlled by both positive &#147;eat&#148; and
	negative &#147;do not eat&#148; signals. Tumor cells may express &#147;eat&#148; signals (e.g.,
	calreticulin) that make themselves visible to macrophages. To counterbalance
	this increased visibility the tumor cells often express high levels of CD47,
	which transmits a &#147;do not eat&#148; signal by binding signal regulatory protein
	alpha, or SIRP&#945;, on the surface of macrophages. We believe that the higher
	expression of CD47 on the tumor cell helps it evade destruction by the
	macrophage by overwhelming any activating &#147;eat&#148; signals.
</P>
<P ALIGN=JUSTIFY>
	SIRP&#945;Fc is an
	antibody-like protein that consists of the CD47-binding domain of human SIRP&#945;
	linked to the Fc region of a human immunoglobulin. It is designed to act as a
	soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.
	Neutralization of the inhibitory CD47 signal enables the activation of
	macrophage anti-tumor effects by the pro-phagocytic &#147;eat&#148; signals. The Fc region
	of SIRP&#945;Fc may, depending on its identity, also assist in the activation of
	macrophages by engaging Fc receptors.
</P>
<P ALIGN=JUSTIFY>
	Figure 1, below, illustrates how SIRP&#945;Fc blocks the CD47 &#147;do
	not eat&#148; signal and engages activating Fc receptors on macrophages, leading to
	tumor cell phagocytosis.
</P>
<P ALIGN=CENTER>
	- 5 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage66"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_6">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-2X6X1.JPG" BORDER=0 WIDTH="635" HEIGHT="313">
</P>
<BR>
<P ALIGN=JUSTIFY>
	In addition to their direct anti-tumor activity, macrophages
	can also function as antigen-presenting cells and stimulate antigen-specific T
	cells. Thus it is possible that increasing tumor cell phagocytosis after SIRP&#945;Fc
	exposure may result in enhanced adaptive immunity. In support of this, CD47
	antibody blockade has been recently shown to augment antigen presentation and
	prime an anti-tumor cytotoxic T cell response in immune-competent mice. CD47
	blockade has also been reported to promote tumor-specific T cell responses
	through a dendritic cell-based mechanism, although the effect of SIRP&#945;Fc on
	dendritic cells is currently unknown.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	Fc has broad clinical
	potential
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We believe that SIRP&#945;Fc has broad clinical potential in both
	hematological and solid tumors. High expression of the CD47 &#147;do not eat&#148; signal
	on tumor cells has been observed in AML, MDS, chronic myeloid leukemia, or CML,
	acute lymphoblastic leukemia, or ALL, diffuse large B cell lymphoma, or DLBCL,
	chronic lymphocytic leukemia, or CLL, follicular lymphoma, mantle cell lymphoma,
	marginal zone lymphoma, multiple myeloma and in the following solid tumors:
	bladder, brain, breast, colon, leiomyosarcoma, liver, melanoma, ovarian and
	prostate. In a number of these cancers high CD47 expression was shown to have
	negative clinical consequences, correlating with more aggressive disease and
	poor survival. In normal karyotype AML patients, for example, high CD47
	expression was correlated with worse event-free survival (6.8 vs. 17.1 months)
	and worse overall survival (9.1 vs. 22.1 months) compared to low CD47
	expression. These data are consistent with CD47 providing a survival advantage
	to tumor cells. Furthermore, numerous studies have shown that antibody blockade
	of CD47 has demonstrated activity in mice engrafted with human tumors. We
	collaborate with academic investigators to explore the therapeutic potential of
	SIRP&#945;Fc in a variety of solid tumor models.
</P>
<P ALIGN=JUSTIFY>
	In vitro studies with primary tumor samples obtained from AML,
	MDS, multiple myeloma, B cell-ALL and T-cell ALL demonstrated that SIRP&#945;Fc
	frequently triggered significantly macrophage-mediated tumor cell phagocytosis
	compared to control treatment. Similar results were observed with tumor cell
	lines established from patients with B lymphoma and CML.
</P>
<P ALIGN=JUSTIFY>
	Figure 2, below, shows how SIRP&#945;Fc (TTI-621) triggers
	macrophage-mediated phagocytosis of many different human blood cancer samples.
</P>
<P ALIGN=CENTER>
	- 6 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage67"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_7">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-2X7X1.JPG" BORDER=0 WIDTH="690" HEIGHT="379">
</P>
<BR>
<P ALIGN=JUSTIFY>
	The p value is a probability value, with values &lt;0.05
	considered statistically significant versus control treatment. NS indicates
	p&gt;0.05, which is considered not statistically significant versus control
	treatment.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	SIRP
</I>
</B>
<B>
<I>
	&#945;
</I>
</B>
<B>
<I>
	&#150; Minimal Red Blood
	Cell Binding - Competition
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	SIRP&#945;Fc competes directly with CD47 blocking antibodies from
	Forty Seven Inc. (recently licensed from Stanford University) and Celgene
	Corporation, both of which have entered early clinical development. Novimmune SA
	has a bispecific (anti-CD47/anti-CD19) antibody program in preclinical
	development. Vasculox is also developing a CD47 antibody. Alexo Therapeutics is
	developing mutated, high affinity SIRP&#945; monomers as adjuvants for use with
	anti-cancer antibodies. Both Vasculox and Alexo Therapeutics are in the
	preclinical phase of development.
</P>
<P ALIGN=JUSTIFY>
	We believe that our approach of using SIRP&#945;, the natural
	binding partner for CD47, may have important advantages over treatment with
	CD47-specific antibodies. In April 2015, we presented data at the 106th American
	Association for Cancer Research annual meeting demonstrating that our SIRP&#945;Fc
	fusion proteins exhibit minimal binding to human red blood cells, or RBCs,
	compared to anti-CD47 monoclonal antibodies. These data build upon preliminary
	results announced at the 2014 American Association for Cancer Research annual
	meeting.
</P>
<P ALIGN=JUSTIFY>
	Figure 3, below, shows how SIRP&#945;Fc binding to human RBCs (n=43
	donors) compares to five CD47-specific antibodies.
</P>
<P ALIGN=CENTER>
	- 7 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage68"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_8">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_EXHIBIT99-2X8X1.JPG" BORDER=0 WIDTH="286" HEIGHT="259">
<BR>
<P ALIGN=JUSTIFY>
	The very low RBC binding profile of our SIRP&#945;Fc proteins may
	provide three important advantages over other CD47 blocking agents. First, there
	may be a lower risk of experiencing drug-induced anemia with SIRP&#945;Fc. This
	potential advantage may translate into improved patient care, particularly in
	diseases such as AML where almost all patients experience cytopenias including
	anemia. Second, SIRP&#945;Fc may remain in circulation for longer intervals compared
	to CD47 antibodies, which have been demonstrated to bind strongly to circulating
	RBCs and may thus be more likely to be removed from circulation. The ability of
	RBCs to absorb and remove circulating CD47-specific antibodies, an &#147;antigen-sink
	effect&#148;, may necessitate high doses of antibody in order to effectively target
	the tumor cells, which may lead to potentially higher off-target toxicity.
	Therefore, SIRP&#945;Fc may be associated with both improved tolerability and drug
	kinetics compared with CD47-specific antibodies based on these preclinical
	analyses. Third, antibodies that bind RBCs have the potential to interfere with
	laboratory blood typing tests. The minimal binding of TTI-621 to human RBCs may
	minimize this interference compared to anti-CD47 antibodies.
<B>
<I>
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Combination Therapy
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We believe that SIRP&#945;Fc enhancement of macrophage activity and
	possibly T cell responses could be synergistic with other immune-mediated
	therapies. Published studies conducted by third parties provide evidence that
	SIRP&#945;Fc may be useful in combination with approved anti-cancer antibodies (e.g.
	Rituxan&#174;, Herceptin&#174;, Campath&#174;, and Erbitux&#174;). Since many cancer antibodies work
	at least in part by activating cells of the innate immune system, it may be
	possible to enhance the potency of these agents by blocking the negative &#147;do not
	eat&#148; CD47 signal that tumor cells deliver to macrophages. We hypothesize that
	SIRP&#945;Fc may act synergistically with other immunological agents, including T
	cell checkpoint inhibitors (e.g. pembrolizumab and nivolumab), cancer vaccines,
	oncolytic viruses or chimeric antigen receptor, or CAR T cells.
</P>
<P ALIGN=JUSTIFY>
<B>
	Small Molecule Program
</B>
</P>
<P ALIGN=JUSTIFY>
	On January 26, 2016, we acquired all the outstanding shares of
	Fluorinov, a privately-held oncology company that has developed a proprietary
	medicinal chemistry platform using unique fluorine chemistry, which permits the
	creation of new chemical entities from validated drugs and drug candidates with
	improved pharmacological properties, potentially leading to increased safety and
	efficacy. Fluorinov&#146;s most advanced preclinical oncology programs include
	potent, orally-available, bromodomain and proteasome inhibitors, as well as
	epidermal growth factor receptor antagonists with increased uptake in the brain,
	all of which have been differentiated from competitors and have potential for
	best-in-class status. In addition, a number of compounds directed at undisclosed
	immuno-oncology targets are currently in the discovery phase.
</P>
<P ALIGN=CENTER>
	- 8 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage69"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_9">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The terms of the acquisition were an upfront payment of $10
	million plus up to $35 million of additional future payments that are contingent
	on us achieving certain clinical and regulatory milestones with an existing
	Fluorinov compound. We will also have an obligation to pay royalty payments on
	future sales of such compounds. The upfront payment was subject to adjustment
	based on the net working capital of Fluorinov and other adjustments at the time
	of closing. At our discretion, up to 50% of the future contingent payments can
	be satisfied through the issuance of common shares of Trillium provided that the
	aggregate number of common shares issuable under such payments will not exceed
	1,558,447 common shares unless shareholder approval has first been obtained. In
	addition, any such future share issuance remains subject to final approval from
	our board of directors and receipt of any requisite approvals under the
	applicable rules of the Toronto Stock Exchange and the NASDAQ Stock Market. We
	have also committed to use commercially reasonable efforts to monetize
	Fluorinov&#146;s central nervous system, or CNS, assets and share 50% of the net
	proceeds with Fluorinov shareholders.
</P>
<P ALIGN=JUSTIFY>
<B>
	Plan of Operations
</B>
</P>
<P ALIGN=JUSTIFY>
	Over the next 12 months, our primary focus is the advancement
	of our Phase I clinical trial of SIRP&#945;Fc in patients with advanced hematologic
	malignancies. We also plan to conduct preclinical research in solid tumors and
	in combination studies to identify future potential clinical indications.
</P>
<P ALIGN=JUSTIFY>
	We also plan to advance one, or possibly two, of Fluorinov&#146;s preclinical programs through the Investigational New Drug, or IND-enabling
	phase using our internal development group, while at the same time focusing our
	new chemistry group on several immuno-oncology discovery programs.
</P>
<P ALIGN=JUSTIFY>
<B>
	Capital Markets
</B>
</P>
<P ALIGN=JUSTIFY>
	We were listed on the TSX Venture Exchange, or TSXV, until
	April 22, 2014 when we migrated to the Toronto Stock Exchange, or TSX. We traded
	under the symbol &#147;SSS&#148; until June 6, 2014 when the symbol was changed to &#147;TR&#148;.
	We were listed on the OTCQX International under the symbol &#147;SCTPF&#148; from May 20,
	2013 until we began trading on the NASDAQ Capital Market under the symbol &#147;TRIL&#148;
	on December 19, 2014.
</P>
<P ALIGN=JUSTIFY>
<B>
	Legal Proceedings
</B>
</P>
<P ALIGN=JUSTIFY>
	To our knowledge, there have not been any legal or arbitration
	proceedings, including those relating to bankruptcy, receivership or similar
	proceedings, those involving any third party, and governmental proceedings
	pending or known to be contemplated, which may have, or have had in the recent
	past, significant effect our financial position or profitability.
</P>
<P ALIGN=JUSTIFY>
	Also, to our knowledge, there have been no material proceedings
	in which any director, any member of senior management, or any of our affiliates
	is either a party adverse to us or any of our subsidiaries or has a material
	interest adverse to us or any of our subsidiaries.
</P>
<P ALIGN=CENTER>
	- 9 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage70"></A>
<A NAME="EXHIBIT99-2_HTM_PAGE_10">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	RESULTS OF OPERATIONS
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
	For the three months and years ended December 31, 2015 and
	2014
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Overview
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Since inception, we have incurred losses while advancing the
	research and development of our products. Net loss for the three months ended
	December 31, 2015 of $2,988,843 was lower than the loss of $4,214,862 for the
	three months ended December 31, 2014. Net loss for the year ended December 31,
	2015 of $14,733,699 exceeded the loss of $12,881,820 for the year ended December
	31, 2014. Research and development costs for both 2015 periods were
	significantly higher than 2014 due mainly to higher costs for our SIRP&#945;Fc
	development program including increased personnel costs. The loss for the three
	months ended December 31, 2015 was lower than the comparative period due mainly
	to a net foreign exchange gain of $2,163,429.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Research and Development
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Research and development expenses by program for the years
	ended December 31, 2015 and 2014 were as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Three months
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Three months
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	ended
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	ended
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Year ended
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Year ended
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31,
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31,
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31,
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31,
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	2015
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	2014
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	2015
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	2014
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	SIRP&#945;Fc
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	4,332,644
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	3,828,172
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	17,978,930
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9,372,467
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Tigecycline
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	125
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	1,091,297
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Other
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	32,939
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	6,650
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	71,161
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	132,044
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Total
</B>
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="10%">
	4,365,583
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="10%">
	3,834,947
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="10%">
	18,050,091
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="10%">
	10,595,808
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Note:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(1)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Research and development expenditures in the above table
	include all direct and indirect costs for the programs, personnel costs,
	intellectual property related costs net of recoveries, share-based
	compensation and research and development overhead, and is net of
	government assistance. Research and development overhead costs have been
	allocated to the programs based mainly on personnel time spent on the
	programs.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	During 2015, most of our resources were focused on the
	development of our SIRP&#945;Fc program. For the year ended December 31, 2015,
	research and development costs increased over the same period in the prior year
	as we completed IND-enabling toxicology studies, incurred manufacturing costs to
	supply our clinical trial, completed the IND submission and initiated the Phase
	I trial in 2015. Personnel costs were also higher in 2015 as we added staff to
	manage our expanded research and development activities. In 2014, we
	discontinued our tigecycline program and recorded an impairment charge of
	$429,763.
</P>
<P ALIGN=JUSTIFY>
	Components of research and development expenses for the three
	months ended December 31, 2015 and 2014 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
<B>
	&nbsp;
<STRONG>
	$
</STRONG>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD WIDTH="12%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD WIDTH="12%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Research and development programs excluding
	the below items
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	2,764,541
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	2,650,581
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#FFFFFF>
	Salaries, fees and short-term benefits
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
<B>
	1,143,872
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
	718,714
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Share-based compensation
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	520,853
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	258,995
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#FFFFFF>
	Amortization of intangible assets
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
<B>
	84,837
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
	84,837
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Depreciation of property and equipment
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	32,513
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	15,429
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT BGCOLOR=#FFFFFF>
	Tax credits
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
<B>
	(181,033
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#FFFFFF>
	106,391
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#FFFFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	&nbsp;4,365,583
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	&nbsp;3,834,947
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: 3PX DOUBLE #000000; " ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 10 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage71"></A>
<A NAME="EXHIBIT99-2_HTM_PAGE_11">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Components of research and development expenses for the years
	ended December 31, 2015 and 2014 were as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Research and development programs excluding
	the below items
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	12,083,797
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	5,893,030
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Salaries, fees and short-term benefits
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
<B>
	4,120,109
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	2,311,755
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Share-based compensation
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	1,942,173
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,626,824
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Amortization of intangible assets
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
<B>
	339,348
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	610,776
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Impairment of intangible assets
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	429,763
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Depreciation of property and equipment
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
<B>
	118,394
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	47,208
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Tax credits
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	(553,730
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(323,548
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%">
<B>
	18,050,091
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%">
	10,595,808
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	The increase in research and development program expenses for
	the three months ended December 31, 2015 compared to the three months ended
	December 31, 2014 was due mainly to higher facility costs and advisory fees
	related to our IND filing, partially offset by lower program costs. Salaries,
	fees and short-term benefits increased in the three months ended December 31,
	2015 due to higher staffing and salaries compared to the same period in 2014.
	Share-based compensation increased due mainly to new options granted in 2015
	with higher fair values as determined by the Black-Scholes option pricing model.
</P>
<P ALIGN=JUSTIFY>
	The increase in research and development program expenses for
	the year ended December 31, 2015 compared to the year ended December 31, 2014
	was due mainly to completion of IND-enabling toxicology studies, manufacturing
	costs to supply our clinical trial, costs to prepare and submit our IND and
	initiation of the Phase I trial in 2015 for SIRP&#945;Fc. Salaries, fees, and
	short-term benefits increased for the year ended December 31, 2015 due mainly to
	additional research and development personnel hired in 2015. Amortization and
	impairment of intangible assets was lower in the year ended December 31, 2015
	due to the discontinuation of the tigecycline program in 2014. Depreciation
	expense was higher in 2015 due to higher purchases of new lab equipment.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P ALIGN=JUSTIFY>
<B>
<I>
	General and Administrative
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Components of general and administrative expenses for the three
	months ended December 31, 2015 and 2014 were as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	&nbsp;$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	General and administrative expenses
	excluding the below items
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	460,582
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	181,117
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Salaries, fees and short-term benefits
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
<B>
	119,620
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	198,941
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	DSU units issued for director compensation
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	240,000
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Share-based
	compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
<B>
	71,339
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	59,788
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	891,541
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	439,846
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 11 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage72"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_12">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Components of general and administrative expenses for the years
	ended December 31, 2015 and 2014 were as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	General and administrative expenses
	excluding the below items
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	1,521,639
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,198,181
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Salaries, fees and short-term benefits
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
<B>
	898,381
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	694,849
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	DSU units issued for director compensation
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	540,000
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	240,000
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Share-based
	compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
<B>
	224,327
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	444,430
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	3,184,347
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	2,577,460
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	General and administrative expenses for the three months ended
	December 31, 2015 were higher than the comparable prior year period due mainly
	to expenses related to the Fluorinov acquisition and higher insurance costs
	related to our NASDAQ stock exchange listing. DSU units issued for director
	compensation were higher for the three months ended December 31, 2015 as DSUs
	were not used for director compensation in the comparable 2014 period.
</P>
<P ALIGN=JUSTIFY>
	General and administrative expenses for the year ended December
	31, 2015 were higher than the comparable prior year period due mainly to higher
	insurance costs and expenses related to the Fluorinov acquisition, partially
	offset by lower stock exchange filing fees. Salaries, fees and short-term
	benefits increased in 2015 over 2014 due mainly to higher administrative
	staffing. The value of DSUs issued for director compensation increased in 2015,
	and share-based compensation expense was lower in 2015 due mainly to fewer stock
	options issued to administrative personnel in the year.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Finance income and costs
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Components of finance income for the three months ended
	December 31, 2015 and 2014 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Interest income
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	135,928
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	93,634
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Net foreign
	currency gain
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
<B>
	2,163,429
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	2,299,357
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	93,634
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Components of finance income for the years ended December 31,
	2015 and 2014 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Interest income
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	488,486
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	378,692
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Net foreign
	currency gain
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
<B>
	6,106,703
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	6,595,189
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	378,692
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 12 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage73"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_13">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Finance income for the three months and year ended December 31,
	2015 was higher than the prior year comparable periods due mainly to a net
	foreign currency gain of $2,163,429 and $6,106,703, respectively, due mainly to
	holding U.S. dollar denominated cash with a strengthening U.S. dollar. Interest
	income in 2015 was also higher due to higher average cash balances.
</P>
<P ALIGN=JUSTIFY>
	Finance costs for the year ended December 31, 2015 were
	comparable to the prior year periods.
</P>
<P ALIGN=JUSTIFY>
<B>
	Liquidity and Capital Resources
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Cash, working capital, and debt
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Since inception, we have financed our operations primarily from
	sales of equity, proceeds from the exercise of warrants and stock options, and
	from interest income on funds available for investment. Our primary capital
	needs are for funds to support our scientific research and development
	activities including staffing, facilities, manufacturing, preclinical studies
	and clinical trials, administrative costs and for working capital.
</P>
<P ALIGN=JUSTIFY>
	We have experienced operating losses and cash outflows from
	operations since incorporation, will require ongoing financing in order to
	continue our research and development activities, and we have not earned
	significant revenue or reached successful commercialization of our products. Our
	future operations are dependent upon our ability to finance our cash
	requirements which will allow us to continue our research and development
	activities and the commercialization of our products. There can be no assurance
	that we will be successful in continuing to finance our operations.
</P>
<P ALIGN=JUSTIFY>
	On April 7, 2015, we completed an underwritten public offering
	of common shares and non-voting convertible preferred shares in the United
	States. In the offering, we sold 1,750,754 common shares and 1,077,605 Series II
	Non-Voting Convertible First Preferred Shares at a price of U.S. $19.50 per
	share, including 228,359 common shares sold pursuant to the full exercise of the
	underwriters&#146; option to purchase additional common shares. The gross proceeds
	from this offering were $68,875,067 (U.S. $55,153,000) before deducting offering
	expenses of $4,913,443.
</P>
<P ALIGN=JUSTIFY>
	The Series II Non-Voting Convertible First Preferred Shares
	sold in the offering are non-voting and are convertible into common shares, on a
	one-for-one basis (subject to adjustment), at any time at the option of the
	holder, subject to certain restrictions on conversion. Holders may not convert
	Series II Non-Voting Convertible First Preferred Shares into common shares if,
	after giving effect to the exercise of conversion, the holder and its joint
	actors would have beneficial ownership or direction or control over common
	shares in excess of 4.99% of the then outstanding common shares. This limit may
	be raised at the option of the holder on 61 days&#146; prior written notice: (i) up
	to 9.99%, (ii) up to 19.99%, subject to clearance of a personal information form
	submitted by the holder to the Toronto Stock Exchange, and (iii) above 19.99%,
	subject to approval by the Toronto Stock Exchange and shareholder approval.
</P>
<P ALIGN=JUSTIFY>
	On May 29, 2015, we filed a base shelf prospectus with the
	British Columbia, Alberta, Manitoba, Ontario and Nova Scotia securities
	commissions in Canada and a Form F-10 registration statement with the United
	States Securities and Exchange Commission, or SEC, that provides that we may
	sell under the prospectus from time to time over the following 25 months up to
	U.S. $100 million, in one or more offerings, of common shares, First Preferred
	shares, warrants to purchase common shares, or units comprising a combination of
	common shares, First Preferred shares and/or warrants.
</P>
<P ALIGN=JUSTIFY>
	Our cash totaled $86,770,542 at December 31, 2015 compared to
	$26,165,056 at December 31, 2014. As at December 31, 2015, our working capital
	increased to $85,369,945 compared to $23,989,252 at December 31, 2014 due mainly
	to funds received in the April 7, 2015 offering, warrant exercises, and foreign
	exchange gains, partially offset by cash used in operations. Accounts payable
	and accrued liabilities as at December 31, 2015 of $3,233,749 were comparable to
	the balance of $3,248,984 at December 31, 2014. Amounts receivable as at
	December 31, 2015 were $974,822 compared to $344,416 at December 31, 2014. The
	increase in amounts receivable was due mainly to the recording of expected
	refundable tax credits on research and development activities and refundable
	withholding taxes in the year ended December 31, 2015.
</P>
<P ALIGN=CENTER>
	- 13 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage74"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_14">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	We are indebted to the Federal Economic Development Agency for
	Southern Ontario, or FedDev, under a non-interest bearing contribution agreement
	and are making monthly repayments of $9,586 through November 2019. As at
	December 31, 2015, the balance repayable is $440,935. The loan payable was
	discounted using an estimated market interest rate of 15%. Interest expense
	accretes on the discounted loan amount until it reaches its face value at
	maturity.
</P>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, we have a deferred lease inducement of
	$348,205 for a new facility lease. The inducement benefit will be recognized
	over the expected term of the lease.
</P>
<P ALIGN=JUSTIFY>
	We have a long-term liability of $60,109 related to certain
	discontinued technologies. This liability was discounted using an estimated
	market interest rate of 15% and interest expense is accreting.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Cash flows from operating activities
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Cash used in operating activities increased to $18,298,112 for
	the year ended December 31, 2015, compared to $7,448,068 for the year ended
	December 31, 2014, due mainly to higher research and development expenses in the
	current year.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Cash flows from investing activities
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Cash used in investing activities totaled $750,382 for the year
	ended December 31, 2015, compared to cash provided by investing activities of
	$352,995 for the year ended December 31, 2014. The increase was due to higher
	purchases of property and equipment compared to the prior year.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Cash flows from financing activities
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Cash provided by financing activities totaled $73,642,984 for
	the year ended December 31, 2015, compared to $803,623 for the year ended
	December 31, 2014. The increase was due mainly to the completion of an
	underwritten public offering of common shares and non-voting convertible
	preferred shares in April 2015.
</P>
<P ALIGN=JUSTIFY>
<B>
	Contractual Obligations and Contingencies
</B>
</P>
<P ALIGN=JUSTIFY>
	We enter into research, development and license agreements in
	the ordinary course of business where we receive research services and rights to
	proprietary technologies. Milestone and royalty payments that may become due
	under various agreements are dependent on, among other factors, clinical trials,
	regulatory approvals and ultimately the successful development of a new drug,
	the outcome and timing of which is uncertain.
</P>
<P ALIGN=JUSTIFY>
	Under the license agreement for SIRP&#945;Fc, we have future
	contingent milestones payable of $35,000 related to successful patent grants,
	$100,000, $200,000 and $300,000 on the first patient dosed in phase I, II and
	III trials respectively, and regulatory milestones on their first achievement
	totalling $5,000,000.We are also required to pay 20% of any sublicensing
	revenues to the licensors on the first $50 million of sublicensing revenues, and
	pay 15% of any sublicensing revenues to the licensors after the first $50
	million of sublicensing revenue received.
</P>
<P ALIGN=JUSTIFY>
	Under two agreements with Catalent pursuant to which we
	acquired the right to use a proprietary expression system for the manufacture of
	two SIRP&#945;Fc constructs, we have future contingent milestones on pre-marketing
	approval of up to U.S. $875,000 and aggregate sales milestone payments of up to
	U.S. $28.8 million for each agreement.
</P>
<P ALIGN=CENTER>
	- 14 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage75"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_15">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	We periodically enter into research and license agreements with
	third parties that include indemnification provisions customary in the industry.
	These guarantees generally require us to compensate the other party for certain
	damages and costs incurred as a result of claims arising from research and
	development activities undertaken by or on our behalf. In some cases, the
	maximum potential amount of future payments that could be required under these
	indemnification provisions could be unlimited. These indemnification provisions
	generally survive termination of the underlying agreement. The nature of the
	indemnification obligations prevents us from making a reasonable estimate of the
	maximum potential amount it could be required to pay. Historically, we have not
	made any indemnification payments under such agreements and no amount has been
	accrued in our audited consolidated financial statements with respect to these
	indemnification obligations.
</P>
<P ALIGN=JUSTIFY>
	Other than as disclosed below, we did not have any contractual
	obligations relating to long-term debt obligations, capital (finance) lease
	obligations, operating lease obligations, purchase obligations or other
	long-term liabilities reflected on our balance sheet as at December 31, 2015:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="32%" COLSPAN=7>
<B>
	Payment due by period
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="11%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	Less than
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	1 to 3
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	3 to 5
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	More than
</B>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
<B>
	Contractual Obligations
</B>
<SUP>
	(1)(2)
</SUP>
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	Total
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	1 year
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	years
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	years
</B>
</TD>
<TD NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=CENTER WIDTH="11%">
<B>
	5 years
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Long-Term Debt Obligations
<SUP>
	(3)
</SUP>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;440,935
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;105,446
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;230,064
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;105,425
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;-
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Capital (Finance) Lease Obligations
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Operating Lease Obligations
<SUP>
	(4)
</SUP>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	2,510,227
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	266,435
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	457,882
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	496,901
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	1,289,009
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Purchase Obligations
<SUP>
	(5)
</SUP>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	8,614,808
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	4,788,286
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	3,826,522
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Other Long-Term Liabilities
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Reflected on our Balance Sheet
<SUP>
	(6)
</SUP>
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="11%">
	309,634
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="11%">
	249,525
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="11%">
	60,109
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="11%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
<B>
	11,875,604
</B>
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
<B>
	5,409,692
</B>
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
<B>
	4,574,577
</B>
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
<B>
	602,326
</B>
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="11%" BGCOLOR=#E6EFFF>
	&nbsp;
<B>
	1,289,009
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Notes:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(1)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Contractual obligations in the above table do not include
	amounts in accounts payable and accrued liabilities on our balance sheet
	as at December 31, 2015. Annual technology license fees currently
	approximating $50,000 are not included in the above table.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(2)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Contingent milestones under the UHN license agreement and
	the Catalent expression system agreements are not included in the above
	table.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(3)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Amounts due to FedDev repayable in equal monthly
	installments of $9,586 through November 2019.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(4)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Includes operating lease obligations for laboratory and
	office facilities.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(5)
</SUP>
</TD>
<TD>
<P ALIGN="JUSTIFY">
	Purchase obligations represent significant research and
	development contracts and other commitments that include the clinical
	research organization agreement for conducting the Phase I trial, and
	other preclinical and manufacturing activities.
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(6)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Long-term liability related to the cessation of the
	development of our regenerative medicine products.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 15 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage76"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_16">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	Description of Share Capital
</B>
</P>
<P ALIGN=JUSTIFY>
	The continuity of the number of our issued and outstanding
	common and preferred shares for the year ended December 31, 2014, the year ended
	December 31, 2015, and to the date of this MD&amp;A is presented below:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="13%">
	Number of Series I
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="13%">
	Number of Series II
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="13%">
	Number of
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="13%">
	Preferred Shares
<SUP>
	(1
</SUP>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="3%">
<SUP>
	)
</SUP>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="13%">
	Preferred Shares
<SUP>
	(2
</SUP>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="3%">
<SUP>
	)
</SUP>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="13%">
	Common Shares
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="13%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="13%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="13%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance December 31, 2013
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	77,895,165
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	121,752,380
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Consolidation 1 for 30
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	(117,693,972
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Issued on exercise of stock options
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	2,614
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Issued on exercise of warrants
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	86,540
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Preferred shares converted to common shares
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	(8,390,476
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	279,682
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Balance at December 31, 2014
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	69,504,689
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	4,427,244
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Issued on exercise of stock options
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	6,666
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Issued on exercise of warrants
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	1,087,603
</TD>
<TD ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Issued in public offering
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	1,077,605
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	1,750,754
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Preferred shares
	converted to common shares
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	(15,716,110
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	523,870
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance at December 31, 2015
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	53,788,579
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	1,077,605
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	7,796,137
</TD>
<TD ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Preferred shares
	converted to common shares
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	(562,388
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	18,746
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="3%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance at the date of this MD&amp;A
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	53,226,191
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	1,077,605
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	7,814,883
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="3%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Notes:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(1)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Convertible at a ratio of 30 Series I Preferred Shares
	for one common share.
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<SUP>
	(2)
</SUP>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Convertible at a ratio of one Series II Preferred Share
	for one common share.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	Share capital issued &#150;
</I>
</B>
<I>
</I>
<B>
<I>
	for the year
	ended December 31, 2015
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	On April 7, 2015, we completed an underwritten public offering
	of common shares and non-voting convertible preferred shares in the United
	States. In the offering, we sold 1,750,754 common shares and 1,077,605 Series II
	Non-Voting Convertible First Preferred Shares at a price of U.S. $19.50 per
	share, including 228,359 common shares sold pursuant to the full exercise of the
	underwriters&#146; option to purchase additional common shares. The gross proceeds
	from this offering were $68,875,067 (U.S. $55,153,000) before deducting offering
	expenses of $4,913,443.
</P>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2015, 1,087,603 common
	shares were issued on the exercise of 32,628,425 warrants for proceeds of
	$9,515,154 and 6,666 stock options were exercised for proceeds of $49,995.
</P>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2015, 15,716,110 Series I
	First Preferred Shares were converted into 523,870 common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Share capital issued &#150; for the year ended December 31,
	2014
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	On November 14, 2014, we consolidated our outstanding common
	shares issuing one post-consolidated share for each 30 pre-consolidated shares.
	All references in this MD&amp;A to the number of common shares, deferred share
	units and stock options refer to the post-consolidation amounts.
</P>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2014, 2,596,251 warrants
	were exercised for 86,540 common shares and for proceeds of $946,813 and 2,614
	stock options were exercised for proceeds of $19,600. Also, 909,091 warrants
	issued in March 2011 expired unexercised.
</P>
<P ALIGN=JUSTIFY>
	During the year ended December 31, 2014, 8,390,476 Series I
	First Preferred Shares were converted into 279,682 common shares.
</P>
<P ALIGN=CENTER>
	- 16 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage77"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_17">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	Warrants
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As a result of the November 14, 2014 common share
	consolidation, the ratio of the number of warrants exercisable for one common
	share was adjusted from one warrant for one common share to 30 warrants for
	one common share. The number of warrants outstanding was not adjusted.
</P>
<P ALIGN=JUSTIFY>
	The continuity of the number of issued and outstanding warrants
	for the year ended December 31, 2014, the year ended December 31, 2015, and to
	the date of this MD&amp;A is presented below:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Number of
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance December 31, 2013
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	142,230,123
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Exercised
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	(2,596,251
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Expired
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(909,091
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Balance at December 31, 2014
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	138,724,781
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Exercised
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(32,628,425
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT>
	Balance at
	December 31, 2015 and the date of this MD&amp;A
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%">
	106,096,356
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	The following table shows the number of warrants outstanding,
	the exercise prices, and the number of common shares issuable on exercise of the
	warrants and the exercise price per common share for 30 warrants at December 31,
	2015:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="10%">
	Exercise
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	Common shares
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	Price per
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	Exercise
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	Issuable
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="10%">
	Common Share
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	Expiry
	dates
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="10%">
	Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="10%">
	Price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="10%">
	on Exercise
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="10%">
	(30 Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="10%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="10%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="10%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="10%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	March 15, 2018
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9,213,780
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;0.40
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	307,126
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;12.00
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	March 27, 2018
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	300,000
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	&nbsp;0.40
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	10,000
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD ALIGN=RIGHT WIDTH="10%">
	&nbsp;12.00
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT BGCOLOR=#E6EFFF>
	December 13, 2018
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	96,582,576
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;0.28
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	3,219,419
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;8.40
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT>
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="10%">
	106,096,356
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="10%">
	3,536,545
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Our board of directors authorized or ratified the issuances of
	the warrants set forth in the table above and the issuance of one common share
	upon the due exercise of every 30 warrants in accordance with its terms and the
	receipt by us of the designated exercise price payable in respect of the share
	prior to the time of expiry on the designated expiry date.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Stock Options
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have a 10% rolling stock option plan, or the 2014 Stock
	Option Plan, which was approved by our shareholders at our annual general
	meeting held on May 27, 2014. Pursuant to the 2014 Stock Option Plan, we may
	grant stock options to purchase up to an aggregate of 10% of our issued and
	outstanding common shares plus 10% of the total number of common shares into
	which the outstanding First Preferred Shares may be converted. Options granted
	under the 2014 Stock Option plan are equity-settled, have a vesting period of
	four years and have a maximum term of ten years. As at December 31, 2015, the
	Company was entitled to issue an additional 87,048 stock options under the 2014
	Stock Option Plan.
</P>
<P ALIGN=CENTER>
	- 17 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage78"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_18">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The continuity of the number of issued and outstanding stock
	options for the year ended December 31, 2014, the years ended December 31, 2015,
	and to the date of this MD&amp;A is presented below:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Number of
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Weighted Average
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Options
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Exercise Price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance December 31, 2013
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	97,372
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	9.94
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Granted
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	499,883
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	9.78
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Exercised
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(2,614
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	7.50
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Cancelled/
	forfeited
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	(4,500
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	16.58
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance at December 31, 2014
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	590,141
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	9.76
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Granted
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	347,359
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	21.40
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Exercised
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(6,666
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	7.50
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Cancelled/forfeited
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	(3,000
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	30.00
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance at December 31, 2015 and at the date of this
	MD&amp;A
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	927,834
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;14.07
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	Deferred Share Unit Plan
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our shareholders approved the 2014 DSU Plan on May 27, 2014.
	The 2014 DSU Plan is intended to promote a greater alignment of long-term
	interests between our non-executive directors and executive officers and our
	shareholders through the issuance of DSUs. Since the value of a DSU increases or
	decreases with the market price of the common shares, DSUs reflect a philosophy
	of aligning the interests of directors and executive officers with those of the
	shareholders by tying compensation to share price performance. The Board of
	Directors intends to use DSUs issued under the 2014 DSU Plan, as well as stock
	options issued under the 2014 Stock Option Plan, as part of our overall director
	and executive officer compensation program. A total of 28,777 units were issued
	during the year ended December 31, 2014 and 23,011 units were issued during the
	year ended December 31, 2015 for payment of director fees. We had 51,788 units
	outstanding as at December 31, 2015. We have reserved for issuance up to 66,667
	common shares under the 2014 DSU Plan.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<P ALIGN=JUSTIFY>
<B>
<I>
	Fully Diluted Share Capital
</I>
</B>
<I>
</I>
</P>
<P ALIGN=JUSTIFY>
	The number of issued and outstanding common shares, Series I
	First Preferred Shares, Series II First Preferred Shares warrants, stock options
	and DSUs on a fully converted basis as at December 31, 2015 was as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	Number of common
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	share equivalents
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Common shares
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	7,796,137
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Series I First Preferred Shares
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	1,792,953
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Series II First Preferred Shares
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,077,605
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Warrants
</TD>
<TD ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%">
	3,536,545
</TD>
<TD ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Stock options
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	927,834
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Deferred share
	units
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	51,788
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	Fully diluted common shares as at December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	15,182,862
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 18 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage79"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_19">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	Shareholder Rights Plan
</I>
</B>
<I>
</I>
</P>
<P ALIGN=JUSTIFY>
	On October 17, 2013 our shareholders adopted a shareholder
	rights plan, or the 2013 Rights Plan, and approved certain amendments on May 27,
	2014, or the Rights Plan Amendment, and which together with the 2013 Rights Plan
	may be referred to as the Rights Plan. The Rights Plan is designed to provide
	adequate time for the Board of Directors and the shareholders to assess an
	unsolicited takeover bid for the Company, to provide the Board of Directors with
	sufficient time to explore and develop alternatives for maximizing shareholder
	value if a takeover bid is made, and to provide shareholders with an equal
	opportunity to participate in a takeover bid and receive full and fair value for
	their common shares. The Rights Plan will expire at the close of our annual
	meeting of shareholders in 2016.
</P>
<P ALIGN=JUSTIFY>
	The rights issued under the Rights Plan initially attach to and
	trade with the common shares and no separate certificates will be issued unless
	an event triggering these rights occurs. The rights will become exercisable only
	when a person, including any party related to it, acquires or attempts to
	acquire 20% or more of the outstanding common shares without complying with the
	&#147;Permitted Bid&#148; provisions of the Rights Plan or without approval of the Board
	of Directors. Should such an acquisition occur or be announced, each right
	would, upon exercise, entitle a rights holder, other than the acquiring person
	and related persons, to purchase common shares at an approximate 50% discount to
	the market price at the time.
</P>
<P ALIGN=JUSTIFY>
	Under the Rights Plan, a Permitted Bid is a bid made to all
	holders of the common shares and which is open for acceptance for not less than
	60 days. If at the end of 60 days at least 50% of the outstanding common shares,
	other than those owned by the offeror and certain related parties have been
	tendered, the offeror may take up and pay for the common shares but must extend
	the bid for a further 10 days to allow other shareholders to tender. The
	issuance of common shares upon the exercise of the rights is subject to receipt
	of certain regulatory approvals.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<P ALIGN=JUSTIFY>
<B>
	Related Parties
</B>
</P>
<P ALIGN=JUSTIFY>
	For the years ended December 31, 2015 and 2014, our key
	management personnel were the Board of Directors, Chief Executive Officer, Chief
	Financial Officer, Chief Scientific Officer, Chief Medical Officer, and Chief
	Development Officer.
</P>
<P ALIGN=JUSTIFY>
	Compensation for our key management personnel for the years
	ended December 31, 2015 and 2014 was as follows:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="12%">
	&nbsp;
</TD>
<TD WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Salaries, fees and short-term benefits
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	2,595,536
</B>
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,708,717
</TD>
<TD ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Share-based
	compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
<B>
	2,433,710
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="12%">
	2,281,561
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	5,029,246
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	3,990,278
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 3PX DOUBLE" ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	Executive officers and directors participate in the 2014 Stock
	Option Plan and the 2014 DSU Plan, and officers participate in our benefit
	plans. Directors receive annual fees for their services. As at December 31,
	2015, the key management personnel controlled less than 1% of our voting shares.
</P>
<P ALIGN=JUSTIFY>
	Outstanding balances with related parties at the period-end are
	unsecured, interest free and settlement occurs in cash. There have been no
	guarantees provided or received for any related party receivables or payables.
	For the years ended December 31, 2015 and 2014, $0 and $7,916, respectively, was
	paid to a former director for consulting fees.
</P>
<P ALIGN=CENTER>
	- 19 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage80"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_20">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	Trend Information
</B>
</P>
<P ALIGN=JUSTIFY>
	Historical patterns of expenditures cannot be taken as an
	indication of future expenditures. The amount and timing of expenditures and
	therefore liquidity and capital resources vary substantially from period to
	period depending on the number of research and development programs being
	undertaken at any one time, the stage of the development programs, the timing of
	significant expenditures for manufacturing, toxicology and pharmacology studies
	and clinical trials, and the availability of funding from investors and
	prospective commercial partners.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<P ALIGN=JUSTIFY>
<B>
	Selected Annual Financial Information
</B>
</P>
<DIV>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " BORDERCOLOR=#000000 CELLSPACING=0 CELLPADDING=3 WIDTH="100%" BORDER=1>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="13%">
<B>
	2015
<BR>
</B>
<B>
	$
</B>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="13%">
<B>
	2014
<BR>
</B>
<B>
	$
</B>
</TD>
<TD NOWRAP ALIGN=RIGHT WIDTH="13%">
<B>
	2013
<BR>
</B>
<B>
	$
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Interest income
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	488,486
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	378,692
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	44,113
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Net loss
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	14,733,699
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	12,881,820
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	4,289,308
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Net loss per share
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	2.22
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	3.06
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	3.16
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Total assets
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	90,039,468
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	28,186,032
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	35,087,386
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Total long-term
	liabilities
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	678,700
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	353,293
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	446,313
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
	In 2013 we acquired the SIRP&#945;Fc program and raised capital in
	December 2013 to take the program forward into IND-enabling studies. In 2014, we
	significantly increased our research and development activities including
	manufacturing and preclinical studies resulting in a higher net loss in 2014. We
	raised additional funds in April 2015 and completed manufacturing, IND-enabling
	studies and submitted our IND for a first-in-human trial of SIPRaFc in 2015. The
	net loss for the year ended December 31, 2015 included a net foreign exchange
	gain of $6,106,703 that resulted mainly from holding U.S. denominated cash with
	a strengthening U.S. dollar exchange rate. Interest income increased in 2014 and
	2015 due mainly to higher average cash balances. Although a higher net loss in
	2014 and 2015, the net loss per share decreased due to a higher issued and
	outstanding number of common shares issued in the two financings. Total assets
	increased significantly in 2015 as the April 2015 financing raised net proceeds
	of $64.0 million. Long-term liabilities increased in 2015 due mainly to
	long-term lease inducements on a new office and laboratory facility that will be
	recognized over the expected lease term.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<P ALIGN=JUSTIFY>
<B>
	Selected Quarterly Financial Information
</B>
</P>
<DIV>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " BORDERCOLOR=#000000 CELLSPACING=0 CELLPADDING=3 WIDTH="100%" BORDER=1>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	2015
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q4-2015
<BR>
</B>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q3-2015
<BR>
</B>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q2-2015
<BR>
</B>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q1-2015
<BR>
</B>
<B>
	$
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Revenue
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Research and development expenses
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	4,365,583
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	4,954,811
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	4,713,316
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	4,016,381
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	General and administrative expenses
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	891,541
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	721,549
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	966,438
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	604,819
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Net loss for the
	period
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	2,988,843
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	1,505,979
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	5,568,564
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	4,670,313
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Basic and diluted net loss per share*
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.40
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.21
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.80
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.98
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Cash
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	86,770,542
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	89,082,852
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	89,545,097
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	25,702,189
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 20 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage81"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_21">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<BR>
<DIV>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " BORDERCOLOR=#000000 CELLSPACING=0 CELLPADDING=3 WIDTH="100%" BORDER=1>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	2014
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q4-2014
<BR>
</B>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q3-2014
<BR>
</B>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q2-2014
<BR>
</B>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	Q1-2014
<BR>
</B>
<B>
	$
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Revenue
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	-
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Research and development expenses
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	3,834,947
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	2,089,977
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	3,105,402
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	1,565,482
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	General and administrative expenses
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	439,846
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	500,072
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	1,075,961
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	561,581
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Net loss for the
	period
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	4,214,862
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	2,526,527
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	4,100,371
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	2,040,060
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Basic and diluted net loss per share*
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.97
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.60
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.99
</TD>
<TD ALIGN=RIGHT WIDTH="13%">
	0.50
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
	Cash
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	26,165,056
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	27,754,378
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	30,041,001
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=RIGHT WIDTH="13%">
	31,864,387
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	*
</B>
	Note: Loss per share has been
	calculated for all periods on a post-share consolidation basis.
</P>
<P ALIGN=JUSTIFY>
	Research and development expenses increased through 2014 as the
	SRIPaFc development program advanced and were higher in 2015 due to higher costs
	associated with IND-enabling toxicology studies, preparing the IND submission
	and initiating the Phase I clinical trial. Research and development expenses for
	the second quarter of 2014 were higher due to higher non-cash share-based
	compensation and the recognition of an impairment charge on return of the
	tigecycline rights back to UHN. General and administrative expenses for the
	second quarter of 2014 were higher due mainly to higher non-cash share-based
	compensation expenses and costs associated with migrating to the TSX. General
	and administrative costs for the second quarter of 2015 were higher than the
	first quarter of 2015 due mainly to the issuance of DSUs for director fees. The
	net loss for the third and fourth quarters of 2015 were lower due mainly to net
	foreign exchange gains of $4,019,251 and $2,163,429, respectively, that resulted
	mainly from holding U.S. denominated cash with a strengthening U.S. dollar
	exchange rate.
</P>
<P ALIGN=JUSTIFY>
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P ALIGN=JUSTIFY>
	We do not have any off-balance sheet arrangements that have, or
	are reasonably likely to have, a current or future effect on our financial
	condition, revenues or expenses, results of operations, liquidity, capital
	expenditures or capital resources that are material to investors.
</P>
<P ALIGN=JUSTIFY>
<B>
	Quantitative &amp; Qualitative Disclosures About Market
	Risk
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Fair Value
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	IFRS 13,
<I>
	Fair Value Measurement
</I>
	provides a hierarchy of
	valuation techniques based on whether the inputs to those valuation techniques
	are observable or unobservable. Observable inputs are those which reflect market
	data obtained from independent sources, while unobservable inputs reflects our
	assumptions with respect to how market participants would price an asset or
	liability. These two inputs used to measure fair value fall into the following
	three different levels of the fair value hierarchy:
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Level 1 Quoted prices in active markets
	for identical instruments that are observable.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Level 2 Quoted prices in active markets
	for similar instruments; inputs other than quoted prices that are observable and
	derived from or corroborated by observable market data.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Level 3 Valuations derived from
	valuation techniques in which one or more significant inputs are unobservable.
</P>
<P ALIGN=JUSTIFY>
	The hierarchy requires the use of observable market data when
	available.
</P>
<P ALIGN=CENTER>
	- 21 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage82"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_22">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	We have classified cash and marketable securities as Level 1.
	The loan payable has been classified as Level 2.
</P>
<P ALIGN=JUSTIFY>
	Cash, marketable securities, amounts receivable, accounts
	payable and accrued liabilities, and other current liabilities, due within one
	year, are all short-term in nature and, as such, their carrying values
	approximate fair values. The fair value of the non-current loan payable and
	long-term liability is estimated by discounting the expected future cash flows
	at the cost of money to us, which is equal to its carrying value.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Risks
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are exposed to credit risk, liquidity risk, interest rate
	risk and currency risk. Our Board of Directors has overall responsibility for
	the establishment and oversight of our risk management framework. The Audit
	Committee is responsible for reviewing our risk management policies.
</P>
<P ALIGN=JUSTIFY>
<I>
	Credit risk
</I>
</P>
<P ALIGN=JUSTIFY>
	Credit risk is the risk of financial loss to the Company if a
	counterparty to a financial instrument fails to meet its contractual
	obligations, and arises principally from the Company&#146;s cash and amounts
	receivable. The carrying amount of these financial assets represents the maximum
	credit exposure. The Company follows an investment policy to mitigate against
	the deterioration of principal and to enhance the Company&#146;s ability to meet its
	liquidity needs. Cash is on deposit with major Canadian chartered banks and the
	Company invests in high grade short-term instruments. Amounts receivable are
	primarily comprised of amounts due from the federal government.
</P>
<P ALIGN=JUSTIFY>
<I>
	Liquidity risk
</I>
</P>
<P ALIGN=JUSTIFY>
	Liquidity risk is the risk that the Company will not be able to
	meet its financial obligations as they fall due. The Company is a development
	stage company and is reliant on external fundraising to support its operations.
	Once funds have been raised, the Company manages its liquidity risk by investing
	in cash and short-term instruments to provide regular cash flow for current
	operations. It also manages liquidity risk by continuously monitoring actual and
	projected cash flows. The Board of Directors reviews and approves the Company&#146;s
	operating and capital budgets, as well as any material transactions not in the
	ordinary course of business. The majority of the Company&#146;s accounts payable and
	accrued liabilities have maturities of less than three months.
</P>
<P ALIGN=JUSTIFY>
<I>
	Interest rate risk
</I>
</P>
<P ALIGN=JUSTIFY>
	Interest rate risk is the risk that the fair value or future
	cash flows of a financial instrument will fluctuate because of changes in market
	interest rates. The Company holds its cash in bank accounts or high interest
	savings accounts which have a variable rate of interest. The Company manages its
	interest rate risk by holding highly liquid short-term instruments and by
	holding its investments to maturity, where possible. For the years ended
	December 31, 2015 and 2014, the Company earned interest income of $488,486 and
	$378,692, respectively. Therefore, a 1% change in the average interest rate for
	the years ended December 31, 2015 and 2014, would have a net impact on finance
	income of $4,885 and $3,787, respectively.
</P>
<P ALIGN=CENTER>
	- 22 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage83"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_23">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<I>
	Currency risk
</I>
</P>
<P ALIGN=JUSTIFY>
	The Company is exposed to currency risk related to the
	fluctuation of foreign exchange rates and the degree of volatility of those
	rates. Currency risk is limited to the portion of the Company&#146;s business
	transactions denominated in currencies other than the Canadian dollar which are
	primarily expenses in US dollars. As at December 31, 2015 and 2014, the Company
	held US dollar cash in the amount of US$44,547,591 and US$142,558 and had US
	dollar denominated accounts payable and accrued liabilities in the amount of
	US$1,033,319 and US$1,910,430, respectively. Therefore, a 1% change in the
	foreign exchange rate would have a net impact on finance costs as at December
	31, 2015 and 2014 of $435,143 and $17,679, respectively.
</P>
<P ALIGN=JUSTIFY>
	US dollar expenses for the years ended December 31, 2015 and
	2014 were approximately US$8,700,000 and US$3,260,000, respectively. Varying the
	US exchange rate for the years ended December 31, 2015 and 2014 to reflect a 5%
	strengthening of the Canadian dollar would have decreased the net loss by
	approximately $435,000 and $163,000, respectively, assuming that all other
	variables remained constant.
</P>
<P ALIGN=JUSTIFY>
<B>
	Implications of Being an Emerging Growth Company
</B>
</P>
<P ALIGN=JUSTIFY>
	We are an &#147;emerging growth company&#148; under the U.S. Jumpstart
	Our Business Startups Act of 2012, or the JOBS Act, and will continue to qualify
	as an &#147;emerging growth company&#148; until the earliest to occur of: (a) the last day
	of the fiscal year during which we have total annual gross revenues of
	$1,000,000,000 (as such amount is indexed for inflation every 5 years by the
	SEC) or more; (b) the last day of our fiscal year following the fifth
	anniversary of the date of the first sale of our common shares pursuant to an
	effective registration statement under the Securities Act; (c) the date on which
	we have, during the previous 3-year period, issued more than $1,000,000,000 in
	non-convertible debt; or (d) the date on which we are deemed to be a &#147;large
	accelerated filer&#148;, as defined in Rule 12b&#150;2 of the Exchange Act.
</P>
<P ALIGN=JUSTIFY>
	Generally, a company that registers any class of its securities
	under Section 12 of the Exchange Act is required to include in the second and
	all subsequent annual reports filed by it under the Exchange Act, a management
	report on internal control over financial reporting and, subject to an exemption
	available to companies that meet the definition of a &#147;smaller reporting company&#148;
	in Rule 12b-2 under the Exchange Act, an auditor attestation report on
	management&#146;s assessment of the company&#146;s internal control over financial
	reporting. However, for so long as we continue to qualify as an emerging growth
	company, we will be exempt from the requirement to include an auditor
	attestation report in our annual reports filed under the Exchange Act, even if
	we do not qualify as a &#147;smaller reporting company&#148;. In addition, Section
	103(a)(3) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, has been
	amended by the JOBS Act to provide that, among other things, auditors of an
	emerging growth company are exempt from any rules of the Public Company
	Accounting Oversight Board requiring mandatory audit firm rotation or a
	supplement to the auditor&#146;s report in which the auditor would be required to
	provide additional information about the audit and the financial statements of
	the company.
</P>
<P ALIGN=JUSTIFY>
	Any U.S. domestic issuer that is an emerging growth company is
	able to avail itself of the reduced disclosure obligations regarding executive
	compensation in periodic reports and proxy statements, and to not present to its
	shareholders a non-binding advisory vote on executive compensation, obtain
	approval of any golden parachute payments not previously approved, or present
	the relationship between executive compensation actually paid and our financial
	performance. So long as we are a foreign private issuer, we are not subject to
	such requirements, and will not become subject to such requirements even if we
	were to cease to be an emerging growth company.
</P>
<P ALIGN=JUSTIFY>
	As a reporting issuer under the securities legislation of the
	Canadian provinces of Ontario, British Columbia, Manitoba, Nova Scotia and
	Alberta, we are required to comply with all new or revised accounting standards
	that apply to Canadian public companies. Pursuant to Section 107(b) of the JOBS
	Act, an emerging growth company may elect to utilize an extended transition
	period for complying with new or revised accounting standards for public
	companies until such standards apply to private companies. We have elected not
	to utilize this extended transition period.
</P>
<P ALIGN=CENTER>
	- 23 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage84"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_24">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
	Critical Accounting Estimates
</B>
</P>
<P ALIGN=JUSTIFY>
	The preparation of financial statements in conformity with IFRS
	requires management to make judgments, estimates and assumptions that affect the
	application of accounting policies and the reported amounts of assets and
	liabilities, revenue and expenses and the related disclosures of contingent
	assets and liabilities and the determination of the Company&#146;s ability to
	continue as a going concern. Actual results could differ materially from these
	estimates and assumptions. The Company reviews its estimates and underlying
	assumptions on an ongoing basis. Revisions are recognized in the period in which
	the estimates are revised and may impact future periods.
</P>
<P ALIGN=JUSTIFY>
	The areas involving a higher degree of judgment or complexity,
	or areas where assumptions and estimates are significant to the financial
	statements have been set out in Note 2 of our annual audited consolidated
	financial statements for the year ended December 31, 2015.
</P>
<P ALIGN=JUSTIFY>
<B>
	Accounting Policies
</B>
</P>
<P ALIGN=JUSTIFY>
	Our significant accounting policies are outlined in our annual
	audited consolidated financial statements for the year ended December 31, 2015.
	This MD&amp;A should be read in conjunction with the annual audited consolidated
	financial statements for the year ended December 31, 2015.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	New standards and interpretations not yet
	effective
</I>
</B>
<I>
</I>
</P>
<P ALIGN=JUSTIFY>
	IFRS 9 Financial Instruments
</P>
<P ALIGN=JUSTIFY>
	In October 2010, the IASB published amendments to IFRS 9
	Financial Instruments, or IFRS 9, which provides added guidance on the
	classification and measurement of financial liabilities. In July 2014, the IASB
	issued its final version of IFRS 9, which completes the classification and
	measurement, impairment and hedge accounting phases of the IASB&#146;s project to
	replace IAS 39. The final standard is mandatorily effective for annual periods
	beginning on or after January 1, 2018, with earlier application permitted. We
	are reviewing the standard to determine the impact that the adoption of this
	standard may have on the consolidated financial statements.
</P>
<P ALIGN=JUSTIFY>
	IFRS 15 Revenue from Contracts with Customers
</P>
<P ALIGN=JUSTIFY>
	In May 2014, the IASB issued IFRS 15 Revenue from Contracts
	with Customers, or IFRS 15, which covers principles for reporting about the
	nature, amount, timing and uncertainty of revenue and cash flows arising from
	contracts with customers. IFRS 15 is effective for annual periods beginning on
	or after January 1, 2018. Entities will transition following either a full or
	modified retrospective approach. We are reviewing the standard to determine the
	impact that the adoption of this standard may have on the consolidated financial
	statements.
</P>
<P ALIGN=JUSTIFY>
	IFRS 16 Leases
</P>
<P ALIGN=JUSTIFY>
	In January 2016, the IASB has issued IFRS 16 Leases, or IFRS
	16, its new leases standard that requires lessees to recognize assets and
	liabilities for most leases on their balance sheets. Lessees applying IFRS 16
	will have a single accounting model for all leases, with certain exemptions.
	Lessor accounting is substantially unchanged. The new standard will be effective
	from January 1, 2019 with limited early application permitted. We have not yet
	begun the process of evaluating the impact of this standard on our consolidated
	financial statements.
</P>
<P ALIGN=JUSTIFY>
	Other accounting standards or amendments to existing accounting
	standards that have been issued, but have future effective dates, are either not
	applicable or are not expected to have a significant impact on our consolidated
	financial statements.
</P>
<P ALIGN=CENTER>
	- 24 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage85"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_25">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	RISK FACTORS
</B>
</P>
<P ALIGN=JUSTIFY>
<I>
	An investment in our common shares involves a high degree of
	risk and should be considered speculative. An investment in our common shares
	should only be undertaken by those persons who can afford the total loss of
	their investment. You should carefully consider the risks and uncertainties
	described below, as well as other information contained in this MD&amp;A. The
	risks and uncertainties below are not the only ones we face. Additional risks
	and uncertainties not presently known to us or that we believe to be immaterial
	may also adversely affect our business. If any of the following risks occur, our
	business, financial condition and results of operations could be seriously
	harmed and you could lose all or part of your investment. Further, if we fail to
	meet the expectations of the public market in any given period, the market price
	of our common shares could decline. We operate in a highly competitive
	environment that involves significant risks and uncertainties, some of which are
	outside of our control.
</I>
</P>
<P ALIGN=JUSTIFY>
<B>
	Risks Related to our Business and our Industry
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We expect to incur future losses and we may never become
	profitable.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have incurred losses of $14.7 million, $12.9 million and
	$4.3 million for the years ended December 31, 2015, 2014, and 2013,
	respectively, and expect to incur an operating loss for the year ending December
	31, 2015. We have an accumulated deficit since inception through December 31,
	2015 of $65.3 million. We believe that operating losses will continue as we are
	planning to incur significant costs associated with the clinical development of
	SIRP&#945;Fc. Our net losses have had and will continue to have an adverse effect on,
	among other things, our shareholders&#146; equity, total assets and working capital.
	We expect that losses will fluctuate from quarter to quarter and year to year,
	and that such fluctuations may be substantial. We cannot predict when we will
	become profitable, if at all.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We currently have no product revenue and will not be able
	to maintain our operations and research and development without additional
	funding.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	To date, we have generated no product revenue and cannot
	predict when and if we will generate product revenue. Our ability to generate
	product revenue and ultimately become profitable depends upon our ability, alone
	or with partners, to successfully develop our product candidates, obtain
	regulatory approval, and commercialize products, including any of our current
	product candidates, or other product candidates that we may develop, in-license
	or acquire in the future. We do not anticipate generating revenue from the sale
	of products for the foreseeable future. We expect our research and development
	expenses to increase in connection with our ongoing activities, particularly as
	we advance our product candidates through clinical trials.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our prospects depend on the success of our product
	candidates which are at early stages of development, and we may not generate
	revenue for several years, if at all, from these products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Given the early stage of our product development, we can make
	no assurance that our research and development programs will result in
	regulatory approval or commercially viable products. To achieve profitable
	operations, we, alone or with others, must successfully develop, gain regulatory
	approval, and market our future products. We currently have no products that
	have been approved by the U.S. Food and Drug Administration, or FDA, Health
	Canada, or HC, or any similar regulatory authority. To obtain regulatory
	approvals for our product candidates being developed and to achieve commercial
	success, clinical trials must demonstrate that the product candidates are safe
	for human use and that they demonstrate efficacy. While we have commenced a
	phase I trial for SIRP&#945;Fc, we have not yet completed a phase I clinical trial or
	subsequent required clinical trials.
</P>
<P ALIGN=JUSTIFY>
	Many product candidates never reach the stage of clinical
	testing and even those that do have only a small chance of successfully
	completing clinical development and gaining regulatory approval. Product
	candidates may fail for a number of reasons, including, but not limited to,
	being unsafe for human use or due to the failure to provide therapeutic benefits
	equal to or better than the standard of treatment at the time of testing.
	Unsatisfactory results obtained from a particular study relating to a research
	and development program may cause us or our collaborators to abandon commitments
	to that program. Positive results of early preclinical research may not be
	indicative of the results that will be obtained in later stages of preclinical
	or clinical research. Similarly, positive results from early-stage clinical
	trials may not be indicative of favorable outcomes in later-stage clinical
	trials. We can make no assurance that any future studies, if undertaken, will
	yield favorable results.
</P>
<P ALIGN=JUSTIFY>
	We recently acquired several preclinical and discovery research
	programs in our acquisition of Fluorinov, including certain assets relating to
	the treatment of central nervous system disorders. While we conducted extensive
	due diligence before making this acquisition, our assessment of the Fluorinov
	technologies may not be accurate. Therefore, our expectations about whether
	various clinical and regulatory milestones with an existing Fluorinov compound
	or development of a future program on the Fluorinov development platform will be
	achieved may not be borne out fully or at all. We have made a commitment to
	attempt to
	monetize the Fluorinov central nervous system assets and, if successful, to share the net proceeds
	with the Fluorinov vendors. As this is not a core competency of the Company, our
	efforts to monetize these assets or any other Fluorinov assets may not be
	successful. We can make no assurances that toxicology, or other preclinical,
	studies will yield results that will allow us to proceed with clinical trials in
	humans.
</P>
<P ALIGN=CENTER>
	- 25 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage86"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_26">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The early stage of our product development makes it
	particularly uncertain whether any of our product development efforts will prove
	to be successful and meet applicable regulatory requirements, and whether any of
	our product candidates will receive the requisite regulatory approvals, be
	capable of being manufactured at a reasonable cost or be successfully marketed.
	If we are successful in developing our current and future product candidates
	into approved products, we will still experience many potential obstacles such
	as the need to develop or obtain manufacturing, marketing and distribution
	capabilities. If we are unable to successfully commercialize any of our
	products, our financial condition and results of operations may be materially
	and adversely affected.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We rely and will continue to rely on third parties to
	plan, conduct and monitor our preclinical studies and clinical trials, and their
	failure to perform as required could cause substantial harm to our
	business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We rely and will continue to rely on third parties to conduct a
	significant portion of our preclinical and clinical development activities.
	Preclinical activities include in vivo studies providing access to specific
	disease models, pharmacology and toxicology studies, and assay development.
	Clinical development activities include trial design, regulatory submissions,
	clinical patient recruitment, clinical trial monitoring, clinical data
	management and analysis, safety monitoring and project management. If there is
	any dispute or disruption in our relationship with third parties, or if they are
	unable to provide quality services in a timely manner and at a feasible cost,
	our active development programs will face delays. Further, if any of these third
	parties fails to perform as we expect or if their work fails to meet regulatory
	requirements, our testing could be delayed, cancelled or rendered
	ineffective.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We rely on contract manufacturers over whom we have
	limited control. If we are subject to quality, cost or delivery issues with the
	preclinical and clinical grade materials supplied by contract manufacturers, our
	business operations could suffer significant harm.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have limited manufacturing experience and rely on contract
	manufacturing organizations, or CMOs to manufacture our product candidates for
	larger preclinical studies and clinical trials. We produce small quantities of
	our product candidates at bench scale in our laboratory facilities for use in
	smaller preclinical studies. We rely on CMOs for manufacturing, filling,
	packaging, storing and shipping of drug product in compliance with cGMP
	regulations applicable to our products. The FDA ensures the quality of drug
	products by carefully monitoring drug manufacturers&#146; compliance with cGMP
	regulations. The cGMP regulations for drugs contain minimum requirements for the
	methods, facilities and controls used in manufacturing, processing and packing
	of a drug product.
</P>
<P ALIGN=JUSTIFY>
	We contracted with Catalent for the manufacture of the SIRP&#945;Fc
	protein to supply drug product for our phase I clinical trial. The manufacture
	of recombinant proteins uses well established processes including a protein
	expression system. Catalent is producing SIRP&#945;Fc using their proprietary GPEx&#174;
	expression system. We believe that Catalent has the capacity, the systems, and
	the experience to supply SIRP&#945;Fc for our phase I clinical trial and we may
	consider using Catalent for manufacturing for later clinical trials. However,
	since the Catalent manufacturing facility where SIRP&#945;Fc is being produced was
	only recently established, it has not been inspected by the FDA. Any
	manufacturing failures or delays or compliance issues could cause delays in the
	conduct of SIRP&#945;Fc preclinical studies and clinical trials.
</P>
<P ALIGN=JUSTIFY>
	There can be no assurances that CMOs will be able to meet our
	timetable and requirements. We have not contracted with alternate suppliers in
	the event Catalent is unable to scale up production, or if Catalent otherwise
	experiences any other significant problems. If we are unable to arrange for
	alternative third-party manufacturing sources on commercially reasonable terms
	or in a timely manner, we may be delayed in the development of our product
	candidates. Further, contract manufacturers must operate in compliance with cGMP
	and failure to do so could result in, among other things, the disruption of
	product supplies. Our dependence upon third parties for the manufacture of our
	products may adversely affect our profit margins and our ability to develop and
	deliver products on a timely and competitive basis.
</P>
<P ALIGN=CENTER>
	- 26 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage87"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_27">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	If clinical trials of our product candidates fail to
	demonstrate safety and efficacy to the satisfaction of regulatory authorities or
	do not otherwise produce positive results, we would incur additional costs or
	experience delays in completing, or ultimately be unable to complete, the
	development and commercialization of our product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Before obtaining marketing approval from regulatory authorities
	for the sale of our product candidates, we must conduct preclinical studies in
	animals and extensive clinical trials in humans to demonstrate the safety and
	efficacy of the product candidates. Clinical testing is expensive and difficult
	to design and implement, can take many years to complete and has uncertain
	outcomes. The outcome of preclinical studies and early clinical trials may not
	predict the success of later clinical trials, and interim results of a clinical
	trial do not necessarily predict final results. A number of companies in the
	pharmaceutical and biotechnology industries have suffered significant setbacks
	in advanced clinical trials due to lack of efficacy or unacceptable safety
	profiles, notwithstanding promising results in earlier trials. We do not know
	whether the clinical trials we may conduct will demonstrate adequate efficacy
	and safety to result in regulatory approval to market any of our product
	candidates in any jurisdiction. A product candidate may fail for safety or
	efficacy reasons at any stage of the testing process. A major risk we face is
	the possibility that none of our product candidates under development will
	successfully gain market approval from the FDA or other regulatory authorities,
	resulting in us being unable to derive any commercial revenue from them after
	investing significant amounts of capital in multiple stages of preclinical and
	clinical testing.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we experience delays in clinical testing, we will be
	delayed in commercializing our product candidates, and our business may be
	substantially harmed.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We cannot predict whether any clinical trials will begin as
	planned, will need to be restructured, or will be completed on schedule, or at
	all. Our product development costs will increase if we experience delays in
	clinical testing. Significant clinical trial delays could shorten any periods
	during which we may have the exclusive right to commercialize our product
	candidates or allow our competitors to bring products to market before us, which
	would impair our ability to successfully commercialize our product candidates
	and may harm our financial condition, results of operations and prospects. The
	commencement and completion of clinical trials for our products may be delayed
	for a number of reasons, including delays related, but not limited, to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure by regulatory authorities to grant permission to
	proceed or placing the clinical trial on hold;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	patients failing to enroll or remain in our trials at the
	rate we expect;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	suspension or termination of clinical trials by
	regulators for many reasons, including concerns about patient safety or
	failure of our contract manufacturers to comply with cGMP requirements;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	any changes to our manufacturing process that may be
	necessary or desired;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	delays or failure to obtain clinical supply from contract
	manufacturers of our products necessary to conduct clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	product candidates demonstrating a lack of safety or
	efficacy during clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	patients choosing an alternative treatment for the
	indications for which we are developing any of our product candidates or
	participating in competing clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	patients failing to complete clinical trials due to
	dissatisfaction with the treatment, side effects or other reasons;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	reports of clinical testing on similar technologies and
	products raising safety and/or efficacy concerns;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	competing clinical trials and scheduling conflicts with
	participating clinicians;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	clinical investigators not performing our clinical trials
	on their anticipated schedule, dropping out of a trial, or employing
	methods not consistent with the clinical trial protocol, regulatory
	requirements or other third parties not performing data collection and
	analysis in a timely or accurate manner;
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 27 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage88"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_28">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure of our contract research organizations, or CROs,
	to satisfy their contractual duties or meet expected deadlines;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	inspections of clinical trial sites by regulatory
	authorities or Institutional Review Boards, or IRBs, or ethics committees
	finding regulatory violations that require us to undertake corrective
	action, resulting in suspension or termination of one or more sites or the
	imposition of a clinical hold on the entire study;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	one or more IRBs or ethics committees rejecting,
	suspending or terminating the study at an investigational site, precluding
	enrollment of additional subjects, or withdrawing its approval of the
	trial; or
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure to reach agreement on acceptable terms with
	prospective clinical trial sites.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Our product development costs will increase if we experience
	delays in testing or approval or if we need to perform more or larger clinical
	trials than planned. Additionally, changes in regulatory requirements and
	policies may occur, and we may need to amend study protocols to reflect these
	changes. Amendments may require us to resubmit our study protocols to regulatory
	authorities or IRBs or ethics committees for re-examination, which may impact
	the cost, timing or successful completion of that trial. Delays or increased
	product development costs may have a material adverse effect on our business,
	financial condition and prospects.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we have difficulty enrolling patients in clinical
	trials, the completion of the trials may be delayed or cancelled.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As our product candidates advance from preclinical testing to
	clinical testing, and then through progressively larger and more complex
	clinical trials, we will need to enroll an increasing number of patients that
	meet our eligibility criteria. There is significant competition for recruiting
	cancer patients in clinical trials, and we may be unable to enroll the patients
	we need to complete clinical trials on a timely basis or at all. The factors
	that affect our ability to enroll patients are largely uncontrollable and
	include, but are not limited to, the following:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	size and nature of the patient population;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	eligibility and exclusion criteria for the
	trial;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	design of the study protocol;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	competition with other companies for clinical
	sites or patients;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the perceived risks and benefits of the product
	candidate under study;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the patient referral practices of physicians;
	and
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the number, availability, location and
	accessibility of clinical trial sites.
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we are unable to successfully develop companion
	diagnostics for our therapeutic product candidates, or experience significant
	delays in doing so, we may not achieve marketing approval or realize the full
	commercial potential of our therapeutic product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We may develop companion diagnostics for our therapeutic
	product candidates. We expect that, at least in some cases, regulatory
	authorities may require the development and regulatory approval of a companion
	diagnostic as a condition to approving our therapeutic product candidates. We
	have limited experience and capabilities in developing or commercializing
	diagnostics and plan to rely in large part on third parties to perform these
	functions. We have not begun to develop companion diagnostics for any of our
	therapeutic product candidates.
</P>
<P ALIGN=JUSTIFY>
	Companion diagnostics are subject to regulation by the FDA, HC,
	and comparable foreign regulatory authorities as medical devices and may require
	separate regulatory approval or clearance prior to commercialization. If we, or
	any third parties that we engage to assist us, are unable to successfully
	develop companion diagnostics for our therapeutic product candidates, or
	experience delays in doing so, our business may be substantially harmed.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Regulatory approval processes are lengthy, expensive and
	inherently unpredictable. Our inability to obtain regulatory approval for our
	product candidates would substantially harm our business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our development and commercialization activities and product
	candidates are significantly regulated by a number of governmental entities,
	including the FDA, HC, and comparable authorities in other countries. Regulatory
	approvals are required prior to each clinical trial and we may fail to obtain
	the necessary approvals to commence or continue clinical testing. We must comply
	with regulations concerning the manufacture, testing, safety, effectiveness,
	labeling, documentation, advertising, and sale of products and product
	candidates and ultimately must obtain regulatory approval before we can
	commercialize a product candidate. The time required to obtain approval by such
	regulatory authorities is unpredictable but typically takes many years following
	the commencement of preclinical studies and clinical trials. Any analysis of
	data from clinical activities we perform is subject to confirmation and
	interpretation by regulatory authorities, which could delay, limit or prevent
	regulatory approval. Even if we believe results from our clinical trials are
	favorable to support the marketing of our product candidates, the FDA or other
	regulatory authorities may disagree. In addition, approval policies,
	regulations, or the type and amount of clinical data necessary to gain approval
	may change during the course of a product candidate&#146;s clinical development and
	may vary among jurisdictions. We have not obtained regulatory approval for any
	product candidate and it is possible that none of our existing product
	candidates or any future product candidates will ever obtain regulatory
	approval.
</P>
<P ALIGN=CENTER>
	- 28 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage89"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_29">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	We could fail to receive regulatory approval for our product
	candidates for many reasons, including, but not limited to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	disagreement with the design or implementation of our
	clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure to demonstrate that a product candidate is safe
	and effective for its proposed indication;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure of clinical trials to meet the level of
	statistical significance required for approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	failure to demonstrate that a product candidate&#146;s
	clinical and other benefits outweigh its safety risks;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	disagreement with our interpretation of data from
	preclinical studies or clinical trials;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the insufficiency of data collected from clinical trials
	of our product candidates to support the submission and filing of a BLA or
	other submission to obtain regulatory approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	deficiencies in the manufacturing processes or the
	failure of facilities of CMOs with whom we contract for clinical and
	commercial supplies to pass a pre-approval inspection; or
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	changes in the approval policies or regulations that
	render our preclinical and clinical data insufficient for approval.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	A regulatory authority may require more information, including
	additional preclinical or clinical data to support approval, which may delay or
	prevent approval and our commercialization plans, or we may decide to abandon
	the development program. If we were to obtain approval, regulatory authorities
	may approve any of our product candidates for fewer or more limited indications
	than we request, may grant approval contingent on the performance of costly
	post-marketing clinical trials, or may approve a product candidate with a label
	that does not include the labeling claims necessary or desirable for the
	successful commercialization of that product candidate. Moreover, depending on
	any safety issues associated with our product candidates that garner approval,
	the FDA may impose a risk evaluation and mitigation strategy, thereby imposing
	certain restrictions on the sale and marketability of such products.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We will require additional capital to finance our
	operations, which may not be available to us on acceptable terms, or at all. As
	a result, we may not complete the development and commercialization of our
	product candidates or develop new product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As a research and development company, our operations have
	consumed substantial amounts of cash since inception. We expect to spend
	substantial funds to continue the research, development and testing of our
	product candidates and to prepare to commercialize products subject to FDA
	approval in the U.S. and similar approvals in other jurisdictions. We will also
	require significant additional funds if we expand the scope of our current
	clinical plans for the SIRP&#945;Fc program or if we were to acquire any new assets
	and advance their development. Therefore, for the foreseeable future, we will
	have to fund all of our operations and development expenditures from cash on
	hand, equity or debt financings, through collaborations with other biotechnology
	or pharmaceutical companies or through financings from other sources. We expect
	that our existing cash at December 31, 2015 of $86,770,542 will enable us to
	fund our current operating plan requirements for at least the next twelve
	months. Additional financing will be required to meet our long term liquidity
	needs. If we do not succeed in raising additional funds on acceptable terms, we
	might not be able to complete planned preclinical studies and clinical trials or
	pursue and obtain approval of any product candidates from the FDA and other
	regulatory authorities. It is possible that future financing will not be
	available or, if available, may not be on favorable terms. The availability of
	financing will be affected by the achievement of our corporate goals, the
	results of scientific and clinical research, the ability to obtain regulatory
	approvals, the state of the capital markets generally and with particular
	reference to drug development companies, the status of strategic alliance
	agreements and other relevant commercial considerations. If adequate funding is
	not available, we may be required to delay, reduce or eliminate one or more of
	our product development programs, or obtain funds through corporate partners or
	others who may require us to relinquish significant rights to product candidates
	or obtain funds on less favorable terms than we would otherwise accept. To the
	extent that external sources of capital become limited or unavailable or
	available on onerous terms, our intangible assets and our ability to continue
	our clinical development plans may become impaired, and our assets, liabilities,
	business, financial condition and results of operations may be materially or
	adversely affected.
</P>
<P ALIGN=CENTER>
	- 29 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage90"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_30">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	We face competition from other biotechnology and
	pharmaceutical companies and our financial condition and operations will suffer
	if we fail to effectively compete.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	The biotechnology and pharmaceutical industries are intensely
	competitive and subject to rapid and significant technological change. Our
	competitors include large, well-established pharmaceutical companies,
	biotechnology companies, and academic and research institutions developing
	cancer therapeutics for the same indications we are targeting and competitors
	with existing marketed therapies. Many other companies are developing or
	commercializing therapies to treat the same diseases or indications for which
	our product candidates may be useful. Although there are no approved therapies
	that specifically target the CD47 pathway, some competitors use therapeutic
	approaches that may compete directly with our product candidates. For example,
	SIRP&#945;Fc is in direct competition with CD47 blocking antibodies from Stanford
	University, Celgene Corporation, and Novimmune SA.
</P>
<P ALIGN=JUSTIFY>
	Many of our competitors have substantially greater financial,
	technical and human resources than we do and have significantly greater
	experience than us in conducting preclinical testing and human clinical trials
	of product candidates, scaling up manufacturing operations and obtaining
	regulatory approvals of products. Accordingly, our competitors may succeed in
	obtaining regulatory approval for products more rapidly than we do. Our ability
	to compete successfully will largely depend on:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the efficacy and safety profile of our product candidates
	relative to marketed products and other product candidates in development;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to develop and maintain a competitive
	position in the product categories and technologies on which we focus;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	the time it takes for our product candidates to complete
	clinical development and receive marketing approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to obtain required regulatory approvals;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to commercialize any of our product
	candidates that receive regulatory approval;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	our ability to establish, maintain and protect
	intellectual property rights related to our product candidates; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	acceptance of any of our product candidates that receive
	regulatory approval by physicians and other healthcare providers and
	payers.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Competitors have developed and may develop technologies that
	could be the basis for products that challenge the differentiated nature and
	potential for best-in-class product development programs and discovery research
	capabilities of Fluorinov. Some of those products may have an entirely different
	approach or means of accomplishing the desired therapeutic effect than our
	products and may be more effective or less costly than our products. The success
	of our competitors and their products and technologies relative to our
	technological capabilities and competitiveness could have a material adverse
	effect on the future pre-clinical and clinical trials of our products, including
	our ability to obtain the necessary regulatory approvals for the conduct of such
	trials. This may further negatively impact our ability to generate future
	product development programs with improved pharmacological properties using
	Fluorinov technology.
</P>
<P ALIGN=CENTER>
	- 30 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage91"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_31">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	If we are not able to compete effectively against our current
	and future competitors, our business will not grow and our financial condition
	and operations will substantially suffer.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We heavily rely on the capabilities and experience of our
	key executives and scientists and the loss of any of them could affect our
	ability to develop our products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	The loss of Dr. Niclas Stiernholm, our President and Chief
	Executive Officer, or other key members of our staff, including Dr. Robert Uger,
	our Chief Scientific Officer, Dr. Eric Sievers, our Chief Medical Officer, James
	Parsons, our Chief Financial Officer, Dr. Penka Petrova, our Chief Development
	Officer, or Dr. Malik Slassi, our Senior Vice President, Discovery Research
	could harm us. We have employment agreements with Drs. Stiernholm, Uger,
	Sievers, Petrova and Slassi and Mr. Parsons, although such employment agreements
	do not guarantee their retention. We also depend on our scientific and clinical
	collaborators and advisors, all of whom have outside commitments that may limit
	their availability to us. In addition, we believe that our future success will
	depend in large part upon our ability to attract and retain highly skilled
	scientific, managerial, medical, clinical and regulatory personnel, particularly
	as we expand our activities and seek regulatory approvals for clinical trials.
	We enter into agreements with our scientific and clinical collaborators and
	advisors, key opinion leaders and academic partners in the ordinary course of
	our business. We also enter into agreements with physicians and institutions who
	will recruit patients into our clinical trials on our behalf in the ordinary
	course of our business. Notwithstanding these arrangements, we face significant
	competition for these types of personnel from other companies, research and
	academic institutions, government entities and other organizations. We cannot
	predict our success in hiring or retaining the personnel we require for
	continued growth. The loss of the services of any of our executive officers or
	other key personnel could potentially harm our business, operating results or
	financial condition.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our employees may engage in misconduct or other improper
	activities, including noncompliance with regulatory standards and requirements,
	which could have a material adverse effect on our business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are exposed to the risk of employee fraud or other
	misconduct. Misconduct by employees could include failures to comply with FDA
	regulations, provide accurate information to the FDA, comply with manufacturing
	standards we have established, comply with federal and state health-care fraud
	and abuse laws and regulations, report financial information or data accurately
	or disclose unauthorized activities to us. In particular, sales, marketing and
	business arrangements in the healthcare industry are subject to extensive laws
	and regulations intended to prevent fraud, kickbacks, self-dealing, and other
	abusive practices. These laws and regulations may restrict or prohibit a wide
	range of pricing, discounting, marketing and promotion, sales commission,
	customer incentive programs and other business arrangements. Employee misconduct
	could also involve the improper use of information obtained in the course of
	clinical trials, which could result in regulatory sanctions and serious harm to
	our reputation. If any such actions are instituted against us, and we are not
	successful in defending ourselves or asserting our rights, those actions could
	have a substantial impact on our business and results of operations, including
	the imposition of substantial fines or other sanctions.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We may expand our business through the acquisition of
	companies or businesses or by entering into collaborations or by in-licensing
	product candidates, each of which could disrupt our business and harm our
	financial condition.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have in the past and may in the future seek to expand our
	pipeline and capabilities by acquiring one or more companies or businesses,
	entering into collaborations, or in-licensing one or more product candidates.
	For example, in January 2016, we acquired Fluorinov, a small molecule medicinal
	chemistry company with preclinical oncology assets and a potential discovery
	platform. In April 2013, we in-licensed tigecycline which was subsequently
	returned to the UHN in 2014. Acquisitions, collaborations and in-licenses
	involve numerous risks, including, but not limited to:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	substantial cash expenditures;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	technology development risks;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	potentially dilutive issuances of equity
	securities;
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 31 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage92"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_32">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	incurrence of debt and contingent liabilities, some of
	which may be difficult or impossible to identify at the time of
	acquisition;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	difficulties in assimilating the operations of the
	acquired companies;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	potential disputes regarding contingent consideration;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	diverting our management&#146;s attention away from other
	business concerns;
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	entering markets in which we have limited or no direct
	experience; and
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
<P ALIGN=JUSTIFY>
	potential loss of our key employees or key employees of
	the acquired companies or businesses.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	We have experience in making acquisitions, entering
	collaborations, and in-licensing product candidates, however, we cannot provide
	assurance that any acquisition, collaboration or in-license will result in
	short-term or long-term benefits to us. We may incorrectly judge the value or
	worth of an acquired company or business or in-licensed product candidate. In
	addition, our future success would depend in part on our ability to manage the
	rapid growth associated with some of these acquisitions, collaborations and
	in-licenses. We cannot provide assurance that we would be able to successfully
	combine our business with that of acquired businesses, manage a collaboration or
	integrate in-licensed product candidates. Furthermore, the development or
	expansion of our business may require a substantial capital investment by
	us.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Negative results from clinical trials or studies of
	others and adverse safety events involving the targets of our products may have
	an adverse impact on our future commercialization efforts
</I>
</B>
	.
</P>
<P ALIGN=JUSTIFY>
	From time to time, studies or clinical trials on various
	aspects of biopharmaceutical products are conducted by academic researchers,
	competitors or others. The results of these studies or trials, when published,
	may have a significant effect on the market for the biopharmaceutical product
	that is the subject of the study. The publication of negative results of studies
	or clinical trials or adverse safety events related to our product candidates,
	or the therapeutic areas in which our product candidates compete, could
	adversely affect our share price and our ability to finance future development
	of our product candidates, and our business and financial results could be
	materially and adversely affected.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We face the risk of product liability claims, which could
	exceed our insurance coverage and produce recalls, each of which could deplete
	our cash resources.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are exposed to the risk of product liability claims alleging
	that use of our product candidates caused an injury or harm. These claims can
	arise at any point in the development, testing, manufacture, marketing or sale
	of our product candidates and may be made directly by patients involved in
	clinical trials of our product candidates, by consumers or healthcare providers
	or by individuals, organizations or companies selling our products. Product
	liability claims can be expensive to defend, even if the product or product
	candidate did not actually cause the alleged injury or harm.
</P>
<P ALIGN=JUSTIFY>
	Insurance covering product liability claims becomes
	increasingly expensive as a product candidate moves through the development
	pipeline to commercialization. We currently maintain clinical trial liability
	insurance coverage of $10 million. However, there can be no assurance that such
	insurance coverage is or will continue to be adequate or available to us at a
	cost acceptable to us or at all. We may choose or find it necessary under our
	collaborative agreements to increase our insurance coverage in the future. We
	may not be able to secure greater or broader product liability insurance
	coverage on acceptable terms or at reasonable costs when needed. Any liability
	for damages resulting from a product liability claim could exceed the amount of
	our coverage, require us to pay a substantial monetary award from our own cash
	resources and have a material adverse effect on our business, financial
	condition and results of operations. Moreover, a product recall, if required,
	could generate substantial negative publicity about our products and business,
	inhibit or prevent commercialization of other products and product candidates or
	negatively impact existing or future collaborations.
</P>
<P ALIGN=JUSTIFY>
	In addition, some of our licensing and other agreements with
	third parties require or might require us to maintain product liability
	insurance. If we cannot maintain acceptable amounts of coverage on commercially
	reasonable terms in accordance with the terms set forth in these agreements, the
	corresponding agreements would be subject to termination, which could have a
	material adverse impact on our operations.
</P>
<P ALIGN=CENTER>
	- 32 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage93"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_33">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	We may not achieve our publicly announced milestones
	according to schedule, or at all.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	From time to time, we may announce the timing of certain events
	we expect to occur, such as the anticipated timing of results from our clinical
	trials. These statements are forward-looking and are based on the best estimates
	of management at the time relating to the occurrence of such events. However,
	the actual timing of such events may differ from what has been publicly
	disclosed. The timing of events such as initiation or completion of a clinical
	trial, filing of an application to obtain regulatory approval, or announcement
	of additional clinical trials for a product candidate may ultimately vary from
	what is publicly disclosed. These variations in timing may occur as a result of
	different events, including the nature of the results obtained during a clinical
	trial or during a research phase, problems with a CMO or a CRO or any other
	event having the effect of delaying the publicly announced timeline. We
	undertake no obligation to update or revise any forward-looking information,
	whether as a result of new information, future events or otherwise, except as
	otherwise required by law. Any variation in the timing of previously announced
	milestones could have a material adverse effect on our business plan, financial
	condition or operating results and the trading price of common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We are exposed to the financial risk related to the
	fluctuation of foreign exchange rates and the degrees of volatility of those
	rates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We may be adversely affected by foreign currency fluctuations.
	To date, we have been primarily funded through issuances of equity, proceeds
	from the exercise of warrants and stock options and from interest income on
	funds available for investment, which are all denominated both in Canadian and
	U.S. dollars. Also, a growing portion of our expenditures are in U.S. dollars,
	and we are therefore subject to foreign currency fluctuations which may, from
	time to time, impact our financial position and results of operations.
</P>
<P ALIGN=JUSTIFY>
<B>
	Risks Related to Intellectual Property
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we are unable to adequately protect and enforce our
	intellectual property, our competitors may take advantage of our development
	efforts or acquired technology and compromise our prospects of marketing and
	selling our key products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We control two patent families relating to SIRP&#945;. One family
	relates to the use of SIRP&#945; to treat cancer. The other family relates our drug
	as a composition of matter, SIRP&#945;Fc.
</P>
<P ALIGN=JUSTIFY>
	More recently, we acquired the patent portfolio of Fluorinov,
	which embraces patent filings that cover eleven different inventions. With the
	exception of one process scheme, these patent filings each claim a family of
	small molecule drugs as compositions of matter, together with claims for their
	production and their medical uses. These drugs target cancer for the most part,
	and some related medical end-uses.
</P>
<P ALIGN=JUSTIFY>
	Our success will depend in part upon our ability to protect our
	intellectual property and proprietary technologies and upon the nature and scope
	of the intellectual property protection we receive. For example, some of our
	patent portfolio covers primarily methods of medical use but not compositions of
	matter. The ability to compete effectively and to achieve partnerships will
	depend on our ability to develop and maintain proprietary aspects of our
	technology and to operate without infringing on the proprietary rights of
	others. The presence of such proprietary rights of others could severely limit
	our ability to develop and commercialize our products, to conduct our existing
	research and could require financial resources to defend litigation, which may
	be in excess of our ability to raise such funds. There is no assurance that our
	pending patent applications or those that we intend to acquire will be approved
	in a form that will be sufficient to protect our proprietary technology and gain
	or keep any competitive advantage that we may have.
</P>
<P ALIGN=CENTER>
	- 33 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage94"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_34">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	The patent positions of pharmaceutical companies can be highly
	uncertain and involve complex legal, scientific and factual questions for which
	important legal principles remain unresolved. Patents issued to us or our
	respective licensors may be challenged, invalidated or circumvented. To the
	extent our intellectual property, including licensed intellectual property,
	offers inadequate protection, or is found to be invalid or unenforceable, we are
	exposed to a greater risk of direct competition. If our intellectual property
	does not provide adequate protection against our competitors&#146; products, our
	competitive position could be adversely affected, as could our business,
	financial condition and results of operations. Both the patent application
	process and the process of managing patent disputes can be time consuming and
	expensive, and the laws of some foreign countries may not protect our
	intellectual property rights to the same extent as do the laws of Canada and the
	United States.
</P>
<P ALIGN=JUSTIFY>
	We will be able to protect our intellectual property from
	unauthorized use by third parties only to the extent that our proprietary
	technologies, key products, and any future products are covered by valid and
	enforceable intellectual property rights including patents or are effectively
	maintained as trade secrets, and provided we have the funds to enforce our
	rights, if necessary.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If we lose our licenses from third-party owners we may be
	unable to continue a substantial part of our business.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are party to licenses that give us rights to intellectual
	property that is necessary or useful for a substantial part of our business.
	Pursuant to our exclusive license agreement with UHN and the Hospital for Sick
	Children, or HSC, under which we license certain patent rights for our key
	products and their uses, we are required to use commercially reasonable efforts
	to commercialize products based on the licensed rights and pay certain royalties
	and sublicensing revenue to UHN and HSC. These licenses require that we pay
	development milestone payments, regulatory milestone payments, royalties on net
	sales, and sublicensing revenues, as well as annual maintenance fees.
</P>
<P ALIGN=JUSTIFY>
	We have also entered into agreements allowing us to manufacture
	SIRP&#945;Fc using Catalent&#146;s proprietary GPEx&#174; expression system. The consideration
	includes payments at the time we successfully reach a series of development and
	sales milestones. We may also enter into licenses in the future to access
	additional third-party intellectual property.
</P>
<P ALIGN=JUSTIFY>
	If we fail to pay annual maintenance fees, development and
	sales milestones, or it is determined that we did not use commercially
	reasonable efforts to commercialize licensed products, we could lose our
	licenses which could have a material adverse effect on our business and
	financial condition.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We may require additional third-party licenses to
	effectively develop and manufacture our key products and are currently unable to
	predict the availability or cost of such licenses.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	A substantial number of patents have already been issued to
	other biotechnology and pharmaceutical companies. To the extent that valid
	third-party patent rights cover our products or services, we or our strategic
	collaborators would be required to seek licenses from the holders of these
	patents in order to manufacture, use or sell these products and services, and
	payments under them would reduce our profits from these products and services.
	We are currently unable to predict the extent to which we may wish or be
	required to acquire rights under such patents, the availability and cost of
	acquiring such rights, and whether a license to such patents will be available
	on acceptable terms or at all. There may be patents in the U.S. or in foreign
	countries or patents issued in the future that are unavailable to license on
	acceptable terms. Our inability to obtain such licenses may hinder or eliminate
	our ability to manufacture and market our products.
</P>
<P ALIGN=CENTER>
	- 34 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage95"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_35">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	Changes in patent law and its interpretation could
	diminish the value of patents in general, thereby impairing our ability to
	protect our product candidates.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As is the case with other biotechnology and pharmaceutical
	companies, our success is heavily dependent on intellectual property rights,
	particularly patents. Obtaining and enforcing patents in the biopharmaceutical
	industry involves technological and legal complexity, and obtaining and
	enforcing biopharmaceutical patents is costly, time-consuming and inherently
	uncertain. The U.S. Supreme Court has ruled on several patent cases in recent
	years, either narrowing the scope of patent protection available in certain
	circumstances or weakening the rights of patent owners in certain situations. In
	addition to increasing uncertainty with regard to our and our licensors&#146; or
	collaborators&#146; ability to obtain patents in the future, this combination of
	events has created uncertainty with respect to the value of patents, once
	obtained. Depending on decisions by the U.S. Congress, the federal courts, and
	the U.S. Patent and Trademark Office, or USPTO, the laws and regulations
	governing patents could change in unpredictable ways that would weaken our and
	our licensors&#146; or collaborators&#146; ability to obtain new patents or to enforce
	existing patents and patents we and our licensors or collaborators may obtain in
	the future.
</P>
<P ALIGN=JUSTIFY>
	Recent patent reform legislation could increase the
	uncertainties and costs surrounding the prosecution of our and our licensors&#146; or
	collaborators&#146; patent applications and the enforcement or defense of our or our
	licensors&#146; or collaborators&#146; issued patents. On September 16, 2011, the
	Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law.
	The Leahy-Smith Act includes a number of significant changes to U.S. patent law.
	These include provisions that affect the way patent applications are prosecuted
	and may also affect patent litigation. The USPTO recently developed new
	regulations and procedures to govern administration of the Leahy-Smith Act, and
	many of the substantive changes to patent law associated with the Leahy-Smith
	Act, and in particular, the first to file provisions, only became effective on
	March 16, 2013. Accordingly, it is not clear what, if any, impact the
	Leahy-Smith Act will have on the operation of our business. However, the
	Leahy-Smith Act and its implementation could increase the uncertainties and
	costs surrounding the prosecution of our or our licensors&#146; or collaborators&#146;
	patent applications and the enforcement or defense of our or our licensors&#146; or
	collaborators&#146; issued patents, all of which could have a material adverse effect
	on our business and financial condition.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Litigation regarding patents, patent applications, and
	other proprietary rights may be expensive, time consuming and cause delays in
	the development and manufacturing of our key products.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our success will depend in part on our ability to operate
	without infringing the proprietary rights of third parties. The pharmaceutical
	industry is characterized by extensive patent litigation. Other parties may
	have, or obtain in the future, patents and allege that the use of our
	technologies infringes these patent claims or that we are employing their
	proprietary technology without authorization.
</P>
<P ALIGN=JUSTIFY>
	In addition, third parties may challenge or infringe upon our
	existing or future patents. Proceedings involving our patents or patent
	applications or those of others could result in adverse decisions regarding:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the patentability of our inventions relating to
	our key products; and/or
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	the enforceability, validity, or scope of
	protection offered by our patents relating to our key products.
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	If we are unable to avoid infringing the patent rights of
	others, we may be required to seek a license, defend an infringement action, or
	challenge the validity of the patents in court. Regardless of the outcome,
	patent litigation is costly and time consuming. In some cases, we may not have
	sufficient resources to bring these actions to a successful conclusion. In
	addition, if we do not obtain a license, develop or obtain non-infringing
	technology, fail to defend an infringement action successfully or have infringed
	patents declared invalid, we may:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	incur substantial monetary damages;
</TD>
</TR>
<TR VALIGN=TOP>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	encounter significant delays in bringing our
	key products to market; and/or
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 35 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage96"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_36">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="5%">
</TD>
<TD ALIGN=LEFT>
	&#149;
</TD>
<TD ALIGN=LEFT WIDTH="90%">
	be precluded from participating in the
	manufacture, use or sale of our key products or methods of treatment
	requiring licenses.
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	Even if we are successful in these proceedings, we may incur
	substantial costs and divert management time and attention in pursuing these
	proceedings, which could have a material adverse effect on us.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our reliance on third parties requires us to share our
	trade secrets, which increases the possibility that a competitor will discover
	them.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Because we rely on third parties to develop our products, we
	must share trade secrets with them. We seek to protect our proprietary
	technology in part by entering into confidentiality agreements and, if
	applicable, material transfer agreements, collaborative research agreements,
	consulting agreements or other similar agreements with our collaborators,
	advisors, employees and consultants prior to beginning research or disclosing
	proprietary information. These agreements typically restrict the ability of our
	collaborators, advisors, employees and consultants to publish data potentially
	relating to our trade secrets. Our academic collaborators typically have rights
	to publish data, provided that we are notified in advance and may delay
	publication for a specified time in order to secure our intellectual property
	rights arising from the collaboration. In other cases, publication rights are
	controlled exclusively by us, although in some cases we may share these rights
	with other parties. We also conduct joint research and development programs
	which may require us to share trade secrets under the terms of research and
	development collaboration or similar agreements. Despite our efforts to protect
	our trade secrets, our competitors may discover our trade secrets, either
	through breach of these agreements, independent development or publication of
	information including our trade secrets in cases where we do not have
	proprietary or otherwise protected rights at the time of publication. A
	competitor&#146;s discovery of our trade secrets may impair our competitive position
	and could have a material adverse effect on our business and financial
	condition.
</P>
<P ALIGN=JUSTIFY>
<B>
	Risks Related to Our Common Shares
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our common share price has been volatile in recent years,
	and may continue to be volatile.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	The market prices for securities of biopharmaceutical
	companies, including ours, have historically been volatile. In the year ended
	December 31, 2015, our common shares traded on the TSX, at a high of $37.27 and
	a low of $10.50 per share. In the year ended December 31, 2014, on the TSXV/TSX
	our common shares traded at a high of $22.20 and a low of $6.30 per share. A
	number of factors could influence the volatility in the trading price of our
	common shares, including changes in the economy or in the financial markets,
	industry related developments, the results of product development and
	commercialization, changes in government regulations, and developments
	concerning proprietary rights, litigation and cash flow. Our quarterly losses
	may vary because of the timing of costs for manufacturing, preclinical studies
	and clinical trials. Also, the reporting of adverse safety events involving our
	products and public rumors about such events could cause our share price to
	decline or experience periods of volatility. Each of these factors could lead to
	increased volatility in the market price of our common shares. In addition,
	changes in the market prices of the securities of our competitors may also lead
	to fluctuations in the trading price of our common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We have never paid dividends and do not expect to do so
	in the foreseeable future.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We have not declared or paid any cash dividends on our common
	or preferred shares to date. The payment of dividends in the future will be
	dependent on our earnings and financial condition in addition to such other
	factors as our board of directors considers appropriate. Unless and until we pay
	dividends, shareholders may not receive a return on their shares. There is no
	present intention by our board of directors to pay dividends on our shares.
</P>
<P ALIGN=CENTER>
	- 36 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage97"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_37">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	Future sales or issuances of equity securities and the
	conversion of outstanding securities to common shares could decrease the value
	of the common shares, dilute investors&#146; voting power, and reduce our earnings
	per share.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We may sell additional equity securities in future offerings,
	including through the sale of securities convertible into equity securities, to
	finance operations, acquisitions or projects, and issue additional common shares
	if outstanding warrants or stock options are exercised, or preferred shares are
	converted to common shares, which may result in dilution. See the information in
	the section of this MD&amp;A entitled &#147;Description of Share Capital&#148; for details
	of our outstanding securities convertible into common shares. We filed a base
	shelf prospectus with securities commissions in Canada and a Form F-10
	registration statement with the SEC on May 29, 2015 that provides that we may
	sell under the prospectus from time to time over the following 25 months up to
	U.S. $100 million, in one or more offerings, of common shares, First Preferred
	shares, warrants to purchase common shares, or units comprising a combination of
	common shares, First Preferred shares and/or warrants. Subject to receipt of any
	required regulatory approvals, subscribers of the December 2013 private
	placement who purchased a minimum of 10% of the securities sold under the
	offering received rights to purchase our securities in future financings to
	enable each such shareholder to maintain their percentage holding in our common
	shares for so long as the subscriber holds at least 10% of the outstanding
	common shares on a fully-diluted basis. Shareholders who do not have this future
	financing participation right may be disadvantaged in participating in such
	financings.
</P>
<P ALIGN=JUSTIFY>
	Our board of directors has the authority to authorize certain
	offers and sales of additional securities without the vote of, or prior notice
	to, shareholders. Based on the need for additional capital to fund expected
	expenditures and growth, it is likely that we will issue additional securities
	to provide such capital. Such additional issuances may involve the issuance of a
	significant number of common shares at prices less than the current market price
	for our common shares.
</P>
<P ALIGN=JUSTIFY>
	Sales of substantial amounts of our securities, or the
	availability of such securities for sale, as well as the issuance of substantial
	amounts of our common shares upon conversion of outstanding convertible equity
	securities, could adversely affect the prevailing market prices for our
	securities and dilute investors&#146; earnings per share. A decline in the market
	prices of our securities could impair our ability to raise additional capital
	through the sale of securities should we desire to do so.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We are likely a &#147;passive foreign investment company,&#148;
	which may have adverse U.S. federal income tax consequences for U.S.
	shareholders
</I>
</B>
	.
</P>
<P ALIGN=JUSTIFY>
	U.S. investors should be aware that we believe we were
	classified as a passive foreign investment company, or PFIC, during the tax
	years ended December 31, 2015 and 2014, and based on current business plans and
	financial expectations, we expect that we will be a PFIC for the current tax
	year and may be a PFIC in future tax years. If we are a PFIC for any year during
	a U.S. shareholder&#146;s holding period of our common shares, then such U.S.
	shareholder generally will be required to treat any gain realized upon a
	disposition of our common shares, or any so-called &#147;excess distribution&#148;
	received on our common shares, as ordinary income, and to pay an interest charge
	on a portion of such gain or distributions, unless the shareholder makes a
	timely and effective &#147;qualified electing fund&#148; election, or QEF
<B>
</B>
	Election,
	or a &#147;mark-to-market&#148; election with respect to our shares. A U.S. shareholder
	who makes a QEF Election generally must report on a current basis its share of
	our net capital gain and ordinary earnings for any year in which we are a PFIC,
	whether or not we distribute any amounts to our shareholders. A U.S. shareholder
	who makes the mark-to-market election generally must include as ordinary income
	each year the excess of the fair market value of the common shares over the
	shareholder&#146;s adjusted tax basis therein. Each U.S. shareholder should consult
	its own tax advisors regarding the PFIC rules and the U.S. federal income tax
	consequences of the acquisition, ownership and disposition of our common shares.
</P>
<P ALIGN=CENTER>
	- 37 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage98"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_38">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<B>
<I>
	It may be difficult for non-Canadian investors to obtain
	and enforce judgments against us because of our Canadian incorporation and
	presence.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are a corporation existing under the laws of the Province of
	Ontario, Canada. Several of our directors and officers, and several of the
	experts are residents of Canada, and all or a substantial portion of their
	assets, and a substantial portion of our assets, are located outside the United
	States. Consequently, although we have appointed an agent for service of process
	in the United States, it may be difficult for holders of our securities who
	reside in the United States to effect service within the United States upon
	those directors and officers, and the experts who are not residents of the
	United States. It may also be difficult for holders of our securities who reside
	in the United States to realize in the United States upon judgments of courts of
	the United States predicated upon our civil liability and the civil liability of
	our directors, officers and experts under the United States federal securities
	laws. Investors should not assume that Canadian courts (i) would enforce
	judgments of United States courts obtained in actions against us or such
	directors, officers or experts predicated upon the civil liability provisions of
	the United States federal securities laws or the securities or &#147;blue sky&#148; laws
	of any state or jurisdiction of the United States or (ii) would enforce, in
	original actions, liabilities against us or such directors, officers or experts
	predicated upon the United States federal securities laws or any securities or
	&#147;blue sky&#148; laws of any state or jurisdiction of the United States. In addition,
	the protections afforded by Canadian securities laws may not be available to
	investors in the United States.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	If there are substantial sales of our common shares, the
	market price of our common shares could decline.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Sales of substantial numbers of our common shares could cause a
	decline in the market price of our common shares. Any sales by existing
	shareholders or holders who exercise their warrants or stock options may have an
	adverse effect on our ability to raise capital and may adversely affect the
	market price of our common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	We are an &#147;emerging growth company,&#148; and we cannot be
	certain if the reduced reporting requirements applicable to emerging growth
	companies will make our common shares less attractive to investors.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	We are an &#147;emerging growth company,&#148; as defined in the JOBS
	Act. For as long as we continue to be an emerging growth company, we may take
	advantage of exemptions from various reporting requirements that are applicable
	to other public companies that are not emerging growth companies, including not
	being required to comply with the auditor attestation requirements of Section
	404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
	executive compensation in our periodic reports and exemptions from the
	requirements of holding a nonbinding advisory vote on executive compensation and
	shareholder approval of any golden parachute payments not previously approved.
	We could be an emerging growth company for up to five years, although
	circumstances could cause us to lose that status earlier. We cannot predict if
	investors will find our common shares less attractive because we may rely on
	these exemptions. If some investors find our common shares less attractive as a
	result, there may be a less active trading market for our common shares and our
	share price may be more volatile.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Any failure to maintain an effective system of internal
	controls may result in material misstatements of our consolidated financial
	statements or cause us to fail to meet our reporting obligations or fail to
	prevent fraud; and in that case, our shareholders could lose confidence in our
	financial reporting, which would harm our business and could negatively impact
	the price of our common shares.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	Effective internal controls are necessary for us to provide
	reliable financial reports and prevent fraud. If we fail to maintain an
	effective system of internal controls, we might not be able to report our
	financial results accurately or prevent fraud; and in that case, our
	shareholders could lose confidence in our financial reporting, which would harm
	our business and could negatively impact the price of our common shares. While
	we believe that we have sufficient personnel and review procedures to allow us
	maintain an effective system of internal controls, we cannot provide assurance
	that we will not experience potential material weaknesses in our internal
	control. Even if we conclude that our internal control over financial reporting
	provides reasonable assurance regarding the reliability of financial reporting
	and the preparation of consolidated financial statements for external purposes
	in accordance with International Financial Reporting Standards, as issued by the
	International Accounting Standards Board, because of its inherent limitations,
	internal control over financial reporting may not prevent or detect fraud or
	misstatements. Failure to implement required new or improved controls, or
	difficulties encountered in their implementation, could harm our results of
	operations or cause us to fail to meet our future reporting obligations.
</P>
<P ALIGN=CENTER>
	- 38 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage99"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_39">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
	If we fail to timely achieve and maintain the adequacy of our
	internal control over financial reporting, we may not be able to produce
	reliable financial reports or help prevent fraud. Our failure to achieve and
	maintain effective internal control over financial reporting could prevent us
	from complying with our reporting obligations on a timely basis, which could
	result in the loss of investor confidence in the reliability of our consolidated
	financial statements, harm our business and negatively impact the trading price
	of our common shares.
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	As a foreign private issuer, we are not subject to
	certain United States securities law disclosure requirements that apply to a
	domestic United States issuer, which may limit the information which would be
	publicly available to our shareholders.
</I>
</B>
</P>
<P ALIGN=JUSTIFY>
	As a foreign private issuer, we are not required to comply with
	all the periodic disclosure requirements of the Exchange Act, and therefore,
	there may be less publicly available information about us than if we were a
	United States domestic issuer. For example, we are not subject to the proxy
	rules in the United States and disclosure with respect to our annual meetings
	will be governed by Canadian requirements.
<B>
</B>
</P>
<P ALIGN=JUSTIFY>
<B>
<I>
	Our charter documents and certain Canadian legislation
	could delay or deter a change of control, limit attempts by our shareholders to
	replace or remove our current management and limit the market price of our
	common shares.
</I>
</B>
<B>
</B>
</P>
<P ALIGN=JUSTIFY>
	Our authorized preferred shares are available for issuance from
	time to time at the discretion of our board of directors, without shareholder
	approval. Our articles grant our board of directors the authority to determine
	the special rights and restrictions granted to or imposed on any unissued series
	of preferred shares, and those rights may be superior to those of our common
	shares. Further, the Investment Canada Act subjects any acquisition of control
	of a company by a non-Canadian to government review if the value of the assets
	as calculated pursuant to the legislation exceeds a threshold amount or in other
	circumstances determined at the discretion of the Canadian government. A
	reviewable acquisition may not proceed unless the relevant minister is satisfied
	that the investment is likely to be of net benefit to Canada and the Canadian
	government is satisfied that no other important concerns arise from the
	acquisition of control. Any of the foregoing could prevent or delay a change of
	control and may deprive or limit strategic opportunities to our shareholders to
	sell their shares.
</P>
<P ALIGN=CENTER>
<B>
	DISCLOSURE CONTROLS AND INTERNAL CONTROLS OVER FINANCIAL
	REPORTING
</B>
</P>
<P ALIGN=JUSTIFY>
	We have implemented a system of internal controls that we
	believe adequately protects our assets and is appropriate for the nature of our
	business and the size of our operations. Our internal control system was
	designed to provide reasonable assurance that all transactions are accurately
	recorded, that transactions are recorded as necessary to permit preparation of
	financial statements in accordance with IFRS, and that our assets are
	safeguarded.
</P>
<P ALIGN=JUSTIFY>
	These internal controls include disclosure controls and
	procedures designed to ensure that information required to be disclosed by us is
	accumulated and communicated as appropriate to allow timely decisions regarding
	required disclosure.
</P>
<P ALIGN=JUSTIFY>
	Internal control over financial reporting means a process
	designed by or under the supervision of the Chief Executive Officer and the
	Chief Financial Officer to provide reasonable assurance regarding the
	reliability of financial reporting and the preparation of financial statements
	for external purposes in accordance with IFRS as issued by the IASB. The
	internal controls are not expected to prevent and detect all misstatements due
	to error or fraud.
</P>
<P ALIGN=JUSTIFY>
	There were no changes in our internal control over financial
	reporting that occurred during the three months ended December 31, 2015 that
	have materially affected, or are reasonably likely to materially affect, our
	internal control over financial reporting. As at December 31, 2015, we have
	assessed the effectiveness of our internal control over financial reporting and
	disclosure controls and procedures using the Committee of Sponsoring
	Organizations of the Treadway Commission&#146;s 2013 framework. Based on their
	evaluation, the Chief Executive Officer and the Chief Financial Officer have
	concluded that these controls and procedures are effective.
</P>
<P ALIGN=CENTER>
	- 39 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage100"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-2_HTM_PAGE_40">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" ALIGN=LEFT>
<B>
	Management&#146;s
	Discussion and Analysis
</B>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
<B>
	ADDITIONAL INFORMATION
</B>
</P>
<P ALIGN=JUSTIFY>
	Additional information for Trillium can be found on SEDAR at
	www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml.
</P>
<P ALIGN=CENTER>
	- 40 -
</P>
<HR ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage101"></A>
<A NAME="EXHIBIT99-3_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_3"></A>
<HR NOSHADE ALIGN="CENTER" WIDTH=100% SIZE=3 COLOR="BLACK">
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_1">
</A>
<P ALIGN=CENTER>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/09/0001062993-16-008235_FINANCIALSX1X1.JPG" BORDER=0 WIDTH="269" HEIGHT="193">
</P>
<P ALIGN=CENTER>
<B>
	(formerly Stem Cell Therapeutics Corp.)
</B>
</P>
<P ALIGN=CENTER>
<B>
	CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P ALIGN=CENTER>
<B>
	FOR THE YEARS ENDED
<BR>
	DECEMBER 31, 2015 AND 2014
</B>
</P>
<P ALIGN=CENTER>
	96 Skyway Avenue
<BR>
	Toronto, Ontario M9W 4Y9
<BR>
	www.trilliumtherapeutics.com
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage102"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_2">
</A>
<P ALIGN=CENTER>
<B>
	INDEPENDENT AUDITORS&#146; REPORT OF REGISTERED PUBLIC ACCOUNTING
	FIRM
</B>
</P>
<P ALIGN=JUSTIFY>
	To the Shareholders of
<BR>
<B>
	Trillium Therapeutics Inc.
</B>
</P>
<P ALIGN=JUSTIFY>
	We have audited the accompanying consolidated financial
	statements of
<B>
	Trillium Therapeutics Inc
</B>
	. which comprise the consolidated
	statements of financial position as at December 31, 2015 and 2014, and the
	consolidated statements of loss and comprehensive loss, changes in equity and
	cash flows for the years then ended, and a summary of significant accounting
	policies and other explanatory information.
</P>
<P ALIGN=JUSTIFY>
<B>
	Management&#146;s responsibility for the consolidated financial
	statements
</B>
</P>
<P ALIGN=JUSTIFY>
	Management is responsible for the preparation and fair
	presentation of these consolidated financial statements in accordance with
	International Financial Reporting Standards, as issued by the International
	Accounting Standards Board, and for such internal control as management
	determines is necessary to enable the preparation of consolidated financial
	statements that are free from material misstatement, whether due to fraud or
	error.
</P>
<P ALIGN=JUSTIFY>
<B>
	Auditors&#146; responsibility
</B>
</P>
<P ALIGN=JUSTIFY>
	Our responsibility is to express an opinion on these
	consolidated financial statements based on our audits. We conducted our audits
	in accordance with Canadian generally accepted auditing standards and the
	standards of the Public Company Accounting Oversight Board (United States).
	Those standards require that we comply with ethical requirements and plan and
	perform the audit to obtain reasonable assurance about whether the consolidated
	financial statements are free from material misstatement. We were not engaged to
	perform an audit of the Company&#146;s internal control over financial reporting. Our
	audits included consideration of internal control over financial reporting as a
	basis for designing audit procedures that are appropriate in the circumstances,
	but not for the purpose of expressing an opinion on the effectiveness of the
	Company&#146;s internal control over financial reporting. Accordingly, we express no
	such opinion.
</P>
<P ALIGN=JUSTIFY>
	An audit involves performing procedures to obtain audit
	evidence about the amounts and disclosures in the consolidated financial
	statements. The procedures selected depend on the auditors&#146; judgment, including
	the assessment of the risks of material misstatement of the consolidated
	financial statements, whether due to fraud or error. An audit also includes, on
	a test basis, evidence supporting the amounts and disclosures in the
	consolidated financial statements, evaluating the appropriateness of accounting
	policies used and the reasonableness of accounting estimates made by management,
	as well as evaluating the overall presentation of the consolidated financial
	statements.
</P>
<P ALIGN=JUSTIFY>
	We believe that the audit evidence we have obtained in our
	audits is sufficient and appropriate to provide a basis for our audit
	opinion.
</P>
<P ALIGN=JUSTIFY>
<B>
	Opinion
</B>
</P>
<P ALIGN=JUSTIFY>
	In our opinion, the consolidated financial statements present
	fairly, in all material respects, the financial position of
<B>
	Trillium
	Therapeutics Inc.
</B>
	as at December 31, 2015 and 2014, and its financial
	performance and its cash flows for the years then ended in accordance with
	International Financial Reporting Standards, as issued by the International
	Accounting Standards Board.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="50%">
	/s/ Ernst &amp; Young LLP
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Toronto, Canada
</TD>
<TD ALIGN=RIGHT WIDTH="50%">
	Chartered Professional Accountants
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	March 9, 2016
</TD>
<TD ALIGN=RIGHT WIDTH="50%">
	Licensed Public Accountants
</TD>
</TR>
</TABLE>
<BR>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage103"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_3">
</A>
<BR>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Consolidated Statements of Financial Position
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	As at
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	As at
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Note
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31, 2015
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	December 31, 2014
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<B>
	ASSETS
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Current
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Cash
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	86,770,542
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	26,165,056
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Amounts receivable
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	4
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	974,822
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	344,416
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Prepaid expenses
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	1,181,481
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	1,008,225
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total current assets
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	88,926,845
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	27,517,697
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Property and equipment
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	5
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	897,390
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	235,402
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Intangible assets
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	6
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	93,585
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	432,933
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Other assets
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	121,648
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total non-current assets
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	1,112,623
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	668,335
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total assets
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	90,039,468
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	28,186,032
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	LIABILITIES
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Current
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Accounts payable and accrued
	liabilities
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	7
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	3,233,749
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	3,248,984
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Other current liabilities
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	8
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	323,151
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	279,461
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total current liabilities
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	3,556,900
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	3,528,445
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Loan payable
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	8
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	270,386
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	283,352
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Deferred lease inducement
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	8
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	348,205
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Long-term liability
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	8
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	60,109
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	69,941
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total non-current liabilities
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	678,700
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	353,293
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total liabilities
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	4,235,600
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	3,881,738
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	EQUITY
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Common shares
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	103,340,072
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	49,505,792
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Series I preferred shares
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	7,797,773
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	10,076,151
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Series II preferred shares
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	24,369,384
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Warrants
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	6,926,019
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9,283,332
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Contributed surplus
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	8,660,355
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	5,995,055
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Deficit
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(65,289,735
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(50,556,036
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total equity
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	85,803,868
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	24,304,294
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Total liabilities and equity
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	90,039,468
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	28,186,032
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Commitments and contingencies
<I>
	[note 14]
</I>
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Approved by the Board and authorized for issue on March 9,
	2016:
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	(signed) Luke Beshar, Director
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	(signed) Henry Friesen, Director
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<I>
	See accompanying notes to the consolidated financial
	statements
</I>
</P>
<P ALIGN=CENTER>
	- 1 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage104"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_4">
</A>
<BR>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Consolidated Statements of Loss and Comprehensive
	Loss
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Year ended
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Year ended
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<STRONG>
	Note
</STRONG>
	&nbsp;&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31, 2015
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	December 31, 2014
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	EXPENSES
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Research and development
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	11
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	18,050,091
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	10,595,808
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	General and administrative
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	12
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	3,184,347
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	2,577,460
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Operating expenses
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	21,234,438
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	13,173,268
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Finance income
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	13
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(6,595,189
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	(378,692
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Finance costs
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	13
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	84,948
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	87,244
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Net
	finance income
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(6,510,241
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(291,448
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Net loss before income taxes
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	14,724,197
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	12,881,820
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Current income tax expense
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	10
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	9,502
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	-
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Net loss and comprehensive loss for the year
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	14,733,699
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	12,881,820
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Basic and diluted loss per common share
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	(c)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(2.22
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(3.06
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P ALIGN=JUSTIFY>
<I>
	See accompanying notes to the consolidated financial
	statements
</I>
</P>
<P ALIGN=CENTER>
	- 2 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage105"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_5">
</A>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Consolidated Statements of Changes in Equity
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 8PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="11%" COLSPAN=4>
<U>
	Common
	shares
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="11%" COLSPAN=4>
<U>
	Series I
	preferred shares
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="11%" COLSPAN=4>
<U>
	Series II
	preferred shares
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="11%" COLSPAN=4>
<U>
	Warrants
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Contributed
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	surplus
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Deficit
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	Total
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="4%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(note 9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(note 9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(note 9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(note 9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(note 9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	Balance, December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	4,427,244&nbsp;&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	49,505,792
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	69,504,689
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	10,076,151
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	138,724,781
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	9,283,332
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	5,995,055
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	(50,556,036
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	24,304,294
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Net loss and
	comprehensive
</B>
<BR>
<B>
	loss for the period
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	(14,733,699
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	(14,733,699
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Transactions with owners
</B>
<BR>
<B>
	of the
	Company, recognized
</B>
<BR>
<B>
	directly in equity
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="4%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Shares
	issued,&nbsp;
<BR>
	&nbsp; net of issue costs
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	1,750,754
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	39,592,240
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	1,077,605
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	24,369,384
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	63,961,624
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Exercise of warrants
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	1,087,603
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	11,872,467
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(32,628,425
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(2,357,313
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	9,515,154
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Exercise of stock
	options
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	6,666
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	91,195
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	(41,200
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	49,995
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Conversion of preferred shares
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	523,870
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	2,278,378
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(15,716,110
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(2,278,378
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Share-based compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	2,706,500
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
	2,706,500
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Total transactions with
</B>
<BR>
<B>
	owners of the Company
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	3,368,893
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	53,834,280
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(15,716,110
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(2,278,378
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	1,077,605
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	24,369,384
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(32,628,425
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	(2,357,313
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	2,665,300
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%">
	76,233,273
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Balance, December 31, 2015
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<STRONG>
	7,796,137
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<STRONG>
	103,340,072
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	53,788,579
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	7,797,773
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	1,077,605
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	24,369,384
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	106,096,356
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	6,926,019
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	8,660,355
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	(65,289,735
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="4%" BGCOLOR=#E6EFFF>
<B>
	85,803,868
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 8PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="15%" COLSPAN=4>
<U>
	Common
	shares
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="15%" COLSPAN=4>
<U>
	Series I
	preferred shares
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=CENTER WIDTH="15%" COLSPAN=4>
<U>
	Warrants
</U>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Contributed
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Amount
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	surplus
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Deficit
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	Total
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	#
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="6%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	Balance, December 31, 2013
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	4,058,408
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	47,191,303
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	77,895,165
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	11,292,525
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	142,230,123
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	9,818,179
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	3,280,656
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(37,674,216
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	33,908,447
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Net loss and
	comprehensive
</B>
<BR>
<B>
	loss for the period
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(12,881,820
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(12,881,820
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Transactions with owners
</B>
<BR>
<B>
	of the
	Company, recognized
</B>
<BR>
<B>
	directly in equity
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="6%">
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Exercise of warrants
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	86,540
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	1,065,015
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(2,596,251
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(118,202
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	946,813
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Exercise of stock options
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	2,614
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	33,100
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(13,500
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	19,600
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Conversion of
	preferred shares
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	279,682
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	1,216,374
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(8,390,476
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	(1,216,374
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Expiry of warrants
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(909,091
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(416,645
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	416,645
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
	&nbsp; Share-based compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	2,311,254
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
	2,311,254
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Total transactions with
</B>
<BR>
<B>
	owners of the Company
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	368,836
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	2,314,489
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(8,390,476
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(1,216,374
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(3,505,342
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	(534,847
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	2,714,399
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%">
	3,277,667
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<P STYLE="TEXT-INDENT: -15PT; MARGIN-LEFT: 15PT">
<B>
	Balance, December 31, 2014
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<STRONG>
	4,427,244
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	49,505,792
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	69,504,689
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	10,076,151
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	138,724,781
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	9,283,332
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	5,995,055
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	(50,556,036
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="6%" BGCOLOR=#E6EFFF>
<B>
	24,304,294
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=JUSTIFY>
<I>
	See accompanying notes to the consolidated financial
	statements
</I>
</P>
<P ALIGN=CENTER>
	- 3 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage106"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_6">
</A>
<BR>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Consolidated Statements of Cash Flows
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	Year ended
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Year ended
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Note
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	December 31, 2015
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	December 31, 2014
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	OPERATING ACTIVITIES
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Net loss for the year
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(14,733,699
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(12,881,820
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Adjustments for items not
	affecting cash
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp; &nbsp; &nbsp; &nbsp;Share-based
	compensation
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	2,706,500
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	2,311,254
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp; &nbsp; &nbsp;
	&nbsp;Interest accretion
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	8,13
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	73,391
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	69,770
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp; &nbsp; &nbsp; &nbsp;Amortization of
	intangible assets
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	6,11
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	339,348
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	610,776
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp; &nbsp; &nbsp;
	&nbsp;Impairment of intangible assets
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	6,11
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	-
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	429,763
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp; &nbsp; &nbsp; &nbsp;Depreciation of
	property and equipment
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	5,11
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	118,394
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	47,208
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp; &nbsp; &nbsp;
	&nbsp;Non-cash change in deferred lease inducement
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	105,805
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp; &nbsp; &nbsp; &nbsp;Unrealized foreign exchange gain
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(6,010,996
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(17,401,257
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	(9,413,049
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Changes in non-cash working capital balances
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp; &nbsp; &nbsp;
	&nbsp;Amounts receivable
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(630,406
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	82,818
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp; &nbsp; &nbsp; &nbsp;Prepaid expenses
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(173,256
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(913,656
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp; &nbsp; &nbsp;
	&nbsp;Accounts payable and accrued liabilities
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(15,235
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	2,579,124
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp; &nbsp; &nbsp; &nbsp;Other current
	liabilities
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	43,690
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	216,695
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Increase in other assets
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(121,648
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Cash used in operating activities
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(18,298,112
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(7,448,068
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	INVESTING ACTIVITIES
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Purchase of property and
	equipment
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	5
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(750,382
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	(173,603
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Net
	change in marketable securities
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	-
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	526,598
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Cash provided by (used) in investing activities
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(750,382
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	352,995
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	FINANCING ACTIVITIES
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Change in loan payable
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	8
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(68,761
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(115,031
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Receipt of deferred lease
	inducement
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	8
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	212,400
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Change in long-term liability
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	8
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(27,428
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(47,759
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Issue of share capital, net of issuance costs
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	73,526,773
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	966,413
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Cash provided by financing activities
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	73,642,984
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	803,623
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Impact of foreign exchange rate on cash
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	6,010,996
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Net increase (decrease) in
	cash during the year
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	60,605,486
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	(6,291,450
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Cash, beginning of year
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	26,165,056
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	32,456,506
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Cash, end of year
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	86,770,542
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	26,165,056
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Supplemental cash flow
	information
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Preferred shares converted to common shares (note 9)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	2,278,378
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	1,216,374
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P ALIGN=JUSTIFY>
<I>
	See accompanying notes to the consolidated financial
	statements
</I>
</P>
<P ALIGN=CENTER>
	- 4 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage107"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_7">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	1.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Corporate information
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Trillium Therapeutics Inc. (the
	&#147;Company&#148; or &#147;Trillium&#148;) is a Canadian public immuno-oncology company developing
	innovative therapies for the treatment of cancer. The Company was incorporated
	under the laws of the Province of Alberta on March 31, 2004 with nominal share
	capital and filed Articles of Continuance to change its jurisdiction to Ontario
	on November 7, 2013. On June 1, 2014, the Company amalgamated with its
	wholly-owned subsidiary Trillium Therapeutics Inc. (&#147;Trillium Privateco&#148;) and
	changed its name from Stem Cell Therapeutics Corp. to Trillium Therapeutics Inc.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company&#146;s head office is located at
	96 Skyway Avenue, Toronto, Ontario, M9W 4Y9 and is listed on the Toronto Stock
	Exchange under the symbol TR and on the NASDAQ Stock Exchange under the symbol
	TRIL.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	2.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Basis of presentation
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(a)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Statement of compliance
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The consolidated financial statements
	have been prepared in accordance with International Financial Reporting
	Standards (&#147;IFRS&#148;), as issued by the International Accounting Standards Board
	(&#147;IASB&#148;).
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	These consolidated financial statements
	were approved by the Company&#146;s Board of Directors on March 9, 2016.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(b)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Basis of measurement
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	These consolidated financial statements
	have been prepared on the historical cost basis, except for held-for-trading
	financial assets which are measured at fair value.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(c)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Functional and presentation
	currency
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	These consolidated financial statements
	are presented in Canadian dollars, which is the Company's functional
	currency.
<B>
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(d)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Use of significant estimates and
	assumptions
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The preparation of financial statements
	in conformity with IFRS requires management to make judgments, estimates and
	assumptions that affect the application of accounting policies and the reported
	amounts of assets and liabilities, revenue and expenses and the related
	disclosures of contingent assets and liabilities and the determination of the
	Company&#146;s ability to continue as a going concern. Actual results could differ
	materially from these estimates and assumptions. The Company reviews its
	estimates and underlying assumptions on an ongoing basis. Revisions are
	recognized in the period in which the estimates are revised and may impact
	future periods.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Management has applied significant
	estimates and assumptions to the following:
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Valuation of share-based compensation
	and warrants
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Management measures the costs for
	share-based compensation and warrants using market-based option valuation
	techniques. Assumptions are made and estimates are used in applying the
	valuation techniques. These include estimating the future volatility of the
	share price, expected dividend yield, expected risk-free interest rate, future
	employee turnover rates, future exercise behaviours and corporate performance.
	Such estimates and assumptions are inherently uncertain. Changes in these
	assumptions affect the fair value estimates of share-based payments and
	warrants.
</P>
<P ALIGN=CENTER>
	- 5 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage108"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_8">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	2.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Basis of presentation
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Impairment of long lived assets
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Long-lived assets are reviewed for
	impairment upon the occurrence of events or changes in circumstances indicating
	that the carrying value of the asset may not be recoverable. For the purpose of
	measuring recoverable amounts, assets are grouped at the lowest levels for which
	there are separately identifiable cash flows (cash-generating units). The
	recoverable amount is the higher of an asset&#146;s fair value less costs to sell and
	value in use (being the present value of the expected future cash flows of the
	relevant asset or cash-generating unit). An impairment loss is recognized for
	the amount by which the asset&#146;s carrying amount exceeds its recoverable amount.
	Management evaluates impairment losses for potential reversals when events or
	circumstances warrant such consideration.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Intangible assets
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company estimates the useful lives
	of intangible assets from the date they are available for use in the manner
	intended by management and at least annually reviews the useful lives to reflect
	management's intent about developing and commercializing the assets.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	3.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Significant accounting
	policies
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The accounting policies set out below
	have been applied consistently to all periods presented in these consolidated
	financial statements.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(a)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Basis of consolidation
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	These consolidated financial statements
	include the accounts of the Company and its wholly-owned subsidiaries, Stem Cell
	Therapeutics Inc. to the date of its dissolution on September 17, 2014, and
	Trillium Privateco from April 9, 2013, the date of acquisition to the date of
	its amalgamation with the Company on June 1, 2014.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Investments in entities where the
	Company is exposed, or has rights, to variable returns from its involvement with
	the investee and has the ability to affect those returns through its power over
	the investee, are considered subsidiaries due to the control exercised over the
	investee by the Company. Subsidiaries are fully consolidated from the date at
	which control is determined to have occurred and are de-consolidated from the
	date that the Company no longer controls the entity. The financial statements of
	the subsidiaries are prepared for the same reporting period as the Company,
	using consistent accounting policies. Intercompany transactions, balances and
	unrealized gains and losses on transactions between subsidiaries are
	eliminated.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(b)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Foreign currency
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Transactions in foreign currencies are
	translated to the functional currency at the rate on the date of the
	transactions. Monetary assets and liabilities denominated in foreign currencies
	are retranslated at the spot rate of exchange as at the reporting date. All
	differences are taken to profit or loss. Non-monetary items that are measured in
	terms of historical cost in a foreign currency are translated using the exchange
	rate as at the date of the initial transaction. Non-monetary items measured at
	fair value in a foreign currency are translated using the exchange rate at the
	date when the fair value was determined.
</P>
<P ALIGN=CENTER>
	- 6 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage109"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_9">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	3.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Significant accounting policies
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(c)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Financial instruments
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Financial assets
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	A financial asset is classified at fair
	value through profit or loss if it is held for trading or is designated as such
	upon initial recognition. Attributable transaction costs are recognized in
	profit or loss as incurred. Financial assets at fair value through profit or
	loss are measured at fair value and changes therein are recognized in profit or
	loss.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<I>
	Loans and receivables
<BR>
</I>
	Loans
	and receivables are non-derivative financial assets with fixed or determinable
	payments that are not quoted in an active market. Loans and receivables are
	initially recognized at fair value plus transaction costs and subsequently
	measured at amortized cost using the effective interest rate method less any
	impairment losses. The Company has classified its amounts receivable as loans
	and receivables.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<I>
	Derecognition
<BR>
</I>
	A financial
	asset is derecognized when the rights to receive cash flows from the asset have
	expired or when the Company has transferred its rights to receive cash flows
	from the asset.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Financial liabilities
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Financial liabilities are recognized
	initially at fair value plus any directly attributable transaction costs, and
	subsequently at amortized cost using the effective interest method. The Company
	has classified its accounts payable and accrued liabilities, and loan payable as
	financial liabilities.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<I>
	Derecognition
<BR>
</I>
	A financial
	liability is derecognized when its contractual obligations are discharged,
	cancelled or expired.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Equity
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Common shares, preferred shares and
	warrants to purchase common shares are classified as equity. Incremental costs
	directly attributable to the issue of common shares, preferred shares and
	warrants are recognized as a deduction from equity, net of any tax effects.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(d)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Property and equipment
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<I>
	Recognition and measurement
<BR>
</I>
	Items of property and equipment are measured at cost less accumulated
	depreciation and accumulated impairment losses. Cost includes the expenditure
	that is directly attributable to the acquisition of the asset. When parts of an
	item of property and equipment have different useful lives, they are accounted
	for as separate items (major components) of property and equipment. Gains and
	losses on disposal of an item of property and equipment are determined by
	comparing the proceeds from disposal with the carrying amount of property and
	equipment, and are recognized in profit or loss.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<I>
	Subsequent costs
<BR>
</I>
	The cost of
	replacing a part of an item of property and equipment is recognized in the
	carrying amount of the item if it is probable that the future economic benefits
	embodied within the part will flow to the Company, and its cost can be measured
	reliably. The carrying amount of the replaced part is then derecognized. The
	costs of the day-to-day servicing of property and equipment are recognized in
	profit or loss as incurred.
</P>
<P ALIGN=CENTER>
	- 7 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage110"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_10">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	3.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Significant accounting policies
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<I>
	Depreciation
</I>
<BR>
	The estimated
	useful lives and the methods of depreciation for the current and comparative
	periods are as follows:
</P>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" NOWRAP ALIGN=LEFT WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD NOWRAP ALIGN=LEFT>
	Asset
</TD>
<TD NOWRAP ALIGN=LEFT WIDTH="50%">
	Basis
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Lab equipment
</TD>
<TD ALIGN=LEFT WIDTH="50%" BGCOLOR=#E6EFFF>
	20% declining balance
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Computer equipment
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	30% declining balance
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT BGCOLOR=#E6EFFF>
	Office equipment
</TD>
<TD ALIGN=LEFT WIDTH="50%" BGCOLOR=#E6EFFF>
	20% declining balance
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Leaseholds
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT WIDTH="50%">
	Straight-line over expected lease term
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Estimates for depreciation methods,
	useful lives and residual values are reviewed at each reporting period-end and
	adjusted if appropriate. Depreciation expense is recognized in research and
	development expenses.
<B>
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(e)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Intangible assets
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Research and development
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Expenditures on research activities,
	undertaken with the prospect of gaining new scientific or technical knowledge
	and understanding, are recognized in profit or loss as incurred.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Development activities involve a plan
	or design for the production of new or substantially improved products and
	processes. Development expenditures are capitalized only if development costs
	can be measured reliably, the product or process is technically and commercially
	feasible, future economic benefits are probable, and the Company intends to
	complete development and has sufficient resources to complete development and to
	use or sell the asset. Other development expenditures are expensed as incurred.
	No internal development costs have been capitalized to date.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Research and development expenses
	include all direct and indirect operating expenses supporting the products in
	development. The costs incurred in establishing and maintaining patents are
	expensed as incurred.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Intangible assets
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Intangible assets that are acquired
	separately and have finite useful lives are measured at cost less accumulated
	amortization and accumulated impairment losses. Subsequent expenditures are
	capitalized only when they increase the future economic benefits embodied in the
	specific asset to which it relates. All other expenditure is recognized in
	profit or loss as incurred.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Amortization is recognized in profit or
	loss on a straight-line basis over the estimated useful lives of intangible
	assets from the date they are available for use in the manner intended by
	management. The period that the technologies acquired in the Trillium Privateco
	acquisition are available for use is estimated at three years, which reflects
	management's intent about developing and commercializing the assets.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The amortization method and
	amortization period of an intangible asset with a finite life is reviewed at
	least annually. Changes in the expected useful life or the expected pattern of
	consumption of future economic benefits embodied in the asset are accounted for
	by changing the amortization period or method, as appropriate, and are treated
	as changes in accounting estimates. The amortization expense on intangible
	assets with finite lives is recognized in research and development expenses.
</P>
<P ALIGN=CENTER>
	- 8 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage111"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_11">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	3.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Significant accounting policies
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(f)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Impairment
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Financial assets
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	A financial asset not carried at fair
	value through profit or loss is assessed at each reporting date to determine
	whether there is objective evidence that it is impaired. A financial asset is
	impaired if objective evidence indicates that a loss event has occurred after
	the initial recognition of the asset, and that the loss event had a negative
	effect on the estimated future cash flows of that asset that can be estimated
	reliably.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	An impairment test is performed, on an
	individual basis, for each material financial asset. Other individually
	non-material financial assets are tested as groups of financial assets with
	similar risk characteristics. Impairment losses are recognized in profit or
	loss.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	An impairment loss in respect of a
	financial asset measured at amortized cost is calculated as the difference
	between its carrying amount and the present value of the estimated future cash
	flows discounted at the asset's original effective interest rate. Losses are
	recognized in profit or loss and reflected in an allowance account against the
	respective financial asset. Interest on the impaired asset continues to be
	recognized through the unwinding of the discount. When a subsequent event causes
	the amount of impairment loss to decrease, the decrease in impairment loss is
	reversed through profit or loss.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Non-financial assets
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The carrying amounts of the Company's
	non-financial assets are reviewed at each reporting date to determine whether
	there is any indication of impairment. If such an indication exists, the
	recoverable amount is estimated.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The recoverable amount of an asset or a
	cash-generating unit is the greater of its value in use and its fair value less
	costs to sell. In assessing value in use, the estimated future cash flows are
	discounted to their present value using a pre-tax discount rate that reflects
	current market assessments of the time value of money and the risks specific to
	the asset or cash-generating unit. For the purpose of impairment testing, assets
	that cannot be tested individually are grouped together into the smallest group
	of assets that generate cash inflows from continuing use that are largely
	independent of cash inflows of other assets or cash-generating units. An
	impairment loss is recognized if the carrying amount of an asset or its related
	cash-generating unit exceeds its estimated recoverable amount. Impairment losses
	for intangible assets are recognized in research and development expenses.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Impairment losses recognized in prior
	periods are assessed at each reporting date for any indications that the loss
	has decreased or no longer exists. An impairment loss is reversed if there has
	been a change in the estimates used to determine the recoverable amount. An
	impairment loss is reversed only to the extent that the asset's carrying amount
	does not exceed the carrying amount that would have been determined, net of
	depreciation or amortization, if no impairment loss had been recognized.
<B>
</B>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(g)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Provisions
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	A provision is recognized if, as a
	result of a past event, the Company has a present legal or constructive
	obligation that can be estimated reliably, and it is probable that an outflow of
	economic benefits will be required to settle the obligation. Provisions are
	assessed by discounting the expected future cash flows at a pre-tax rate that
	reflects current market assessments of the time value of money and the risks
	specific to the liability. The unwinding of the discount on provisions is
	recognized in finance costs.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	A provision for onerous contracts is
	recognized when the unavoidable costs of meeting the obligations under the
	contract exceed the economic benefits expected to be received under it. The
	provision is measured at the present value of the lower of the expected cost of
	terminating the contract and the expected net cost of continuing with the
	contract.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(h)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Government assistance
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Government assistance relating to
	research and development is recorded as a reduction of expenses when the related
	expenditures are incurred.
</P>
<P ALIGN=CENTER>
	- 9 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage112"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_12">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	3.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Significant accounting policies
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(i)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share-based compensation
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The grant-date fair value of
	share-based payment awards granted to employees is recognized as personnel
	costs, with a corresponding increase in contributed surplus, over the period
	that the employees unconditionally become entitled to the awards. The amount
	recognized as an expense is adjusted to reflect the number of awards for which
	the related service and non-market vesting conditions are expected to be met,
	such that the amount ultimately recognized as an expense is based on the number
	of awards that met the related service and non-market performance conditions at
	the vesting date.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	For equity-settled share-based payment
	transactions, the Company measures the goods or services received, and the
	corresponding increase in contributed surplus, directly, at the fair value of
	the goods or services received, unless that fair value cannot be estimated
	reliably. If the Company cannot estimate reliably the fair value of the goods or
	services received, it measures their value by reference to the fair value of the
	equity instruments granted. Transactions measured by reference to the fair value
	of the equity instruments granted have their fair values remeasured at each
	vesting and reporting date until fully vested.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(j)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Income taxes
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Deferred tax is recognized in respect
	of temporary differences between the carrying amounts of assets and liabilities
	for financial reporting purposes and the amounts used for taxation purposes.
	Deferred tax is not recognized for temporary differences on the initial
	recognition of assets or liabilities in a transaction that is not a business
	combination and that affects neither accounting nor taxable income nor loss.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Deferred tax assets and liabilities are
	offset if there is a legally enforceable right to offset current tax assets and
	liabilities, and they relate to income taxes levied by the same tax authority on
	the same taxable entity.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Deferred tax is measured at the tax
	rates that are expected to be applied to temporary differences when they
	reverse, based on the laws that have been enacted or substantively enacted at
	the reporting date. A deferred tax asset is recognized for unused tax losses,
	tax credits and deductible temporary differences, to the extent that it is
	probable that future taxable profits will be available against which they can be
	utilized.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Investment tax credits earned from
	scientific research and development expenditures are recorded when
	collectability is reasonably assured.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(k)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Loss per share
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Basic loss per share is computed by
	dividing the net loss available to common shareholders by the weighted average
	number of shares outstanding during the reporting period. Diluted loss per share
	is computed similar to basic loss per share except that the weighted average
	number of shares outstanding are increased to include additional shares for the
	assumed exercise of stock options, deferred share units, warrants, and
	conversion of preferred shares, if dilutive. The number of additional shares is
	calculated by assuming that outstanding preferred shares would convert to common
	shares and that outstanding stock options and warrants were exercised and that
	the proceeds from such exercises were used to acquire common stock at the
	average market price during the reporting period. The inclusion of the Company's
	stock options, deferred share units, warrants and preferred shares in the
	computation of diluted loss per share has an anti-dilutive effect on the loss
	per share and therefore, they have been excluded from the calculation of diluted
	loss per share.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(l)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	New standards and interpretations not yet
	effective
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	IFRS 9
<I>
	Financial Instruments
</I>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	In October 2010, the IASB published
	amendments to IFRS 9
<I>
	Financial Instruments
</I>
	(&#147;IFRS 9&#148;), which provides
	added guidance on the classification and measurement of financial liabilities.
	In July 2014, the IASB issued its final version of IFRS 9, which completes the
	classification and measurement, impairment and hedge accounting phases of the
	IASB&#146;s project to replace IAS 39. The final standard is mandatorily effective
	for annual periods beginning on or after January 1, 2018, with earlier
	application permitted. The Company is reviewing the standard to determine the
	impact that the adoption of this standard may have on the consolidated financial
	statements.
</P>
<P ALIGN=CENTER>
	- 10 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage113"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_13">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	3.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Significant accounting policies
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	IFRS 15
<I>
	Revenue from Contracts with
	Customers
</I>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	In May 2014, the IASB issued IFRS 15
<I>
	Revenue from Contracts with Customers
</I>
	(&#147;IFRS 15&#148;), which covers
	principles for reporting about the nature, amount, timing and uncertainty of
	revenue and cash flows arising from contracts with customers. IFRS 15 is
	effective for annual periods beginning on or after January 1, 2018. Entities
	will transition following either a full or modified retrospective approach. The
	Company is reviewing the standard to determine the impact that the adoption of
	this standard may have on the consolidated financial statements.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	IFRS 16
<I>
	Leases
</I>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	In January 2016, the IASB has issued
	IFRS 16
<I>
	Leases
</I>
	(&#147;IFRS 16&#148;), its new leases standard that requires lessees
	to recognize assets and liabilities for most leases on their balance sheets.
	Lessees applying IFRS 16 will have a single accounting model for all leases,
	with certain exemptions. Lessor accounting is substantially unchanged. The new
	standard will be effective from January 1, 2019 with limited early application
	permitted. The Company has not yet begun the process of evaluating the impact of
	this standard on its consolidated financial statements.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Other accounting standards or
	amendments to existing accounting standards that have been issued, but have
	future effective dates, are either not applicable or are not expected to have a
	significant impact on the Company&#146;s consolidated financial statements. The
	Company assesses the impact of adoption of future standards on its consolidated
	financial statements, but does not anticipate significant changes in 2016.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	4.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Amounts receivable
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	December 31,
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	December 31,
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Government receivable
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	957,951
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	344,416
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Other amounts receivable
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	16,871
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	974,822
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	344,416
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 11 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage114"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_14">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	5.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Property and equipment
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Computer
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Office
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Lab
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	equipment
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	equipment and
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	equipment
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	and software
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	leaseholds
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Total
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Cost
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Balance, December 31, 2013
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	111,025
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	18,111
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9,381
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	138,517
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Additions
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	141,051
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	21,917
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	10,635
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	173,603
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Balance, December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	252,076
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	40,028
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	20,016
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	312,120
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Additions
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	457,796
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	57,180
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	265,406
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	780,382
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Balance, December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	709,872
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	97,208
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	285,422
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	1,092,502
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Accumulated depreciation
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance, December 31, 2013
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	14,723
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	14,004
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	783
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	29,510
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Depreciation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	33,366
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9,554
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	4,288
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	47,208
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance, December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	48,089
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	23,558
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	5,071
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	76,718
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Depreciation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	86,577
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	26,679
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	5,138
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	118,394
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	134,666
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	50,237
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	10,209
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	195,112
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Net carrying amounts
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	203,987
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	16,470
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	14,945
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	235,402
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	575,206
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	46,971
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	275,213
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	897,390
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	6.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Intangible assets
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	Total
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
<B>
	Cost
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Balance, December 31, 2013
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	2,103,751
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Disposals
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(1,085,714
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Balance December 31, 2014 and 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	1,018,037
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Accumulated amortization
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance, December 31, 2013
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	630,279
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Amortization
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	610,776
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Disposals
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(655,951
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Balance, December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	585,104
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Amortization
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	339,348
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Balance, December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	924,452
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
<B>
	Net carrying amounts
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	December 31, 2014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	432,933
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	December 31, 2015
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	93,585
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	As at December 31, 2015, intangible
	assets were comprised of licensed patent rights related to the SIRP&#945;Fc program
	acquired in 2013 in the amount of $1,018,037.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company returned rights related to
	tigecycline and recorded an impairment loss of $429,763 in the second quarter of
	2014.
</P>
<P ALIGN=CENTER>
	- 12 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage115"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_15">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	7.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Accounts payable and accrued
	liabilities
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	December 31,
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	December 31,
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Trade and other payables
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	1,401,462
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,604,533
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Accrued liabilities
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	1,728,636
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	1,585,823
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Due to related parties (note 15)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	103,651
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	58,628
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	3,233,749
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	3,248,984
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Amounts due to related parties
	represent expense reimbursements, accrued vacation payable and directors&#146; fees
	payable.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	8.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Non-current
	liabilities
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(a)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	Trillium is indebted to the Federal Economic Development
	Agency for Southern Ontario under a non-interest bearing contribution
	agreement and is making monthly repayments of $9,586 through November
	2019. As at December 31, 2015 and 2014, the balance repayable was $440,935
	and $555,968, respectively. The loan payable was discounted using an
	estimated market interest rate of 15%. Interest expense accretes on the
	discounted loan amount until it reaches its face value at
	maturity.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(b)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	As at December 31, 2015 and 2014, the Company has a
	deferred lease inducement of $348,205 and nil, respectively, for a new
	facility lease. The inducement benefit will be recognized over the
	expected term of the lease.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(c)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	As at December 31, 2015 and 2014, the Company has a
	long-term liability of $60,109 and $69,941, respectively, related to
	certain discontinued technologies. This liability has been discounted
	using an estimated market interest rate of 15% and interest expense is
	accreting.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD WIDTH="5%">
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The current portions of the loan payable and long-term
	liability are included in other current liabilities in the statements of
	financial position.
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	9.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(a)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Authorized
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The authorized share capital of the
	Company consists of an unlimited number of common shares, Class B shares and
	First Preferred Shares, in each case without nominal or par value. Common shares
	are voting and may receive dividends as declared at the discretion of the Board
	of Directors. Class B shares are non-voting and convertible to common shares at
	the holder&#146;s discretion, on a one-for-one basis. Upon dissolution or wind-up of
	the Company, Class B shares participate rateably with the common shares in the
	distribution of the Company&#146;s assets. Preferred shares have voting rights as
	decided upon by the Board of Directors at the time of grant. Upon dissolution or
	wind-up of the Company, First Preferred Shares are entitled to priority over
	common and Class B shares.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company has Series I First
	Preferred Shares that are non-voting, may receive dividends as declared at the
	discretion of the Board of Directors, and are convertible to common shares at
	the holder&#146;s discretion, on the basis of 30 Series I First Preferred Shares for
	one common share.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company has Series II First
	Preferred Shares that are non-voting, may receive dividends as declared at the
	discretion of the Board of Directors, and are convertible to common shares at
	the holder&#146;s discretion, on the basis of one Series II First Preferred Share for
	one common share.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Holders may not convert Series I or
	Series II Non-Voting Convertible First Preferred Shares into common shares if,
	after giving effect to the exercise of conversion, the holder and its joint
	actors would have beneficial ownership or direction or control over common
	shares in excess of 4.99% of the then outstanding common shares. This limit may
	be raised at the option of the holder on 61 days&#146; prior written notice: (i) up
	to 9.99%, (ii) up to 19.99%, subject to clearance of a personal information form
	submitted by the holder to the Toronto Stock Exchange, and (iii) above 19.99%,
	subject to approval by the Toronto Stock Exchange and shareholder approval.
</P>
<P ALIGN=CENTER>
	- 13 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage116"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_16">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	9.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(b)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital issued &#150; year ended December 31,
	2015
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	On April 7, 2015, the Company completed
	an underwritten public offering of common shares and non-voting convertible
	preferred shares in the United States. In the offering, Trillium sold 1,750,754
	common shares and 1,077,605 Series II Non-Voting Convertible First Preferred
	Shares at a price of U.S. $19.50 per share, including 228,359 common shares sold
	pursuant to the full exercise of the underwriters&#146; option to purchase additional
	common shares. The gross proceeds to Trillium from this offering were
	$68,875,067 (U.S. $55,153,000) before deducting offering expenses of $4,913,443.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	During the year ended December 31,
	2015, 1,087,603 common shares were issued on the exercise of 32,628,425 warrants
	for proceeds of $9,515,154 and 6,666 stock options were exercised for proceeds
	of $49,995.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	During the year ended December 31,
	2015, 15,716,110 Series I First Preferred Shares were converted into 523,870
	common shares.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Share capital issued &#150; year ended
	December 31, 2014
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	On November 14, 2014, the Company
	consolidated its outstanding common shares issuing one post-consolidated share
	for each 30 pre-consolidated shares. All references in these consolidated
	financial statements and notes to the number of common shares, deferred share
	units and stock options have been adjusted to the post-consolidation amounts.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	During the year ended December 31,
	2014, 2,596,251 warrants were exercised for 86,540 common shares and for
	proceeds of $946,813 and 2,614 stock options were exercised for proceeds of
	$19,600. Also, 909,091 warrants issued in March 2011 expired unexercised.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	During the year ended December 31,
	2014, 8,390,476 Series I First Preferred Shares were converted into 279,682
	common shares.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(c)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Weighted average number of common
	shares
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The weighted average number of common
	shares outstanding for the purposes of calculating earnings per share have been
	adjusted for 2015 and 2014 to the post-consolidated number. The
	post-consolidated weighted average number of common shares outstanding for the
	years ended December 31, 2015 and 2014 were 6,641,161 and 4,202,900,
	respectively. The Company has not adjusted its weighted average number of common
	shares outstanding in the calculation of diluted loss per share, as any
	adjustment would be antidilutive.
</P>
<P ALIGN=CENTER>
	- 14 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage117"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_17">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	9.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(d)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Warrants
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	All warrants were exercisable on
	issuance. As a result of the November 14, 2014 common share consolidation, the
	ratio of the number of warrants exercisable for one common share was adjusted
	from one warrant for each common share to 30 warrants for each common share.
	The number of warrants outstanding was not adjusted.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The following table shows the number of
	warrants outstanding, the exercise prices, and the number of common shares
	issuable on exercise of the warrants and the exercise price per common share for
	30 warrants as at December 31, 2015:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Exercise
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	common shares
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	price per
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	issuable
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	common share
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	Expiry dates
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	on exercise
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	(30 warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	March 15, 2018
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	9,213,780
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	0.40
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	307,126
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	12.00
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	March 27, 2018
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	300,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	0.40
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	10,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	12.00
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	December 13, 2018
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	96,582,576
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	0.28
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	3,219,419
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	8.40
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	106,096,356
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	3,536,545
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Changes in the number of warrants
	outstanding during the years ended December 31 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Weighted
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Weighted
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	warrants
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance, beginning of year
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	138,724,781
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	&nbsp;0.29
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	142,230,123
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;0.30
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Exercised
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(32,628,425
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	0.29
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(2,596,251
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	0.36
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Expired
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	-
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	-
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	(909,091
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	1.60
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance, end of year
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	106,096,356
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	&nbsp;0.29
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	138,724,781
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;0.29
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(e)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Stock option plan
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company has a 10% rolling stock
	option plan (the &#147;2014 Stock Option Plan&#148;) that was approved by the Company&#146;s
	shareholders at its annual general meeting held on May 27, 2014. Pursuant to the
	2014 Stock Option Plan, the Company may grant stock options to purchase up to an
	aggregate of 10% of the Company&#146;s issued and outstanding common shares plus 10%
	of the total number of common shares into which the outstanding Series I First
	Preferred Shares may be converted. Options granted under the 2014 Stock Option
	plan are equity-settled, have a vesting period of four years and have a maximum
	term of ten years. As at December 31, 2015, the Company was entitled to issue an
	additional 87,048 stock options under the 2014 Stock Option Plan.
<B>
</B>
</P>
<P ALIGN=CENTER>
	- 15 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage118"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_18">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	9.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital (continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Changes in the number of options
	outstanding during the years ended December 31 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Weighted
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Weighted
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	Number of
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	exercise
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	options
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	options
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="10%">
	price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Balance, beginning of year
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	590,141
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
<B>
	$
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	&nbsp;9.76
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	97,372
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;9.94
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Granted
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	347,359
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	21.40
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	499,883
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	9.78
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Exercised
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	(6,666
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
<B>
	7.50
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	(2,614
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%" BGCOLOR=#E6EFFF>
	7.50
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Cancelled/forfeited
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	(3,000
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	30.00
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	(4,500
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	16.58
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Balance, end of year
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	927,834
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	14.07
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	590,141
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;9.76
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="10%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Options exercisable, end of year
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	333,927
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
<B>
	10.94
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	219,470
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="10%">
	&nbsp;10.13
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The following table reflects stock
	options outstanding at December 31, 2015:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="29%" COLSPAN=4>
	Stock options
	outstanding
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="29%" COLSPAN=4>
	Stock options
	exercisable
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	Weighted average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	remaining
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	Number
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	contractual life
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	Weighted average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	Exercisable
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	Weighted average
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT>
	Exercise prices
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	outstanding
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	(in years)
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	exercise price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	number
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="13%">
	exercise price
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT BGCOLOR=#E6EFFF>
	$7.50
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	74,841
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	7.3
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	7.50
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	49,903
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	7.50
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT>
	$8.34
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	215,758
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	8.4
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	8.34
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	107,878
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	8.34
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT BGCOLOR=#E6EFFF>
	$10.35
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	264,127
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	8.3
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	10.35
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	132,064
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	10.35
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT>
	$15.30
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	6,666
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	8.1
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	15.30
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	3,333
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	15.30
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT BGCOLOR=#E6EFFF>
	$18.90
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	13,332
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	8.2
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	18.90
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	6,666
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	18.90
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT>
	$19.33
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	220,859
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	9.9
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	19.33
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	-
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	19.33
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT BGCOLOR=#E6EFFF>
	$23.44
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	85,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	9.3
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	23.44
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	28,332
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	23.44
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT>
	$28.05
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	29,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	9.4
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	28.05
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
<B>
	-
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	28.05
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=RIGHT BGCOLOR=#E6EFFF>
	$28.52
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	12,500
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	9.4
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	28.52
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
<B>
	-
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	$
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%" BGCOLOR=#E6EFFF>
	28.52
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT>
	$30.00
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	5,751
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	0.6
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	30.00
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	5,751
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	30.00
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="13%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	927,834
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	8.7
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	14.07
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	333,927
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="13%">
	10.94
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 16 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage119"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_19">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	9.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital (continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Share-based compensation expense was
	determined based on the fair value of the options at the date of measurement
	using the Black-Scholes option pricing model with the weighted average
	assumptions for the years ended December 31 as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 1PX SOLID; BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT BGCOLOR=#E6EFFF>
	Expected option life
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	6
	years
</B>
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	6 years
</TD>
<TD VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Risk-free interest rate
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	1.2%
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	1.7%
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Dividend yield
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	0%
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	0%
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Expected volatility
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	83%
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	90%
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Black-Scholes option pricing model
	was developed to estimate the fair value of freely tradable, fully transferable
	options without vesting restrictions, which significantly differs from the
	Company's stock option awards. This model also requires highly subjective
	assumptions, including future stock price volatility and average option life,
	which significantly affect the calculated values.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The risk-free interest rate is based on
	the implied yield on a Government of Canada zero-coupon issue with a remaining
	term equal to the expected term of the option. Expected volatility was
	determined using a combination of historical volatilities of a peer group of
	biotechnology companies and the Company&#146;s own historical volatility. The life of
	the options is estimated considering the vesting period at the grant date, the
	life of the option and the average length of time similar grants have remained
	outstanding in the past. The forfeiture rate is an estimate based on historical
	evidence and future expectations. The dividend yield was excluded from the
	calculation since it is the present policy of the Company to retain all earnings
	to finance operations and future growth.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	For the years ended December 31, 2015
	and 2014, the Company issued 347,359 and 499,883 stock options with a fair value
	of $5,227,499 and $3,580,892 and a weighted average grant date fair value of
	$15.05 and $7.16, respectively.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(f)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Deferred Share Unit Plan
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The 2014 Deferred Share Unit Plan (the
	&#147;2014 DSU Plan&#148;) promotes greater alignment of long-term interests between
	non-executive directors and executive officers of the Company and its
	shareholders through the issuance of deferred share units (&#147;DSUs&#148;). Since the
	value of a DSU increases or decreases with the market price of the common
	shares, DSUs reflect a philosophy of aligning the interests of directors and
	executive officers with those of the shareholders by tying compensation to share
	price performance. For the years ended December 31, 2015 and 2014, a total of
	23,011 and 28,777 DSUs were issued for payment of directors&#146; fees, respectively.
	The Company has reserved for issuance up to 66,667 common shares under the 2014
	DSU Plan and 51,788 DSUs were outstanding as at December 31, 2015.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(g)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Shareholder Rights Plan
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	On October 17, 2013 the Company&#146;s
	shareholders adopted a shareholder rights plan (the &#147;2013 Rights Plan&#148;) and
	approved certain amendments on May 27, 2014 (the &#147;Rights Plan Amendment&#148; which
	together with the 2013 Rights Plan may be referred to as the &#147;Rights Plan&#148;). The
	Rights Plan is designed to provide adequate time for the Board of Directors and
	the shareholders to assess an unsolicited takeover bid for the Company, to
	provide the Board of Directors with sufficient time to explore and develop
	alternatives for maximizing shareholder value if a takeover bid is made, and to
	provide shareholders with an equal opportunity to participate in a takeover bid
	and receive full and fair value for their common shares. The Rights Plan will
	expire at the close of the Company&#146;s annual meeting of shareholders in 2016.
</P>
<P ALIGN=CENTER>
	- 17 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage120"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_20">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	9.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Share capital (continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The rights issued under the Rights Plan
	initially attach to and trade with the common shares and no separate
	certificates will be issued unless an event triggering these rights occurs. The
	rights will become exercisable only when a person, including any party related
	to it, acquires or attempts to acquire 20% or more of the outstanding common
	shares without complying with the &#147;Permitted Bid&#148; provisions of the Rights Plan
	or without approval of the Board of Directors. Should such an acquisition occur
	or be announced, each right would, upon exercise, entitle a rights holder, other
	than the acquiring person and related persons, to purchase common shares at an
	approximate 50% discount to the market price at the time.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Under the Rights Plan, a Permitted Bid
	is a bid made to all holders of the common shares and which is open for
	acceptance for not less than 60 days. If at the end of 60 days at least 50% of
	the outstanding common shares, other than those owned by the offeror and certain
	related parties have been tendered, the offeror may take up and pay for the
	common shares but must extend the bid for a further 10 days to allow other
	shareholders to tender. The issuance of common shares upon the exercise of the
	rights is subject to receipt of certain regulatory approvals.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	10.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Income taxes
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Income taxes have not been recognized
	in the consolidated statements of loss and comprehensive loss, as the Company
	has been incurring losses since inception, and it is not probable that future
	taxable profits will be available against which the accumulated tax losses can
	be utilized.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(a)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Unrecognized deferred tax
	assets
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	As at December 31, 2015 and 2014,
	deferred tax assets have not been recognized with respect to the following
	items:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Non-capital losses carried
	forward
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	11,750,952
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	9,234,460
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Tax credits carryforward
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	3,090,833
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	2,607,496
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Tax basis of property and
	equipment and intangible assets in excess of accounting basis
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	1,577,156
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,413,171
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Scientific research and experimental
	development expenditures
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	5,524,225
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	4,801,014
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Share issue costs and other
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	493,476
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	436,795
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	22,436,642
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	18,492,936
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(b)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	As at December 31, 2015 and 2014, the Company has
	available research and development expenditures of approximately
	$20,846,000 and $18,117,000, respectively, for income tax purposes which
	may be carried forward indefinitely to reduce future years&#146; taxable
	income. As at December 31, 2015 and 2014, the Company also has unclaimed
	Canadian scientific research and development tax credits of $3,920,000 and
	$3,293,000, respectively, which are available to reduce future taxes
	payable with expiries from 2017 through 2034. The benefit of these
	expenditures and tax credits has not been recorded in the
	accounts.
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(c)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	As at December 31, 2015, the Company has accumulated
	non-capital losses for federal and provincial income tax purposes in
	Canada which are available for application against future taxable income.
	The benefit of these losses has not been recorded in the
	accounts.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER>
	- 18 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage121"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_21">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	10.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Income taxes (continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The non-capital tax losses expire as
	follows:
</P>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	Federal
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	2025
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	3,213,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	2026
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	6,457,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	2027
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	4,659,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	2028
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	4,144,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	2029
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	3,736,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	2030
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	1,819,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	2031
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,387,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	2032
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	2,715,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	2033
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,971,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	2034
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	5,001,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	2035
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	9,241,000
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	44,343,000
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(d)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The reconciliation of the Canadian statutory income tax
	rate applied to the net loss for the year to the income tax recovery is as
	follows:
</P>
</TD>
</TR>
</TABLE>
<BR>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Statutory income tax rate
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	26.5%
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	26.5%
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Income tax recovery based on
	statutory income tax rate
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	(3,901,912
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(3,413,682
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Investment tax credits
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	(473,156
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
<B>
	)
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	(1,091,870
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Share-based compensation and
	other
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	485,009
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	657,494
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Change in unrecognized tax assets
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	3,899,561
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	3,848,058
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Income tax expense
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	9,502
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	-
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	11.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Research and development
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Components of research and development
	expenses for the years ended December 31 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Research and development
	programs, excluding the below items
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	12,083,797
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	5,893,030
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Salaries, fees and short-term benefits
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	4,120,109
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	2,311,755
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Share-based compensation
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	1,942,173
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,626,824
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Amortization of intangible assets
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	339,348
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	610,776
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Impairment of intangible
	assets
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	-
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	429,763
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Depreciation of property and equipment
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	118,394
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	47,208
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Tax credits
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	(553,730
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
<B>
	)
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	(323,548
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	)
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	18,050,091
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	10,595,808
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN=CENTER>
	- 19 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage122"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_22">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	12.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	General and administrative
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Components of general and
	administrative expenses for the years ended December 31 were as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	General and administrative
	expenses, excluding the below items
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	1,521,639
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,198,181
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Salaries, fees and short-term benefits
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	898,381
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	694,849
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	DSU units issued for director
	compensation
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	540,000
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	240,000
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Share-based compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	224,327
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	444,430
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	3,184,347
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	2,577,460
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	13.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Finance income and finance
	costs
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Finance income for the years ended
	December 31 was as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
<B>
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Interest income
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	488,486
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	378,692
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Net
	foreign currency gain
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	6,106,703
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	6,595,189
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	378,692
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Finance costs for the years ended
	December 31 were as follows:
</P>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Bank charges
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	11,557
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	7,212
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT>
	Accreted interest
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	73,391
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	69,770
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Net foreign currency loss
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	-
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	10,262
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	84,948
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	87,244
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	14.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Commitments and
	contingencies
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	As at December 31, 2015, the Company
	had capital commitments for the acquisition of property and equipment of
	approximately $1,026,000.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	As at December 31, 2015, the Company
	had obligations to make future payments, representing significant research and
	development contracts and other commitments that are known and committed in the
	amount of approximately $7,789,000. These contracts include the clinical
	research organization agreement for conducting the Phase I trial, and other
	preclinical and manufacturing activities.&nbsp; The Company also has minimum lease payments
	relating to operating lease commitments in the amount of $266,000 over the next
	12 months, $955,000 from 12 to 60 months, and $1,289,000 thereafter.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company enters into research,
	development and license agreements in the ordinary course of business where the
	Company receives research services and rights to proprietary technologies.
	Milestone and royalty payments that may become due under various agreements are
	dependent on, among other factors, clinical trials, regulatory approvals and
	ultimately the successful development of a new drug, the outcome and timing of
	which is uncertain. Under the license agreement for SIRP&#945;Fc, the Company has
	future contingent milestones payable of $35,000 related to successful patent
	grants, $100,000, $200,000 and $300,000 on the first patient dosed in phase I,
	II and III trials respectively, and regulatory milestones on their first
	achievement totalling $5,000,000. The Company is required to pay 20% of any
	sublicensing revenues to the licensors on the first $50 million of sublicensing
	revenues, and pay 15% of any sublicensing revenues to the licensors after the
	first $50 million of sublicensing revenue received.
</P>
<P ALIGN=CENTER>
	- 20 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage123"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_23">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	14.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Commitments and contingencies
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company entered into two agreements
	with Catalent Pharma Solutions in August 2014 pursuant to which Trillium
	acquired the right to use a proprietary expression system for the manufacture of
	two SIRP&#945;Fc constructs. Consideration for each license includes potential
	pre-marketing approval milestones of up to U.S. $875,000 and aggregate sales
	milestone payments of up to U.S. $28.8 million.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company periodically enters into
	research and license agreements with third parties that include indemnification
	provisions customary in the industry. These guarantees generally require the
	Company to compensate the other party for certain damages and costs incurred as
	a result of claims arising from research and development activities undertaken
	by or on behalf of the Company. In some cases, the maximum potential amount of
	future payments that could be required under these indemnification provisions
	could be unlimited. These indemnification provisions generally survive
	termination of the underlying agreement. The nature of the indemnification
	obligations prevents the Company from making a reasonable estimate of the
	maximum potential amount it could be required to pay. Historically, the Company
	has not made any indemnification payments under such agreements and no amount
	has been accrued in the audited consolidated financial statements with respect
	to these indemnification obligations.
<I>
</I>
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	15.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Related parties
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	For the years ended December 31, 2015
	and 2014, the key management personnel of the Company were the Board of
	Directors, Chief Executive Officer, Chief Medical Officer, Chief Scientific
	Officer, Chief Financial Officer and the Chief Development Officer.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Compensation for key management
	personnel of the Company for the years ended December 31 was as follows:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<DIV ALIGN=RIGHT>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="95%" BORDER=0>
<TR VALIGN=TOP>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
<B>
	2015
</B>
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	2014
</TD>
<TD STYLE="BORDER-TOP: #000000 2PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;
<STRONG>
	$
</STRONG>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="1%">
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=RIGHT WIDTH="12%">
	&nbsp;$
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM NOWRAP ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM NOWRAP>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="1%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="12%">
	&nbsp;
</TD>
<TD VALIGN=BOTTOM NOWRAP WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Salaries, fees and short-term
	benefits
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	2,595,536
</B>
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	1,708,717
</TD>
<TD VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT>
	Share-based compensation
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
<B>
	2,433,710
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%">
	2,281,561
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%">
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT BGCOLOR=#E6EFFF>
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
<B>
	5,029,246
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="1%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=RIGHT WIDTH="12%" BGCOLOR=#E6EFFF>
	3,990,278
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" VALIGN=BOTTOM ALIGN=LEFT WIDTH="2%" BGCOLOR=#E6EFFF>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Executive officers and directors
	participate in the 2014 Stock Option Plan and the 2014 DSU Plan, and officers
	participate in the Company&#146;s benefit plans. Directors receive annual fees for
	their services. As at December 31, 2015, the key management personnel controlled
	approximately 1% of the voting shares of the Company.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Under IFRS, the acquisition of
	Fluorinov Pharma Inc. (&#147;Fluorinov&#148;) was considered a related party transaction
	as two Company directors were determined to be related parties of Fluorinov (see
	Note 19). One Company director was a director of Fluorinov and had an ownership
	position in Fluorinov at the time of acquisition of less than 2%, and the second
	director was a director of an entity that was a beneficiary of a trust that was
	a shareholder and debenture holder of Fluorinov. The two directors declared
	their conflict of interest and abstained from all discussions and decisions
	concerning the Fluorinov acquisition. Accordingly, the Company determined that
	the consideration paid on the acquisition was made on terms equivalent to those
	that prevail in arm&#146;s length transactions.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Outstanding balances with related
	parties at the year-end are unsecured, interest free and settlement occurs in
	cash. There have been no guarantees provided or received for any related party
	receivables or payables. For the years ended December 31, 2015 and 2014, a
	former director was paid consulting fees of $0 and $7,916, respectively.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	16.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Operating segment
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company has a single operating
	segment, the research and development therapies for the treatment of cancer.
	Substantially all of the Company&#146;s operations, assets, and employees are in
	Canada.
</P>
<P ALIGN=CENTER>
	- 21 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage124"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_24">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	17.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Management of capital
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company defines its capital as
	share capital, warrants and contributed surplus. The Company&#146;s objectives when
	managing capital are to ensure there are sufficient funds available to carry out
	its research and development programs. To date, these programs have been funded
	primarily through the sale of equity securities and the exercise of common share
	purchase warrants. The Company also sources non-dilutive funding by accessing
	grants, government assistance and tax incentives, and through partnerships with
	corporations and research institutions. The Company uses budgets and purchasing
	controls to manage its costs. The Company is not exposed to any externally
	imposed capital requirements.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	18.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Financial instruments
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Fair value
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	IFRS 13
<I>
	Fair Value Measurement
</I>
	provides a hierarchy of valuation techniques based on whether the inputs to
	those valuation techniques are observable or unobservable. Observable inputs are
	those which reflect market data obtained from independent sources, while
	unobservable inputs reflect the Company&#146;s assumptions with respect to how market
	participants would price an asset or liability. These two inputs used to measure
	fair value fall into the following three different levels of the fair value
	hierarchy:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="10%">
	Level 1
</TD>
<TD ALIGN=LEFT WIDTH="80%">
<P ALIGN=JUSTIFY>
	Quoted prices in active markets for identical instruments
	that are observable.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
</TD>
<TD ALIGN=LEFT WIDTH="10%">
	Level 2
</TD>
<TD ALIGN=LEFT WIDTH="80%">
<P ALIGN=JUSTIFY>
	Quoted prices in active markets for similar instruments;
	inputs other than quoted prices that are observable and derived from or
	corroborated by observable market data.
</P>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="10%">
	Level 3
</TD>
<TD ALIGN=LEFT WIDTH="80%">
<P ALIGN=JUSTIFY>
	Valuations derived from valuation techniques in which one
	or more significant inputs are unobservable.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The hierarchy requires the use of
	observable market data when available.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company has classified cash as
	Level 1. The loan payable has been classified as Level 2.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Cash, amounts receivable, accounts
	payable and accrued liabilities, and other current liabilities, due within one
	year, are all short-term in nature and, as such, their carrying values
	approximate fair values. The fair value of the non-current loan payable is
	estimated by discounting the expected future cash flows at the cost of money to
	the Company, which is equal to its carrying value.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
<B>
	Risks
</B>
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company has exposure to credit
	risk, liquidity risk, interest rate risk and currency risk. The Company&#146;s Board
	of Directors has overall responsibility for the establishment and oversight of
	the Company&#146;s risk management framework. The Audit Committee of the Board is
	responsible for reviewing the Company&#146;s risk management policies.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(a)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Credit risk
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Credit risk is the risk of financial
	loss to the Company if a counterparty to a financial instrument fails to meet
	its contractual obligations, and arises principally from the Company&#146;s cash and
	amounts receivable. The carrying amount of these financial assets represents the
	maximum credit exposure. The Company follows an investment policy to mitigate
	against the deterioration of principal and to enhance the Company&#146;s ability to
	meet its liquidity needs. Cash is on deposit with major Canadian chartered banks
	and the Company invests in high grade short-term instruments. Amounts receivable
	are primarily comprised of amounts due from the federal government.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(b)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Liquidity risk
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Liquidity risk is the risk that the
	Company will not be able to meet its financial obligations as they fall due. The
	Company is a development stage company and is reliant on external fundraising to
	support its operations. Once funds have been raised, the Company manages its
	liquidity risk by investing in cash and short-term instruments to provide
	regular cash flow for current operations. It also manages liquidity risk by
	continuously monitoring actual and projected cash flows. The Board of Directors
	reviews and approves the Company&#146;s operating and capital budgets, as well as any
	material transactions not in the ordinary course of business. The majority of
	the Company&#146;s accounts payable and accrued liabilities have maturities of less
	than three months.
</P>
<P ALIGN=CENTER>
	- 22 -
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage125"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-3_HTM_PAGE_25">
</A>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	TRILLIUM THERAPEUTICS INC.
</B>
</TD>
</TR>
<TR>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	Notes to the Consolidated Financial Statements
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
<B>
	For the years ended December 31, 2015 and 2014
</B>
</TD>
</TR>
<TR VALIGN=TOP>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID" ALIGN=LEFT>
	Amounts in
	Canadian Dollars
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	18.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Financial instruments
	(continued)
</B>
</P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(c)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Interest rate risk
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	Interest rate risk is the risk that the
	fair value or future cash flows of a financial instrument will fluctuate because
	of changes in market interest rates. The Company holds its cash in bank accounts
	or high interest savings accounts which have a variable rate of interest. The
	Company manages its interest rate risk by holding highly liquid short-term
	instruments and by holding its investments to maturity, where possible. For the
	years ended December 31, 2015 and 2014, the Company earned interest income of
	$488,486 and $378,692, respectively. Therefore, a 1% change in the average
	interest rate for the years ended December 31, 2015 and 2014, would have a net
	impact on finance income of $4,885 and $3,787, respectively.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	(d)
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Currency risk
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	The Company is exposed to currency risk
	related to the fluctuation of foreign exchange rates and the degree of
	volatility of those rates. Currency risk is limited to the portion of the
	Company&#146;s business transactions denominated in currencies other than the
	Canadian dollar which are primarily expenses in US dollars. As at December 31,
	2015 and 2014, the Company held US dollar cash in the amount of US$44,547,591
	and US$142,558 and had US dollar denominated accounts payable and accrued
	liabilities in the amount of US$1,033,319 and US$1,910,430, respectively.
	Therefore, a 1% change in the foreign exchange rate would have a net impact on
	finance costs as at December 31, 2015 and 2014 of $435,143 and $17,679,
	respectively.
</P>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	US dollar expenses for the years ended
	December 31, 2015 and 2014 were approximately US$8,700,000 and US$3,260,000,
	respectively. Varying the US exchange rate for the years ended December 31, 2015
	and 2014 to reflect a 5% strengthening of the Canadian dollar would have
	decreased the net loss by approximately $435,000 and $163,000, respectively,
	assuming that all other variables remained constant.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
<B>
	19.
</B>
</TD>
<TD>
<P ALIGN=JUSTIFY>
<B>
	Events after the balance sheet
	date
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-LEFT: 5%" ALIGN=JUSTIFY>
	On January 26, 2016, the Company
	acquired all of the outstanding shares of Fluorinov, a private oncology company,
	for an upfront payment of $10 million plus up to $35 million of additional
	future payments that are contingent on Trillium achieving certain clinical and
	regulatory milestones with an existing Fluorinov compound. Trillium will also
	have an obligation to pay royalty payments on future sales of such compounds.
	The upfront payment was subject to adjustment based on the net working capital
	of Fluorinov and other adjustments at the time of closing. At Trillium&#146;s
	discretion, up to 50% of the future contingent payments can be satisfied through
	the issuance of common shares of Trillium provided that the aggregate number of
	common shares issuable under such payments will not exceed 1,558,447 common
	shares unless shareholder approval has first been obtained. In addition, any
	such future share issuance remains subject to final approval from Trillium&#146;s
	board of directors and receipt of any requisite approvals under the applicable
	rules of the Toronto Stock Exchange and the NASDAQ Stock Market. Trillium has
	also committed to use commercially reasonable efforts to monetize Fluorinov&#146;s
	CNS assets and share 50% of the net proceeds with Fluorinov shareholders. The
	acquisition of Fluorinov will be accounted for as a business combination under
	the acquisition method of accounting. The Company will record the assets
	acquired and liabilities assumed at their fair values as of the acquisition
	date. Due to the limited amount of time since the acquisition date, the
	preliminary acquisition valuation for the business combination is incomplete at
	this time. As a result, the Company is unable to provide the amounts recognized
	as of the acquisition date for the major classes of assets acquired and
	liabilities assumed.
</P>
<P ALIGN=CENTER>
	- 23 -
</P>
<HR ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage126"></A>
<A NAME="EXHIBIT99-4_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_4"></A>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage127"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-4_HTM_PAGE_11">
</A>
<P ALIGN=RIGHT>
<B>
	Exhibit 99.4
</B>
</P>
<P ALIGN=CENTER>
<B>
	CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE
<BR>
</B>
<B>
	SECURITIES EXCHANGE ACT OF 1934
</B>
</P>
<P ALIGN=JUSTIFY>
	I, Niclas Stiernholm, certify that:
</P>
<P ALIGN=JUSTIFY>
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 40-F of Trillium
	Therapeutics Inc.;
</P>
<P ALIGN=JUSTIFY>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any
	untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such
	statements were made, not misleading with respect to the period covered by this
	report;
</P>
<P ALIGN=JUSTIFY>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other
	financial information included in this report, fairly present in all material
	respects the financial condition, results of operations and cash flows of the
	issuer as of, and for, the periods presented in this report;
</P>
<P ALIGN=JUSTIFY>
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issuer&#146;s other certifying officer and I are responsible
	for establishing and maintaining disclosure controls and procedures (as defined
	in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
	financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
	for the issuer and have:
</P>
<P ALIGN=JUSTIFY>
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures,
	or caused such disclosure controls and procedures to be designed under our
	supervision, to ensure that material information relating to the issuer,
	including its consolidated subsidiaries, is made known to us by others within
	those entities, particularly during the period in which this report is being
	prepared;
</P>
<P ALIGN=JUSTIFY>
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused
	such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of
	financial reporting and the preparation of financial statements for external
	purposes in accordance with generally accepted accounting principles;
</P>
<P ALIGN=JUSTIFY>
	(c)
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures
	and presented in this report our conclusions about the effectiveness of the
	disclosure controls and procedures, as of the end of the period covered by this
	report based on such evaluation; and
</P>
<P ALIGN=JUSTIFY>
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in
	the issuer&#146;s internal control over financial reporting that occurred during the
	period covered by the annual report that has materially affected, or is
	reasonably likely to materially affect, the issuer&#146;s internal control over
	financial reporting; and
</P>
<P ALIGN=JUSTIFY>
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issuer&#146;s other certifying officer and I have disclosed,
	based on our most recent evaluation of internal control over financial
	reporting, to the issuer&#146;s auditors and the audit committee of the issuer&#146;s
	board of directors (or persons performing the equivalent function):
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage128"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-4_HTM_PAGE_12">
</A>
<P ALIGN=JUSTIFY>
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
	significant deficiencies and material weaknesses in the design or operation of
	internal control over financial reporting which are reasonably likely to
	adversely affect the issuer&#146;s ability to record, process, summarize and report
	financial information; and
</P>
<P ALIGN=JUSTIFY>
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves
	management or other employees who have a significant role in the issuer&#146;s
	internal control over financial reporting.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT COLSPAN=2>
	Date: March 9, 2016
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD BORDERCOLOR="#000000">
	&nbsp;
</TD>
<TD WIDTH="50%" STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1" BORDERCOLOR="#000000">
	/s/ Niclas Stiernholm
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%" STYLE="BORDER-TOP-STYLE: SOLID; BORDER-TOP-WIDTH: 1">
	Niclas Stiernholm
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	President and Chief Executive Officer
</TD>
</TR>
</TABLE>
<BR>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>
<A NAME="eolPage129"></A>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage130"></A>
<A NAME="EXHIBIT99-5_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_5"></A>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage131"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-5_HTM_PAGE_13">
</A>
<P ALIGN=RIGHT>
<B>
	Exhibit 99.5
</B>
</P>
<P ALIGN=CENTER>
<B>
	CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE
	SECURITIES
<BR>
</B>
<B>
	EXCHANGE ACT OF 1934
</B>
</P>
<P ALIGN=JUSTIFY>
	I, James Parsons, certify that:
</P>
<P ALIGN=JUSTIFY>
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 40-F of Trillium
	Therapeutics Inc.;
</P>
<P ALIGN=JUSTIFY>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any
	untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such
	statements were made, not misleading with respect to the period covered by this
	report;
</P>
<P ALIGN=JUSTIFY>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other
	financial information included in this report, fairly present in all material
	respects the financial condition, results of operations and cash flows of the
	issuer as of, and for, the periods presented in this report;
</P>
<P ALIGN=JUSTIFY>
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issuer&#146;s other certifying officer and I are responsible
	for establishing and maintaining disclosure controls and procedures (as defined
	in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
	financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
	for the issuer and have:
</P>
<P ALIGN=JUSTIFY>
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures,
	or caused such disclosure controls and procedures to be designed under our
	supervision, to ensure that material information relating to the issuer,
	including its consolidated subsidiaries, is made known to us by others within
	those entities, particularly during the period in which this report is being
	prepared;
</P>
<P ALIGN=JUSTIFY>
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused
	such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of
	financial reporting and the preparation of financial statements for external
	purposes in accordance with generally accepted accounting principles;
</P>
<P ALIGN=JUSTIFY>
	(c)
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures
	and presented in this report our conclusions about the effectiveness of the
	disclosure controls and procedures, as of the end of the period covered by this
	report based on such evaluation; and
</P>
<P ALIGN=JUSTIFY>
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in
	the issuer&#146;s internal control over financial reporting that occurred during the
	period covered by the annual report that has materially affected, or is
	reasonably likely to materially affect, the issuer&#146;s internal control over
	financial reporting; and
</P>
<P ALIGN=JUSTIFY>
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issuer&#146;s other certifying officer and I have disclosed,
	based on our most recent evaluation of internal control over financial
	reporting, to the issuer&#146;s auditors and the audit committee of the issuer&#146;s
	board of directors (or persons performing the equivalent function):
</P>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage132"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-5_HTM_PAGE_14">
</A>
<P ALIGN=JUSTIFY>
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
	significant deficiencies and material weaknesses in the design or operation of
	internal control over financial reporting which are reasonably likely to
	adversely affect the issuer&#146;s ability to record, process, summarize and report
	financial information; and
</P>
<P ALIGN=JUSTIFY>
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves
	management or other employees who have a significant role in the issuer&#146;s
	internal control over financial reporting.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT COLSPAN=2>
	Date: March 9, 2016
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD WIDTH="50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD BORDERCOLOR="#000000">
	&nbsp;
</TD>
<TD WIDTH="50%" STYLE="BORDER-BOTTOM-STYLE: SOLID; BORDER-BOTTOM-WIDTH: 1" BORDERCOLOR="#000000">
	/s/ James Parsons
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%" STYLE="BORDER-TOP-STYLE: SOLID; BORDER-TOP-WIDTH: 1">
	James Parsons
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=LEFT WIDTH="50%">
	Chief Financial Officer
</TD>
</TR>
</TABLE>
<BR>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>
<A NAME="eolPage133"></A>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage134"></A>
<A NAME="EXHIBIT99-6_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_6"></A>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage135"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-6_HTM_PAGE_15">
</A>
<P ALIGN=RIGHT>
<B>
	Exhibit 99.6
</B>
<B>
</B>
</P>
<P ALIGN=CENTER>
<B>
	CERTIFICATION PURSUANT TO
<BR>
</B>
<B>
	18 U.S.C. SECTION 1350,
<BR>
	AS ADOPTED PURSUANT TO
<BR>
</B>
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF
	2002
</B>
</P>
<P ALIGN=JUSTIFY STYLE="TEXT-INDENT:5%">
	In connection with the Annual
	Report of Trillium Therapeutics Inc. (the &#147;Company&#148;) on Form 40-F for the year
	ended December 31, 2015, as filed with the Securities and Exchange Commission on
	the date hereof (the &#147;Report&#148;), I, Niclas Stiernholm, President and Chief
	Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350,
	as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to
	the best of my knowledge:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	1.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The Report fully complies with the requirements of
	section 13(a) or 15(d) of the Securities Exchange Act of 1934;
	and
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	2.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The information contained in the Report fairly presents,
	in all material respects, the financial condition and results of
	operations of the Company.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<U>
	/s/ Niclas Stiernholm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
<BR>
	Niclas Stiernholm
<BR>
	President and Chief Executive Officer
</P>
<P ALIGN=JUSTIFY>
	March 9, 2016
</P>
<HR COLOR="#000000" SIZE="5">
</EFX_EXHIBIT_99>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage136"></A>
<A NAME="EXHIBIT99-7_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_7"></A>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage137"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-7_HTM_PAGE_16">
</A>
<P ALIGN=RIGHT>
<B>
	Exhibit 99.7
</B>
</P>
<P ALIGN=CENTER>
<B>
	CERTIFICATION PURSUANT TO
<BR>
	18 U.S.C. SECTION 1350,
<BR>
	AS
	ADOPTED PURSUANT TO
<BR>
</B>
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P ALIGN=JUSTIFY STYLE="TEXT-INDENT:5%">
	In connection with the Annual
	Report of Trillium Therapeutics Inc. (the &#147;Company&#148;) on Form 40-F for the year
	ended December 31, 2015, as filed with the Securities and Exchange Commission on
	the date hereof (the &#147;Report&#148;), I, James Parsons, Chief Financial Officer of the
	Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to
	Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0 BCLLIST>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	1.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The Report fully complies with the requirements of
	section 13(a) or 15(d) of the Securities Exchange Act of 1934;
	and
</P>
</TD>
</TR>
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="5%">
	2.
</TD>
<TD>
<P ALIGN=JUSTIFY>
	The information contained in the Report fairly presents,
	in all material respects, the financial condition and results of
	operations of the Company.
</P>
</TD>
</TR>
</TABLE>
<P ALIGN=JUSTIFY>
<U>
	/s/ James Parsons&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
<BR>
	James Parsons
<BR>
	Chief Financial
	Officer
</P>
<P ALIGN=JUSTIFY>
	March 9, 2016
</P>
<HR ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage138"></A>
<A NAME="EXHIBIT99-8_HTM"></A>
<EFX_EXHIBIT_99>
<A NAME="FIS_EXHIBIT_99_8"></A>
<HR STYLE="PAGE-BREAK-AFTER: ALWAYS" ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
<A NAME="eolPage139"></A>
<!--$$/PAGE=-->
<A NAME="EXHIBIT99-8_HTM_PAGE_17">
</A>
<P ALIGN=RIGHT>
<B>
	Exhibit 99.8
</B>
</P>
<P ALIGN=CENTER>
	Consent of Independent Registered Public Accounting Firm
</P>
<P ALIGN=JUSTIFY>
	We consent to the reference to our Firm under the caption
	&#147;Interest of Experts&#148;, and to the use in the Annual Report on Form 40-F and to
	the use and incorporation by reference into the registration statement on Form
	F-10 (File No. 333- 204551) of Trillium Therapeutics Inc., of our report dated
	March 9, 2016, with respect to the consolidated statements of financial position
	of Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) as at
	December 31, 2015 and 2014, and the consolidated statements of loss and
	comprehensive loss, changes in equity, and cash flows for the years then
	ended.
</P>
<TABLE STYLE="BORDER-COLOR: BLACK; FONT-SIZE: 10PT; BORDER-COLLAPSE: COLLAPSE; " CELLSPACING=0 CELLPADDING=0 WIDTH="100%" BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	&nbsp;
</TD>
<TD ALIGN=RIGHT WIDTH="50%">
	/s/ Ernst &amp; Young LLP
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	Toronto, Canada
</TD>
<TD ALIGN=RIGHT WIDTH="50%">
	Chartered Professional Accountants
</TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT>
	March 9, 2016
</TD>
<TD ALIGN=RIGHT WIDTH="50%">
	Licensed Public Accountants
</TD>
</TR>
</TABLE>
<BR>
<HR ALIGN=CENTER WIDTH="100%" COLOR=BLACK NOSHADE SIZE=5>
</EFX_EXHIBIT_99>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
